SUPPLEMENT

FY2023 — Annual financial statements

FY2023PDF · 217 pages4.7 MB
for the year ended 30 June 2023
ANNUAL
FINANCIAL
STATEMENTS

-- 1 of 217 --

1	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
HOW WE REPORT TO OUR
STAKEHOLDERS	CONTENTS
Basis of preparation
The consolidated and separate Annual Financial Statements have been
prepared in accordance with IFRS Accounting Standards, its interpretations
adopted by the IASB, the South African Institute of Chartered Accountants
(SAICA) Financial Reporting Guides Limited as issued by the Accounting
Practices Committee, Financial pronouncements as issued by the Financial
Reporting Standards Council, the JSE Limited Listings Requirements, JSE
Debt Listings Requirements as well as the South African Companies Act.
They have been prepared in accordance with the going concern principle
using the historical cost basis except where otherwise stated in the
accounting policies (refer Annexure B).
The Annual Financial Statements have been prepared under the
supervision of Deon Viljoen CA(SA), Group Chief Financial Officer. The
Annual Financial Statements are reviewed by management, the Discovery
Limited Audit Committee and Board, and are audited by the external
auditors of the Group.
The embedded value statements has been prepared by Peter Bolink (FASSA)
and supervised by Andrew Rayner (FASSA, FIA).
A copy of the set of annual consolidated financial statements with the
signatures of the directors is available at the Company’s registered office.
DISCOVERY LIMITED
Registration number 1999/007789/06
Our governance report includes information on our governance
philosophy, leadership and our compliance with King IV™.
GOVERNANCE REPORT
An overview of the Group’s performance against our Integrated
Sustainability Framework and, where appropriate, against
relevant standards and frameworks.
SUSTAINABILITY REPORT
ANNUAL FINANCIAL RESULTS
PRESENTATION AND BOOKLET
Provides an overview of Discovery’s financial performance and can
be accessed at www.discovery.co.za/corporate/investor-relations
The consolidated financial results, embedded value and five-year
review of the Discovery Group, as well as the separate financial
results of Discovery Limited.
GROUP ANNUAL FINANCIAL STATEMENTS
THIS REPORT
Our primary report to our shareholders, providers of financial
capital and other key stakeholders, detailing how we created,
preserved or eroded value for our stakeholder groups.
INTEGRATED ANNUAL REPORT
Discovery’s climate change response regarding governance,
strategy, risk management, and metrics and targets related to the
Group’s environmental impact.
TASK FORCE ON CLIMATE-RELATED
FINANCIAL DISCLOSURE (TCFD) REPORT
Communicates material tax disclosure information to
demonstrate our commitment to tax transparency and operating
as a force for good through our tax contributions.
TAX TRANSPARENCY REPORT
Outlines our remuneration policy and implementation approach
and factors influencing our remuneration-related decisions.
REMUNERATION REPORT
CONSOLIDATED FINANCIAL STATEMENTS
2 	Directors’ responsibility statement
3 	Group Chief Executive and Group Chief Financial Officer’s
internal financial control responsibility statement
3 	Certificate by the Company Secretary
4 	Report of the Discovery Limited Audit Committee
10 	Independent auditors’ report
15 	Directors’ report
18 	Group statement of financial position
19 	Group income statement
20 	Group statement of other comprehensive income
21 	Group statement of cash flows
22 	Group statement of changes in equity
23 	Notes to the Group annual financial statements
DISCOVERY LIMITED COMPANY
126 	Company statement of financial position
127 	Company income statement
127 	Company statement of other comprehensive income
128 	Company statement of cash flows
129 	Company statement of changes in equity
130 	Notes to the Company annual financial statements
ANNEXURES
148 	Annexure A – Group structure
150 	Annexure B – Group accounting policies
195 	Annexure C – Directorate
200 	Annexure D – Unaudited analysis of shareholders
201 	Annexure E – Embedded value statement
213 	Annexure F – Unaudited five-year review
214 	Glossary

-- 2 of 217 --

2	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Directors’ responsibility statement
for the year ended 30 June 2023
The directors of Discovery are required by the Companies
Act, No. 71 of 2008, as amended (Companies Act), to
maintain adequate accounting records and to prepare
financial statements for each financial year which fairly
present the state of affairs of Discovery at the end of the
financial year, and of the results and cash flows for the
period. In preparing the accompanying Annual Financial
Statements, International Financial Reporting Standards
have been used and reasonable estimates have been
made. The Annual Financial Statements incorporate
full and responsible disclosure, in line with Discovery’s
philosophy on corporate governance.
The directors have reviewed Discovery’s budget and
cash flow forecast for the year to 30 June 2024. On the
basis of this review, and in light of the current financial
position and available cash resources, the directors
have no reason to believe that Discovery will not be a
going concern for the foreseeable future. The going
concern basis has therefore been adopted in preparing
the Annual Financial Statements.
The directors are responsible for Discovery’s systems of
internal control, which include internal financial controls
in the various subsidiaries that are designed to provide
reasonable, but not absolute, assurance against material
misstatement and loss. Discovery maintains internal
financial controls to provide assurance regarding:
 Safeguarding of assets against unauthorised use
or disposition, and
 The maintenance of proper accounting records,
written or electronic and the reliability of financial
information used within the business, or for the
publication thereof, including submissions to the
Companies and Intellectual Property Commission
(CIPC).
The controls contain self-monitoring mechanisms, and
actions are taken to correct deficiencies as they are
identified. Even an effective system of internal control,
no matter how well designed, has inherent limitations,
including the possibility of circumvention and the
overriding of controls. An effective system of control
therefore aims to provide reasonable assurance with
respect to the reliability of financial information and,
in particular, the presentation of Annual Financial
Statements.
To the best of their knowledge and belief, based on
the above, the directors are satisfied that no material
breakdown in the operation of the systems of internal
control and procedures has occurred during the year
under review.
Discovery’s external auditors, PricewaterhouseCoopers
Inc. and KPMG Inc., have audited the Annual Financial
Statements and their unqualified report appears on
pages 10 to 14.
The Annual Financial Statements of Discovery for the
year ended 30 June 2023, which appear on pages 18 to
199 have been approved by the Board of Directors
on 20 September 2023 and are signed on its behalf by:
Mark Tucker
Chairperson
Adrian Gore
Group Chief Executive
DIRECTORS’ RESPONSIBILITY TO THE SHAREHOLDERS
OF DISCOVERY LIMITED AND ITS SUBSIDIARIES
(DISCOVERY OR THE GROUP)

-- 3 of 217 --

3	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Group Chief Executive and Group Chief Financial Officer’s
internal financial control responsibility statement
for the year ended 30 June 2023
Certificate by the Company Secretary
for the year ended 30 June 2023
After due, careful, and proper consideration, in accordance with the JSE Listings Requirements 3.84(k), each of the directors, whose names
are stated below, hereby confirm that:
 The Annual Financial Statements set out on pages 18 to 199 fairly present, in all material respects, the financial position, financial
performance and cashflows of the issuer in terms of IFRS;
 To best of our knowledge and belief, no facts have been omitted or untrue statements made that would make the Annual Financial
Statements false or misleading;
 Internal financial controls have been put in place to ensure that material information relating to the issuer and its consolidated
subsidiaries have been provided to effectively prepare the financial statements of the issuer;
 The internal financial controls are adequate and effective and can be relied upon in compiling the Annual Financial Statements, having
fulfilled our role and function as executive directors with primary responsibility for implementation and execution of controls;
 Where we are not satisfied, we have disclosed to the Discovery Limited Audit Committee and the auditors any deficiencies in design and
operational effectiveness of the internal financial controls, and have remediated or taken steps to remedy the deficiencies; and
 We are not aware of any fraud involving directors.
Adrian Gore 	Deon Viljoen
Group Chief Executive 	Group Chief Financial Officer
20 September 2023 	20 September 2023
It is hereby certified in terms of section 88(2)(e) of the Companies Act, that Discovery Limited has for the year ended 30 June 2023 lodged
with the Companies and Intellectual Property Commission (CIPC) all such returns as are required by a public company in terms of this Act
and that all such returns are true, correct and up to date.
Ayanda Ceba
Company Secretary
20 September 2023

-- 4 of 217 --

4	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Report of the Discovery Limited Audit Committee
for the year ended 30 June 2023
We are pleased to present the Discovery Limited Audit Committee’s (DLAC) report for the financial year ended 30 June 2023. Our report details
how we accomplished our various statutory obligations as well as our key focus areas and the significant audit matters we considered during
the period.
This report has been prepared based on the requirements of the Companies Act, the King Report on Corporate Governance™ for South Africa,
2016 (King IV™), the JSE Listings Requirements, the JSE Debt Listings Requirements and other applicable regulatory requirements.
TERMS OF REFERENCE, ROLES AND RESPONSIBILITIES
The DLAC is an independent statutory committee constituted under section 94 (7) of the Companies Act. The DLAC’s main objective, as set
out in its Terms of Reference, is to assist the Board in fulfilling its oversight responsibilities and evaluating the adequacy and efficiency of
accounting policies, internal financial controls (IFCs) and financial and corporate reporting processes.
In addition, the DLAC assesses the effectiveness of the internal auditors and the independence and effectiveness of the joint external
auditors, as well as considers and recommends to shareholders the appointment of the joint external auditors.
Structure of the audit committees in Discovery Group
The scope of the DLAC extends to all activities of the Discovery Limited Group and all its subsidiaries, both locally and internationally. Prior
to implementing the revised Subsidiary Governance Framework (SGF), the DLAC also acted as the statutory Audit Committee of Discovery
Life Limited and Discovery Insure Limited.
Composition and governance
The DLAC consists of a minimum of three independent non-executive directors of the Discovery Limited Board of Directors. During the
financial year ended 30 June 2023, the committee held six meetings per the standard meeting cycle, one ad hoc meeting and an annual
trilateral meeting with the Prudential Authority.
The DLAC has the appropriate balance, diversity of knowledge, financial skills, and experience to execute its duties effectively. The membership,
qualifications, and attendance of the members of the DLAC for the year ended 30 June 2023 are as follows:
Committee member1 	Qualifications
Number of meetings
eligible to attend
Number of meetings
attended
D Macready (Chairperson) 	BCom (Hons), CTA, CA (SA) 	6 	6
M Hlahla 	BA (Hons) (Economics), MA 	6 	5
M Schreuder 	BCom (Hons), FIA, FASSA 	6 	6
1 L Chiume and KC Ramon were both appointed as independent non-executive directors and as members of the Discovery Limited Audit Committee, with
effect from 18 September 2023.
In addition to their membership on the DLAC, the committee members also serve across all key Board committees so as to ensure a
collective and integrated oversight of key matters across the Discovery Group.
Committee member 	Actuarial committee
Risk and compliance
committee
Remuneration
committee
Social and Ethics
committee
D Macready 	x 	x
M Hlahla 	x 	x
M Schreuder 	x 	x
The Chairperson of Discovery’s Board and other non-executive directors are entitled to attend any meetings upon request. The Group Chief
Executive Officer, Group Chief Financial Officer, Chairperson of the Actuarial Committee, and executive directors attend meetings or parts
of meetings by invitation only. Other members of management are invited to attend meetings to provide the DLAC with greater insights into
specific issues or areas of the Group. The Chairperson has regular contact with the management team to discuss relevant matters directly.

-- 5 of 217 --

5	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Report of the Discovery Limited Audit Committee continued
for the year ended 30 June 2023
MEETINGS CYCLE FOR THE YEAR
For the financial year ended 30 June 2023, the DLAC held the following meetings and regulatory engagements:
Committee meetings: The DLAC convened six scheduled meetings. This included an ad hoc meeting to specifically consider the Annual
Financial Statements and results, which included the disclosures on the transition to IFRS 17 Insurance Contracts (IFRS 17).
Management engagement: The DLAC Chairperson meets regularly with the Group Chief Financial Officer, the Heads of Actuarial, Risk and
Compliance, and executive management where necessary.
Auditor engagements: The internal and external auditors have direct access to the Chairperson, including closed sessions without
management during the year, on any matter they consider relevant to fulfilling the DLAC’s responsibilities. In addition, the Chairperson
meets regularly with internal audit and the external auditors before each meeting and at other times as necessary by either party before
Committee meetings.
Regulatory engagements: The DLAC participated in the annual bilateral and trilateral meetings as set up with the respective regulatory
bodies.
Subsidiary Audit Committee Engagement: The DLAC Chairperson meets regularly with the individual Chairpersons of the subsidiary audit
committees and can attend their subsidiary meetings as an invitee. Subsidiary Chairpersons are invited formally to give feedback to the DLAC
during reporting periods.
Annual General Meeting: The DLAC Chairman attends Annual General Meetings and is available to answer any questions concerning
matters pertaining to the Committee’s responsibilities.
KEY FOCUS AREAS FOR THE FINANCIAL YEAR 2023
The section discusses how the DLAC delivered against its key focus areas for the financial year 2023 as set out in the DLAC’s last year’s report.
Subsidiary Governance Framework
During the financial year 2023, the DLAC was actively involved in the revision and implementation of Discovery’s revised SGF. Implementing the
new framework has significantly enhanced and strengthened the governance and oversight of subsidiaries within the broader Discovery multi-
national groupings whilst maintaining its common purpose, values and Shared-Value business model.
The implementation of the SGF has resulted in the formation of new independent statutory Audit Committees for Discovery Life and
Invest, Discovery Insure and Discovery Health. These new Subsidiary Audit Committees supplement the existing independent Audit
Committees of the Discovery Group Europe Limited grouping which incorporates both VitalityLife and VitalityHealth, the Discovery Bank
Holdings Limited grouping, as well as the Vitality Group International Audit and Finance Committee.
IFRS 17 Insurance Contracts
The successful transition and implementation of IFRS 17 was a key focus of the DLAC. The Chairperson of DLAC is also the Chairperson of
the IFRS 17 Governance Committee, a subset of the various Discovery and UK Vitality Audit and Actuarial committees. The DLAC and the IFRS
17 Governance Committee receive detailed feedback from the respective IFRS 17 project groups which allows for appropriate debates on
key policy and modelling elections. Note 30 of Annexure B sets out in more detail the governance structures of the IFRS 17 project.
The DLAC has played an integral role in the overall governance oversight of the IFRS 17 project which included the appropriateness, integrity
and veracity of key policy elections and interpretations as well as consideration of the disclosures, communication and overall assurance
obtained of the impact on transition from IFRS 4 Insurance Contracts (IFRS 4) to IFRS 17.
The past year has seen the final quantification of the transition position to IFRS 17 as at 1 July 2022, the summary of which is set out in note
30 of Annexure B. The following key activities were concluded under the IFRS 17 project:
 Discovery has modelled full retrospective application of IFRS 17 up to 30 June 2022 for all material insurance portfolios. The benefit of
such a significant exercise has enabled a rigorous and informed debate on accounting policy elections and modelling. The fully
retrospective approach has allowed Discovery to evaluate how its products behave during various scenarios, such as the financial crises
of 2008, volatile periods of market movements in foreign exchange and interest rates, and the COVID-19 pandemic.
 Discovery subject matter experts on IFRS Accounting Standards, Tax and Actuarial actively partake in various insurance industry forums
to keep close to recent market practices and developments. This ensures that debates on the various accounting policy elections and
modelling are well thought through and benchmarked to best industry practices. In particular, Discovery has remained closely attuned
to the developments in tax legislation in both South Africa and the United Kingdom to clearly understand any impacts the legislation
could have on Discovery’s recognised assets and liabilities.
 The members of the Discovery Board, the DLAC and various other Board sub-committees, and executives of the various insurance
business lines have had extensive training sessions on IFRS 17, including the practical interpretation and application within the context
of the Discovery Group businesses.
 The DLAC was consulted and provided input into the IFRS 17 Investor communications to the market.
 KPMG Inc., as the current joint auditor, and Deloitte & Touche, as the proposed joint auditor following the mandatory audit firm rotation
of PricewaterhouseCoopers Inc., have been engaged to provide the external audit assurance for IFRS 17 in their capacity as the external
auditors for the financial year ending 30 June 2024, the first financial year that Discovery will apply IFRS 17. A combined assurance
approach is being followed whereby group internal and external audits incrementally test the new IFRS 17 landscape.
 The focus in the next six months is finalising and producing IFRS 17 compliant financial statements for the first interim reporting period
for the six months ending 31 December 2023, including restated information for the financial year ended 30 June 2023 and the interim
reporting period for the six months ended 31 December 2022. A key consideration for DLAC going forward is to obtain assurance as to
the ‘business-as-usual’ IFRS 17 financial, data, processes and financial reporting controls.

-- 6 of 217 --

6	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Report of the Discovery Limited Audit Committee continued
for the year ended 30 June 2023
Implementation of the second phase of the audit firm rotation plan
Discovery continued implementing the second phase of the audit firm rotation plan, which sees PricewaterhouseCoopers Inc. finalise its
tenure as joint external auditor for the financial year ended 30 June 2023.
As noted at the time, Discovery had early commenced its process for both the anticipated regulations by the Prudential Authority of the
South African Reserve Bank for insurance groups that have joint external auditors and the required auditor rotation rules issued by the
Independent Regulatory Board of Auditors (IRBA) in South Africa. Under its rotation plan, the shareholders approved KPMG Inc. as joint
external auditor from the financial year ended 30 June 2022. As a result, KPMG Inc. will have had two years of continuity alongside the
outgoing joint auditor PricewaterhouseCoopers Inc. At the Annual General Meeting of November 2022, the shareholders also approved the
appointment of Deloitte & Touche as joint external auditors from 1 July 2023.
The DLAC noted the Supreme Court of Appeal ruling in May 2023, which set aside the Mandatory Audit Firm Rotation (MAFR) rule issued by
the IRBA. Despite this ruling, the DLAC considers it appropriate to continue with the rotation in auditors, supported by the following
considerations:
 It is consistent with the vote at the Annual General Meeting, where shareholders overwhelmingly supported the appointment of
Deloitte & Touche with effect from 1 July 2023 as joint auditors.
 Deloitte & Touche, having regard for the timing of audit firm rotation, were appointed with KPMG Inc. as the external audit assurance
providers on IFRS 17. Therefore, Deloitte & Touche, with KPMG Inc., are best placed to continue as external auditors, with IFRS 17 being
effective from 1 July 2023 for Discovery.
 Within Discovery Group, a conglomerate encompassing a diverse range of businesses, the significance of maintaining a strong
independent oversight as well as business insight cannot be overstated. This insight is underpinned by the rigorous, disciplined, and
fresh perspectives offered through rotational roles, ensuring a seamless transition whilst preserving the invaluable continuity offered
by the incumbent team members.
Effective functioning of the Group’s financial systems and control environment
Discovery continues to maintain a strong risk culture and has implemented appropriate and effective IFCs to enable the integrity and
reliability of the financial statements. These IFCs safeguard, verify, and maintain accountability of Discovery’s financial position and
performance.
The DLAC is responsible for assessing Discovery’s system of internal financial and accounting controls. In this regard, the DLAC has evaluated
the adequacy and effectiveness of Discovery’s system of internal controls and made appropriate recommendations to the Board. This has
included a formal documented review by the internal audit function of Discovery’s internal financial controls system’s design, implementation,
and effectiveness.
Discovery has successfully completed the third year of the internal financial control attestation process in terms of paragraph 3.84(k) of the
JSE Limited Listings Requirements. Any deficiencies in design and operating effectiveness of IFCs identified via the Group’s three lines of
defence are reported to the DLAC. The DLAC considered the identified deficiencies together with the appropriateness of management’s
response, including remediation, reliance on compensatory controls, and additional review procedures. The DLAC noted and supports the
Group Chief Executive Officer and Group Chief Financial Officer positive attestations under their names and signature.
The DLAC believes that, based on the results of these reviews, Discovery’s IFCs effectively produce accurate financial information and a fair
presentation of the financial performance of Discovery in the Annual Financial Statements.
KEY ACTIVITIES OF THE DLAC FOR THE FINANCIAL YEAR 2023
Key audit matters
The DLAC annually assesses the Key Audit Matters (KAMs) reported by the external auditors and considers the key judgements and
estimates pertaining to the Annual Financial Statements. Accordingly, the KAMs of the joint auditors for the current period were addressed
as follows.
Key Audit Matter 	How the DLAC addressed the matter
Valuation of assets and liabilities
arising from insurance contracts
The DLAC reviewed reports from the Group Chief Actuary and the external auditors on
actuarial assumptions and basis changes. The DLAC evaluated the appropriateness of actuarial
assumptions used in the setting of reserves, including negative Rand reserves, taking into
account recommendations made by the Actuarial Committee.
The annual assessment for
impairment of goodwill and
intangible assets
The DLAC reviewed the impairment assessments based on the latest business planning inputs.
It considered the sensitivity of these estimates to various scenarios. The most material of these is
the valuation of Discovery Bank, which is sensitive to the discount rate, business plan performance
and, most notably, the terminal growth rate. Management re-engaged an external valuator to
perform an independent valuation. This valuation and the work performed by the auditors
provided acceptable headroom at a Discovery Bank and Group levels against its respective
carrying values
Note 4 Significant accounting estimates and judgement in applying accounting policies of the
financial statements sets out the respective significant accounting estimates and judgements.
Further information is also included in note 10, Goodwill.

-- 7 of 217 --

7	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Report of the Discovery Limited Audit Committee continued
for the year ended 30 June 2023
KEY ACTIVITIES OF THE DLAC FOR THE FINANCIAL YEAR 2023 continued
Key audit matters continued
Other significant matters considered
Significant matters are those that the DLAC views as significant or material in nature, requiring either the exercise of judgement or
matters otherwise considered subjective from an accounting or auditing perspective. The following areas received a key focus from the DLAC
during the year:
 Evaluation of management’s assessment of impairment of specified assets under IAS 36 Impairment of Assets. In addition to focusing on
the goodwill of Discovery Bank, as noted in the KAMs above, the DLAC also considered the goodwill of VitalityHealth and VitalityLife and
the carrying value of material associates. The DLAC is satisfied that there was no risk of impairment of any material assets.
 Review of the supportability of deferred tax assets raised on assessed losses.
Financial statement and accounting practices
The DLAC has reviewed the accounting policies of all entities included in the consolidated Annual Financial Statements and is satisfied that
they are appropriate, consistently applied and comply with IFRS Accounting Standards. The DLAC is satisfied that Discovery has established
financial reporting procedures so as to ensure access to all financial information required by the issuer to prepare and report on the financial
statements of Discovery effectively. The DLAC confirmed the going concern basis for the preparation of both Interim and Annual Financial
Statements
During the year, the DLAC reviewed the following financial reporting matters to ensure the integrity and fairness of financial information:
 Reviewed and debated the key accounting, actuarial and tax judgements and assumptions, including external audit’s KAMs and were
satisfied with how these were addressed.
 Reviewed financial information included in the Group’s interim and year-end results announcements to ensure the accuracy and
integrity of financial data disclosed externally.
 As part of its annual work plan, the DLAC evaluates management’s assessment of the findings in the most recent JSE’s Proactive
Monitoring Report. Management performs a detailed assessment of the JSE’s findings against Discovery’s Annual Financial Statements
to identify any potential areas of non-compliance or potential improvements or enhancements in disclosures. The review was completed
in November 2022 with the release of the JSE’s Proactive Monitoring Report 2022. No significant deficiencies were identified, but smaller
changes were incorporated into the interim results and Annual Financial Statements in light of recommendations from the report.
 Evaluated the consistent application of accounting policies for insurance reserves.
 An established DLAC process receives and appropriately considers any concerns or complaints relating to Discovery’s accounting
and reporting practices. The DLAC immediately deals with any such issues raised. No issues have been raised during the course of
the financial year.
Finally, the DLAC has considered accounting treatments of significant or unusual transactions and accounting judgements. The DLAC has
evaluated management’s judgements and reporting decisions in relation to the Integrated annual report and ensured all material
disclosures have been included. In addition, it has reviewed both financial and non-financial information, forward-looking statements,
and sustainability information.
RESTATEMENT AS A RESULT OF PRIOR PERIOD ERROR – RECLASSIFICATION OF UNIT-LINKED INSURANCE CONTRACTS TO
UNIT-LINKED INVESTMENT CONTRACTS
As noted in note 45 of the Discovery consolidated results, Discovery has restated its previously published results for an error in the
classification of certain unit-linked policies.
As part of the IFRS 17 project, Discovery performed a full reassessment of all insurance contracts to ensure the products were correctly
included in the scope of IFRS 17. Discovery identified that certain offshore unit-linked policies do not transfer significant insurance risk as
required under IFRS 17. Instead of being classified as unit-linked insurance contracts, these policies should have been accounted for as unit-
linked investment contracts under IFRS 9 Financial Instruments. As the definition of identification of significant insurance risk under IFRS 17
and IFRS 4 is the same; the change in treatment and restatement of previously published information is required under IFRS 4 in the current
period.
The DLAC has reviewed the proposed correction by management, the control environment to process the correction, and the external
audit work to ensure the changes were made correctly. In addition, the DLAC considered the disclosures in the financial statements,
required communication with the relevant regulatory bodies and confirmed it had discharged all its obligations as required.
CLIMATE, NATURE AND BIODIVERSITY AND ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)
The DLAC also:
 Performed review of the Sustainability Report, including understanding sources of data, metrics, methodologies and narrative.
 Considered the level of both internal and external assurance obtained on ESG reporting and disclosures, including reviews of the
workplans and procedures.
 Performed review of the Task Force for Climate-Related Disclosures (TFCD) Report, focusing on the disclosure of climate-related risks,
opportunities, and financial implications.

-- 8 of 217 --

8	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Report of the Discovery Limited Audit Committee continued
for the year ended 30 June 2023
KEY ACTIVITIES OF THE DLAC FOR THE FINANCIAL YEAR 2023 continued
External audit
The DLAC is responsible for the appointment, compensation and oversight of the independent joint external auditors, namely KPMG Inc.
and PricewaterhouseCoopers Inc, who were appointed as joint auditors effective 1 July 2022.
 The DLAC has assessed the independence and objectivity of the external auditors and is satisfied that the external auditors are
independent of Discovery. The requisite assurance was sought and provided by the auditors that internal governance processes within
each audit firm support and demonstrate its claim to independence.
 The DLAC has also reviewed the appropriate JSE accreditation of the individual audit partners responsible for the audit sign-off and the
respective auditors’ most recent IRBA inspection reports.
 A formal policy exists in respect of the provision of non-audit services by the external auditors of Discovery and its subsidiaries, and a
formal procedure governs the process whereby the auditors are appointed to provide any non-audit services, including a limitation on
fees for non-audit services which shall not exceed 25% of each joint auditor audit fee. Non-audit services rendered by
PricewaterhouseCoopers Inc. were less than 1% of the total audit fees. KPMG Inc. did not provide any non-audit services. In addition, as
part of ensuring the independence of Deloitte & Touche as the proposed incoming auditor, the DLAC also considered any non-audit
services rendered by Deloitte to the same standard as the existing auditors. During the period, Deloitte & Touche did not render any
non-audit services.
 The Chairperson of the DLAC pre-approves the nature and extent of any non-audit services that the external auditors provide in terms
of the agreed pre-approval policy, and the schedule of approved non-audit services is reviewed annually by the DLAC.
 The DLAC, following consultation with executive management, approved the engagement letter, terms, audit plan, main areas of focus,
and budgeted audit fees for the year ended 30 June 2023. This approval of the audit plan included specific consideration as to the
allocation of work between the joint auditors.
 The DLAC Chairperson met with both KPMG Inc. and PricewaterhouseCoopers Inc. lead partners prior to every DLAC meeting to
discuss the 2022/23 audit plan, key areas of focus, scope and findings, including suitability of any reliance on Group Internal Audit.
The DLAC met with the external auditors independently twice for the year under review.
 In terms of the conditions laid out in section 94(8) of the Companies Act and based on its assessment, taking consideration of the criteria
of King IV™, the JSE and general guidance to Audit Committees, the DLAC is satisfied with the performance and quality of the external
audit, the external auditor firms and lead partners for the year ended 30 June 2023.
 The DLAC received feedback from the external auditors on the audit of the Annual Financial Statements of the Group, the critical
accounting estimates and judgements, and cross reviews, including the Summary of Audit Differences for the year ended 30 June 2023.
The DLAC notes the unqualified independent auditors’ report in relation to Discovery Limited and the Group.
Group Internal Audit (GIA)
GIA provides independent objective assurance that the governance processes, including professional ethics, the management of risk and
systems of internal controls, are both adequate and effective. The Chief Audit Executive (CAE) has a functional reporting line to the DLAC
Chairperson and an administrative reporting line to the Group Chief Financial Officer.
The DLAC is satisfied that the GIA displays high professional objectivity and professional ethics in performing its work.
In assessing the quality, performance, and delivery of the internal audit plan, including the scope of the work performed, the level of
resources and coverage of the audit plan, the DLAC took cognisance of the following:
 Reviewed and approved the internal audit charter and audit plan and evaluated the independence, effectiveness, and performance in
line with its charter.
 Challenged the audit plan’s focus, relevance, and risk-based emphasis.
 Considered reports on the Group’s internal control systems, specifically focusing on the effectiveness of IFCs, including financial
reporting controls.
 Reviewed significant issues raised by the internal audit processes and the adequacy of corrective action and accountability taken in
response to such findings.
 Assessed the independence and effectiveness of the Chief Audit Executive, the internal audit function and the quality and extent of audit
resources and found them satisfactory.
 Received the annual assessment provided by internal audit confirming the effectiveness of Discovery’s governance, risk management
and control processes.
 Reviewed the external auditors’ annual assessment of the internal audit in terms of the requirements of ISA 610 Using the Work of Internal
Auditors, reaffirming the extent of reliance that could be placed on the internal audit work.

-- 9 of 217 --

9	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Report of the Discovery Limited Audit Committee continued
for the year ended 30 June 2023
OTHER MATTERS CONSIDERED BY THE DLAC
In further fulfilling its duties and discharging its obligations for the year ended 30 June 2023, the DLAC also considered:
Matter considered 	Outcome
Evaluation of the expertise and
experience of the finance function
and financial director
The DLAC reviewed and satisfied itself with the appropriateness of Discovery’s finance function’s
expertise, resources, and experience, including the Group Chief Financial Officer, Mr Deon Viljoen.
Combined assurance 	The combined assurance model provides an integrated plan of the various activities and sources
of assurance, including risk and compliance, external and internal audit, corporate finance
functions and the Actuarial Committees. The DLAC has reviewed and noted the combined
assurance model, which has been implemented throughout the Group and considers that the
model is appropriate in addressing Discovery’s risks.
Whistleblowing 	The DLAC receives and deals with any complaints or whistleblowing, whether from within or
outside Discovery, relating to Discovery’s accounting practices and internal audit, the content or
auditing of Discovery’s financial statements, the internal financial controls of Discovery and related
matters. No such whistleblowing was received during the financial year.
Ethics and compliance 	The DLAC is responsible for reviewing any major breach of Discovery’s code of conduct and ethics
and relevant legal, regulatory, and other obligations reported to the DLAC by the Social and Ethics
Committee. The DLAC is satisfied that there has been no material breach of these standards or
material non-compliance with laws and regulations. The DLAC is satisfied that it has complied with
all its legal, regulatory, and other obligations during the period under review.
KEY FOCUS AREAS FOR THE FINANCIAL YEAR 2024
The DLAC will remain focused on:
 Evaluating the effectiveness of the DLAC and its subsidiary Audit Committees relative to the SGF objectives, with particular
emphasis on, skills, capacity, and workplans to ensure the members are enabled to fulfil their roles effectively.
 Enhance the capabilities, skills and oversight and effectiveness of the DLAC by expanding the audit committee with additional members.
This expansion is intended to bring in diverse expertise and perspectives that can contribute to more robust decision-making, improved
risk management, and a higher level of assurance in financial matters.
 A comprehensive analysis of Discovery’s ESG financial reporting practices in comparison to industry-leading standards and emerging
trends. It aims to identify areas where Discovery can improve its ESG reporting, aligning it with best practices, the newly published IFRS
Sustainability Disclosure Standards’ and staying ahead of evolving global expectations in ESG disclosure. The findings from this project
will guide future reporting strategies and sustainability initiatives.
 Implement a specific project to ensure ongoing assurance for IFRS 17 systems, data, models, and reporting, as part of ‘business as usual’
processes. This includes the IFRS 17 restatement of comparative information, and investor presentations.
 Review the effectiveness of GIA and the appropriateness of the insourcing model. The review will assess whether the current insourcing
model is suitable, especially in areas where risks are evolving rapidly, such as cybersecurity, IT General Controls (ITGCs), and core
actuarial modeling within IFRS 17. The goal is to ensure that the GIA function is optimally structured to provide timely and comprehensive
assessments of risk and compliance across these critical domains.
 Facilitate the audit firm rotation from PricewaterhouseCoopers Inc. to Deloitte & Touche.
CONCLUSION
The DLAC is satisfied that it has complied with all statutory duties and duties given to it by the Board under its Terms of Reference.
The DLAC has reviewed the consolidated and separate financial statements of Discovery Limited for the year ended 30 June 2023 and, based
on the information provided to the DLAC, considers that Discovery complies, in all material respects, with the requirements of the Companies
Act and IFRS Accounting Standards.
The DLAC has recommended the Annual Financial Statements to the Board for approval. The Board has subsequently approved the Annual
Financial Statements, which will be open for discussion at the forthcoming Annual General Meeting.
D Macready
Chairperson: Discovery Limited Audit Committee
20 September 2023

-- 10 of 217 --

10	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Independent Auditors’ report
for the year ended 30 June 2023
To the shareholders of Discovery Limited
REPORT ON THE AUDIT OF THE CONSOLIDATED AND SEPARATE FINANCIAL
STATEMENTS
Our opinion
We have audited the consolidated and separate financial statements of Discovery Limited (the Group and Company), set out on
pages 18 to 199 which comprise:
 the Group and Company statements of financial position at 30 June 2023;
 the Group and Company income statements for the year then ended;
 the Group and Company statements of other comprehensive income for the year then ended;
 the Group and Company statements of changes in equity for the year then ended;
 the Group and Company statements of cash flows for the year then ended; and
 the notes to the Group and Company annual financial statements (including Annexures A, B and C), including a summary of significant
accounting policies.
In our opinion, the consolidated and separate financial statements present fairly, in all material respects, the consolidated and separate
financial position of Discovery Limited at 30 June 2023, and its consolidated and separate financial performance and consolidated and
separate cash flows for the year then ended in accordance with IFRS Accounting Standards and the requirements of the Companies Act of
South Africa.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are
further described in the Auditors’ responsibilities for the audit of the consolidated and separate financial statements section of our report.
We are independent of the Group and Company in accordance with the Independent Regulatory Board for Auditors’ Code of Professional
Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of financial statements in
South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical
requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the corresponding sections of the International
Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (including International Independence Standards).
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

-- 11 of 217 --

11	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Independent Auditors’ report continued
for the year ended 30 June 2023
Key audit matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated and separate
financial statements of the current period. These matters were addressed in the context of our audit of the consolidated and separate financial
statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.
We have determined that there are no key audit matters to communicate in respect of the separate financial statements of the Company.
Valuation of assets and liabilities arising from individual life insurance contracts
Refer to Section 13 of Annexure B – Group accounting policies, and notes 2, 4.1, 5 and 18 to the consolidated financial statements.
Key audit matter 	How our audit addressed the key audit matter
At 30 June 2023, the Group held assets arising from insurance
contracts to the value of R63 865 million and liabilities arising
from insurance contracts of R114 807 million.
The assets and liabilities arising from insurance contracts
related to both individual life and group life policies, with the
key audit matter focusing on individual life policies (insurance
contracts) underwritten by Discovery Life and Vitality Life.
The actuarial value of those individual life assets and liabilities
arising from insurance contracts that are long-term in nature is
determined based on a prospective discounted cash flow
valuation basis, calculated as the difference between the
present value of future benefit payments plus expenses and the
present value of future premiums.
In valuing these assets and liabilities arising from insurance
contracts, management applies significant judgement and
various assumptions are made, including best estimate
assumptions regarding the future expected claims experience,
premium income, expenses and commission. Changes to these
assumptions may result in a material change to the valuation.
The most significant assumptions made in determining the
value of these assets and liabilities arising from insurance
contracts relate to:
 Impact of the Vitality status distribution on mortality,
morbidity and the level of surrender and lapses. The Group
is unique due to its Vitality programme as policyholders are
provided access to several services and benefits that
encourage healthy lifestyle choices and are awarded Vitality
points, which ultimately determine their Vitality status. The
mortality, morbidity and lapse assumptions within the
valuation are specifically impacted by the Vitality status of
the policyholder. Furthermore, the Vitality status informs
future expected policyholder behaviour and adjustments
are therefore made to the mortality, morbidity, and lapse
assumptions to reflect the expected impact of the Vitality
programme.
 Use of discretionary margins with respect to profit
recognition. Discovery Life Limited writes profitable
insurance products and applying the reserving basis using
only compulsory margins as prescribed by regulations
would result in a premature recognition of future profits at
the inception of new business contracts; and therefore,
certain discretionary margins are added to the best estimate
assumptions. This is however limited to the extent of actual
acquisition costs incurred and these discretionary margins
are reset at each valuation date to reflect the underlying
profitability of the portfolio. Changes to the discretionary
margins have a direct impact on the profit recognition in a
period and the Group has therefore established a
framework as disclosed in Section 13 of Annexure B – Group
accounting policies, to utilise the available discretionary
margin in a specified order.
We considered the valuation of assets and liabilities arising from
insurance contracts to be a key audit matter in our audit of the
consolidated financial statements, as it involves complex and
subjective judgements about future events, including policyholder
behaviour and economic conditions.
The primary procedures we performed to address this key audit
matter included the following:
We involved our actuarial specialist to assist in:
 Gaining an understanding of the Group’s actuarial internal
control environment and governance, including the
functioning of the Group’s Actuarial Committee (and where
applicable, the subsidiaries’ Actuarial Committees) and
testing the design and implementation of key controls.
 Testing the design and implementation of the liability
build-up control to support the sources of profit and
corroborate the movements in the liability to relevant
underlying information, from both internal and external
sources.
 Evaluating the appropriateness of the valuation methodology
applied by the Group to determine the value of assets and
liabilities arising from insurance contracts. In doing so, we
considered the principles and integrity of the Group’s models
against acceptable industry standards.
 Challenging management with respect to the appropriateness
of all significant assumptions adopted in the determination of
the valuation of assets and liabilities arising from insurance
contracts by comparing these assumptions to the results of
historical actuarial experience investigations conducted by
management, including benchmarking these assumptions
against life insurance industry trends to determine whether
they are reasonable and supportable.
 Evaluating the compliance of the valuation of the assets and
liabilities arising from insurance contracts against the
requirements of the Financial Soundness Valuation (FSV)
basis as described in the Standard of Actuarial Practice (SAP)
104 and the Group’s accounting policies as set out in Section
13 of Annexure B – Group Accounting policies.
In respect of the impact of the Vitality programme on the
valuation of assets and liabilities arising from insurance contracts
relating to individual life policies underwritten by the Group:
 Evaluating, on a sample basis, the reasonability of the
Group’s assumptions in setting the Discovery Vitality status
distribution, and the progression between statuses, by
comparing these against historical trends; and
 Evaluating, on a sample basis, the integrity of the data inputs
captured in the models by assessing whether the inputs used
are consistent with historical actual experience.
Use of discretionary margins with respect to profit recognition:
 Assessing whether all acquisition costs were appropriately
captured in the determination of the discretionary margins
at 30 June 2023 by comparing these input amounts to the
audited acquisition cost amounts included in the Group’s
income statement; and
 Evaluating the appropriateness of the calculation of the
discretionary margin transfer against the requirements of
the methodology set out in the Group’s accounting policies in
Section 13 of Annexure B – Group Accounting policies.

-- 12 of 217 --

12	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Independent Auditors’ report continued
for the year ended 30 June 2023
Impairment assessment of goodwill for the Discovery Bank cash-generating unit (CGU)
Refer to Section 7 and 8 of Annexure B – Group accounting policies, and notes 4.2 and 10 to the consolidated financial statements.
Key audit matter 	How our audit addressed the key audit matter
At 30 June 2023, the Group held goodwill in relation to the
Discovery Bank cash-generating unit (CGU) at a carrying value of
R2 417 million. This goodwill arose from the acquisition of the
DiscoveryCard business.
In accordance with the requirements of IAS 36 Impairment of
Assets (IAS 36), the Group annually assesses goodwill allocated to
the Discovery Bank CGU for impairment. The recoverable
amount of the Discovery Bank CGU is estimated on a fair value
less costs to sell basis, using the income approach. Estimation
uncertainty is inherent in the determination of fair value less
costs to sell given the significant unobservable inputs into the
calculation, which results in the fair value estimate being
categorised as level 3 in terms of the fair value hierarchy in IFRS
13 Fair Value Measurement.
Management has applied judgement in determining the inputs
used in deriving their fair value estimate for the Discovery Bank
CGU. These inputs include customer growth rates, customer
behaviour assumptions and the expensing of system-build costs,
which drive forecasts of future cashflows. In addition,
management has applied judgement in the determination of
their estimated discount rate, notably the beta factor used in
deriving a cost of equity, and the terminal growth rate.
We considered the impairment assessment of goodwill for the
Discovery Bank CGU to be a key audit matter in our audit of the
consolidated financial statements, as it involves complex and
subjective judgements and is subject to estimation uncertainty.
The primary procedures we performed to address this key
audit matter included the following:
 Gaining an understanding of the process followed by
management to assess goodwill for the Discovery Bank CGU
for impairment, including the derivation of management’s
key assumptions and testing the design and implementation
of certain key controls related to this assessment.
 Assessing management’s attribution of assets and liabilities to
the Discovery Bank CGU against the requirements of IAS 36.
 Assessing the appropriateness of disclosures included in the
consolidated financial statements in accordance with the
group accounting policies and the requirements of IAS 36.
We involved our valuation and economic specialists to assist in:
 Evaluating the appropriateness of the valuation methodology
applied by management to calculate the recoverable amount
of the Discovery Bank CGU. In doing so, we considered the
principles and integrity of the discounted cash flow model
against the requirements of IAS 36 and acceptable industry
standards.
 Evaluating the appropriateness of management’s
assumptions against external market data or industry
benchmarks, including the discount rate applied, customer
growth rates and customer behavioural assumptions that
drive forecasted cashflows. This includes an assessment of
the reasonableness of the capital requirements and credit
loss ratios applied in the future cashflows. We also assess
the expensing of system build costs.
 Performing various sensitivity analyses over management’s
forecast cash flows, customer growth rates, the terminal
growth rate and discount rate applied to assess the impact
of changes in these key assumptions on the recoverable
amount of the Discovery Bank CGU.

-- 13 of 217 --

13	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Other information
The directors are responsible for the other information. The other information comprises the information included in the document titled
“Discovery Annual Financial Statements for the year ended 30 June 2023”, which includes the Directors’ report, the Report of the Discovery
Limited Audit Committee and the Certificate by the Company Secretary as required by the Companies Act of South Africa, which we obtained
prior to the date of this auditors’ report, and the document titled “Discovery Integrated Annual Report for the year ended 30 June 2023”, which
is expected to be made available to us after that date. The other information does not include the consolidated and the separate financial
statements and our auditors’ report thereon.
Our opinion on the consolidated and separate financial statements does not cover the other information and we do not and will not express
an audit opinion or any form of assurance conclusion thereon.
In connection with our audit of the consolidated and separate financial statements, our responsibility is to read the other information and,
in doing so, consider whether the other information is materially inconsistent with the consolidated and separate financial statements, or
our knowledge obtained in the audit, or otherwise appears to be materially misstated.
If, based on the work we have performed on the other information obtained prior to the date of this auditors’ report, we conclude that there
is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.
Responsibilities of the directors for the consolidated and separate financial statements
The directors are responsible for the preparation and fair presentation of the consolidated and separate financial statements in accordance
with IFRS Accounting Standards and the requirements of the Companies Act of South Africa, and for such internal control as the directors
determine is necessary to enable the preparation of consolidated and separate financial statements that are free from material
misstatement, whether due to fraud or error.
In preparing the consolidated and separate financial statements, the directors are responsible for assessing the Group and Company’s ability to
continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless
the directors either intend to liquidate the Group and/or Company or to cease operations, or have no realistic alternative but to do so.
Auditors’ responsibilities for the audit of the consolidated and separate financial statements
Our objectives are to obtain reasonable assurance about whether the consolidated and separate financial statements as a whole are free from
material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a
high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when
it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be
expected to influence the economic decisions of users taken on the basis of these consolidated and separate financial statements.
As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit.
We also:
 Identify and assess the risks of material misstatement of the consolidated and separate financial statements, whether due to fraud or
error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to
provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting
from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
 Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group’s and the Company’s internal control.
 Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made
by the directors.
 Conclude on the appropriateness of the directors’ use of the going concern basis of accounting and, based on the audit evidence
obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group’s and the
Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention
in our auditors’ report to the related disclosures in the consolidated and separate financial statements or, if such disclosures are
inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors’ report.
However, future events or conditions may cause the Group and/or the Company to cease to continue as a going concern.
 Evaluate the overall presentation, structure and content of the consolidated and separate financial statements, including the disclosures,
and whether the consolidated and separate financial statements represent the underlying transactions and events in a manner that
achieves fair presentation.
 Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to
express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the
Group audit. We remain solely responsible for our audit opinion.
Independent Auditors’ report continued
for the year ended 30 June 2023

-- 14 of 217 --

14	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Auditors’ responsibilities for the audit of the consolidated and separate financial statements
continued
We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit
findings, including any significant deficiencies in internal control that we identify during our audit.
We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to
communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where
applicable, actions taken to eliminate threats or safeguards applied.
From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the
consolidated and separate financial statements of the current period and are therefore the key audit matters. We describe these matters in
our auditors’ report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we
determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be
expected to outweigh the public interest benefits of such communication.
Report on other legal and regulatory requirements
In terms of the IRBA Rule published in Government Gazette Number 39475 dated 4 December 2015, we report that KPMG Inc. and
PricewaterhouseCoopers Inc. have been the joint auditors of Discovery Limited for two years.
Prior to the commencement of the joint audit relationship, PricewaterhouseCoopers Inc. was the sole auditor of Discovery Limited for
twenty-one years.
PricewaterhouseCoopers Inc. 	KPMG Inc.
Director: Andrew Taylor 	Director: Mark Danckwerts
Registered Auditor 	Registered Auditor
Jukskei View 	KPMG Crescent
4 Lisbon Lane 	85 Empire Road
Waterfall City 	Parktown
2090 	2193
South Africa 	South Africa
21 September 2023 	21 September 2023
Independent Auditors’ report continued
for the year ended 30 June 2023

-- 15 of 217 --

15	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
NATURE OF BUSINESS
Discovery Limited (the Company) is listed on the JSE Limited and is an integrated financial services organisation specialising in health
insurance, life assurance, wellness, investments and savings, short-term insurance and banking.
Discovery is a shared value insurance and banking company whose purpose and ambition are achieved through a pioneering business
model that incentivises people to be healthier and enhances and protects their lives.
Our unique and sophisticated Shared-value insurance model delivers better health and value for clients, superior actuarial dynamics for
the insurer and a healthier society. It is a powerful platform of integrated assets and capabilities, which has positioned us well to respond
to the following key trends that were accelerated by COVID-19 and remain relevant:
 a focus on health, wellness and resilience (nature of risk)
 accelerated use of technology and increased digitisation
 increased importance of purpose and trust
YEAR UNDER REVIEW
The year under review was characterised by significant macroeconomic uncertainty, with several issues coalescing. The period saw sustained
inflationary pressures, rising interest rates, a particularly strong US dollar, increasing consumer pressure and a cost-of-living crisis in many
regions. These pressures have constrained economic growth, following short-lived rebounds experienced by many countries post-COVID,
with severe energy shortages in South Africa proving to be a further constraint.
For the year ended 30 June 2023, normalised operating profit for the Group increased by 24% to R11 661 million (2022: R9 384 million)
following a robust performance across each composite. Core new business annualised premium income (API) was up 6% to R23 025 million
(up 12% to R22 788 million excluding products of VitalityInvest and Ping An Health Insurance Company of China Limited (PAHI) reinsurance
business in rundown), with particularly strong growth from the South African (SA) and United Kingdom (UK) composites. Persistency
continued to exceed expectations in all businesses. The Group continued to streamline some new initiatives with a focus on those
businesses expected to generate significant value. In the previous financial year, the Group announced its decision to exit the UK investment
market (VitalityInvest) and more recently has decided to terminate VitalityCar, extracting from the challenging UK motor insurance market.
The following table demonstrates the contribution of key businesses to the growth in normalised profit from operations of 24% compared
to the prior year. The weakening of the rand over the year contributed to the translated growth rate for the UK and Vitality Global (VG)
composites with the latter also benefiting from a strong dollar over the year under review.
Business
Normalised	Normalised
profit from	profit from
operations	operations
(Current	(Current
period, in	period, in
R million)	R million)
% change	% change
(Current	(Current
period vs	period vs
prior period)	prior period)
Core new	Core new
business	business
API	API22
(Current	(Current
period, in	period, in
R million)	R million)
% change	% change
(Current	(Current
period vs	period vs
prior period)	prior period)
Discovery Health 	3 854 	7% 	8 678 	19%
Discovery Life 	4 807 	19% 	2 838 	12%
Discovery Invest 	1 560 	30% 	3 050 	4%
Discovery Insure – Personal 1 	62 	(138%) 	1 249 	0%
Discovery Vitality 	16 	78% 	372 	45%
Discovery Bank 	(767) 	23%
Other initiatives and central costs 	(436) 	88% 	631 	(25%)
– SA new initiatives 	(312) 	28% 	631 	(25%)
– Central costs 	(124)
SA Composite 	9 096 	22% 	16 818 	11%
VitalityHealth3 	1 283 	(3%) 	2 064 	19%
VitalityLife 	1 039 	55% 	1 721 	37%
Closure costs of VitalityInvest and VitalityCar in run down 	(455) 	(1%)
Other initiatives and central costs 	(79) 	32%
UK Composite 	1 788 	21% 	3 785 2 	26%
Vitality Health International – PAHI 	596 	76% 	2 1852 	(1%)
Vitality Health International – Other 	(195) 	1%
Vitality Network 	411 	26%
Other initiatives and central costs 	(35) 	46%
VG Composite 	777 	74% 	2 185 	(1%)
11 661 	24% 	22 788
1 Includes Discovery Insure’s share of equity accounted losses of R19 million (2022: R13 million).
2 Core new business API excludes products in rundown of VitalityInvest and PAHI reinsurance business.
Core new business API for the UK composite increased 3% including VitalityInvest. Core new business API for PAHI decreased 18% including PAHI
reinsurance business.
3 The difference between VitalityHealth normalised profit compared to that shown in the segment information is the accelerated write-off in the current year
of the VitalityCar’s capitalised systems and intangible assets, with a pre-tax impact of R189 million. The write-off is disclosed in this table in Closure costs
of VitalityInvest and VitalityCar in run down. Closure costs include
– VitalityInvest R266 million (30 June 2022: R458 million)
– VitalityCar R189 million (30 June 2022: nil).
Directors’ report
for the year ended 30 June 2023

-- 16 of 217 --

16	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Directors’ report continued
for the year ended 30 June 2023
Normalised headline earnings increased 32% to R7 678 million (2022: R5 816 million) while headline earnings increased 5% to R5 490 million
(2022: R5 204 million) negatively impacted by the effect of a significant increase in both real and nominal interest rates in SA.
The return on opening embedded value (RoEV) of 13.2%, benefited from translation and foreign exchange gains as a result of the weakening
rand combined with strong local currency growth for Discovery’s offshore operations. R2.6 billion of positive non-economic experience
variances were generated over the year, reflecting the positive dynamics of the shared value insurance model. However, this was offset by
higher long-term rates in SA and UK which created a significant impact on the economic basis within the embedded value and constrained
new business margins materially.
SHARE CAPITAL
Details of the authorised and issued share capital, together with details of shares issued during the year, are set out in note 8 to the Company
Annual Financial Statements.
OWNERSHIP
For details of shareholders, refer to Annexure D.
GROUP STRUCTURE
The Company is directly and indirectly the holding company of subsidiaries and investments as set out in Annexure A. In addition, Discovery
is required to consolidate certain unit trusts which are deemed to be under the Group’s control in terms of IFRS 10 Consolidated Financial
Statements. These are also set out in Annexure A.
DIVIDENDS
Details of dividends paid and declared are set out in note 43 and note 44 to the Annual Financial Statements.
CAPITAL
Solvency and liquidity tests
The directors have performed the requisite solvency and liquidity tests where required by the Companies Act as amended.
Liquidity and solvency as well as the Group’s capital position remained strong and is robust under various stress scenarios across the Group.
Statutory capital requirements
With effect from 1 July 2018, the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential Standards were implemented in South
Africa. Discovery Life and Discovery Insure are regulated under the Insurance Act, while VitalityHealth and VitalityLife are regulated under
the European Solvency II regulatory regime, which was implemented from 1 January 2016. The values below are estimated based on
information extracted from the audited Annual Financial Statements.
June 2023 	June 2022
Statutory capital requirements 	Cover 	Statutory capital requirements 	Cover
Discovery Life 	R20 809 million 	1.9 times 	R20 322 million 	1.7 times
Discovery Insure 	R1 113 million 	1.6 times 	R1 138 million 	1.2 times
Vitality Health 	GBP130.8 million 	GBP117.2 million
(R3 138 million) 	1.4 times 	(R2 344 million) 	1.5 times
Vitality Life 	GBP272.1 million 	GBP297.1 million
(R6 528 million) 	2.1 times 	(R5 943 million) 	2.1 times

-- 17 of 217 --

17	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
DIRECTORS AND PRESCRIBED OFFICERS
The following were directors and prescribed officers of the Company during the current financial year unless otherwise indicated:
Executive directors 	Independent non-executive directors
A Gore (Group Chief Executive) 	ME Tucker (Chairperson) 	T Mboweni
Dr A Ntsaluba2 	L Chiume4 	KC Ramon5
A Pollard2 	N Hlahla 	M Schreuder
B Swartzberg 	FN Khanyile 	B van Kralingen
DM Viljoen (Group Chief Financial Officer) 	D Macready 	SV Zilwa
Dr TV Mapha
Prescribed officers 	Non-executive directors
HD Kallner2,3 	HL Bosman1
NS Koopowitz2,3 	R Farber
1 Retired effective 1 December 2022 following conclusion of the Company’s Annual General Meeting. This follows the unbundling by Rand Merchant
Investment Holdings Limited of its shareholding in Discovery Limited earlier in 2022. He also resigned as chairperson and member of the Risk and
Compliance Committee and as a member of the Remuneration Committee and the Nominations Committee. He has also retired as a non-executive
director of Discovery Life Limited, Discovery Health (Pty) Limited and Discovery Vitality (Pty) Limited.
2 Stepped down from the Board effective 1 March 2023 as part of a change in governance structures.
3 Transitioned to Prescribed Officer with effect from 1 March 2023 as part of a change in governance structures.
4 Appointed with effect from 18 September 2023. She is also a member of the Discovery Limited Audit Committee and the Group and South African Risk
and Compliance Committees. She brings a wealth of financial services and investment experience.
5 Appointed with effect from 18 September 2023. She is a member of the Discovery Limited Audit Committee and the Social and Ethics Committee.
She brings diverse leadership and board experience in multiple sectors.
The notice for the forthcoming Annual General Meeting of shareholders will include those names of individuals that retire by rotation
and are eligible and available for re-election.
DIRECTORS’ INTERESTS
Details of the directors’ emoluments, participation in share incentive schemes and interests in the Company are reflected in Annexure C.
No material contracts involving directors’ interests were entered into in the current year. The directors had no interest in any third party
or company responsible for managing any of the business activities of Discovery.
INDEMNIFICATION AND INSURANCE OF DIRECTORS AND OFFICERS
The Company entered into agreements to indemnify its directors to the extent permitted by law against all liabilities including legal costs
incurred by the director in connection with or as a consequence of the director acting in any capacity, including as an authorised
representative of a Group company. During the financial year, the Company paid insurance premiums in respect of a Directors and Officers
Liability insurance contract, which insures directors and officers of the Company against certain liabilities arising in the course of their duties
to the Company or Group companies. Details of the nature of the liabilities covered and the amount of premium paid are not disclosed as
such disclosure is prohibited under the terms of the contract.
COMPANY SECRETARY
Nobuhle Mbongo resigned as the Group Company Secretary with effect from 31 March 2023 to pursue another opportunity outside of
the Group.
In the interim, Ayanda Manqele, the current Deputy Company Secretary, was appointed Acting Group Company Secretary, with effect from
31 May 2023 until 31 August 2023. Ayanda Ceba was appointed as Group Company Secretary of Discovery with effect from 1 September
2023, following the resignation of the Group Company Secretary.
Registered office 	Postal address
1 Discovery Place 	PO Box 786722
Sandton 	Sandton
2196 	2146
BORROWING POWERS
The directors may exercise all the powers of the Company to borrow money. In terms of the Memorandum of Incorporation, the borrowing
powers of the Company are unlimited. In terms of the Insurance Act, both Discovery Life and Discovery Insure may not encumber its assets
or directly or indirectly borrow.
EVENTS AFTER THE REPORTING DATE
Refer to Group note 44 for a list of the events after reporting date.
AUDITORS
It will be proposed at the Annual General Meeting of shareholders, that KPMG Inc. and Deloitte & Touche be appointed as joint external
auditors in accordance with section 90(1) of the Companies Act.
Directors’ report continued
for the year ended 30 June 2023

-- 18 of 217 --

18	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Group statement of financial position
at 30 June 2023
R million 	Notes
Group
2023
Restated 1
Group
2022
Restated1
Group
1 July 2021
Assets
Goodwill 	10 	5 406 	4 912 	4 879
Intangible assets 	7 	6 982 	6 539 	6 371
Property and equipment 	6 	3 910 	3 811 	4 188
Assets arising from insurance contracts 	5 	63 865 	56 645 	50 483
Deferred tax asset 	24 	4 404 	4 455 	3 948
Deferred acquisition costs 	8 	799 	640 	585
Assets arising from contracts with customers 	9A 	2 201 	1 692 	1 375
Investment in equity-accounted investees 	11 	7 024 	6 008 	3 459
Financial assets
– Loans and advances to customers at amortised cost 	12 	4 702 	3 944 	3 361
– Investments at amortised cost 	12 	9 910 	7 161 	5 604
– Investments at fair value through profit or loss 	12 	155 426 	141 494 	130 937
– Derivative financial instruments at fair value through profit or loss 	13 	119 	276 	249
Insurance receivables, contract receivables and other receivables 	14 	16 059 	13 113 	10 533
Non-current assets held for sale 	11.2.1 	– 	171 	–
Current tax asset 	41 	220 	391
Reinsurance contracts 	15 	709 	511 	445
Cash and cash equivalents 	16 	20 370 	19 775 	20 013
TOTAL ASSETS 	301 927 	271 367 	246 821
Equity
Capital and reserves
Ordinary share capital and share premium 	17.1 	10 351 	10 178 	10 151
Perpetual preference share capital 	17.2 	779 	779 	779
Other reserves 	8 622 	3 621 	1 935
Retained earnings 	44 218 	38 972 	33 550
Equity attributable to equity holders of the Company 	63 970 	53 550 	46 415
Non-controlling interest 	4 	5 	4
TOTAL EQUITY 	63 974 	53 555 	46 419
Liabilities
Liabilities arising from insurance contracts 	18 	114 807 	108 067 	100 041
Liabilities arising from reinsurance contracts 	19 	14 669 	13 192 	12 525
Deferred tax liability 	24 	9 559 	9 335 	8 814
Contract liabilities to customers 	9A 	656 	944 	776
Financial liabilities
– Borrowings at amortised cost 	20 	20 586 	20 584 	19 493
– Other payables 	22 	14 780 	15 123 	14 904
– Deposits from customers 	23 	14 333 	10 881 	8 985
– Investment contracts at fair value through profit or loss 	21 	48 044 	38 637 	33 354
– Derivative financial instruments at fair value through profit or loss 	13 	20 	202 	826
Employee benefits 	25 	334 	320 	315
Current tax liability 	165 	527 	369
TOTAL LIABILITIES 	237 953 	217 812 	200 402
TOTAL EQUITY AND LIABILITIES 	301 927 	271 367 	246 821
1 The comparative information has been restated. Refer to note 45 for detail.
The order in which individual line items are presented in the Statement of financial position has been amended to better reflect their respective liquidity, as far
as possible, from least liquid to the most liquid items. No values were reclassified or restated between line items.

-- 19 of 217 --

19	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Group income statement
for the year ended 30 June 2023
R million 	Notes
Group
2023
Restated1
Group
2022
Insurance premium revenue 	59 671 	58 312
Reinsurance premiums 	(10 136) 	(8 262)
Net insurance premium revenue 	26 	49 535 	50 050
Fee income from administration business 	9B 	14 757 	12 752
Vitality income 	9B 	3 891 	3 495
Net banking fee and commission 	965 	645
Banking fee and commission income 	9B 	1 292 	853
Banking fee and commission expense 	(327) 	(208)
Net banking interest and similar income 	574 	318
Bank interest and similar income using the effective interest rate 	1 318 	811
Bank interest and similar expense using the effective interest rate 	(744) 	(493)
Investment income using the effective interest rate method 	27 	772 	296
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	28 	14 373 	(1 825)
Other income 	1 544 	1 341
Net income 	86 411 	67 072
Net claims and policyholders’ benefits 	29 	(40 135) 	(30 715)
Claims and policyholders’ benefits 	(46 746) 	(38 022)
Insurance claims recovered from reinsurers 	6 611 	7 218
Recapture of reinsurance 	– 	89
Acquisition costs 	30 	(6 213) 	(4 758)
Marketing and administration expenses 	31 	(28 905) 	(25 209)
Amortisation of intangibles from business combinations 	(56) 	(59)
Expected credit losses 	(139) 	(67)
Recovery of expenses from reinsurers 	3 593 	2 859
Net transfer to/from assets and liabilities under insurance contracts 	(322) 	(1 297)
– Change in assets arising from insurance contracts 	5 860 	5 786
– Change in assets arising from reinsurance contracts 	135 	63
– Change in liabilities arising from insurance contracts 	(3 992) 	(6 738)
– Change in liabilities arising from reinsurance contracts 	(328) 	(577)
– Economic assumptions adjustments net of discretionary margins 	(1 997) 	169
Fair value adjustment to liabilities under investment contracts 	(5 572) 	32
Profit from operations 	8 662 	7 858
Finance costs 	33 	(1 941) 	(1 658)
Foreign exchange gains 	34 	150 	155
Impairment of goodwill 	(9) 	–
(Losses)/gains on dilution and/or disposal of equity-accounted investments 	(5) 	33
Reversal of impairment of equity-accounted investments 	– 	134
Share of net profits from equity-accounted investments 	515 	422
Profit before tax 	7 372 	6 944
Income tax expense 	35 	(2 052) 	(1 465)
Profit for the year 	5 320 	5 479
Profit attributable to:
– Ordinary shareholders 	5 258 	5 422
– Preference shareholders 	69 	56
– Non-controlling interest 	(7) 	1
5 320 	5 479
Earnings per share for profit attributable to ordinary shareholders of the
Company during the year (cents): 	36
– Basic 	785.4 	825.5
– Diluted 	781.5 	817.8
1 The comparative information has been restated. Refer to note 45 for detail.

-- 20 of 217 --

20	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Group statement of other comprehensive income
for the year ended 30 June 2023
R million
Group
2023
Group
2022
Profit for the year 	5 320 	5 479
Items that are or may be subsequently reclassified to profit or loss:
Currency translation differences 	4 107 	467
– Unrealised gains 	4 222 	467
– Tax on unrealised gains 	(115) 	–
Cash flow hedges 	76 	309
– Unrealised gains 	76 	322
– Tax on unrealised gains 	– 	(2)
– Gains recycled to profit or loss 	(1) 	(10)
– Tax on recycled gains 	1 	(1)
Share of other comprehensive income from equity-accounted investments 	419 	601
– Change in fair value of debt instruments at fair value through other comprehensive income 	(23) 	17
– Currency translation differences 	442 	584
Items that may not be reclassified to profit or loss:
Share of other comprehensive income from equity-accounted investments 	7 	–
– Change in fair value of equity instruments at fair value through other comprehensive income 	7 	–
Other comprehensive income for the year, net of tax 	4 609 	1 377
Total comprehensive income for the year 	9 929 	6 856
Attributable to:
– Ordinary shareholders 	9 867 	6 799
– Preference shareholders 	69 	56
– Non-controlling interest 	(7) 	1
Total comprehensive income for the year 	9 929 	6 856

-- 21 of 217 --

21	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Group statement of cash flows
for the year ended 30 June 2023
R million 	Notes
Group
2023
Group
2022
Cash flow from operating activities 	2 549 	3 597
Cash generated by operations 	37.1 	8 308 	20 943
Purchase of investments held to back policyholder liabilities 	(62 773) 	(56 588)
Proceeds from disposal of investments held to back policyholder liabilities 	55 908 	38 411
Cash generated from operating activities 	1 443 	2 766
Dividends received 	28 	728 	600
Interest received 	27&28 	3 718 	2 824
Interest paid 	37.4 	(1 501) 	(1 412)
Taxation paid 	37.2 	(1 839) 	(1 181)
Cash flow from investing activities 	(2 236) 	(4 704)
Purchase of financial assets 	(30 966) 	(32 878)
Proceeds from disposal of financial assets 	30 932 	31 482
Purchase of property and equipment 	(551) 	(275)
Proceeds from disposal of property and equipment 	2 	25
Purchase of software and other intangible assets 	(1 760) 	(1 567)
Proceeds from disposal of software and other intangible assets 	– 	2
Acquisition of business net of cash 	(3) 	–
Additional investment in equity-accounted investments 	(182) 	(1 593)
Proceeds from sale of non-current asset held for sale 	184 	–
Dividends from equity-accounted investments 	108 	100
Cash flow from financing activities 	(1 234) 	518
Dividends paid to preference shareholders 	(69) 	(56)
Proceeds from borrowings 	37.3 	7 442 	3 261
Repayment of borrowings 	37.3 	(8 607) 	(2 687)
Net decrease in cash and cash equivalents 	(921) 	(589)
Cash and cash equivalents at beginning of the year 	19 619 	20 013
Exchange gains on cash and cash equivalents 	1 639 	195
Cash and cash equivalents including bank overdraft at end of the year 	16 	20 337 	19 619
Reconciliation to Statement of financial position
Cash and cash equivalents 	20 370 	19 775
Bank overdraft included in borrowings at amortised cost 	20 	(33) 	(156)
Cash and cash equivalents including bank overdraft at end of the year 	16 	20 337 	19 619

-- 22 of 217 --

DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023	22
Group statement of changes in equity
for the year ended 30 June 2023
Attributable to equity holders of the Company
R million
Share capital
and
share
premium
Preference
share
capital
Share-based
payment
reserve
Investment
reserve 1
Translation
reserve
Hedging
reserve
Retained
earnings 	Total
Non-
controlling
interest
Total
Equity
Year ended 30 June 2023
At beginning of the year 	10 178 	779 	798 	35 	2 823 	(35) 	38 972 	53 550 	5 	53 555
Total comprehensive income for the year 	– 	69 	– 	(16) 	4 549 	76 	5 258 	9 936 	(7) 	9 929
Profit for the year 	– 	69 	– 	– 	– 	– 	5 258 	5 327 	(7) 	5 320
Other comprehensive income 	– 	– 	– 	(16) 	4 549 	76 	– 	4 609 	– 	4 609
Transactions with owners 	173 	(69) 	392 	– 	– 	– 	(12) 	484 	6 	490
Share issue 	514 	– 	– 	– 	– 	– 	– 	514 	– 	514
Increase in treasury shares 	(514) 	– 	– 	– 	– 	– 	– 	(514) 	– 	(514)
Delivery of treasury shares 	173 	– 	(161) 	– 	– 	– 	(12) 	– 	– 	–
Acquisition of subsidiaries with non-controlling interest 	– 	– 	– 	– 	– 	– 	– 	– 	6 	6
Employee share option schemes:
– Value of employee services, net of tax 	– 	– 	553 	– 	– 	– 	– 	553 	– 	553
Dividends paid to preference shareholders 	– 	(69) 	– 	– 	– 	– 	– 	(69) 	– 	(69)
At end of the year 	10 351 	779 	1 190 	19 	7 372 	41 	44 218 	63 970 	4 	63 974
Year ended 30 June 2022
At beginning of the year 	10 151 	779 	489 	18 	1 772 	(344) 	33 550 	46 415 	4 	46 419
Total comprehensive income for the year 	– 	56 	– 	17 	1 051 	309 	5 422 	6 855 	1 	6 856
Profit for the year 	– 	56 	– 	– 	– 	– 	5 422 	5 478 	1 	5 479
Other comprehensive income 	– 	– 	– 	17 	1 051 	309 	– 	1 377 	– 	1 377
Transactions with owners 	27 	(56) 	309 	– 	– 	– 	– 	280 	– 	280
Share issue 	443 	– 	– 	– 	– 	– 	– 	443 	– 	443
Increase in treasury shares 	(443) 	– 	– 	– 	– 	– 	– 	(443) 	– 	(443)
Delivery of treasury shares 	27 	– 	(17) 	– 	– 	– 	– 	10 	– 	10
Employee share option schemes:
– Value of employee services 	– 	– 	326 	– 	– 	– 	– 	326 	– 	326
Dividends paid to preference shareholders 	– 	(56) 	– 	– 	– 	– 	– 	(56) 	– 	(56)
At end of the year 	10 178 	779 	798 	35 	2 823 	(35) 	38 972 	53 550 	5 	53 555
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt instruments measured at FVOCI, in terms of IFRS 9 Financial Instruments.

-- 23 of 217 --

23	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
1. 	SEGMENT INFORMATION
Discovery’s operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision-maker (CODM). The CODM have been identified as the Chief Executive Officers of Discovery’s businesses, as identified in
the segment information, who make strategic decisions regarding these businesses.
An operating segment is a component of an entity:
(a) 	That engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses
relating to transactions with other components of the same entity);
(b) 	Whose operating results are regularly reviewed by the entity’s CODM to make decisions about resources to be allocated to the
segment and assess its performance; and
(c) 	For which discrete financial information is available.
An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may
be operating segments before earning revenues.
Discovery will report separately information about an operating segment that meets any of the following quantitative thresholds:
(a) 	Its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 percent or more of
the combined revenue, internal and external, of all operating segments;
(b) 	The absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount, of (i) the combined
reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating
segments that reported a loss; and
(c) 	Its assets are 10 percent or more of the combined assets of all operating segments.
Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed,
if management believes that information about the segment would be useful to users of the financial statements.
Discovery may combine information about operating segments that do not meet the quantitative thresholds with information about
other operating segments that do not meet the quantitative thresholds to produce a reportable segment only if the operating
segments have similar economic characteristics.
The Group has identified its reportable segments based on a combination of products and services offered to customers and the
location of the markets served.
The following summary describes the operations of each of the Group’s reportable segments:
(i) 	Health South Africa: administers and provides managed care services to medical schemes and renders administration
services to other business segments within the Group.
(ii) 	Life South Africa: offers a range of insurance and financial solutions to the Group’s clients against the financial impact of
lifestyle-changing events in South Africa.
(iii) Invest South Africa: offers, through a range of investment fund choices, including Discovery managed unit trusts, a
comprehensive and flexible range of investment choices. These products are sold through a number of investment wrappers
including Discovery Life policies and are offered to individuals in South Africa.
(iv) Vitality South Africa: offers health and lifestyle benefits with selected partners to the Group’s clients.
(v) 	Insure South Africa: offers a range of personal line insurance (motor, building, household content and portable possessions)
to the Group’s clients against the financial impact of loss or damage. The segment also includes Discovery’s interest in
Cambridge Mobile Telematics (CMT).
(vi) Bank South Africa: offers retail banking solutions, including deposits and loans and advances, to clients in the South African
market. The Bank is still in a start-up phase. It also includes DiscoveryCard.
(vii) Health United Kingdom: offers consumer-engaged private medical insurance products to employer groups and individuals in
the UK. All contracts in this segment are short-term insurance contracts.
(viii) Life United Kingdom: offers a risk-only life assurance product. All contracts in this segment are long-term assurance contracts
offered to both employer groups and individuals in the UK.
(ix) All other segments: includes those segments that do not meet the quantitative thresholds set out in IFRS 8 Operating Segments
and cannot be aggregated with another reportable segment. It includes the following operating segments:
– Insure South Africa commercial: provides commercial short-term risk insurance products to the South African market.
– SA Distribution: provides sales and distribution services in respect of all SA products.
– Vitality Group: provides a Vitality platform to international insurance businesses.
– Other new business development costs: expenses incurred to investigate new products and markets.
– UK, United States of America (USA), SA and Singapore head office costs, where not allocated to another segment.
– Invest UK: includes investment products to individuals in the UK and is currently in wind-down.
Notes to the Group annual financial statements
for the year ended 30 June 2023

-- 24 of 217 --

24	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
1. 	SEGMENT INFORMATION continued
The Chief Executive Officers assess the performance of the reportable segments based on normalised profit/loss from operations.
Items which are excluded from the normalised profit/loss from operations are separately disclosed in the segment information to
reconcile back to the segment results.
The segment information is presented on the same basis as reported to the CODM. The segment total is then adjusted for
accounting reclassifications and entries required to produce IFRS compliant results. These adjustments include the following:
(i) The VitalityLife results are reclassified to account for the contractual arrangement in respect of the business written on the
Prudential Assurance Company (PAC) license, as an insurance contract which Discovery issues under IFRS 4 Insurance Contracts;
(ii) Unit trusts which the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s
results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit trusts into Discovery’s
results, effectively being the income and expenses relating to units held by third parties;
(iii) The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments; and
(iv) The effects of reclassifying items to align to IFRS results.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 25 of 217 --

DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023	25
R million
SA
Health
SA
Life
SA
Invest
SA
Insure2
SA
Vitality
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments3
IFRS
total
30 June 2023
Income statement
Insurance premium revenue 	245 	16 620 	15 104 	5 177 	– 	– 	13 670 	7 835 	1 808 	60 459 	(788) 	59 671
Reinsurance premiums 	(1) 	(3 852) 	– 	(414) 	– 	– 	(2 149) 	(4 277) 	(231) 	(10 924) 	788 	(10 136)
Net insurance premium revenue 	244 	12 768 	15 104 	4 763 	– 	– 	11 521 	3 558 	1 577 	49 535 	– 	49 535
Fee income from administration businesses 	8 571 	– 	3 099 	17 	– 	– 	46 	– 	3 024 	14 757 	– 	14 757
Vitality income 	– 	– 	– 	– 	2 573 	– 	462 	238 	618 	3 891 	– 	3 891
Net banking fee and commission income 	– 	– 	– 	– 	– 	943 	– 	– 	22 	965 	– 	965
Banking fee and commission income 	– 	– 	– 	– 	– 	1 292 	– 	– 	– 	1 292 	– 	1 292
Banking fee and commission expense 	– 	– 	– 	– 	– 	(349) 	– 	– 	22 	(327) 	– 	(327)
Net bank interest and similar income 	– 	– 	– 	– 	– 	574 	– 	– 	– 	574 	– 	574
Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	– 	1 318 	– 	– 	– 	1 318 	– 	1 318
Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	– 	(744) 	– 	– 	– 	(744) 	– 	(744)
Investment income earned on assets backing policyholder liabilities 	– 	8 	– 	159 	– 	– 	81 	199 	15 	462 	(462) 	–
Net fair value gains on financial assets at fair value through profit or loss 	(6) 	678 	10 904 	– 	(1) 	– 	– 	(1 213) 	1 839 	12 201 	2 172 	14 373
Other income 	1 395 	3 	– 	– 	1 	– 	48 	– 	97 	1 544 	– 	1 544
Finance income/(charge) on negative reserve funding 	– 	– 	– 	– 	– 	– 	– 	1 098 	– 	1 098 	(1 098) 	–
Intersegment funding 1 	– 	(492) 	492 	– 	– 	– 	– 	– 	– 	– 	– 	–
Net income 	10 204 	12 965 	29 599 	4 939 	2 573 	1 517 	12 158 	3 880 	7 192 	85 027 	612 	85 639
Net claims and policyholders’ benefits 	(74) 	(8 182) 	(13 304) 	(2 810) 	– 	– 	(5 370) 	(973) 	(9 422) 	(40 135) 	– 	(40 135)
Claims and policyholders’ benefits 	(75) 	(11 452) 	(13 304) 	(3 153) 	– 	– 	(7 138) 	(2 514) 	(9 668) 	(47 304) 	558 	(46 746)
Insurance claims recovered from reinsurers 	1 	3 270 	– 	343 	– 	– 	1 768 	1 541 	246 	7 169 	(558) 	6 611
Acquisition costs 	(35) 	(1 833) 	(1 262) 	(784) 	(119) 	– 	(1 146) 	(2 449) 	317 	(7 311) 	1 098 	(6 213)
Expected credit losses 	– 	– 	– 	– 	– 	(139) 	– 	– 	– 	(139) 	– 	(139)
Marketing and administration expenses
– depreciation and amortisation 	(140) 	(6) 	(12) 	(64) 	(9) 	(314) 	(420) 	(49) 	(794) 	(1 808) 	(169) 	(1 977)
– derecognition of intangible assets and property and equipment 	(4) 	– 	– 	(3) 	– 	– 	(241) 	(19) 	(57) 	(324) 	– 	(324)
– impairment of property and equipment 	– 	– 	– 	– 	– 	– 	(45) 	– 	– 	(45) 	– 	(45)
– other expenses 	(6 097) 	(2 347) 	(1 267) 	(1 100) 	(2 429) 	(1 831) 	(4 998) 	(2 453) 	(3 937) 	(26 459) 	(100) 	(26 559)
Recovery of expenses from reinsurers 	– 	– 	– 	– 	– 	– 	1 320 	2 272 	1 	3 593 	– 	3 593
Transfer from assets/liabilities under insurance contracts
– change in assets arising from insurance contracts 	– 	4 412 	– 	– 	– 	– 	– 	768 	– 	5 180 	680 	5 860
– change in assets arising from reinsurance contracts 	– 	49 	– 	– 	– 	– 	61 	18 	10 	138 	(3) 	135
– change in liabilities arising from insurance contracts 	– 	(230) 	(10 868) 	(100) 	– 	– 	(226) 	(31) 	7 376 	(4 079) 	87 	(3 992)
– change in liabilities arising from reinsurance contracts 	– 	(18) 	– 	– 	– 	– 	– 	73 	– 	55 	(383) 	(328)
Fair value adjustment to liabilities under investment contracts 	– 	(3) 	(1 326) 	– 	– 	– 	– 	– 	(1 264) 	(2 593) 	(2 979) 	(5 572)
Share of net profits from equity-accounted investments 	– 	– 	– 	(16) 	– 	– 	1 	2 	574 	561 	(46) 	515
Normalised profit/(loss) from operations 	3 854 	4 807 	1 560 	62 	16 	(767) 	1 094 	1 039 	(4) 	11 661 	(1 203) 	10 458
Economic assumptions adjustments net of discretionary margins and interest rate derivatives 	– 	(2 811) 	– 	– 	– 	– 	– 	147 	– 	(2 664) 	667 	(1 997)
Economic assumptions adjustments net of discretionary margins 	– 	(2 811) 	– 	– 	– 	– 	– 	1 120 	– 	(1 691) 	(306) 	(1 997)
Fair value losses on VitalityLife interest rate derivatives 	– 	– 	– 	– 	– 	– 	– 	(973) 	– 	(973) 	973 	–
Investment income earned on shareholder investments and cash 	89 	20 	71 	– 	32 	– 	9 	28 	75 	324 	448 	772
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	– 	1 184 	1 184 	(1 184) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	122 	95 	– 	– 	– 	– 	(204) 	(3) 	10 	(10) 	–
Gains from dilution of equity-accounted investments 	– 	– 	– 	(5) 	– 	– 	– 	– 	– 	(5) 	– 	(5)
Impairment of goodwill 	– 	– 	– 	– 	– 	– 	– 	– 	(9) 	(9) 	– 	(9)
Expenses related to PAC book transfer 	– 	– 	– 	– 	– 	– 	– 	(177) 	– 	(177) 	177 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	(46) 	– 	– 	– 	– 	(56) 	(102) 	46 	(56)
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	– 	(134) 	(134) 	134 	–
Finance costs 	(2) 	(1) 	– 	– 	– 	– 	(8) 	(216) 	(1 423) 	(1 650) 	(291) 	(1 941)
Intercompany finance costs 	(362) 	– 	– 	– 	– 	– 	– 	(316) 	(520) 	(1 198) 	1 198 	–
Foreign exchange (loss)/gains 	(4) 	33 	36 	– 	– 	– 	1 	– 	84 	150 	– 	150
Profit/(loss) before tax 	3 575 	2 170 	1 762 	11 	48 	(767) 	1 096 	301 	(806) 	7 390 	(18) 	7 372
Income tax expense 	(972) 	(576) 	(573) 	(21) 	4 	226 	(267) 	53 	56 	(2 070) 	18 	(2 052)
Profit/(loss) for the year 	2 603 	1 594 	1 189 	(10) 	52 	(541) 	829 	354 	(750) 	5 320 	– 	5 320
1 The intersegment funding of R492 million reflects a notional allocation of interest earned on the negative reserve backing policyholders’ funds of guaranteed investment products and hence is transferred to Discovery Invest.
2 This segment relates to SA Insure – Personal lines.
.
1. 	SEGMENT INFORMATION continued
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 26 of 217 --

26	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
R million
SA
Health
SA
Life
SA
Invest4
SA
Insure2
SA
Vitality
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total4
IFRS reporting
adjustments
IFRS
total 4
30 June 2022 Restated 4
Income statement
Insurance premium revenue 	189 	15 041 	14 029 	4 657 	– 	– 	11 299 	6 750 	7 035 	59 000 	(688) 	58 312
Reinsurance premiums 	– 	(3 523) 	– 	(103) 	– 	– 	(1 556) 	(3 600) 	(168) 	(8 950) 	688 	(8 262)
Net insurance premium revenue 	189 	11 518 	14 029 	4 554 	– 	– 	9 743 	3 150 	6 867 	50 050 	– 	50 050
Fee income from administration businesses 	7 910 	– 	2 834 	15 	– 	– 	30 	– 	1 975 	12 764 	(12) 	12 752
Vitality income 	– 	– 	– 	– 	2 338 	– 	392 	227 	538 	3 495 	– 	3 495
Net banking fee and commission income 	– 	– 	– 	– 	– 	633 	– 	– 	12 	645 	– 	645
Banking fee and commission income 	– 	– 	– 	– 	– 	853 	– 	– 	– 	853 	– 	853
Banking fee and commission expense 	– 	– 	– 	– 	– 	(220) 	– 	– 	12 	(208) 	– 	(208)
Net bank interest and similar income 	– 	– 	– 	– 	– 	318 	– 	– 	– 	318 	– 	318
Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	– 	811 	– 	– 	– 	811 	– 	811
Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	– 	(493) 	– 	– 	– 	(493) 	– 	(493)
Investment income earned on assets backing policyholder liabilities 	– 	3 	– 	118 	– 	– 	9 	27 	7 	164 	(164) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	10 	485 	913 	1 	1 	– 	(52) 	(1 390) 	(1 195) 	(1 227) 	(598) 	(1 825)
Other income 	1 241 	12 	– 	– 	– 	– 	32 	– 	56 	1 341 	– 	1 341
Finance income/(charge) on negative reserve funding 	– 	– 	– 	– 	– 	– 	– 	1 368 	– 	1 368 	(1 368) 	–
Intersegment funding 1 	– 	(628) 	628 	– 	– 	– 	– 	– 	– 	– 	– 	–
Net income 	9 350 	11 390 	18 404 	4 688 	2 339 	951 	10 154 	3 382 	8 260 	68 918 	(2 142) 	66 776
Net claims and policyholders’ benefits 	(49) 	(9 222) 	(12 075) 	(3 029) 	– 	– 	(4 331) 	(877) 	(1 132) 	(30 715) 	– 	(30 715)
Claims and policyholders’ benefits 	(49) 	(14 013) 	(12 075) 	(3 151) 	– 	– 	(5 652) 	(2 231) 	(1 346) 	(38 517) 	495 	(38 022)
Insurance claims recovered from reinsurers 	– 	4 791 	– 	122 	– 	– 	1 321 	1 265 	214 	7 713 	(495) 	7 218
Recapture of reinsurance 	– 	– 	– 	– 	– 	– 	– 	89 	– 	89 	– 	89
Acquisition costs 	(27) 	(1 605) 	(1 128) 	(702) 	(111) 	– 	(963) 	(1 884) 	294 	(6 126) 	1 368 	(4 758)
Expected credit losses 	– 	– 	– 	– 	– 	(67) 	– 	– 	– 	(67) 	– 	(67)
Marketing and administration expenses
– depreciation and amortisation 	(106) 	(7) 	(11) 	(60) 	(12) 	(277) 	(458) 	(63) 	(739) 	(1 733) 	(169) 	(1 902)
– derecognition of intangible assets and property and equipment 	– 	– 	– 	(18) 	– 	– 	(1) 	(14) 	(17) 	(50) 	– 	(50)
– other expenses 	(5 568) 	(2 147) 	(1 156) 	(988) 	(2 207) 	(1 597) 	(4 091) 	(2 047) 	(3 032) 	(22 833) 	(424) 	(23 257)
Recovery of expenses from reinsurers 	– 	– 	– 	– 	– 	– 	1 041 	1 818 	– 	2 859 	– 	2 859
Transfer from assets/liabilities under insurance contracts
– change in assets arising from insurance contracts 	– 	5 299 	– 	– 	– 	– 	– 	3 606 	(101) 	8 804 	(3 018) 	5 786
– change in assets arising from reinsurance contracts 	– 	11 	– 	1 	– 	– 	40 	11 	1 	64 	(1) 	63
– change in liabilities arising from insurance contracts 	– 	662 	(3 050) 	(41) 	– 	– 	(65) 	(17) 	(4 488) 	(6 999) 	261 	(6 738)
– change in liabilities arising from reinsurance contracts 	– 	(351) 	– 	– 	– 	– 	– 	(3 244) 	– 	(3 595) 	3 018 	(577)
Fair value adjustment to liabilities under investment contracts 	– 	(2) 	220 	– 	– 	– 	– 	– 	42 	260 	(228) 	32
Share of net profits from equity-accounted investments 	– 	– 	– 	(13) 	– 	– 	2 	– 	474 	463 	(41) 	422
Reversal of impairment of equity-accounted investment 	– 	– 	– 	– 	– 	– 	– 	– 	134 	134 	– 	134
Normalised profit/(loss) from operations 	3 600 	4 028 	1 204 	(162) 	9 	(990) 	1 328 	671 	(304) 	9 384 	(1 376) 	8 008
Economic assumptions adjustments net of discretionary margins and interest rate derivatives 	– 	(651) 	– 	– 	– 	– 	– 	567 	– 	(84) 	253 	169
Economic assumptions adjustments net of discretionary margins 	– 	(651) 	– 	– 	– 	– 	– 	820 	– 	169 	– 	169
Fair value losses on VitalityLife interest rate derivatives 	– 	– 	– 	– 	– 	– 	– 	(253) 	– 	(253) 	253 	–
Investment income earned on shareholder investments and cash 	37 	11 	38 	– 	28 	– 	– 	8 	18 	140 	156 	296
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	5 	913 	918 	(918) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	51 	27 	– 	– 	– 	– 	(454) 	(1) 	(377) 	377 	–
Loss on dilution of equity-accounted investments 	– 	– 	– 	19 	– 	– 	– 	– 	14 	33 	– 	33
Expenses related to PAC book transfer 	– 	– 	– 	– 	– 	– 	– 	(182) 	– 	(182) 	182 	–
Covid-19 vaccination programme 	– 	– 	– 	– 	– 	– 	– 	– 	(157) 	(157) 	157 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	(41) 	– 	– 	– 	– 	(59) 	(100) 	41 	(59)
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	– 	(158) 	(158) 	158 	–
Finance costs3 	(1) 	25 	– 	– 	– 	– 	(6) 	(104) 	(1 290) 	(1 376) 	(282) 	(1 658)
Intercompany finance costs 	(297) 	– 	– 	– 	– 	– 	(4) 	(230) 	(396) 	(927) 	927 	–
Foreign exchange gains/(losses) 	4 	25 	37 	– 	– 	– 	– 	– 	89 	155 	– 	155
Profit/(loss) before tax 	3 343 	3 489 	1 306 	(184) 	37 	(990) 	1 318 	281 	(1 331) 	7 269 	(325) 	6 944
Income tax expense 	(951) 	(718) 	(438) 	43 	(30) 	218 	(285) 	224 	147 	(1 790) 	325 	(1 465)
Profit/(loss) for the year 	2 392 	2 771 	868 	(141) 	7 	(772) 	1 033 	505 	(1 184) 	5 479 	– 	5 479
1 The intersegment funding of R628 million reflects a notional allocation of interest earned on the negative reserve backing policyholders’ funds of guaranteed investment products and hence is transferred to Discovery Invest.
2 This segment relates to SA Insure – Personal lines.
3 Finance costs in Discovery Life includes a reversal of interest payable to the South African Revenue Services provided for in the prior year.
4 The comparative information has been restated. Refer to note 45 for detail.
1. 	SEGMENT INFORMATION continued

-- 27 of 217 --

27	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK
Discovery’s accounting policy to recognise and measure insurance contracts can be viewed in Annexure B, accounting policy 13.
Discovery issues both short-term and long-term contracts that transfer significant insurance risk. Such contracts may also transfer
financial risk. An insurance contract is a contract in which Discovery as issuer and/or insurer accepts significant insurance risk from
the policyholder by agreeing to compensate the policyholder if a specified uncertain future event (the insured event) adversely
affects the policyholder. A significant insurance risk is the possibility of having to pay benefits, on the occurrence of an insured event,
that are significantly more than the benefits payable if the insured event did not occur. There is uncertainty around the timing and/
or the value of the resulting claim.
A large portfolio of independent but similar insurance contracts, allow for the use of probability theory to predict the number and
value of claims over a defined period. Insurance risk, when considering a large portfolio of insurance contracts, is thus the
probability that the actual number of claims over a defined period is different to those expected. This could in turn result in the
value of insurance liabilities being over or underestimated.
Experience shows that the larger the portfolio of similar insurance contracts, the smaller the relative variability of the expected
outcome will be. Discovery reduces claims variability by underwriting policies and by using reinsurance to protect against single
large claims or catastrophe reinsurance to mitigate concentration risks.
Discovery classifies its insurance contracts into five main categories, depending on the duration of the risk and the type of risk
insured. These are:
Contracts which are long term in nature
– 	Individual life insurance: These contracts insure against a comprehensive spectrum of risks, including life cover, severe illness,
disability and income continuation cover.
– 	Investment products with insurance risk: These contracts attract insurance risk arising from additional benefits offered which
mostly insure against mortality or morbidity risks.
Contracts which are short term in nature
– 	Health insurance: These contracts insure policyholders against healthcare-related claims.
– 	Short-term insurance: These monthly contracts insure policyholders against a comprehensive spectrum of short-term risks
including, but not limited to, motor vehicle, household, business, property and liability cover.
– 	Group life insurance: These contracts insure against a comprehensive spectrum of protection benefits on a group basis. Life
cover, severe illness, disability and income continuation benefits are offered.
Refer to note 1 segment information for premium revenue per segment.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 28 of 217 --

28	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
Discovery manages its insurance risk in terms of its risk management framework and holds regulatory and economic capital for
protection against adverse experience. The following summarises the insurance risk associated with the various contracts offered
by Discovery, and how Discovery manages these risks.
Insurance risk 	Description 	How Discovery manages the risk
Risks significant to all insurance business lines
Lapse and
surrender risk
Policyholders have the option to discontinue
or reduce contributions at any time.
Accordingly, there is a risk of financial loss
due to the withdrawal rate, lapses or
premium reductions (with associated
reduced cover) being higher than expected.
The risk is highest during the early duration
of the policy since the acquisition costs and
commission incurred at the inception of the
policy would not yet have been recouped.
Contracts that are long term in nature
For individual life insurance products there
is a risk:
– of reduced profits arising from lower
than expected withdrawals at later
durations of certain policies in cases
where the reserves have turned positive.
This is since withdrawals on such policies
allow the reserves to be released as
profits in the absence of surrender
values being offered; and
– that withdrawals are selective from a
claims experience point of view. For
example, healthy lives may find it easier
to obtain cover elsewhere compared to
less healthy lives.
Future earnings on individual life plans are
dependent on the number of policies
remaining in future years and thus future
earnings are dependent on the lapse rate.
The future expected earnings vary by the
premium funding method chosen by the
policyholder. In general, the higher the
increases, the higher the withdrawal risk to
future earnings.
For investment products with insurance risk,
there is a risk:
– that the surrender value may exceed the
policy value, net of expenses, at early
durations; and
– that withdrawals are higher than
expected. Future earnings arising from
Invest plans are dependent on the value
of assets under management and thus
future earnings are dependent on the
withdrawal and surrender rate.
Contracts that are short term in nature
For Discovery Insure there is a risk of
reduced profits arising from higher than
expected withdrawals at early durations of
policies, resulting in acquisition costs not
being recovered.
Lapse risk is managed as follows:
Product design
Products are designed to be sustainable in the long
term. New product offerings are made available to
existing policyholders as far as possible to prevent
lapse and re-entry risk.
Integration between different product offerings across
Discovery enhances the value proposition of the
overall package of products from Discovery.
For example, Discovery provides unique rewards
and benefits as well as integration to members
which has proven to be a credible risk differentiator.
Premium discounts or cover increases are available
to policyholders who actively engage in a healthier
lifestyle and utilise the Vitality benefits. Better
terms are thus offered to healthy lives compared to
less healthy lives.
No surrender benefit is offered on risk benefits and
thus the loss on withdrawal is reduced.
Commission claw back
Discovery predominantly distributes via
independent brokers, intermediaries and
tied agents.
Commissions are clawed back from intermediaries
where a policy lapses within a specified timeframe
since inception. The amount of commission
clawback depends on the duration of the policy in
months and gradually reduces from 100% to 0% over
a specified period, depending on product sold.
Experience monitoring
Lapse experience is monitored on a monthly basis
and data is analysed to establish possible trends for
which management action can be taken.
Where there is insufficient historic data to provide
credible results, for example within VitalityLife
Whole of Life, reliance is placed on reinsurers’
advice, industry experience as well as experience
from Discovery Life.
Proactive conservation
Targeted conservation campaigns are run pro-
actively. For example, financial advisors are
notified of clients that do not have certain
features on their policies that are correlated with
good persistency. Financial advisors are thus
encouraged to add such features.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 29 of 217 --

29	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
Insurance risk 	Description 	How Discovery manages the risk
Modelling and
data risk
Actuarial liabilities are calculated using
complex discounted cash flow models. There
is a risk that the models do not accurately
project the policy cash flows in the future.
The models rely on data from the
administration system and there is thus a
further risk that the data does not
accurately reflect the policies being valued.
Contracts that are short term have simplified
models reducing modelling risk.
The risk is controlled using specialist actuarial
software that is widely used and accepted in the life
insurance industry throughout the world. This is
tailored for Discovery.
The original actuarial models were tested and verified
using an independent but identical parallel model. Any
changes made are externally and independently
reviewed. Parallel models are developed to test any
modelling changes.
The data for the model is extracted from modern
administration systems and subjected to detailed
checks together with high-level reasonability
checks. Data is checked at each valuation date.
Capital adequacy
requirements and
protection against
adverse
experiences
There is a risk that future premiums,
investment returns and estimates used to
calculate liabilities are insufficient to provide
for variations in actual future experience.
Insurance liabilities are calculated using
best estimates plus the addition of various
margins to avoid premature recognition of
profits and to provide for a buffer against
future adverse experience. In addition,
Discovery maintains shareholder capital to
meet substantial deviations in experience
beyond those provided for in the liability
calculations.
For discussion on how Discovery manages its capital
adequacy requirements, refer to note 2.1.
Liquidity risk 	Liquidity risk is the risk that an entity will
encounter difficulty in meeting obligations
associated with insurance liabilities due to
insufficient cash being available to meet
commitments as and when they become
due. This is exacerbated by timing
mismatches between assets and liabilities.
Discovery maintains sufficient liquid assets to meet
short-term liabilities under base and stress
assumptions. Sufficient liquid assets are held to allow
for the initial cash flow strain when writing new
business.
Contracts that are long term in nature
Currently, Discovery Life’s and VitalityLife’s expected
outflows are mostly long term and the main liquidity
requirement is to fund acquisition expenses on new
business and unexpected fluctuations in benefit
payments. As discussed in note 3.4.3, Discovery
invests primarily in liquid financial assets.
For Discovery Life, large sums assured above a
defined retention level are reinsured, providing
stability in claims experienced and further reducing
liquidity risk.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 30 of 217 --

30	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Insurance risk 	Description 	How Discovery manages the risk
Liquidity risk
continued
There is a need to meet liquidity requirements arising
from Discovery Invest’s Guaranteed Plan book.
Liquidity requirements are managed to ensure a
liquidity buffer is maintained to meet potential
outflows if exit rates are higher than expected. The
liquidity risk on the existing portfolio is thus
relatively small.
VitalityLife also receives partial financing for new
business strain from financing reinsurance treaties
with reinsurers.
For discussion on managing liquidity risk, refer to
note 2.2.
Contracts that are short term in nature
VitalityHealth mostly has expected outflows which
are short term in nature as the vast majority of
claims are expected to be settled within 12 months
of reporting. The existing book is mature and is cash
generative which covers liquidity required for the
cash flow strain of writing consistent levels of new
business.
Discovery Insure holds the majority of working and
solvency capital in cash or near cash instruments to
minimise liquidity risk. Large sums assured above a
defined retention level are reinsured, providing
stability in claims experience and further reducing the
liquidity risk. Catastrophe reinsurance further reduces
this risk.
Concentration risk 	Claims experience risk
There is a risk that a concentration of risk
can lead to worse than expected
experience. The concentration risk is the
highest in group business, since assured
lives live in the same geographical location
and generally work in the same industry or
at the same location.
Discovery has a well-diversified book of business by
source of new business and spread across brokers
and agents.
Furthermore, the claims experience risk is mitigated
through catastrophe reinsurance.
For details of diversification refer to note 2.3.
Withdrawal concentration risk
There is a financial risk of the withdrawal of
a block of policies written by a single
independent intermediary.
Operational and
implementation
risk
Operational risk is defined as the risk of loss
arising from inadequate or failed internal
processes, people and systems or from
external events. Discovery offers a wide
product range, which grows over time due
to further product enhancements and
development.
In order to mitigate operational risk, Discovery
maintains and follows a set of documented
processes and procedures which are reviewed
internally and externally to be in line with industry best
practice. Testing protocols are implemented prior to
launching new systems/products or businesses.
Embedded in Discovery’s processes is the concept of
segregation of duties which ensures that there are
multiple checks on outputs by different areas within
the business and protects against operational and
implementation risk. .
Policy wording/
legal risk
There is a risk that Discovery could be
financially exposed to obligations that
differ from expectations and are not
adequately provided for. The risk could also
arise from legal proceedings.
The risk is managed when new products are
developed and all policy wording is reviewed by legal
advisors and external advice is obtained where
necessary to ensure that terms and conditions are
clearly defined and unambiguous.
2. 	MANAGEMENT OF INSURANCE RISK continued
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 31 of 217 --

31	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Insurance risk 	Description 	How Discovery manages the risk
Regulatory risk 	Discovery operates in a highly regulated
environment which is continuously being
scrutinised and questioned by both
consumers and regulators. This has resulted
in the constant review of the in-force
regulations and the interpretation thereof.
The regulatory risk can thus be defined as
the potential detrimental impact unexpected
changes in regulations, or the interpretation
thereof, may have on Discovery.
Although Discovery endeavours to design
insurance and financial solutions which meet
the requirements of the current regulations in
force, the risk does exist that changes in the
regulations or the interpretation of the
regulations, over time may result in the
current products not fully complying with
the regulations in force in future.
This risk is managed through constantly seeking legal
advice on new product developments. Further, all
insurance products issued by Discovery have to be
approved, including approval from a market conduct
perspective. Depending on the business line, these
are approved either by the Head of the Actuarial
Function or Actuarial Committee.
Discovery is a member of industry-wide bodies that
engage in discussions with policymakers and
regulators.
Discovery’s compliance department enhances
regulatory compliance through audits and by
monitoring developments in the regulatory
environment.
Tax risk 	Tax risk is the risk that the actual future tax
liability is different to what is currently
expected. This could be as a result of an
incorrect interpretation or application of tax
legislation or as a result of changes to
tax legislation.
Clear understanding and close monitoring of tax
changes, with appropriate tax allowance in product
design and pricing.
VitalityLife specific
Tax relief on expenses does not apply to protection
business sold from January 2013 onwards.
Expense risk 	Expense risk is the risk of actual expenses
being higher than expected. Expenses could
exceed expectations due to an increase in
expense inflation or due to a reduction in the
number of in-force policies. A reduction in
the assets under management could be an
expense risk due to the value of fixed costs.
Expenses are monitored on a monthly basis against
budgeted expenses. Any deviation from the budget is
investigated, reported and where necessary, remedial
action is taken.
Reputational risk 	Reputational risk is the risk of negative
market reaction towards Discovery.
Discovery may thus not be able to apply
management policies to reduce risk.
Discovery Life offers policies that integrate
with the product offerings within the Discovery
Group. The reputational risk to Discovery Life
is thus extended to the reputational risk of
the entire Discovery Group.
Reputational risk may also arise on investment
products with insurance risk, if these products
experience worse investment returns than
competitors. This may lead to lower future
new business and higher surrenders.
Reputational risk is carefully monitored. Decisions to
repudiate claims are reviewed by a review committee
comprising of a senior underwriter and claims
assessor, representatives of the legal department and
the medical team, as well as a compliance officer.
Marketing material and policy wording are reviewed
and designed to be clear and unambiguous to avoid
creating unreasonable policyholder expectations.
All products are approved prior to launch, by either
the Head of the Actuarial Function or Actuarial
Committee, depending on the business line. Approval
is obtained prior to launch from a market conduct
perspective.
For investment products with insurance risk, the risk
on investment returns is mitigated through the use of
reputable experienced fund managers and unique,
innovative products covering specific risks.
2. 	MANAGEMENT OF INSURANCE RISK continued
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 32 of 217 --

32	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Insurance risk 	Description 	How Discovery manages the risk
Risks significant to long-term insurance
Mismatching and
market risk
Mismatching is the risk that insurance-
related cash outflows (e.g. benefit payments,
administration expenses) do not match
expected future cash inflows (predominately
future premiums).
Mismatching risk can also arise when
movements in assets and liabilities are out of
line given changes in market risk, i.e. equity
price risk, interest rate risk or currency risk.
The value of assets and liabilities arising
from insurance contracts are subject to
interest rate risk, thus a risk exists that a
change in the discount rate could cause a
change in the value of the assets and
liabilities arising from insurance contracts.
For assets arising from insurance contracts,
Discovery covers the insurance related outflows
by expected future cash inflows (predominately
future premiums).
For liabilities arising from insurance contracts, the
insurance related cash outflows are matched with a
combination of a release of policyholder assets (net of
retained fees), investment return on these assets and
cash inflows.
For further discussion on how Discovery manages this
risk, refer to note 2.4 more specifically:
– For mismatching risk, refer note 2.4.1 and 2.4.2;
– For interest rate risk, refer note 2.4.3; and
– For currency risk, refer note 2.4.4
Underwriting
experience risk
– Individual life
plans and
investment
products with
insurance risk
For individual life plans, there is a risk that
actual mortality and morbidity experience is
higher than expected. This could arise as a
result of the number of claims or the value
of claims being higher than expected. In
addition, there is a risk that the emergence
of a new disease or epidemic can increase
the number of claims.
On guaranteed annuities there is a risk
that mortality experience is lower than
expected and thus income payments
continue for longer than expected.
Investment products with insurance risk may
also carry mortality and morbidity risks.
The risks are managed through various
mechanisms:
Product design and pricing
Products are carefully designed to minimise adverse
selection. Rating factors are applied to standard
premium rates to differentiate between different
levels of risk. For example, premiums are
differentiated by income, education level, smoker
status, gender, medical history and age.
– From January 2013 onwards, no differentiation
of premiums or benefits on the basis of gender is
allowed in the UK.
– Discovery Life has the unique ability to take
additional rating factors into account for example
the current medical scheme claims and lifestyle
factors.
All new premium rates are reviewed and approved
by either the Head of Actuarial Function or Actuarial
Committee. Product integration between the
different product offerings in Discovery helps to
attract healthier lives than average in the market,
leading to positive selection. The product integration
incentivises engagement in the Vitality programme,
which has a positive impact on risk experience.
Selection risk is the risk that worse risks than
expected are attracted and these risks are
then charged inadequate premiums.
Selection risk could also lead to higher than
expected mortality and morbidity experience
on individual life plans or lower mortality on
guaranteed annuity policies.
For certain of the product options offered under the
individual life plans, Discovery has retained the option
to review premium rates annually throughout the life
of the contract because of uncertainties underlying the
value of the benefits offered. Only premiums that can
be predicted with confidence are guaranteed longer
periods. The guarantee provided to the policyholder
will, however, be strengthened based on the
policyholder’s actual annual historic Vitality status.
Discovery Life predominantly operates in the high end of
the South African insurance market where the risk of HIV/
AIDS is lower than for the South African market as a
whole. The impact of HIV/AIDS is considered and allowed
for during the product development and pricing.
2. 	MANAGEMENT OF INSURANCE RISK continued
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 33 of 217 --

33	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Insurance risk 	Description 	How Discovery manages the risk
Underwriting
experience risk
– Individual life
plans and
investment
products with
insurance risk
continued
Underwriting
Underwriting ensures that only insurable risks are
accepted and that premiums reflect the unique
circumstances of each risk.
Financial underwriting is applied to ensure that the
policyholder can justify the amount of cover applied
for. Premium loadings and exclusions are applied
where high risks are identified.
For integrated policies, Discovery Life can
dynamically adjust certain premiums using
the information from the health claims experience
of a policyholder who is also a member of the
Discovery Health Medical Scheme and Vitality. This
provides Discovery Life with an advantageous position
in the market.
Monthly internal quality assurance audits are
performed on underwriting to minimise the risk of
incorrect underwriting decisions.
Reinsurance
Reinsurance protects against volatility in claims
experience and against an accumulation of risk.
Reinsurance is further utilised on a facultative basis
if uncertainty exists over the terms that should be
offered to a particular risk.
In addition, reinsurers provide specialist advice when
designing new products.
Discovery Life utilises surplus and facultative
reinsurance to reinsure amounts in excess of defined
retention levels. Discovery Life is thus protected
against large individual claims.
In addition, catastrophe reinsurance reduces the
risk of an accumulation of risk due to a single event.
Both individual life are covered by catastrophe
reinsurance which covers man-made or natural
catastrophe events.
For VitalityLife, the life, serious illness, disability and
income protection benefits are reinsured with a
maximum retention of GBP150 000. The
unemployment benefit offered as part of the
VitalityLife product is fully reinsured.
Experience monitoring
Experience investigations are conducted and
corrective action is taken where adverse experience
is noted. Experience monitoring is done on at least a
quarterly basis, and in some business lines monthly.
Where there is insufficient historic data to provide
credible results, such as VitalityLife, reliance is
placed on reinsurers’ advice, industry experience
as well as experience from Discovery Life.
2. 	MANAGEMENT OF INSURANCE RISK continued
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 34 of 217 --

34	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Insurance risk 	Description 	How Discovery manages the risk
Risks significant to short-term insurance
Underwriting
experience risk
The risk that claims experience turns out to
be worse than anticipated in the pricing of
the product and that claims reserves are
insufficient to meet insurance liabilities as
they fall due.
The principal risk is that the frequency and/
or severity of claims are greater than
expected. Insurance events are, by their
nature, random and the actual number and
size of events during any one year may vary
from those estimated and experienced in
prior periods.
Frequency of claims can vary depending on,
for instance, the levels of engagement with
the Vitality programme, and severity of
claims can be influenced by new treatments
or changes in medical inflation.
Group Life
Group Life business is reviewed on a contract by
contract basis, with the review period never
exceeding two years. HIV/AIDS risk is specifically
allowed for in the pricing of individual groups.
Group business is underwritten on an employer by
employer basis and additional allowance is made for
the impact of industry class, income and geographic
location on expected claims experience. The free
cover limit is the sum assured that will be given
automatically to a specific life without further specific
underwriting. The free cover limits are set separately
for each scheme depending on the size and cover
chosen by the specific scheme.
In addition to renewal pricing changes, standard
terms and conditions applicable to the company’s
products mitigate the risk of late reporting of claims.
VitalityHealth
New business is written in accordance with approved
pricing assumptions. Underwriting criteria is defined
and aligned to the approved pricing assumptions.
VitalityHealth’s overall premium levels are determined
by its pricing and lapse experience, as well as the
level of new business written.
VitalityHealth can manage the risk of new business
policies through the ability to underwrite policies at
inception or at the point of claim. Aside from large
corporate clients, all other lives covered were
underwritten through either full medical underwriting,
continuation of previous exclusions (if the policy is
moving from another UK health insurer), or
moratorium conditions which limit claims for a
specified period relating to previous conditions.
VitalityHealth is able to manage the insurance risk in
existing business premiums through the annual
repricing of policies at renewal on a risk-related basis;
this is a key differentiator as to why the UK market is
less susceptible to volatility from insurance risk than
South Africa. Whilst policyholders can choose to
cancel their contract mid-term between renewals,
this is not experienced in the SME or corporate
products as the terms and conditions of the contract
do not permit cancellation mid-term unless the
customer is going into administration. Individual
contracts can and do cancel between renewals
however retaining these policies is a key activity for
the business. VitalityHealth is only obligated to
continue to pay for any authorised treatment whilst
premiums are being received from the policyholder.
2. 	MANAGEMENT OF INSURANCE RISK continued
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 35 of 217 --

35	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Insurance risk 	Description 	How Discovery manages the risk
Underwriting
experience risk
continued
Discovery Insure
Discovery Insure aims to manage risk through
diversifying the pool of insured risks by
establishing a balanced portfolio of insurance risks
over a wide geographical area. Short-term insurance
risks are priced on an individual basis, therefore a
minimal cross subsidy exists between risks.
Premiums are calculated using statistical
regression techniques. Insurance risk factors
identified would typically include past insurance history,
type and value of asset covered, measures taken to
protect the asset, primary use of covered item and
various other pertinent factors.
Discovery Insure’s quotation and administration
system calculates risk on an individual basis based
on information captured by brokers and agents for
each risk. Individual risks are accepted
automatically up to cut-off limits which vary by risk
type. Insurance conditions and exclusions are also
automatically set at an individual risk level.
Individual risks greater than the limit are
automatically referred and underwritten by the
underwriting department. No risks are accepted
which exceed the upper limits of the reinsurance
contracts without the necessary facultative cover
being arranged.
Discovery Insure uses telematic devices to manage
risks related to motor vehicle cover. The telemetry
received in respect of vehicles in which the devices
are installed, highlights speeding, harsh breaking,
harsh cornering and other risk related incidents. By
informing the driver of how they are driving and in
turn rewarding them for driving well, the risk of an
accident is reduced. The ’deep install’ device is also
equipped with a stolen vehicle recovery
transponder that increases the probability of
recovering a vehicle should it be stolen.
Reinsurance – VitalityHealth
VitalityHealth currently utilises reinsurance
to better match the high upfront costs of acquisition
with the profit emergence across the lifetime of the
policies written. VitalityHealth currently has quota
share agreements in place with two reinsurers
with an outstanding balance of GBP246.0 million
(R5 902 million) at year end (2022: GBP198.5 million
(R3 971 million)).
2. 	MANAGEMENT OF INSURANCE RISK continued
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 36 of 217 --

36	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Insurance risk 	Description 	How Discovery manages the risk
Underwriting
experience risk
continued
Reinsurance – Discovery Insure
Discovery Insure mitigates its insurance risk
through its reinsurance programme which is
structured to protect the company against material
losses to either a single insured risk, or group of
insured risks in the case of a catastrophe where
there would tend to be a concentration of insured
risks.
Furthermore, Discovery Insure reinsures a portion
of the risk it underwrites to protect the profitability
and the capital of the company. A variety of treaties
are entered into in order to limit losses resulting from
individual and collective insurance risks.
Additional facultative reinsurance is purchased for
certain individual risks that are in excess of the
relevant treaty limits. Discovery Insure only enters
into reinsurance arrangements with reinsurers that
have adequate credit ratings.
Experience monitoring
Across both premiums and claims, recent actual
experience is compared against financial forecasts,
with any deviations investigated. The results provide a
feedback loop into the overall pricing approach,
enabling Discovery to react quickly to any changes in
behaviour.
2.1 	Capital adequacy requirements and protection against adverse experience
Refer to the Directors’ report for a breakdown of Statutory Capital Requirement cover ratios. Discovery manages its capital
requirements in line with the statutory requirements of the relevant Prudential Authorities. During the period Discovery met the
Statutory Capital Requirements.
2.1.1 Discovery Life
Discovery Life is required to demonstrate solvency to the PA in South Africa in accordance with the Insurance Act 18 of 2017
(Insurance Act). Discovery Life thus needs to maintain sufficient shareholder assets (Own Funds), over and above the assets
required to meet policyholder liabilities (best-estimate liabilities plus a prescribed risk margin), to support a multiple of the Solvency
Capital Requirement (SCR). Discovery Life is required to undertake an internal assessment of its risks and capital needs, in addition
to meeting the minimum capital requirements set by the PA. The SCR is calculated in accordance with the Prudential Standards as
issued by the PA. The SCR calculation is intended to approximate a risk-based capital measure and covers the major areas of
insurance risk. It explicitly covers the following key areas of risk to Discovery Life:
– 	Lapse and withdrawal risk
– 	Fluctuations in mortality and morbidity experience including catastrophe risk
– 	Interest rate risk
– 	Equity and property risk
– 	Expense risk
– 	Operational risk
– 	Spread and counterparty default risk
– 	Currency risk
– 	Concentration risk.
2. 	MANAGEMENT OF INSURANCE RISK continued
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 37 of 217 --

37	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.1 	Capital adequacy requirements and protection against adverse experience continued
2.1.1 Discovery Life continued
Discovery Life regularly reviews the capital position and also considers various new business scenarios. Typically, a five-year new
business projection horizon is allowed for and the capital position is assessed at each valuation date during the projection to ensure
an acceptable capital cover is maintained.
Discovery Life has calculated its solvency position in accordance with the Insurance Act and related Prudential Standards since
30 June 2013. A consistent level of solvency cover, comfortably in excess of the statutory minimum, was observed at all valuation dates.
2.1.2 VitalityLife
The Vitality Life business comprises business underwritten directly by VitalityLife (from 1 January 2016) and business underwritten
on behalf of VitalityLife on PAC’s life insurance license (up to 31 December 2015).
Through a number of contractual and loan arrangements, Discovery retains 100% of the insurance risk associated with the VitalityLife
policies underwritten on the PAC life insurance license. All policies are administered by VitalityLife, and they are managed as a single
portfolio. The arrangement with the PAC is accounted for in substance under IFRS as an insurance contract that Discovery issues.
Accordingly, all information for VitalityLife is presented on a combined basis comprising both the business underwritten by
VitalityLife and underwritten on behalf of VitalityLife on the PAC life insurance license.
The business that was underwritten on PAC life insurance license will, as per contractual agreement with PAC, still be valued under
the Solvency I or old capital requirement rules described below until it is transferred to the Vitality Life Limited (VLL) license. After
this date, this business would need to be fully Solvency II compliant. During the financial period ended 30 June 2022, Discovery and
PAC have finalised a contractual agreement to a long-term deferral of the transfer to the VLL license (the Part VII transfer). The
agreement is such that the Part VII transfer is now deferred for the long term with options to extend further and for all intents and
purposes should be viewed as an indefinite deferral.
The business written on its own life insurance license within VitalityLife needs to be fully Solvency II compliant. VitalityLife obtained
its own life insurance license at the end of the calendar year 2015. This significant milestone, together with the implementation of
Solvency II in the UK from 1 January 2016, required a change to the capital requirements of VitalityLife.
SOLVENCY I
The Financial Services Authority (FSA) was replaced by two distinct regulators in 2013 namely the Prudential Regulation Authority (PRA)
and the Finance Conduct Authority (FCA). The PRA is a part of the Bank of England and responsible for the prudential regulation and
supervision of insurers. It sets standards and supervises financial institutions. The FCA regulates the financial services industry in the
UK. Their aim is to protect consumers, ensure the industry remains stable and promote healthy competition between financial services
providers. The Prudential Sourcebook for Insurers (INSPRU) contains standards for capital management.
Capital requirements are calculated based on the concept of two pillars:
– 	Pillar 1, which covers public solvency information that appears within the regulatory returns on the basis of prescriptive rules.
This includes the statutory valuation of liabilities together with a prescribed measure of additional capital, the Long-term
Insurance Capital Requirement (LTICR); and
– 	Pillar 2, the Individual Capital Assessment (ICA), which covers a confidential company-specific assessment of solvency. This
assessment is done on a realistic basis with the aim to protect against risks up to the 99.5 percentile over a one-year period.
The LTICR is a minimum required margin for solvency on the statutory valuation basis and covers the following basic risks:
– 	Mortality risk;
– 	Expense risk;
– 	Market risk; and
– 	Health risk.
The amount of capital that ultimately needs to be held by a life insurance company in the UK is the larger of the Pillar 1 and
Pillar 2 result. VitalityLife is required to provide capital to the PAC equal to one times the Pillar 1 capital requirement, increasing
to one and a half times from the Pillar 1 capital requirements from March 2024 onwards. The cover requirements were observed
at all valuation dates.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 38 of 217 --

38	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.1 	Capital adequacy requirements and protection against adverse experience continued
2.1.2 VitalityLife continued
SOLVENCY II
Capital requirements under Solvency II are calculated using the regulations and guidance originally published by the European
Insurance and Occupational Pensions Authority (EIOPA) and enforced by the PRA in the UK. A Solvency Cover ratio is calculated
which has several components, the key ones are discussed below:
– 	Best estimate liabilities (BEL): policyholder liabilities are calculated on a best estimate basis (excluding any margins) and
discounted at the latest swap curve published by Bank of England;
– 	SCR: 1-in-200 year stresses to the key assumptions are applied to the BEL and the impacts aggregated using specified correlation
matrices;
– 	Risk Margin (RM): 6% of the SCR run-off over time is discounted at the latest swap curve;
– 	Technical Provisions (TP): the sum of the BEL and the RM;
– 	Eligible Own Funds: the net assets of the company available to cover the SCR; negative TP can be included in the eligible Own
Funds ; and
– 	Solvency cover ratio: Eligible Own funds divided by SCR
2.1.3 VitalityHealth
VitalityHealth maintains shareholder capital to meet substantial deviations in experience and to support business growth.
The objective of VitalityHealth’s capital management policy is to define the principles and guiding philosophy for capital management
that ensures capital and solvency levels are managed effectively in line with the defined risk appetites. The policy and objectives are
reviewed at least annually. Alongside ensuring VitalityHealth complies with capital requirements imposed by its regulator (the PRA),
the guiding principles for the policy are to:
– 	Foster an environment of regulatory compliance within the Group’s culture, strategy and decision making;
– 	Continually develop and enhance the Group’s regulatory compliance capability;
– 	Actively communicate the effectiveness and benefits of compliance management to all stakeholders; and
– 	To provide reasonable and independent assurance to the Group’s key management, board and regulator.
VitalityHealth is required to hold sufficient capital (measured in accordance with PRA Rulebook) to meet the PRA capital
requirements. The capital requirements were met at all valuation dates.
With effect from 1 January 2016 the insurance regulatory regime Solvency II was implemented in the UK. Refer to 2.1.2 for discussion
on Solvency II. Under this solvency regime, insurers have the opportunity to either follow the standard formula approach, or apply
to the regulators to move away from this. VitalityHealth follows a standard formula, and as such has a SCR in line with that
prescribed. Annually, the business publicly discloses a Solvency and Financial Condition Report (SFCR) alongside private disclosures
to the regulators on its Own Risk and Solvency Assessment (ORSA). The standard formula approach is also annually reviewed to
determine its appropriateness for the business and as at 30 June 2023 the standard formula review determined it was not an
inappropriate assessment of the risks present in VitalityHealth.
The actual and projected capital position of VitalityHealth is monitored on a regular basis through a number of forums and
governance committees including the Board of Directors as well as through VitalityHealth’s ORSA. In the event that sufficient capital
is not projected to be available, actions would be taken to obtain additional capital or to reduce the amount of risk accepted and
therefore reduce the capital requirement through, for example, reinsurance or investment strategy.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 39 of 217 --

39	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.1 	Capital adequacy requirements and protection against adverse experience continued
2.1.4 Discovery Insure
Similar to Discovery Life, Discovery Insure is required to demonstrate solvency to the PA in accordance with the Insurance Act.
Discovery Insure thus needs to maintain sufficient shareholder assets (Own Funds), over and above the assets required to meet
policyholder liabilities (BEL plus a prescribed risk margin), to support a multiple of the SCR. In addition, Discovery Insure is required
to undertake an internal assessment of its risks and capital needs, in addition to meeting the minimum capital requirements set by
the PA. The SCR is calculated in accordance with the Prudential Standards as issued by the PA. The SCR calculation is intended to
approximate a risk-based capital measure and covers the major areas of short-term insurance risk. It explicitly covers the following
key areas of risk to Discovery Insure:
– Catastrophe risk
– Premium and reserve risk
– Lapse risk
– Interest rate risk
– Equity and property risk
– Expense risk
– Operational risk
– Spread and counterparty default risk
– Currency risk
– Concentration risk.
The internal assessment of risks and capital needs usually considers, amongst others, the following risks:
– Lapse risk not captured in the SCR
– New business volume risk
– Expense risk over and above allocated loss adjustment expense (ALAE) risk
Discovery Insure regularly reviews the capital position and considers various new business scenarios. Typically, a five-year new
business projection horizon is allowed for and the capital position is assessed at each financial year during the projection to ensure
an acceptable capital cover is maintained. The solvency cover was observed at all valuation dates.
2.2 	Liquidity risk
2.2.1 Contracts that are long term in nature
DISCOVERY LIFE, DISCOVERY INVEST AND VITALITYLIFE
For Discovery Life, Discovery Invest and VitalityLife, the discounted expected embedded value cash flows arising from in-force
contracts after policyholder liabilities have been met, net of tax, as at 30 June were as follows:
Gross of reinsurance
R million 	Total 	Year 1 	Years 2 to 5 	Years 6 to 10 	Years 11 to 20 	Years 21+
2023
Discovery Life 	28 547	28 547 	1 651	1 651 	6 274	6 274 	6 799	6 799 	8 219	8 219 	5 604	5 604
Discovery Invest 	9 469	9 469 	735	735 	3 417	3 417 	2 747	2 747 	2 112	2 112 	458	458
VitalityLife 	17 698	17 698 	3 304	3 304 	7 971	7 971 	5 607	5 607 	2 133	2 133 	(1 317)	(1 317)
2022
Discovery Life 	28 101 	1 690 	5 618 	6 382 	8 221 	6 190
Discovery Invest 	8 602 	547 	2 640 	2 677 	2 354 	384
VitalityLife 	12 830 	2 436 	6 194 	4 597 	1 581 	(1 978)
Net of reinsurance
R million 	Total 	Year 1 	Years 2 to 5 	Years 6 to 10 	Years 11 to 20 	Years 21+
2023
Discovery Life 	23 834 	1 072 	4 566 	5 463 	7 454 	5 279
VitalityLife 	11 822 	1 193 	3 606 	4 484 	2 259 	280
2022
Discovery Life 	23 473 	1 298 	4 003 	4 994 	7 367 	5 811
VitalityLife 	8 818 	743 	2 292 	3 723 	1 705 	355
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 40 of 217 --

40	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.2 	Liquidity risk continued
2.2.1 Contracts that are long term in nature continued
The cash flows in the tables above differ from those disclosed in notes 2.4.1 and 2.4.2 since the cash flows in the tables above are
based on best estimate free cash flows after meeting policyholder liabilities, are discounted at the risk discount rate and are capped
at 40 years as per the Discovery Life and Discovery Invest embedded value methodology. Cash flows arising from investment
management contracts are also included. No allowance has been made for new business and related expenses.
2.2.2 Contracts that are short term in nature
VITALITYHEALTH
VitalityHealth maintains sufficient liquid assets to meet short-term liabilities and to allow for the initial cash flow strain when writing new
business. Currently, VitalityHealth’s expected liabilities are mostly short term and the main liquidity requirement is to fund acquisition
expenses on new business, with the existing book mature enough to generate sufficient liquidity to cover cash flow strain of writing
consistent levels of new business.
DISCOVERY INSURE
Discovery Insure holds the majority of working and solvency capital in cash or near cash instruments to minimise liquidity risk. Large
sums assured above a defined retention level are reinsured, providing stability in claims experience and further reducing the
liquidity risk. Catastrophe reinsurance further reduces this risk.
2.3 	Concentration risk
2.3.1 Claims experience risk
DISCOVERY LIFE
Discovery Life maintains a well-diversified portfolio of policies. Reinsurance is further used to protect against the concentration of
risk. Catastrophe reinsurance protects against the accumulation of claims from a single event, for example an airplane crash. The
catastrophe reinsurance for Discovery Life covers single event disasters for up to R975 million where the net of reinsurance impact
is greater than R52 million. For its biggest four group schemes, a further layer of catastrophe reinsurance cover of R3 750 million in
excess of R1 027 million is in place.
Reinsurance removes the exposure to large individual claims. The following graph demonstrates that the distribution of policies by
sum assured is shifted towards lower sum assured due to the reinsurance cover.
0 – 0.5
Before reinsurance 	After reinsurance
Number of Lives
>5.0	4.5 – 5.0	4.0 – 4.5	3.5 – 4.0	3.0 – 3.5	2.5 – 3.0	2.0 – 2.5	1.5 – 2.0	1 – 1.5	0.5 – 1.0
2023 Distribution of Sums Retained: before and after reinsurance (Sum retained – Rm)
0
20 000
40 000
60 000
80 000
100 000
Reinsurance results in a reduction in exposure to large individual sums-at-risk,
leading to this transfer from large to small case sizes
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 41 of 217 --

41	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.3 	Concentration risk continued
2.3.1 Claims experience risk continued
DISCOVERY LIFE CONTINUED
0 – 0.5
Before reinsurance 	After reinsurance
Number of Lives
>5.0	4.5 – 5.0	4.0 – 4.5	3.5 – 4.0	3.0 – 3.5	2.5 – 3.0	2.0 – 2.5	1.5 – 2.0	1 – 1.5	0.5 – 1.0
2022 Distribution of Sums Retained: before and after reinsurance (Sum retained – Rm)
0
20 000
40 000
60 000
80 000
100 000
Reinsurance results in a reduction in exposure to large individual sums-at-risk,
leading to this transfer from large to small case sizes
VITALITYLIFE
VitalityLife maintains a well-diversified portfolio of policies. Reinsurance removes the exposure to large individual claims. The
following graph demonstrates that the distribution of policies by sum assured is shifted towards lower sum assured due to the
reinsurance cover. The profile is largely the same as the prior period, although a shift towards higher sums assured due to annual
benefit increases and inflationary impacts on new business was observed as expected.
0 – 25
Before reinsurance 	After reinsurance
>250	225 – 250	200 – 225	175 – 200	150 – 175	125 – 150	75 – 100	50 – 75	25 – 50 	100 – 125
Number of Lives
2023 Distribution of Sums Retained: before and after reinsurance (Sum retained – GBP’000)
0
40 000
80 000
120 000
160 000
200 000
0 – 25
Before reinsurance 	After reinsurance
>250	225 – 250	200 – 225	175 – 200	150 – 175	125 – 150	75 – 100	50 – 75	25 – 50 	100 – 125
Number of Lives
2022 Distribution of Sums Retained: before and after reinsurance (Sum retained – GBP’000)
0
30 000
60 000
90 000
120 000
150 000
180 000
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 42 of 217 --

42	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.3 	Concentration risk continued
2.3.1 Claims experience risk continued
VITALITYHEALTH
VitalityHealth has the risk of single large medical expense claims arising abroad, or multiple small travel claims due to a single event
which could cause losses. In order to manage these risks VitalityHealth holds a reinsurance policy specifically on travel benefits
which can help to cover the concentration risks from these events. The threshold for a potential claim on the reinsurance for either
of these reasons is GBP250 000.
DISCOVERY INSURE
There is a risk that a concentration of risk can lead to a worse than expected claims experience. In order to manage this
concentration of insurance risk, Discovery has entered into a catastrophe excess of loss reinsurance treaty that would limit the loss
of the Group to pre-determined levels following the occurrence of a localised catastrophe in that area.
Discovery Insure has concentration of policyholders in the main metropolitan areas such as Johannesburg, Pretoria, Cape Town and
Durban. A catastrophic flood, hail, fire or earthquake would result in disproportionate losses in these areas given the accumulation
of risk. Catastrophe reinsurance is used to limit the size of such losses and their impact on the underwriting result.
2.3.2 Withdrawal concentration risk
DISCOVERY LIFE AND VITALITYLIFE
There is a financial risk of the withdrawal of a block of policies written by a single independent intermediary. In order to manage
these risks, Discovery diversifies its book of business by source of new business and spread across its brokers and agents.
Brokers and agents
Maximum exposure to single
intermediary % of total
premium income
2023 	2022 	2023 	2022
Long-term insurance
– Discovery Life 	7 800 	7 500 	1.2% 	1.2%
– VitalityLife 	31 443 	30 199 	3.2% 	2.9%
Small concentration (0 – 99 policies)
Medium concentration (100 – 999 policies)
Large concentration (1 000+ policies)
21%
	28%
51%
2023 API concentration by intermediary
– Discovery Life
Small concentration (0 – 99 policies)
Medium concentration (100 – 999 policies)
Large concentration (1 000+ policies)
21%
28%
51%
2022 API concentration by intermediary
– Discovery Life
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 43 of 217 --

43	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.4 	Mismatching and market risk
2.4.1 Assets arising from insurance contracts
Assets arising from insurance contracts in the Statement of financial position include assets for Discovery Life and VitalityLife.
The reconciliation of the assets arising from insurance contracts disclosed in the cash flows below, to the Statement of financial
position (refer to note 5) is as follows:
R million 	2023 	2022
Assets arising from insurance contracts relating to:
– Discovery Life 	41 263 	39 661
– VitalityLife 	22 602 	16 984
Total 	63 865 	56 645
Cash flows are calculated in accordance with the accounting policies. Contractual premium and benefit increases are recognised in
the cash flow projections.
The expected discounted future cash flows utilised in the calculation of assets arising from insurance contracts are disclosed in the
table below. Discounting is performed using:
– the prevailing risk-free SA and US yield curve for Discovery Life; and
– a modified passive rate for VitalityLife whereby the one-year average of the risk-free gilt yield is used. The assumption is only
changed if the one-year average changes by more than a pre-determined range around the set passive rate.
R million 	Total 	Year 1 	Years 2 to 5 	Years 6 to 10 	Years 11 to 20 	Years 21+
2023
Discovery Life 	41 263 	2 787 	10 210 	9 464 	10 773 	8 029
VitalityLife 	22 602 	4 375 	12 330 	9 413 	9 239 	(12 755)
2022
Discovery Life 	39 661 	2 403 	9 267 	8 761 	10 662 	8 568
VitalityLife 	16 984 	3 746 	10 523 	7 587 	7 012 	(11 884)
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 44 of 217 --

44	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.4 	Mismatching risk continued
2.4.2 Liabilities arising from insurance contracts continued
Refer to page 52 for a breakdown of the assets backing these liabilities. The reconciliation of the liabilities arising from
insurance contracts disclosed in the cash flows below, to the Statement of financial position (refer to note 18) is as follows:
R million 	2023
Restated1
2022
Long-term insurance contract liabilities with fixed and guaranteed terms (note 18) 	22 087 	21 273
Long-term insurance contract liabilities with fixed and guaranteed terms: VitalityInvest 	(34) 	(5)
Long-term insurance contract liabilities with fixed and guaranteed terms 	22 053 	21 268
Negative insurance liability included in unit-linked insurance contracts (note 18) 	(5 770) 	(5 541)
Discovery Invest value of liabilities arising from insurance contracts 	16 283 	15 727
The expected discounted future cash flows in the calculation of liabilities arising from insurance contracts are disclosed in the table
below, allowing for compulsory and discretionary margins. Discounting is performed using the prevailing risk free SA gilt yield curve.
R million 	Total 	Year 1 	Years 2 to 5 	Years 6 to 10 	Years 11 to 20 	Years 21+
2023
Discovery Invest
Long-term insurance
contract liabilities with fixed
and guarantee terms 	(22 053) 	(5 608) 	(14 655) 	(800) 	(682) 	(308)
Negative insurance liability
included in unit-linked
insurance contracts 	5 770 	(41) 	2 121 	2 278 	1 909 	(497)
2022 Restated 1
Discovery Invest
Long-term insurance
contract liabilities with fixed
and guarantee terms 	(21 268) 	(4 460) 	(15 450) 	(540) 	(554) 	(264)
Negative insurance liability
included in unit-linked
insurance contracts 	5 541 	29 	1 667 	2 055 	1 911 	(121)
1 The comparative information has been restated. Refer to note 45 for detail.
2.4.3 Market risk – Interest rate risk
DISCOVERY LIFE
For Discovery Life, increased nominal or real interest rates would result in an adverse impact on the present value of future profits.
Cash flows on a material segment of the book are linked to inflation. While this retains cash flows in real terms, this segment is
exposed to real interest rate movements. The balance of the book is exposed to changes in the nominal rates.
VITALITYLIFE
As a long-term insurance provider in the UK, VitalityLife has significant exposure to long-term interest rate risk, given the impact on
reserves of lower investment rate assumptions related to fixed future premium receipts to meet policy obligations. Accordingly,
lower long-term interest rates and yield assumptions may negatively impact on the valuation of future policy obligations and result
in a valuation loss.
Interest rates in the UK have displayed significant volatility in recent years and after a period of decline have risen sharply in the last
12 months. In recent years, VitalityLife has implemented an interest rate risk mitigation strategy to protect itself against volatility in
interest rates by entering into derivative contracts. This strategy ensures that the VitalityLife business operates well within its pre-
determined risk appetite and removes a large amount of volatility from its earnings and cash flows.
A number of the VitalityLife swaps were removed just before the end of the period under review. In addition, the swaption purchased
in June 2022 was sold. VitalityLife continues to hold interest rate swaps to manage the interest rate risk on the legacy PAC book of
business. At 30 June 2023 the derivative instruments comprised of interest rate swaps, with a nominal value of GBP226.8 million
(R5 441 million). This interest rate swap derivative swaps exposure to variable interest rates in return for a fixed interest rate reference
to the 50-year UK SONIA swap rate (VitalityLife receives the fixed rate and pays the variable rate). The weighted average (by nominal
value) fixed interest rate is 2.248%. The interest rate swap derivative is in place for an extended period of time.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 45 of 217 --

45	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.4 	Mismatching risk continued
2.4.3 Market risk – Interest rate risk continued
VITALITYLIFE continued
Due to the nature of the underlying exposures, the hedge accounting requirements of IFRS were not met. Therefore, these derivative
instruments were classified at fair value with changes recognised in profit or loss throughout the term which may result in volatility in
the reported IFRS earnings of VitalityLife. As at 30 June, the following mark-to-market positions were recorded:
GBP/Rand million
June 2023 	June 2022
Line item in financial statements 	GBP 	R 	GBP 	R
Statement of financial position 	(65.1) 	(1 562) 	19.8 	395
Interest rate swap valuation 	Financial liabilities:
Derivative – financial instruments at fair value
through profit or loss 	– 	– 	(3.9) 	(79)
Other payables:
VitalityLife working capital funding1 	(65.1) 	(1 562) 	12.9 	258
Swaption valuation 	Financial assets:
Derivative – financial instruments at fair value
through profit or loss 	– 	– 	10.8 	216
Income statement 	(54.9) 	(1 177) 	(34.9) 	(707)
Fair value remeasurement 	Net fair value losses on financial assets at fair
value through profit or loss 	(54.9) 	(1 177) 	(47.8) 	(968)
Marketing and administration expenses1 	– 	– 	12.9 	261
1 The VitalityLife results are reclassified to account for the contractual arrangement in respect of the business written on the PAC license, as on
insurance contract which Discovery issues under IFRS 4 Insurance Contracts.
DISCOVERY LIFE AND DISCOVERY INVEST
The outstanding claims and incurred but not reported claims are mostly short term in nature and have consequently been matched
with cash. Reserves backing income contribution benefits in payment are backed by a combination of cash, money market, gilts and
negative Rand reserves of appropriate duration.
The risk arising from the global linkage benefit is fully reinsured and Discovery does not face any net direct market risk.
For Discovery Invest, guaranteed return plan liabilities are backed by a combination of negative Rand reserves and bonds of
appropriate duration. As maturity approaches, cash flows from negative reserves are invested in bonds and therefore a reinvestment
risk exists. Furthermore, investment policy fee income is dependent on the underlying value of policyholders’ investments, which
may be interest rate sensitive.
2.4.4 Market Risk – Currency risk
All of VitalityLife’s insurance benefits and premiums are Pound Sterling denominated as all business is sold in the UK market. A
significant part of operational expenses are Rand denominated as systems and administration are based in South Africa. This
creates a potential mismatching risk.
The Dollar Life Plan, offered by Discovery Life provides a sum insured in US Dollars. Premiums are paid in Rands but linked to the
Rand/USD exchange rate. Certain versions of the Dollar Life Plan provide guarantees on the Rand/USD exchange rate for a specified
period, thereby exposing Discovery Life to currency risk.
Other insurance business lines do not have significant currency risk.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 46 of 217 --

46	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.5 	Sensitivity analysis
The financial impact of the key risks that Discovery is exposed to can be demonstrated by considering the sensitivity of the financial
results to a hypothetical change in the underlying assumptions or prevailing market conditions.
Although the sensitivities demonstrate the impact of a change in assumption, the results generally cannot be extrapolated to
demonstrate the impact on future earnings and earnings forecasts.
For each sensitivity illustrated, all other assumptions have been left unchanged. No allowance has been made for any management
action, for example premium increases, to react to the worse-than-expected experience.
The ranges of sensitivity were chosen for illustration purposes and do not represent the extremes of possible experience. The
sensitivities shown under insurance risks consider a change in the long-term assumption used in the projection model. The following
sensitivities are provided under insurance risk:
 Lapses: The lapse, surrender and withdrawal rates are increased or decreased across all policies and investment plans;
 Long-term investment return and inflation: A parallel shift is assumed in the yield curve. The investment return, inflation,
renewal expense inflation and inflation-linked premium increases are adjusted consistently;
 Renewal expenses: Renewal expense per policy is increased or decreased across all policies and investment plans; and
 Mortality and morbidity: The mortality rate, disability rate and severe illness rates are increased and decreased across all
policies and investment plans.
 Real rate returns: The assumed real rate curve is increased or decreased across all policies and investment plans.
2.5.1 Discovery Life
Gross exposure 	Net of reinsurance
Assets arising
from insurance
contracts
R million
Change
from base
assumption
%
Assets arising
from insurance
contracts
R million
Change
from base
assumption
%
Base: June 2023 assumptions 	41 263 	37 746
Lapses +10% (e.g. from x% to 1.1x%) 	36 791 	(10.8) 	33 404 	(11.5)
Lapses –10% (e.g. from x% to 0.9x%) 	46 603 	12.9 	42 951 	13.8
Investment return and inflation –1% (e.g. from 5% to 4%) 	42 574 	3.2 	39 003 	3.3
Investment return and inflation +1% (e.g. from 5% to 6%) 	40 002 	(3.1) 	36 533 	(3.2)
Expense assumption +10% 	40 686 	(1.4) 	37 169 	(1.5)
Expense assumption –10% 	41 840 	1.4 	38 323 	1.5
Mortality and morbidity +10% 	33 724 	(18.3) 	31 967 	(15.3)
Mortality and morbidity –10% 	49 011 	18.8 	43 728 	15.8
Real curve –1% and inflation +1% 	44 414 	7.6 	40 664 	7.7
Real curve +1% and inflation –1% 	38 755 	(6.1) 	35 440 	(6.1)
Base: June 2022 assumptions 	39 661 	36 182
Lapses +10% (e.g. from x% to 1.1x%) 	34 937 	(11.9) 	31 602 	(12.7)
Lapses –10% (e.g. from x% to 0.9x%) 	45 366 	14.4 	41 735 	15.3
Investment return and inflation –1% (e.g. from 5% to 4%) 	40 928 	3.2 	37 388 	3.3
Investment return and inflation +1% (e.g. from 5% to 6%) 	38 434 	(3.1) 	35 006 	(3.3)
Expense assumption +10% 	39 094 	(1.4) 	35 614 	(1.6)
Expense assumption –10% 	40 230 	1.4 	36 750 	1.6
Mortality and morbidity +10% 	32 044 	(19.2) 	30 321 	(16.2)
Mortality and morbidity –10% 	47 459 	19.7 	42 212 	16.7
Real curve –1% and inflation +1% 	42 977 	8.4 	39 251 	8.5
Real curve +1% and inflation –1% 	37 050 	(6.6) 	33 782 	(6.6)
The above sensitivities reflect the impact on profit or loss if there are no discretionary margins.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 47 of 217 --

47	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.5 	Sensitivity analysis continued
2.5.1 Discovery Life continued
Liabilities arising from insurance contracts consist of outstanding reported claims, Incurred But Not Reported (IBNR) claims and
long-term liabilities relating to fixed and guaranteed contracts and unit-linked contracts. For outstanding reported claims and IBNR
claims any deviation from the best estimate liabilities would have a direct impact on profit.
For long-term insurance liabilities relating to fixed and guaranteed contracts and unit-linked contracts (refer to reconciliation on
note 2.4.2), the sensitivities are detailed in the table below:
Liabilities
under
insurance
contracts
R million
Change
from base
assumption
%
Base: June 2023 assumptions 	16 283
Lapses +10% (e.g. from x% to 1.1x%) 	16 391 	0.7
Lapses –10% (e.g. from x% to 0.9x%) 	16 217 	(0.4)
Investment return and inflation –1% (e.g. from 5% to 4%) 	16 824 	3.3
Investment return and inflation +1% (e.g. from 5% to 6%) 	15 778 	(3.1)
Expense assumption +10% 	16 438 	1.0
Expense assumption –10% 	16 128 	(1.0)
Mortality and morbidity +10% 	16 279 	(0.0)
Mortality and morbidity –10% 	16 288 	0.0
Real curve –1% and inflation +1% 	16 647 	2.2
Real curve +1% and inflation –1% 	15 969 	(1.9)
Base: June 2022 assumptions Restated 1 	15 727
Lapses +10% (e.g. from x% to 1.1x%) 	15 749 	0.1
Lapses –10% (e.g. from x% to 0.9x%) 	15 784 	0.4
Investment return and inflation –1% (e.g. from 5% to 4%) 	16 276 	3.5
Investment return and inflation +1% (e.g. from 5% to 6%) 	15 212 	(3.3)
Expense assumption +10% 	15 868 	0.9
Expense assumption –10% 	15 587 	(0.9)
Mortality and morbidity +10% 	15 736 	0.1
Mortality and morbidity –10% 	15 719 	(0.1)
Real curve –1% and inflation +1% 	15 945 	1.4
Real curve +1% and inflation –1% 	15 547 	(1.1)
1 The comparative information has been restated. Refer to note 45 for detail.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 48 of 217 --

48	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.5 	Sensitivity analysis continued
2.5.2 VitalityLife
Gross exposure 	Net of reinsurance
Assets
arising from
insurance
contracts
R million
Change
from base
assumption
%
Assets
arising from
insurance
contracts
R million
Change
from base
assumption
%
Base: June 2023 assumptions 	22 602 	14 014
Lapses +10% (e.g. from x% to 1.1x%) 	21 951 	(2.9) 	13 363 	(4.6)
Lapses –10% (e.g. from x% to 0.9x%) 	23 275 	3.0 	14 726 	5.1
Investment return and inflation –1% (e.g. from 5% to 4%) 	21 484 	(4.9) 	12 774 	(8.8)
Investment return and inflation +1% (e.g. from 5% to 6%) 	23 260 	2.9 	14 800 	5.6
Expense assumption +10% 	22 116 	(2.2) 	13 528 	(3.5)
Expense assumption –10% 	23 089 	2.2 	14 500 	3.5
Mortality and morbidity +10% 	18 217 	(19.4) 	12 154 	(13.3)
Mortality and morbidity –10% 	27 039 	19.6 	15 872 	13.3
Real curve -1% and inflation +1% 	22 764 	0.7 	14 200 	1.3
Real curve +1% and inflation –1% 	22 356 	(1.1) 	13 749 	(1.9)
Base: June 2022 assumptions 	16 984 	9 853
Lapses +10% (e.g. from x% to 1.1x%) 	16 525 	(2.7) 	9 413 	(4.5)
Lapses –10% (e.g. from x% to 0.9x%) 	17 451 	2.7 	10 297 	4.5
Investment return and inflation –1% (e.g. from 5% to 4%) 	15 487 	(8.8) 	8 382 	(14.9)
Investment return and inflation +1% (e.g. from 5% to 6%) 	17 919 	5.5 	10 809 	9.7
Expense assumption +10% 	16 595 	(2.3) 	9 465 	(3.9)
Expense assumption –10% 	17 374 	2.3 	10 244 	4.0
Mortality and morbidity +10% 	13 646 	(19.7) 	8 397 	(14.8)
Mortality and morbidity –10% 	20 361 	19.9 	11 302 	14.7
Real curve -1% and inflation +1% 	17 790 	4.7 	10 713 	8.7
Real curve +1% and inflation –1% 	15 466 	(8.9) 	8 348 	(15.3)
The above sensitivities reflect the impact on profit or loss if there are no discretionary margins.
2.5.3 VitalityHealth – IBNR Reserves
VitalityHealth’s reserves are set based on the results of a frequency and severity model which looks at the expected cost of each claim
which is authorised for treatment. Historical costs per type of claim and the expected shape of emergence of each claims costs are
compared to the amounts already paid to help determine the appropriate reserve for the business. Within the monthly reserving
process, adjustments to the model results are made where evidence arises that there are changes in development patterns.
The Reserving Committee considers both the model results and other business indicators when setting the actual reserves and it is
attended by colleagues from across the relevant business areas including operational, clinical and risk specialists.
The IBNR is GBP53.5 million (R1 284 million) at 30 June 2023 (2022: GBP43.0 million (R860 million)), which approximates 1.7 months’
worth of claims – which is the expected delay in claims reporting discussed above. Claims provisions at 30 June 2023 include a
supplier settlement. The total of such provisions is GBP2.3 million (R55 million) (2022: GBP2.9 million (R58 million)).
VitalityHealth’s IBNR reserves are sensitive to changes in the business’s invoice processing speeds – which has seen significantly
improved stability over recent years. Currently the IBNR is set using the average expected cost of each claim (in the prior period the
IBNR was set as an 80th percentile reserve in recognition of the volatility in the reserving environment). A 50th and 95th percentile
reserve would result in the following:
Million
2023
Rand
2022
Rand
2023
GBP
2022
GBP
Base case 	1 265.2 	846.5 	52.7 	42.3
50th percentile 	1 222.5 	775.4 	50.9 	38.8
95th percentile 	1 395.5 	933.1 	58.2 	46.6
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 49 of 217 --

49	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	MANAGEMENT OF INSURANCE RISK continued
2.5 	Sensitivity analysis continued
2.5.4 Discovery Insure – IBNR Reserves
Discovery Insure’s IBNR reserves are set based on the Bornhuetter-Ferguson model – a reserving model widely used in the short-term
insurance industry. As with other traditional chain ladder models, the model assumes stability in the reporting and settlement delays
and an expected loss ratio to arrive at a view of ultimate claims. In contrast, the outstanding claims reserve (OCR) is set predominantly
by claims assessors.
The claims reserve for the personal lines business, made up of both the IBNR and OCR reserves, is R428 million at 30 June 2023 (2022:
R480 million). Sensitivity tests were performed with the results as outlined below (in the prior period the IBNR reserve was set at the
71st percentile level). Given the OCR is not probabilistic in nature, the sensitivity tests are performed purely on the IBNR reserve.
R million 	2023 	2022
Base case 	428.2 	479.8
50th percentile 	426.8 	469.0
95th percentile 	444.4 	505.5
3. 	MANAGEMENT OF FINANCIAL RISK
Discovery’s activities expose it to a variety of financial risks. Financial risks include market risk, credit risk and liquidity risk.
Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices
and investment return. Market risk that could impact on future cash flows and hence the value of a financial instrument arises from:
 Equity price risk: The impact of changes in equity prices and dividend income.
 Interest rate risk: The impact of changes in market interest rates.
 Currency risk: The impact of changes in foreign exchange rates.
Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an
obligation.
Liquidity risk is the risk that Discovery will encounter difficulty in meeting obligations associated with financial liabilities due to
insufficient cash or other financial asset being available to meet commitments as and when they become due.
Financial risks are managed by Discovery as follows:
 Discovery has appointed reputable external asset managers to manage its investments.
 The Actuarial Committee reviews the overall matching of shareholder and policyholder assets to their respective liabilities.
 The Capital, Currency, and Investment Committee (CCIC) is a sub-committee of the Group Executive Committee and meets
quarterly to focus on shareholder assets and the performance of asset managers responsible for managing these assets. The
CCIC also sets exposure limits for exposures to individual counterparties.
 Discovery periodically engages external consultants to review past investment decisions.
 The Investment Committee is a sub-committee of the CCIC and meets monthly to make operational decisions regarding
Discovery’s liquidity and foreign currency exposure.
Discovery’s approach in monitoring credit risk
Discovery’s credit risk rating systems and processes differentiate and quantify credit risk across counterparties and asset classes.
Discovery uses different credit rating approaches to monitor credit risk dependent on the financial assets. For financial assets with
externally rated ratings, e.g. Moody’s, the external rating is always used. For non-Moody’s rated instruments, the following
approaches will apply:
RATING SCALES FOR FUNDS
A credit rating, being a ranking of creditworthiness, is allocated to the obligor. Where external ratings are unavailable, internal rating
assessments are conducted through analysis of the latest financial and other relevant information, in a consistent and systematic
manner. Where external ratings are available, the standard rating classifications used by the external rating agencies have been
applied and is mapped to the internal categories per the Group’s internal rating scale. The internal rating scale is based on internal
definitions and influenced by definitions published by the external ratings agency, Moody’s. Where applicable, internal ratings are
mapped to equivalent external Moody’s rating scales.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 50 of 217 --

50	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
Discovery’s approach in monitoring credit risk continued
The Group’s Internal Rating Scale categories for disclosure purposes are defined below:
Group internal grading
for disclosures
Moody’s Investors Service
equivalent of internal rating
S&P Global Ratings equivalent
of internal rating
Discovery internal risk weighting
(RW) grading for internal credit
risk assessment1
Investment grade
Grade Aaa 	Aaa 	AAA 	RW1
Grades Aa1, Aa2, Aa3 	Aa1, Aa2, Aa3 	AA+, AA, AA- 	RW2-RW4
Grades A1, A2, A3 	A1, A2, A3 	A+,A,A- 	RW5-RW7
Grades Baa1, Baa2, Baa3 	Baa, Baa1, Baa2, Baa3 	BBB+,BBB,BBB- 	RW8-RW10
Sub-investment grade
Grades Ba1, Ba2, Ba3 	Ba1, Ba2, Ba3 	BB+, BB, BB- 	RW11-RW14
Grades B1, B2, B3 	B1, B2, B3 	B+, B, B- 	RW16-RW19
Grades Caa1, Caa2, Caa3 	Caa1, Caa2, Caa3 	CCC+, CCC, CCC- 	RW22-RW23
Grades Ca1, Ca2, Ca3 	Ca1, Ca2, Ca3 	CC 	RW24
Default
Grade C 	C 	RD 	RW25
1 Discovery utilises an internal risk weighting (RW) scale, calibrated to external rating agencies to develop internal credit ratings for financial
guarantee contracts and its internal borrowings amongst Discovery Group entities. It is a 25 point rating scale. The ratings are mapped to their
probability of default, which is then calibrated to a similar range of S&P Global Ratings and Moody’s Investors Service ratings.
Where a short-term rating is available, e.g. short-term cash deposits, Discovery includes for the purposes of credit risk disclosures
the financial instrument as per the respective entity’s long-term credit rating.
Discovery’s internal grading for disclosures aligns to Moody’s Investors Service definitions of their respective ratings as follows:
Investment grade 	Aaa 	Obligations rated Aaa are judged to be of the highest quality, subject to the lowest level
of credit risk
Aa 	Obligations rated Aa are judged to be of the highest quality, subject to the lowest level
of credit risk
A 	Obligations rated A are judged to be upper-medium grade and are subject to low credit risk
Baa 	Obligations rated Baa are judged to be medium-grade and subject to moderate credit risk
and as such may possess certain speculative characteristics
Sub-investment grade 	Ba 	Obligations rated Ba are judged to be speculative and are subject to substantial credit risk
B 	Obligations rated B are considered speculative and are subject to high credit risk
Caa 	Obligations rated Caa are judged to be speculative of poor standing and are subject to very
high credit risk
Ca 	Obligations rated Ca are highly speculative and are likely in, or very near, default, with
some prospect of recovery of principal and interest
Default 	C 	Obligations rated C are the lowest rated and are typically in default, with little prospect
for recovery of principal or interest
A numerical modifier may be added to each generic rating classification. Each modifier indicates the following:
 the modifier 1 indicates that the obligation ranks in the higher end of its generic rating category
 the modifier 2 indicates a mid-range ranking; and
 the modifier 3 indicates a ranking in the lower end of that generic rating category.
POOLED FUNDS
The Group invests in funds through which it is also exposed to credit risk of the underlying assets in which the funds are invested.
The Group’s exposure to risk is classified at fund level and not at the underlying asset level. Although funds are not rated, fund
managers are required to invest in credit assets within the defined parameters stipulated in the fund’s mandate. These rules limit
the extent to which fund managers can invest in unlisted and/or unrated credit assets and generally restrict funds to the acquisition
of local currency investment grade assets.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 51 of 217 --

51	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
Discovery’s approach in monitoring credit risk continued
DISCOVERY BANK
Loans and advances to customers are categorised with Discovery Bank’s own internally developed credit models. The Discovery
Bank model uses a 10-point Discovery Risk Grade classification, with each point being in two decrements to further distinguish risk.
The following table summarises how Discovery Bank classifies its loans:
Discovery Risk Category 	Discovery Risk Grades 	Risk of default assessment
Exceptional low risk 	DRG1 – DRG2 	Less than 0.4%
Low risk 	DRG3 – DRG5 	Less than 1.5%
Medium risk 	DRG5 – DRG8 	Less than 6%
High risk 	DRG8 – DRG9 	Less than 24%
Very high risk 	DRG10 	More than 24%
Categorisation of business in the analysis of financial risk
To assist in the analysis of the financial risks that Discovery and its policyholders are exposed to, the Statement of financial position
has been divided into five categories, based on the nature of the products provided by Discovery and the nature of the financial
assets held to back the policyholder liabilities.
 Unit-linked investment contracts: this category relates to contracts issued by Discovery where there is a direct relationship
between the returns earned on the underlying portfolio and the returns credited to the contract. Discovery holds the assets on
which the unit prices are based and as a result there is no mismatch. The market risk (including equity price, interest rate and
currency risk) as well as the credit risk for these contracts is therefore borne by the policyholder and not the Discovery shareholders.
 Unit-linked insurance contracts: this category relates to insurance contracts issued by Discovery which have a component
that is linked to the units of an underlying portfolio. For this component, Discovery holds the assets on which the unit prices are
based. However, the gross unit liabilities are reduced by the present value of future charges less the present value of future
expenses and risk claims. Under IFRS, the unit-linked component is not accounted for separately from the host insurance
contract. These contracts expose both Discovery shareholders and policyholders to financial risks.
 Insurance contracts: this category relates to insurance contracts issued by Discovery which Discovery funds with a portfolio of
matching assets, exposing the Discovery shareholders to financial risk. The financial assets in this category include those
financial assets held within specific portfolios matched to specific liabilities, for example claims reserves and IBNR.
 Shareholder financial assets and liabilities: this category includes the financial assets and financial liabilities that expose the
Discovery shareholders to financial risks, including financial assets and cash backing insurance reserves and statutory capital.
This category includes those financial assets that are not held in specific portfolios matched to insurance related liabilities.
 Shareholder non-financial assets and liabilities: No financial risk disclosures are required for these items.
The financial assets at fair value in each of these categories are sub-categorised into a second tier of classification, namely:
 Equity portfolios
 Debt portfolios
 Money market portfolios
 Multi-asset portfolios
In applying the definitions below, reliance is placed on the classifications by asset managers.
Equity portfolios
The following have been defined as equity portfolios:
 Portfolios that invest a minimum of circa 75% of the market value of the portfolio in equities and generally seek maximum
capital appreciation as their primary goal. These portfolios invest in selected shares across the range of large, mid, and smaller
cap shares. While the managers of these portfolios may subscribe to different investment styles or approaches, their intent is
to produce a risk/return profile that is comparable with the risk/return profile of the overall equities market. The portfolios in
this category offer medium to long-term capital growth as their primary investment objective.
 Investments or portfolios of equity linked notes.
Debt (interest-bearing) portfolios
Interest-bearing portfolios are portfolios that invest exclusively in bond, money market investments and other interest earning
securities. These portfolios may not include equity securities, real estate securities or cumulative preference shares.
In addition to the above the inflation-linked bonds have been defined as Debt portfolios. Inflation-linked bonds are essentially loans
where the principal and interest payments are contractually linked to an inflation measure.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 52 of 217 --

52	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
Money market portfolios
Money market portfolios are portfolios that seek to maximise interest income, preserve the portfolio’s capital, and provide
immediate liquidity. This is achieved by investing in money market instruments with a maturity of less than 13 months while the
average duration of the underlying assets may not exceed 90 days and a weighted average legal maturity of 120 days. The portfolios
are typically characterised as short term, highly liquid vehicles.
Multi-asset portfolios
Multi-asset portfolios are portfolios that invest in a wide spread of investments in the equity, bond, money, and property markets
to maximise total returns, comprising capital and income growth over the long term. These portfolios do not fall within the
thresholds that have been determined for the Equity portfolios or the Debt portfolios.
The following tables reconcile the Group Statement of financial position to the classes of risks and the categories listed on the
previous pages.
Group
R million 	Total
Unit–linked
investment
contracts
Unit–linked
insurance
contracts
Insurance
contracts
Shareholder
Financial
assets and
liabilities
Other
assets and
liabilities
30 June 2023
Assets arising from insurance contracts 	63 865 	– 	– 	63 865 	– 	–
Loans and advances to customers
at amortised cost 	4 702 	– 	– 	– 	4 702 	–
Investments at amortised cost
Unlisted:
– Debt 	6 856 	– 	– 	– 	6 856 	–
– Fixed deposits 	3 054 	– 	– 	– 	3 054 	–
Financial instruments mandatorily
at fair value through profit or loss:
Listed:
– Equity portfolios 	50 204 	22 218 	27 425 	361 	200 	–
– Debt portfolios 	42 172 	8 960 	18 303 	13 521 	1 388 	–
– Money market portfolios 	11 721 	1 685 	2 884 	3 677 	3 475 	–
– Multi-asset portfolios 	33 535 	12 946 	20 247 	246 	96 	–
Unlisted:
– Equity portfolios 	6 321 	387 	5 884 	– 	50 	–
– Debt portfolios 	401 	1 	262 	– 	138 	–
– Money market portfolios 	10 935 	1 034 	1 908 	6 382 	1 611 	–
– Multi-asset portfolios 	137 	– 	137 	– 	– 	–
Derivative financial instruments
at fair value:
– used as cash flow hedges 	59 	– 	– 	– 	59 	–
– not designated as hedging
instruments 	60 	– 	– 	– 	60 	–
Receivables:
– Insurance receivables 	10 316 	– 	– 	– 	10 316 	–
– Contract receivables 	1 268 	– 	– 	– 	1 268 	–
– Other receivables 	4 475 	200 	920 	28 	1 916 	1 411
Reinsurance contracts 	709 	– 	– 	709 	– 	–
Cash and cash equivalents 	20 370 	1 158 	4 202 	639 	14 371 	–
Other non-financial assets 	30 767 	– 	979 	– 	– 	29 788
Total assets 	301 927 	48 589 	83 151 	89 428 	49 560 	31 199
Liabilities arising from insurance
contracts 	114 807 	– 	75 257 	39 550 	– 	–
Liabilities arising from reinsurance
contracts 	14 669 	– 	– 	14 669 	– 	–
Deposits from customers 	14 333 	– 	– 	– 	14 333 	–
Borrowings at amortised cost 	20 586 	11 	21 	1 	20 553 	–
Other payables 	14 780 	533 	1 122 	651 	12 113 	361
Investment contracts at fair value
through profit or loss 	48 044 	48 044 	– 	– 	– 	–
Derivative financial instruments
at fair value:
– used as cash flow hedges 	1 	– 	– 	– 	1 	–
– not designated as hedging
instruments 	19 	1 	2 	– 	16 	–
Other non-financial liabilities 	10 714 	– 	– 	– 	– 	10 714
Total liabilities 	237 953 	48 589 	76 402 	54 871 	47 016 	11 075
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 53 of 217 --

53	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
Group
R million
Restated 1
Total
Restated1
Unit-linked
investment
contracts
Restated 1
Unit-linked
insurance
contracts
Insurance
contracts
Shareholder
Financial
assets and
liabilities
Other
assets and
liabilities
30 June 2022
Assets arising from insurance contracts 	56 645 	– 	– 	56 645 	– 	–
Loans and advances to customers at
amortised cost 	3 944 	– 	– 	– 	3 944 	–
Investments at amortised cost:
Unlisted:
– Debt 	5 205 	– 	– 	– 	5 205 	–
– Fixed deposits 	1 956 	– 	– 	– 	1 956 	–
Financial instruments mandatorily at
fair value through profit or loss:
Listed:
– Equity portfolios 	53 947 	16 270 	37 265 	252 	160 	–
– Debt portfolios 	47 012 	8 594 	18 953 	18 714 	751 	–
– Money market portfolios 	8 052 	415 	830 	327 	6 480 	–
– Multi-asset portfolios 	21 179 	11 330 	9 689 	93 	67 	–
Unlisted:
– Equity portfolios 	4 001 	171 	3 784 	– 	46 	–
– Debt portfolios 	580 	80 	485 	– 	15 	–
– Money market portfolios 	6 628 	1 180 	2 121 	2 131 	1 196 	–
– Multi-asset portfolios 	95 	– 	87 	– 	8 	–
Derivative financial instruments at
fair value:
– used as cash flow hedges 	17 	– 	– 	– 	17 	–
– not designated as hedging
instruments 	259 	9 	12 	– 	238 	–
Non-current asset held for sale 	171 	– 	– 	– 	– 	171
Receivables:
– Insurance receivables 	7 887 	– 	– 	– 	7 887 	–
– Contract receivables 	1 209 	– 	– 	– 	1 209 	–
– Other receivables 	4 017 	370 	890 	13 	1 369 	1 375
Reinsurance contracts 	511 	– 	– 	511 	– 	–
Cash and cash equivalents 	19 775 	1 142 	3 533 	333 	14 767 	–
Other non-financial assets 	28 277 	– 	834 	– 	– 	27 443
Total assets 	271 367 	39 561 	78 483 	79 019 	45 315 	28 989
Liabilities arising from insurance
contracts 	108 067 	– 	70 869 	37 198 	– 	–
Liabilities arising from reinsurance
contracts 	13 192 	– 	– 	13 192 	– 	–
Deposits from customers 	10 881 	– 	– 	– 	10 881 	–
Borrowings at amortised cost 	20 584 	22 	132 	– 	20 430 	–
Other payables 	15 123 	902 	1 107 	438 	12 264 	412
Investment contracts at fair value
through profit or loss 	38 637 	38 637 	– 	– 	– 	–
Derivative financial instruments at
fair value:
– used as cash flow hedges 	56 	– 	– 	– 	56 	–
– not designated as hedging
instruments 	146 	– 	– 	– 	146 	–
Other non-financial liabilities 	11 126 	– 	– 	– 	– 	11 126
Total liabilities 	217 812 	39 561 	72 108 	50 828 	43 777 	11 538
1 The comparative information has been restated. Refer to note 45 for detail.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 54 of 217 --

54	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
The financial risks associated with each category are discussed below.
3.1 	Unit-linked investment contracts
Unit-linked investment contracts relate to contracts where there is a direct relationship between the returns earned on the underlying
portfolio and the returns credited to the contract.
Investments held at risk
of policyholders
R million
Group
2023
Restated1
Group
2022
Financial instruments mandatorily at fair value through profit or loss:
Listed:
– Equity portfolios 	22 218 	16 270
– Debt portfolios 	8 960 	8 594
– Money market portfolios 	1 685 	415
– Multi-asset portfolios 	12 946 	11 330
Unlisted:
– Equity portfolios 	387 	171
– Debt portfolios 	1 	80
– Money market portfolios 	1 034 	1 180
Derivative financial instruments at fair value:
– not designated as hedging instruments 	– 	9
Receivables:
Other receivables at amortised cost 	200 	370
Cash and cash equivalents 	1 158 	1 142
Total assets 	48 589 	39 561
Borrowings at amortised cost 	11 	22
Other payables 	533 	902
Investment contracts at fair value through profit or loss 	48 044 	38 637
Derivative financial instruments at fair value:
– not designated as hedging instruments 	1 	–
Total liabilities 	48 589 	39 561
1 The comparative information has been restated. Refer to note 45 for detail.
3.1.1 Market risk
EQUITY AND INTEREST RATE RISK
Discovery’s primary exposure to market risk from these contracts is the volatility in asset management fees earned by Discovery,
due to the impact of interest rate, equity price and currency movements on the fair value of the assets held in the linked funds, on
which the investment management fees are based. An increase of 10% in the value of the assets would increase the asset
management fees by R78 million per annum (2022: R60 million). A decrease of 10% in the value of the assets would reduce the asset
management fees by R78 million per annum (2022: R60 million).
In respect of IFRS-defined investment management contracts there may be an associated asset for the costs of obtaining contracts.
There is a risk that in the event of adverse market movements, future expected management fees may reduce and consequently
this asset may not be realised and therefore necessitate impairment. There were no impairments necessary in the current or
previous financial year.
CURRENCY RISK
The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with
respect to the US dollar and the UK pound. Foreign exchange risk arises from future commercial transactions and recognised assets
and liabilities. The currency risk is borne by the policyholder.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 55 of 217 --

55	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.1 	Unit-linked investment contracts continued
3.1.2 Credit risk
Credit risk is borne by the policyholder. For the majority of the unit-linked investments, Discovery has invested in mutual funds in
order to provide for obligations under unit-linked investment contract liabilities. Each mutual fund has its own legal constitution and
operates within a mandate that is delegated to the appointed fund manager. Credit risks assumed within the assets held are
controlled by various protection mechanisms within the mandate and in law. Each fund’s trustees or board appoints administrators
who are responsible to ensure that the fund’s mandate and any internal and legislated control procedures are adhered to. In the
event of breach, they are obligated to bring it immediately to the attention of the fund’s trustees or board and management of the
administrators for remedial action.
In the case where unit-linked investment contracts are linked to structured products, Discovery’s policy dictates that these obligations
are matched exactly. At inception of these contracts, assets which have proceeds that exactly match the pay-out under the policy, with
the exception of credit risk, are purchased. Credit risk on these products is therefore also borne by the policyholder.
3.1.3 Liquidity risk
Certain contracts can be surrendered before maturity for a cash surrender value specified in the contractual terms and conditions.
This surrender value is equal to or less than the carrying amount of the contract liabilities. If all the contracts with this option were
surrendered at the financial year-end, a loss of R1 034 million (2022: R935 million) would have been recorded in profit or loss. This
loss would result from an impairment to the asset raised for costs of obtaining contracts, but the impact is reduced by the surrender
penalties receivable. A maturity analysis based on the earliest contractual repayment date would present 100% (2022: 100%) of the
policyholder liabilities due within one year. The assets held to match these policyholder liabilities are realisable in the short term.
3.2 	Unit-linked insurance contracts
A unit-linked insurance contract is an IFRS-defined insurance contract with a component that is linked to the units of an underlying
portfolio.
Investments held at risk
of policyholders
R million
Group
2023
Restated 1
Group
2022
Financial instruments mandatorily at fair value through profit or loss:
Listed:
– Equity portfolios 	27 425 	37 265
– Debt portfolios 	18 303 	18 953
– Money market portfolios 	2 884 	830
– Multi-asset portfolios 	20 247 	9 689
Unlisted:
– Equity portfolios 	5 884 	3 784
– Debt portfolios 	262 	485
– Money market portfolios 	1 908 	2 121
– Multi-asset portfolios 	137 	87
Derivative financial instruments at fair value:
– not designated as hedging instruments 	– 	12
Receivables:
– Other receivables 	920 	890
Cash and cash equivalents 	4 202 	3 533
Other assets 	979 	834
Total assets 	83 151 	78 483
Liabilities arising from insurance contracts 	75 257 	70 869
Borrowings at amortised cost 	21 	132
Other payables 	1 122 	1 107
Derivative financial instruments at fair value:
– not designated as hedging instruments 	2 	–
Total liabilities 	76 402 	72 108
1 The comparative information has been restated. Refer to note 45 for detail.
The assets are greater than the liabilities as a result of the Negative insurance liability of R5 770 million (2022: R5 541 million) included in unit-linked
insurance contracts (refer to note 18) and the deferred tax asset of R979 million (2022: R834 million) in relation to the Individual Policyholder Fund.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 56 of 217 --

56	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.2 	Unit-linked insurance contracts continued
3.2.1 Market risk
Discovery’s primary exposure to market risk from these contracts is the volatility in asset management fees due to the impact of
interest rate, equity price and currency movements on the fair value of the assets held in the linked funds, on which the investment
management fees are based. An increase of 10% in the value of the assets would increase the asset management fees by
R183 million per annum (2022: R147 million). A decrease of 10% in the value of the assets would reduce the asset management fees
by R183 million per annum (2022: R148 million).
3.2.2 Credit risk
The credit risk for the unit-linked insurance contracts is similar to the credit risk for the unit-linked investment contracts. Refer to
section 3.1.2 on the detail for the exposure to the credit risk.
3.2.3 Liquidity risk
All contracts can be surrendered before maturity for a cash surrender value specified in the contractual terms and conditions. This
surrender value is equal to or less than the carrying amount of the contract liabilities. If all the contracts with this option were
surrendered at the financial year-end, a loss of R6 234 million (2022: R5 805 million) would have been recorded in profit or loss. This
loss results from the impairment of assets arising from insurance contracts relating to these contracts, but the impact is reduced
by the surrender penalties receivable.
The assets held to match these policyholder liabilities are highly liquid and are realisable in the short term. A maturity analysis based
on the earliest contractual repayment date is as follows:
Group
R million 	Total
Restated 1
<1
Year
1 – 2
Years
3 – 5
Years
30 June 2023
Unit-linked insurance contracts 	81 031 	80 624 	177 	230
30 June 2022
Unit-linked insurance contracts 	76 448 	76 231 	98 	119
1 The comparative information has been restated. Refer to note 45 for detail.
3.3 	Insurance contracts
For insurance contracts, Discovery funds the insurance liabilities with a portfolio of matching assets.
R million
Group
2023
Group
2022
Assets arising from insurance contracts 	63 865 	56 645
Financial instruments mandatorily at fair value through profit or loss:
Listed:
– Equity portfolios 	361 	252
– Debt portfolios 	13 521 	18 714
– Money market portfolios 	3 677 	327
– Multi-asset portfolios 	246 	93
Unlisted:
– Money market portfolios 	6 382 	2 131
Receivables:
– Other receivables 	28 	13
Reinsurance contracts 	709 	511
Cash and cash equivalents 	639 	333
Total assets 	89 428 	79 019
Liabilities arising from insurance contracts 	39 550 	37 198
Liabilities arising from reinsurance contracts 	14 669 	13 192
Borrowings at amortised cost 	1 	–
Other payables 	651 	438
Total liabilities 	54 871 	50 828
3.3.1 Market risk
When calculating the liabilities arising from insurance contracts, an increase/decrease in the investments would result in an
increase/decrease in the liability but it may not be an equal Rand value movement, resulting in the difference being accrued to the
shareholders. Discovery aims to closely match liabilities with appropriate assets and maintains sufficient assets to protect against
residual mismatches between assets and liabilities at a 99.5% confidence interval over a one-year time horizon.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 57 of 217 --

57	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.3 	Insurance contracts continued
3.3.2 Credit risk
Discovery is exposed to credit risk through financial investments comprising of money market portfolios and debt portfolios entered
into to match policyholders’ insurance contract liabilities. Discovery is exposed to the issuer’s credit standing on these instruments
which is monitored by the CCIC by setting a minimum credit rating. Discovery has appointed reputable asset managers to manage
these instruments.
Group
R million 	Total
Aaa1
Aaa2
Aaa3
Aa1
Aa2
Aa3
A1
A2
A3
Ba1
Ba2
Ba3 	Govt 1
Pooled
funds
30 June 2023
Financial instruments mandatorily
at fair value through profit or loss:
Listed:
– Debt portfolios 	13 521 	– 	28 	2 	753 	12 727 	11
– Money market portfolios 	3 677 	– 	– 	– 	3 677 	– 	–
Unlisted:
– Money market portfolios 	6 382 	– 	372 	199 	5 811 	– 	–
Reinsurance contracts 	709 	– 	370 	339 	– 	– 	–
Cash and cash equivalents 	639 	– 	6 	10 	623 	– 	–
Total 	24 928 	– 	776 	550 	10 864 	12 727 	11
30 June 2022
Financial instruments mandatorily
at fair value through profit or loss:
Listed:
– Debt portfolios2 	18 714 	1 	2 	– 	588 	18 085 	38
– Money market portfolios 	327 	– 	– 	– 	325 	– 	2
Unlisted:
– Money market portfolios 	2 131 	– 	146 	– 	1 967 	18 	–
Reinsurance contracts 	511 	– 	321 	166 	24 	– 	–
Cash and cash equivalents 	333 	– 	– 	1 	332 	– 	–
Total 	22 016 	1 	469 	167 	3 236 	18 103 	40
1 These instruments are issued by the South African government.
2 In the prior period, SA Government bonds of R11 619 million were disclosed under Ba rating. The correct classification should have been Govt. The
classification has been corrected in the table above. .
3.3.3 Liquidity risk
The liquidity risk for assets and liabilities arising from insurance contracts are discussed in insurance risks in note 2 Management
of Insurance Risk. The financial investments held at fair value through profit or loss are realisable in the short term.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 58 of 217 --

58	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities
The shareholders are exposed to financial risk through the following financial assets and liabilities:
Investments held at risk
of shareholders
R million
Group
2023
Group
2022
Loans and advances to customers at amortised cost 	4 702 	3 944
Investments at amortised cost:
Unlisted:
– Debt 	6 856 	5 205
– Fixed deposits 	3 054 	1 956
Financial instruments mandatorily at fair value through profit or loss:
Listed:
– Equity portfolios 	200 	160
– Debt portfolios 	1 388 	751
– Money market portfolios 	3 475 	6 480
– Multi-asset portfolios 	96 	67
Unlisted:
– Equity portfolios 	50 	46
– Debt portfolios 	138 	15
– Money market portfolios 	1 611 	1 196
– Multi-asset portfolios 	– 	8
Derivative financial instruments at fair value:
– used as cash flow hedges 	59 	17
– not designated as hedging instruments 	60 	238
Receivables:
– Insurance receivables 	10 316 	7 887
– Contract receivables 	1 268 	1 209
– Other receivables at amortised cost 	1 916 	1 369
Cash and cash equivalents 	14 371 	14 767
Total assets 	49 560 	45 315
Deposits from customers 	14 333 	10 881
Borrowings at amortised cost 	20 553 	20 430
Other payables 	12 113 	12 264
Derivative financial instruments at fair value:
– used as cash flow hedges 	1 	56
– not designated as hedging instruments 	16 	146
Total liabilities 	47 016 	43 777

-- 59 of 217 --

59	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.1 Market risk
EQUITY PRICE RISK
Investments
Discovery is exposed to equity price risk through its equity investments held that have been classified as investments at fair value
through profit or loss (FVTPL), on the Statement of financial position. To manage its equity risk arising from investments in Equity
portfolios of R250 million (2022: R206 million), the Group diversifies its portfolio and uses experienced asset managers.
For shareholder investments, a reasonable increase of 10% in the equity markets would result in a profit of R20 million before tax
(2022: R16 million). A reasonable decrease of 10% in the equity markets would result in a loss of R20 million before tax (2022:
R16 million). This impact would be recognised in profit or loss and equity. The sensitivity assumes that the equity markets had
increased/decreased by 10% with all other variables held constant.
Discovery is also exposed to equity price risk through its cash-settled share incentive schemes, namely the Phantom share scheme and
the Acquisition share scheme, the details of which are described in note 32. This liability has been included in Other payables at
amortised cost in the Statement of financial position. To manage this risk, Discovery has purchased total return equity swaps (TRS)
from Ba2 and Ba3 (2022: Ba1) South African banks to hedge a portion of its exposure to changes in the Discovery share price.
With effect from 1 July 2022 the hedges became ineffective. Accordingly, Discovery discontinued hedge accounting under IFRS on these
TRSs. Previously accumulated balances in the hedge reserve will be reclassified to profit or loss during the future service period.
INTEREST RATE RISK
Sensitivity to changes in interest rates is relevant to financial assets and financial liabilities bearing floating interest rates due to the
risk that future cash flows will fluctuate. However, sensitivity will also be relevant to fixed-rate financial assets and financial liabilities
that are remeasured to fair value. The table below details the specific interest rate risk that the Group is exposed to:
Group
R million
Carrying
amount 	Fixed 	Floating
Non-interest
bearing
30 June 2023
Loans and advances to customers at amortised cost 	4 702 	– 	4 702 	–
Investments at amortised cost:
Unlisted:
– Debt 	6 856 	6 856 	– 	–
– Fixed deposits 	3 054 	2 783 	271 	–
Financial instruments mandatorily at fair value through
profit or loss:
Listed:
– Debt portfolios 	1 388 	1 012 	376 	–
– Money market portfolios 	3 475 	2 497 	978 	–
– Multi-asset portfolios 	96 	– 	– 	96
Unlisted:
– Debt portfolios 	138 	116 	22 	–
– Money market portfolios 	1 611 	703 	908 	–
Derivative financial instruments at fair value:
– used as cash flow hedges 	59 	59 	– 	–
– not designated as hedging instruments 	60 	– 	31 	29
Receivables:
– Insurance receivables 	10 316 	– 	– 	10 316
– Contract receivables 	1 268 	– 	– 	1 268
– Other receivables at amortised cost 	1 916 	130 	385 	1 401
Cash and cash equivalents 	14 371 	224 	13 387 	760
Total financial assets 	49 310 	14 380 	21 060 	13 870
Deposits from customers 	14 333 	3 434 	10 505 	394
Borrowings at amortised cost 	20 553 	9 052 	11 501 	–
Other payables at amortised cost 	12 113 	8 	3 105 	9 000
Derivative financial instruments at fair value:
– used as cash flow hedges 	1 	1 	– 	–
– not designated as hedging instruments 	16 	– 	– 	16
Total financial liabilities 	47 016 	12 495 	25 111 	9 410
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 60 of 217 --

60	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.1 Market risk continued
Group
R million
Carrying
amount 	Fixed 	Floating
Non-interest
bearing
30 June 2022
Loans and advances to customers at amortised cost 	3 944 	– 	3 944 	–
Investments at amortised cost:
Unlisted:
– Debt 	5 205 	5 2051 	– 	–
– Fixed deposits 	1 956 	1 610 	346 	–
Financial instruments mandatorily at fair value through
profit or loss:
Listed:
– Debt portfolios 	751 	620 	131 	–
– Money market portfolios 	6 480 	2 470 	3 993 	17
– Multi-asset portfolios 	67 	1 	– 	66
Unlisted:
– Debt portfolios 	15 	3 	12 	–
– Money market portfolios 	1 196 	26 	1 170 	–
– Multi-asset portfolios 	8 	– 	– 	8
Derivative financial instruments at fair value:
– used as cash flow hedges 	17 	17 	– 	–
– not designated as hedging instruments 	238 	– 	216 	22
Receivables:
– Insurance receivables 	7 887 	– 	– 	7 887
– Contract receivables 	1 209 	– 	– 	1 209
– Other receivables at amortised cost 	1 369 	259 	10 	1 100
Cash and cash equivalents 	14 767 	122 	14 580 	65
Total financial assets 	45 109 	10 333 	24 402 	10 374
Deposits from customers 	10 881 	3 372 	7 360 	149
Borrowings at amortised cost 	20 430 	9 859 	10 571 	–
Other payables at amortised cost 	12 264 	7 381 	26 	4 857
Derivative financial instruments at fair value:
– used as cash flow hedges 	56 	56 	– 	–
– not designated as hedging instruments 	146 	– 	79 	67
Total financial liabilities 	43 777 	20 668 	18 036 	5 073
1 In the prior period unlisted debt was incorrectly disclosed under Floating, instead of Fixed. This has been corrected in the table above.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 61 of 217 --

61	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.1 Market risk continued
Investments
For shareholder investments with a floating rate at amortised cost a 1% increase/decrease in the local interest rate would result in
an impact on profit or loss (investment income) and equity before tax of R2 million (2022: R67 million). The sensitivity assumes that
the interest rate had increased/decreased by 1% with all other variables held constant.
Borrowings at amortised cost and related hedges
For the floating interest rate borrowings at amortised cost, a 1% increase/decrease in the local interest rate would result in an
impact on profit or loss (finance costs) and equity before tax of R67 million (2022: R65 million). The sensitivity assumes that the
interest rate had increased/decreased by 1% with all other variables held constant.
Discovery is exposed to interest rate risk through long-term borrowings held with various financial institutions. Refer to note 20
Borrowings at amortised costs for a breakdown of the borrowings, including details of fixed rate and floating rate facilities.
2023 	2022
Group
R million 	Ref
Carrying
value
Facility
value
Carrying
value
Facility
value
Interest rate risk from borrowings from banks
Fixed interest rate loan facilities 	4 827 	4 999 	5 737 	5 850
Floating interest rate facilities with floating-to-fixed
interest rate swap 	i 	4 569 	4 518 	5 038 	5 000
Floating interest rate facilities 	3 250 	5 341 	2 411 	5 109
Foreign floating interest rate facilities 	3 682 	3 080 	3 122 	4 281
Total bank borrowings (refer to note 20) 	16 328 	17 938 	16 308 	20 240
i. During prior years and in the current financial year, Discovery entered into long-term borrowing facilities at floating interest
rates, which expose Discovery to cash flow interest rate risk. This risk has been managed by using floating-to-fixed interest rate
swaps. These interest rate swaps have the economic effect of converting the borrowings from floating to fixed rates. Interest is
payable quarterly in arrears, with capital repayable on maturity. The hedge ratio is 1:1.
The Group enters into interest rate swaps that have similar critical terms as the hedged item, such as reference rate, reset dates,
payment dates, maturities, and notional amount. As all critical terms matched during the year, there is an economic relationship.
Under the Group’s policy, the critical terms of the hedging instrument, such as the settlement dates, maturity dates and notional
amount, are matched with the interest rate risk of the hedged item.
Hedge ineffectiveness for interest rate swaps can arise from:
– day one fair value of the swap;
– events leading to mismatch in terms; and
– the credit value/debit value adjustment on the interest rate swaps which is not matched by the loan.
The fair value movement of the notional cash flow interest rate hedge accumulated in equity is as follows:
Group
R million 	2023 	2022
Balance at beginning of the year 	39 	335
Unrealised gains accumulated in equity 	(76) 	(296)
Recycled to profit or loss during the current year1 	(4) 	–
Balance at end of the year 	(41) 	39
The cash flow hedge will be recycled to profit or loss as follows:
Recycled to profit or loss within one year 	(9) 	20
Recycled to profit or loss within two to five years 	(32) 	19
(41) 	39
1 Disclosed as finance costs in profit or loss.

-- 62 of 217 --

62	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.1 Market risk continued
The interest rate swaps held by the Group at 30 June were:
Group
R million
2023 	2022
Nominal
value
Fair value
asset
Nominal
value
Fair value
liability
Maturity date:
21 November 2022 	– 	– 	500 	(7)
2 March 2023 	– 	– 	1 000 	(14)
21 August 2023 	500 	5 	500 	13
21 November 2024 	800 	1 	800 	1
21 November 2024 	1 200 	21 	1 200 	(19)
21 August 2026 	300 	7 	300 	3
21 August 2026 	700 	(1) 	700 	(16)
21 May 2027 	509 	9 	– 	–
21 May 2027 	509 	16 	– 	–
4 518 	58 	5 000 	(39)
Deposits from customers
For the floating interest rate deposits measured at amortised cost a 1% increase/decrease in the local interest rate would result in
an impact on profit or loss (finance cost) and equity before tax of R14.3 million (2022: R10.5 million). The sensitivity assumes that
the interest rate had increased/decreased by 1% with all other variables held constant.
Group
R million
2023
Carrying
value
2022
Carrying
value
Term deposits from customers – fixed rate 	3 434 	3 372
Term deposits from customers – variable rates 	3 232 	1 807
On demand deposits from customers – non-rate sensitive 	394 	149
On demand deposits from customers – variable rate 	7 273 	5 249
Wholesale Negotiable Certificates of Deposit (NCDs) – variable rate 	– 	304
Total customer deposits Discovery Bank 	14 333 	10 881
Non-hedge derivative financial instruments
i. Interest rate swap
VitalityLife has significant exposure to long-term interest rate risk, given the impact on reserves of lower investment rate
assumptions related to fixed future premium receipts to meet policy obligations. Accordingly, lower long-term interest rates and
yield assumptions may negatively impact on the valuation of future policy obligations and result in a valuation loss. Refer to note
2.4.3 for details of the interest rate mitigation strategy implemented.
In addition to the above, VitalityLife has an exposure to the ’FTSE’ Actuaries UK Conventional Gilts over 15 Year Index (‘the index’)
because of products underwritten by the PAC on behalf of VitalityLife. To economically hedge the Vitality UK group’s exposure to the
index, Discovery Holdings Europe Limited (DHEL) has previously been party to a number of over-the-counter total return interest rate
swap derivatives. These derivatives provided DHEL with the capital depreciation/appreciation and coupon payments on a basket of
gilts designed to closely match that of the index in return for a payment of fixed interest to the counterparty. By 30 June 2022 these
derivatives had been exited in DHEL and the associated index risk is now managed directly on the balance sheet of the PAC.
As at 30 June 2023 the mark-to-market position recorded on the PAC balance sheet was a liability of GBP 12.6 million (R302 million)
(2022: asset of GBP 9 million (R180 million)). These derivatives have been presented in Other payables, VitalityLife working capital
funding.
Although the derivative instruments held during the year reduce the exposure to the volatility of the index, they do not qualify for
hedge accounting. Accordingly, these derivatives were classified as financial assets or liabilities carried at fair value through profit
or loss.
Fair value adjustments of GBP 56.6 million (net loss) (R1 213 million) have been recognised in Net fair value gains on financial assets
at fair value through profit or loss (2022: GBP 77.6 million (net loss) (R1 572 million)).
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 63 of 217 --

63	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.1 Market risk continued
Non-hedge derivative financial instruments continued
ii. Derivative instruments used by Discovery’s asset managers
Discovery also has interest rate swap agreements and the value of exposure towards these parties was calculated by taking into
consideration the International Swaps and Derivatives Association (ISDA) agreements in place which allow for netting off between
positive and negative exposures.
The table below details Discovery’s derivative exposure:
Group
R million
Notional
amount
Fair value
asset
Fair value
liability
June 2023
Interest rate contracts:
– floating for fixed swaps 	4 518 	59 	(1)
4 518 	59 	(1)
June 2022
Interest rate contracts:
– floating for fixed swaps 	5 000 	17 	(56)
5 000 	17 	(56)
CURRENCY RISK
The Group operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily with
respect to the US dollar and the UK pound. Foreign exchange risk arises from future commercial transactions and recognised assets
and liabilities. The following table segregates the currency exposure by major currency:
Group
R million 	Total 	Rand
GBP in UK
subsidiary
GBP
other
USD in US
subsidiary
USD
other
Other
currencies
30 June 2023
Loans and advances to customers
at amortised cost 	4 702 	4 702 	– 	– 	– 	– 	–
Investments at amortised cost:
Unlisted:
– Debt 	6 856 	6 856 	– 	– 	– 	– 	–
– Fixed deposits 	3 054 	1 744 	1 205 	– 	– 	105 	–
Financial instruments mandatorily at
fair value through profit or loss:
Listed:
– Equity portfolios 	200 	118 	8 	1 	– 	63 	10
– Debt portfolios 	1 388 	786 	583 	– 	– 	16 	3
– Money market portfolios 	3 475 	829 	2 640 	– 	– 	6 	–
– Multi-asset portfolios 	96 	23 	– 	– 	– 	73 	–
Unlisted:
– Equity portfolios 	50 	50 	– 	– 	– 	– 	–
– Debt portfolios 	138 	138 	– 	– 	– 	– 	–
– Money market portfolios 	1 611 	1 339 	272 	– 	– 	– 	–
Derivative financial instruments
at fair value:
– used as cash flow hedges 	59 	59 	– 	– 	– 	– 	–
– not designated as hedging
instruments 	60 	57 	– 	– 	– 	3 	–
Receivables:
– Insurance receivables 	10 316 	3 110 	7 118 	– 	47 	41 	–
– Contract receivables 	1 268 	913 	– 	– 	348 	– 	7
– Other Receivables 	1 916 	1 272 	332 	3 	217 	90 	2
Cash and cash equivalents 	14 371 	6 213 	5 806 	438 	380 	1 371 	163
Total financial assets 	49 560 	28 209 	17 964 	442 	992 	1 768 	185
Deposits from customers 	14 333 	13 939 	– 	88 	– 	203 	103
Borrowings at amortised cost 	20 553 	16 383 	3 958 	– 	212 	– 	–
Other payables 	12 113 	4 370 	7 391 	7 	161 	141 	43
Derivative financial instruments
at fair value:
– used as cash flow hedges 	1 	1 	– 	– 	– 	– 	–
– not designated as hedging
instrument 	16 	16 	– 	– 	– 	– 	–
Total financial liabilities 	47 016 	34 709 	11 349 	95 	373 	344 	146
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 64 of 217 --

64	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.1 Market risk continued
CURRENCY RISK continued
Group
R million 	Total 	Rand
GBP in UK
subsidiary
GBP
other
USD in US
subsidiary
USD
other
Other
currencies
30 June 2022
Loans and advances to customers
at amortised cost 	3 944 	3 944 	– 	– 	– 	– 	–
Investments at amortised cost:
Unlisted:
– Debt 	5 205 	5 205 	– 	– 	– 	– 	–
– Fixed deposits 	1 956 	1 747 	209 	– 	– 	– 	–
Financial instruments mandatorily at
fair value through profit or loss:
Listed:
– Equity portfolios 	160 	66 	12 	1 	– 	65 	16
– Debt portfolios 	751 	130 	613 	– 	– 	3 	5
– Money market portfolios 	6 480 	2 665 	3 815 	– 	– 	– 	–
– Multi-asset portfolios 	67 	15 	1 	– 	– 	51 	–
Unlisted:
– Equity portfolios 	46 	46 	– 	– 	– 	– 	–
– Debt portfolios 	15 	15 	– 	– 	– 	– 	–
– Money market portfolios 	1 196 	1 196 	– 	– 	– 	– 	–
– Money market portfolios 	8 	– 	8 	– 	– 	– 	–
Derivative financial instruments
at fair value:
– used as cash flow hedges 	17 	17 	– 	– 	– 	– 	–
– not designated as hedging
instruments 	238 	22 	216 	– 	– 	– 	–
Receivables:
– Insurance receivables 	7 887 	3 095 	4 755 	– 	3 	34 	–
– Contract receivables 	1 209 	886 	– 	– 	322 	– 	1
– Other Receivables 	1 369 	936 	320 	– 	58 	53 	2
Cash and cash equivalents 	14 767 	5 721 	7 659 	164 	295 	822 	106
Total financial assets 	45 315 	25 706 	17 608 	165 	678 	1 028 	130
Deposits from customers 	10 881 	10 732 	– 	32 	– 	72 	45
Borrowings at amortised cost 	20 430 	17 027 	3 272 	– 	131 	– 	–
Other payables 	12 264 	5 289 	6 661 	– 	85 	123 	106
Derivative financial instruments
at fair value:
– used as cash flow hedges 	56 	56 	– 	– 	– 	– 	–
– not designated as hedging
instrument 	146 	68 	78 	– 	– 	– 	–
Total financial liabilities 	43 777 	33 172 	10 011 	32 	216 	195 	151
Financial assets and financial liabilities in respect of the Group’s US and UK subsidiaries are accounted for in their functional
currency. Foreign currency movements will be recognised in the foreign currency translation reserve.
The exchange rates at year-end are detailed in the table below (quoted as Rand per foreign currency):
USD 	GBP
30 June 2023 	18.87 	23.99
30 June 2022 	16.47 	20.00
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 65 of 217 --

65	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.1 Market risk continued
CURRENCY RISK continued
Sensitivity analysis
The Group determined that a 10% change is a reasonable expected strengthening/(weakening) of the US dollar and the UK Pound
against the other functional currencies, most notably South African Rand, US Dollar and Pound Sterling. The impact on profit or loss
and equity at 30 June is shown below. For the purpose of the analysis, the foreign exchange impact of intergroup balances which
eliminate on consolidation has been excluded. The effect of translation differences which are recognised separately in other
comprehensive income has also been excluded. This analysis assumes that all other variables, in particular interest rates, remain
constant and ignores any impact of forecast sales and purchases.
Profit or loss 	Equity
R million 	Strengthening 	Weakening Strengthening 	Weakening
30 June 2023
USD 	194 	(194) 	194 	(194)
GBP 	28 	(28) 	28 	(28)
30 June 2022
USD 	278 	(278) 	278 	(278)
GBP 	14 	(14) 	14 	(14)
Investments
Discovery has offshore assets in its investment portfolios. These offshore investments are made for the purpose of seeking
international diversification. There is a risk to future earnings that the value of these assets reduces due to a strengthening in the Rand.
Performance of foreign currency assets is benchmarked against the MSCI World Index, an international index that represents large and
mid-capitalisation companies across 23 developed market countries. Refer to www.msci.com for further detail.
Currency derivative contracts
To manage its foreign exchange risk arising from future commercial transactions, Discovery enters into various currency derivative
contracts. Discovery entered into these contracts with third party banks which have short-term rated risks of P-2 and P-1, as rated
by Moody’s. The fair value of these contracts have been included in financial assets and liabilities. (Refer to note 13).
Discovery entered into these contracts as an economic hedge against foreign currency risk for expenses to be paid in the future.
These transactions are not designated as hedges and as a result gains and losses are recognised in profit or loss. The amount
recognised in profit or loss for the current year was a gain of R11 million (2022: R78 million), with a corresponding derivative asset of
R3 million (2022: Derivative asset and liability of R2 million and R1 million respectively). The notional value of these contracts are
USD2 million (2022: USD5.3 million).
Currency risk for foreign exchange contracts (FECs) are determined with reference to the designated pricing (settlement) currency
of each respective contract. The pricing currency is usually the functional currency of the entity taking out the contract. For the
purposes of currency risk, Discovery discloses FEC contracts using the pricing currency.
Borrowings
Discovery has long-term borrowings in the UK, which exposes the Group to currency risks. These risks are managed by aligning the
currency exposure to the underlying operational assets for which these borrowings have been raised. The currency risk is mitigated
as the cash flows emerging from the underlying assets are in the same currency (GBP) as the interest and capital payments.
Deposits from customers
Discovery Bank offers its customers the option to hold deposits in foreign currency of GBP, USD and EUR. These risks are managed
by aligning the currency exposure to the underlying assets. Discovery Bank does so by holding deposits in foreign currency of GBP,
USD and EUR. The currency risk is therefore matched in a 1:1 ratio to not transfer foreign currency risk to the Group.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 66 of 217 --

66	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.2 Credit risk
Key areas where Discovery is exposed to credit risk are:
 Financial investments comprising money market and debt instruments entered into to invest surplus shareholder
funds: Discovery is exposed to the issuer’s credit standing on these instruments which is monitored by the CCIC by setting a
minimum credit rating and maximum exposures per issuer. Discovery has appointed reputable asset managers to manage
these instruments. Information regarding the aggregated credit risk exposure for debt and money market instruments
categorised by credit ratings is provided below.
 Cash and cash equivalents: This risk is managed by monitoring exposure to external financial institutions against approved
limits per institution. Credit ratings are provided below.
 Certain accounts within the Statement of financial position category of ’Insurance receivables, contract receivables
and other non-financial receivables’.
 Reinsurance assets comprising receivables raised for expected recoveries on projected claims (Discovery’s liability as
primary insurer is not discharged) and amounts due from reinsurers in respect of claims already paid: This risk is limited
as risk premiums are paid monthly to reinsurers and claims can be offset against risk premiums. Further, it is expected that
there will be little build-up of actuarial liability on the reinsurers’ side. The risk thus mainly arises following a period of higher
than expected claims. Credit ratings of reinsurers are considered in reinsurance placement decisions. Credit exposure to
reinsurers is also limited through the use of several reinsurers. Reinsurance is placed with reputable international companies
directly or through their national offices. The reinsurance companies used by Discovery are rated A or higher by A.M. Best, a
rating agency with an exclusive insurance industry focus. Refer to www.ambest.com for further detail. VitalityHealth makes use
of cashless financial reinsurance as a financing tool for new business acquisition costs. The credit ratings of these reinsurers
are Aa3.
 Loans and advances to customers at amortised cost, which arises from credit extended to Discovery Bank customers.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 67 of 217 --

67	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.2 Credit risk continued
The following table details the aggregated credit risk exposure that the Group is exposed to, categorised by the rating scale noted
in section 3 ’Discovery’s approach in monitoring credit risk’.
Group
R million 	Total 	Aaa
Aa1
Aa2
Aa3
A1
A2
A3
Baa1
Baa2
Baa3
Ba1
Ba2
Ba3 	Govt 1
Inter-
nally
rated
Pooled
funds
30 June 2023
Loans and advances to customers at
amortised cost 	4 702 	– 	– 	– 	– 	– 	– 	4 702 	–
Investments at amortised cost:
Unlisted:
– Debt 	6 856 	– 	– 	– 	– 	– 	6 856 	– 	–
– Fixed deposits 	3 054 	– 	– 	1 300 	– 	1 744 	– 	– 	10
Financial instruments mandatorily at fair value
through profit or loss:
Listed:
– Debt portfolios 	1 388 	– 	30 	313 	243 	517 	239 	– 	46
– Money market portfolios 	3 475 	700 	11 	94 	1 940 	459 	70 	– 	201
Unlisted:
– Debt portfolios 	138 	– 	– 	– 	– 	138 	– 	– 	–
– Money market portfolios 	1 611 	25 	– 	247 	– 	1 322 	17 	– 	–
Derivative financial instruments at fair value:
– used as cash flow hedges 	59 	– 	– 	– 	– 	59 	– 	– 	–
– not designated as hedging instruments 	60 	– 	– 	– 	– 	60 	– 	– 	–
Cash and cash equivalents 	14 371 	– 	1 123 	5 848 	464 	3 856 	3 078 	2 	–
35 714 	725 	1 164 	7 802 	2 647 	8 155 10 260 	4 704 	257
30 June 2022
Loans and advances to customers at
amortised cost 	3 944 	– 	– 	– 	– 	– 	– 	3 944 	–
Investments at amortised cost:
Unlisted:
– Debt 	5 205 	– 	– 	– 	– 	– 	5 205 	– 	–
– Fixed deposits 	1 956 	– 	91 	574 	208 	1 083 	– 	– 	–
Financial instruments mandatorily at fair value
through profit or loss:
Listed:
– Debt portfolios 	751 	2 	42 	224 	366 	116 	1 	– 	–
– Money market portfolios 	6 480 	745 	1 348 	1 752 	64 	2 447 	124 	– 	–
Unlisted:
– Debt portfolios 	15 	– 	– 	– 	– 	13 	2 	– 	–
– Money market portfolios 	1 196 	– 	– 	– 	– 	1 184 	12 	– 	–
Derivative financial instruments at fair value:
– used as cash flow hedges 	17 	– 	– 	– 	17 	– 	– 	– 	–
– not designated as hedging instruments 	238 	– 	– 	216 	2 	20 	– 	– 	–
Cash and cash equivalents 	14 767 	– 	7 852 	1 800 	1 011 	1 575 	2 529 	– 	–
34 569 	747 	9 333 	4 566 	1 668 	6 438 	7 873 	3 944 	–
1 These instruments are issued by the South African government.
Financial instruments included in cash and cash equivalents, fixed deposits and treasury bills have high credit quality based on the
rating of counterparties and/or have relatively short-term maturities. Impairment based on the expected credit loss approach was
assessed and considered immaterial. There are no amounts within these balances which are credit impaired or where there has
been a significant increase in credit risk since initial recognition.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 68 of 217 --

68	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.2 Credit risk continued
CREDIT RISK RELATING TO RECEIVABLES
The table below summarises Discovery’s shareholder insurance receivables, contract receivables and other receivables, at 30 June. This
table only relates to shareholder’s credit exposure and will therefore not agree to note 14.
R million
Group
2023
Group
2022
Receivables arising from insurance and reinsurance contracts:
– Premium debtors 	1 070 	801
– Less provision for impairment of premium debtors 	(97) 	(81)
– Reinsurance debtors 	9 343 	7 167
Contract receivables:
– Closed scheme debtors 	120 	107
– Discovery Health Medical Scheme 	775 	724
– Other contract receivables 	377 	382
– Less allowance for expected credit losses 	(4) 	(4)
Other loans and receivables:
– Agents and brokers 	521 	439
– Cash-in-transit debtors 	8 	7
– Consolidated unit trust debtors 	2 	2
– Loans to BEE initiatives 	309 	256
– Security deposit on derivatives1 	27 	72
– Vitality partner debtors 	171 	148
– Other financial receivables 	1 288 	837
– Less allowance for expected credit losses 	(410) 	(392)
13 500 	10 465
1 Refer to note 3.7 for an explanation of the nature of the security deposit (cash collateral).
Credit risk relating to receivables is managed as follows:
i. Premium debtors are not rated by Discovery as exposure to any single customer is insignificant. The premium debtors comprise
amounts receivable from individuals and corporates. In addition, Discovery suspends benefits when contributions are not
received. Premium debtors that are past due are handled by a specialist area in business. Where amounts remain uncollected
for more than six months, the debtors are then handed to specialist debt collection agencies.
ii. VitalityHealth makes use of financial reinsurance as a financing tool for new business acquisition costs. The receipt from the
reinsurer is recognised in profit or loss upfront in the year received. GBP246 million (R5 902 million) (2022: GBP199 million
(R3 981 million)) is outstanding in respect of cashless reinsurance treaties. The credit ratings of these reinsurers are Aa3.
Refer to introduction to note 3.4.2 for detail regarding the management of risk in respect of reinsurance receivables raised for
expected recoveries on projected claims and amounts due from reinsurers in respect of claims already paid. Discovery’s liability
as primary insurer is not discharged.
iii. The Discovery Health Medical Scheme (DHMS) has been rated AAA(za) by Global Credit Ratings. The closed schemes have not
been rated. Payments by DHMS and the other closed schemes are managed by Discovery and are paid by the seventh of the
following month.
iv. Agents and brokers are subject to a comprehensive relationship management programme including credit assessment. Agents
and brokers are not rated by Discovery as exposure to any single intermediary is insignificant. The widespread nature of the
individual amounts combined with this close management relationship reduces credit risk. Most commission claw backs are
offset against future payments and hence the risk of outstanding commission clawbacks is reduced.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 69 of 217 --

69	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.2 Credit risk continued
Discovery ages and pursues unpaid accounts on a monthly basis. The ageing of the components of receivables at 30 June was:
Group
R million
Gross
2023
Impairment
2023
Gross
2022
Impairment
2022
Not past due (current) 	11 760 	(121) 	9 294 	(111)
30 days 	447 	(33) 	267 	(38)
60 days 	211 	(13) 	179 	(23)
90 days 	365 	(8) 	131 	(10)
120 days 	155 	(29) 	95 	(20)
150 days 	189 	(13) 	91 	(10)
>150 days 	884 	(294) 	885 	(265)
14 011 	(511) 	10 942 	(477)
Discovery establishes an allowance for expected credit losses that represents its estimate of expected losses in respect of
receivables that are financial assets. The allowance comprises of a specific loss component that relates to individually significant
exposures, and a collective loss component, established for groups of similar assets. The loss allowance is determined based on
historical data of payment statistics for similar financial assets, and where available without undue cost or effort, incorporates
forward-looking information.
For an analysis of the movement in the allowance for expected credit losses as well as provision for impairment of premium debtors
during the year, refer to note 12 Financial assets and note 14 Insurance receivables, contract receivables and other financial receivables.
3.4.3 Liquidity risk
Cash flow forecasting is performed in the operating entities of the Group and aggregated by Group finance. Group finance monitors
rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs at all times so that
the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities (refer to note 20). Such
forecasting takes into consideration the Group’s debt financing plans, covenant compliance and, if applicable, external regulatory
or legal requirements – such as capital requirements.
Cash held by the operating entities is managed by Group treasury. Group treasury invests it in interest-bearing accounts, time
deposits and money market deposits, choosing instruments with appropriate maturities or sufficient liquidity to provide sufficient
headroom as determined by the above-mentioned forecasts. For information on the liquidity risk management of contracts with
insurance risk, refer to note 2.2 Liquidity risk.
Discovery Bank manages its liquidity risk by comparing the credit utilisation and expected future utilisation of committed
facilities on its loans and advances against the deposits it holds. Discovery Bank performs normal stresses as well as additional
stresses to ensure that it can meet its obligations continuously.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 70 of 217 --

70	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.4 	Shareholder financial assets and liabilities continued
3.4.3 Liquidity risk continued
The table below analyses the Group’s financial assets and liabilities and net-settled interest rate swap derivative financial liabilities
into relevant maturity groupings based on the remaining period at the reporting date to the contractual maturity date. The amounts
are the undiscounted contractual payments and will therefore not agree to the Statement of financial position.
Group
R million 	Total 	<1 year
1 – 2
years
3 – 5
years
6 – 10
years
>10
years
30 June 2023
Loans and advances to customers at
amortised cost 	6 794 	4 076 	2 718 	– 	– 	–
Investments at amortised cost 	10 168 	6 497 	679 	1 916 	1 076 	–
Investments at fair value through profit or loss 	6 958 	5 743 	614 	382 	75 	144
Derivative financial instruments at fair value:
– not designated as hedging instruments 	60 	26 	24 	10 	– 	–
Receivables 	13 505 	8 950 	930 	2 612 	971 	42
Cash and cash equivalents 	14 371 	14 371 	– 	– 	– 	–
Total financial assets 	51 856 	39 663 	4 965 	4 920 	2 122 	186
Deposits from customers 	14 718 	13 233 	605 	880 	– 	–
Borrowings net of interest rate swap
– Borrowings 	16 723 	3 403 	5 752 	7 320 	248 	–
– Interest rate swap 	(58) 	(5) 	(22) 	(31) 	– 	–
Lease liabilities 	6 761 	666 	662 	1 990 	3 351 	92
Other payables at amortised cost 	12 113 	11 729 	77 	295 	12 	–
Derivative financial instruments at fair value:
– not designated as hedging instruments 	16 	16 	– 	– 	– 	–
Total financial liabilities 	50 273 	29 042 	7 074 	10 454 	3 611 	92
30 June 2022
Loans and advances to customers at
amortised cost 	3 944 	2 367 	1 577 	– 	– 	–
Investments at amortised cost 	7 161 	6 927 	234 	– 	– 	–
Investments at fair value through profit or loss 	8 723 	7 651 	149 	393 	114 	416
Derivative financial instruments at fair value:
– not designated as hedging instruments 	238 	14 	224 	– 	– 	–
Receivables 	10 465 	6 338 	1 412 	2 006 	668 	41
Cash and cash equivalents 	14 767 	14 767 	– 	– 	– 	–
Total financial assets 	45 298 	38 064 	3 596 	2 399 	782 	457
Deposits from customers 	10 881 	9 381 	1 133 	367 	– 	–
Borrowings net of interest rate swap
– Borrowings 	15 695 	4 445 	3 883 	7 110 	257 	–
– Interest rate swap 	311 	117 	90 	104 	– 	–
Lease liabilities 	6 723 	190 	1 709 	1 866 	2 487 	471
Other payables at amortised cost 	12 264 	11 970 	117 	44 	7 	126
Derivative financial instruments at fair value:
– not designated as hedging instruments 	146 	41 	26 	– 	– 	79
Total financial liabilities 	46 020 	26 144 	6 958 	9 491 	2 751 	676
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 71 of 217 --

71	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.5 	Capital management
The Group’s capital is defined as capital and reserves attributable as presented on the consolidated statement of financial position.
The Group’s objectives when managing capital are:
 To comply with the statutory capital requirements required by the regulators of the insurance markets where the Group
operates; refer to Capital section of the directors’ report for the statutory capital requirements.
 To maintain a capital buffer in excess of the statutory capital requirements in order to reduce the risk of breaching the statutory
requirement in the event of deviations from the main assumptions affecting the Group’s insurance businesses.
 To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements.
 To achieve an optimal and efficient capital funding profile; and
 To consider capital management needs both in the short term and over a five-year planning horizon.
Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre and
subsidiaries within SA, UK and US. The committee is the governance body for all capital allocation activities across the Group.
A range of capital raising options are available to manage the capital structure of the Group, which includes the issue of new shares,
debt, reinsurance arrangements and other hybrid instruments.
FINANCIAL LEVERAGE RATIO
As part of the capital management process, the Group monitors its capital structure utilising the Financial Leverage Ratio (FLR). This
ratio is calculated as total debt 1 divided by total debt plus total equity. The Group’s strategy is to maintain a prudent FLR of 28% per
the Group Risk Appetite statement. However, the 28% is merely a risk appetite indicator, and not a hard line to indicate any form of
a breach in terms of regulatory or covenant restrictions. The table below summarises the FLR as at 30 June.
R million
Group
2023
Group
2022
– Borrowings at amortised cost (refer to note 20)1 	16 361 	16 464
– Guaranteed deposit facilities 	– 	300
Total debt and guarantees1 	16 361 	16 764
Total equity 	63 974 	53 555
Financial Leverage Ratio (%) 	20.4% 	23.8%
1 Excluding all IFRS 16 lease liabilities of R4 225 million (2022: R4 120 million).
The FLR at 30 June 2023 is in line with Discovery’s risk appetite.
Minimum capital requirements
For Group subsidiaries that operate in the insurance and financial services sectors, the regulator specifies the minimum amount
and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum required
capital must be maintained at all times throughout the period.
With effect from 1 July 2018, the Insurance Act 18 of 2017 and the related Prudential Standards were implemented in South Africa.
Discovery Life and Discovery Insure are regulated under the Insurance Act, while VitalityHealth and VitalityLife are regulated under
the European Solvency II regulatory regime, which was implemented from 1 January 2016.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 72 of 217 --

72	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.5 	Capital management continued
Debt covenants
The following are the key debt covenant ratios and their proximity to breaching the covenant triggers:
Debt covenant and explanation 	Minimum requirement 	Group
2023
Group
2022
Group Debt to EBITDA Ratio:
– Group debt is contractually defined and means
the aggregate consolidated financial indebtedness
of the Group and excludes items such as the
1 Discovery Place (’1 DP’) lease and includes
guarantees issued to third parties.
– EBITDA is contractually defined and specifically
includes items such as dividends from associates,
rental paid on 1 DP and excludes such items
deemed extraordinary, such as economic
assumption adjustments, and specified FinRe
arrangements.
Less than 2.5 times 	1.30 	1.83
Group financial indebtedness to embedded value
– Group financial indebtedness is as per Group Debt
in the calculation.
Less than 30% of Group
embedded value
17.6% 	20.3%
Discovery Life SCR Cover 	SCR cover must be more than 1.1 	1.88 times 	1.74 times
Group embedded value 	Greater than R30 billion 	R98 176
million
R86 258
million
New business embedded value must not be negative 	Positive value of new business for
3 consecutive 6-month periods
June 2023:
R463 million
Dec 2022:
R940 million
June 2022:
R1 124 million
June 2022:
R1 124 million
Dec 2021:
R937 million
June 2021:
R946 million
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 73 of 217 --

73	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.6 	Fair value hierarchy of financial instruments
The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three
levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial
instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or
regulatory agency and those prices represent actual and regularly occurring market transactions on an arm’s length basis.
Level 2: includes financial instruments that are valued using techniques based significantly on observable market data. Instruments
in this category are valued using:
(a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or
(b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on
observable market data.
Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than observable
market data and where at least one input (which could have a significant effect on instruments’ valuation) cannot be based on
observable market data.
R million 	Level 1 	Level 2 	Level 3 	Total
30 June 2023
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	50 204 	6 321 	– 	56 525
– Debt portfolios 	40 852 	1 721 	– 	42 573
– Money market portfolios 	– 	22 656 	– 	22 656
– Multi-asset portfolios 	– 	33 672 	– 	33 672
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	59 	– 	59
– not designated as hedging instruments 	– 	60 	– 	60
Total financial assets 	91 056 	64 489 	– 	155 545
Financial liabilities
Investment contracts at fair value through profit or loss 	– 	48 044 	– 	48 044
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	1 	– 	1
– not designated as hedging instruments 	– 	19 	– 	19
Total financial liabilities 	– 	48 064 	– 	48 064
There where no transfers between level 1 and level 2 during the current financial period.

-- 74 of 217 --

74	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.6 	Fair value hierarchy of financial instruments continued
R million 	Level 1
Restated 1
Level 2 	Level 3
Restated1
Total
30 June 2022
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	54 271 	3 677 	– 	57 948
– Debt portfolios 	46 672 	920 	– 	47 592
– Money market portfolios 	– 	14 680 	– 	14 680
– Multi-asset portfolios 	– 	21 274 	– 	21 274
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	17 	– 	17
– not designated as hedging instruments 	– 	259 	– 	259
Total financial assets 	100 943 	40 827 	– 	141 770
Non-financial assets 	– 	– 	171 	171
Non-current assets held for sale 	– 	– 	171 	171
Financial liabilities
Investment contracts at fair value through profit or loss 	– 	38 637 	– 	38 637
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	56 	– 	56
– not designated as hedging instruments 	– 	146 	– 	146
Total financial liabilities 	– 	38 839 	– 	38 839
1 The comparative information has been restated. Refer to note 45 for detail.
There were no transfers between level 1 and 2 during the current financial year. During the year under review, management
reassessed the observability of significant inputs into fair value determination of money markets and multi-asset portfolios from
level 1 to level 2. The prior period was restated accordingly.
Non-financial assets measured at fair value
During the prior financial period there was a non-recurring fair value measurement for the investment in an associate that has been
categorised as a level 3 fair value. Refer to note 11.2.1 for details on the fair value.
Specific valuation techniques used to value financial instruments in level 2
If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial
instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use of
recent arm’s length market transactions, reference to the current fair value of another instrument that is substantially the same,
discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of prices
obtained in actual market transactions.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 75 of 217 --

75	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.6 	Fair value hierarchy of financial instruments continued
Valuation techniques used in determining the fair value of assets and liabilities:
Instruments 	Valuation technique
Main inputs and
assumptions
Within equity
portfolios,
Equity-linked
notes
The calculation of the daily value of the equity linked investments is made
by the provider of the note. Discovery has procedures in place to ensure
that these prices are correct. Aside from the daily reasonableness checks
versus similar funds and movement since the prior day’s price, the fund
values are calculated with reference to a specific formula or index,
disclosed to the policyholders, which is recalculated by Discovery in order
to check if the price provided by the provider is correct.
For level 2 fair value hierarchy
items:
– discount rate
– spot prices of the underlying
Multi-assets 	The fair values of third-party financial liabilities arising on the consolidation
of mutual funds are determined using the quoted put (exit) price
provided by the fund manager and discounted for the applicable notice
period. The fair value of a financial liability with a demand feature is not
less than the amount payable on demand, discounted from the first date
on which the amount could be required to be paid.
For level 2 fair value hierarchy
items:
– discount rate
Debt portfolios
and Money
market
instruments
Discounted cash flow techniques are most commonly used for the
valuation of debt securities (included in the debt portfolios) and money
market instruments. The future cash flows are discounted using a
risk-adjusted rate.
For level 2 fair value hierarchy
items:
– discount rate, credit spread
Investment
contracts at fair
value through
profit or loss
Unit-linked policies: assets which are linked to the investment contract
liabilities are owned by the Group. The investment contract obliges the
Group to use these assets to settle these liabilities. Therefore, the fair
value of investment contract liabilities is determined with reference to
the fair value of the underlying assets (i.e., amount payable on surrender
of the policies).
Annuity: certain discounted cash flow models are used to determine the
fair value of the stream of future payments.
For level 2 fair value hierarchy
items:
– discount rate
– spot price of underlying
Derivatives 	Standard derivative contracts are valued using market accepted models
and quoted parameter inputs. More complex derivative contracts are
modelled using more sophisticated modelling techniques applicable to
the instrument. Techniques include:
– Discounted cash flow model
– Black-Scholes model
– Combination technique models
For level 2 fair value hierarchy
items:
– discount rate
– spot prices of the underlying
– correlation factors
– volatilities
– earnings yield
– valuation multiples

-- 76 of 217 --

76	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
3. 	MANAGEMENT OF FINANCIAL RISK continued
3.7 	Offsetting financial assets and financial liabilities continued
Financial assets
The following financial assets are subject to offsetting:
Group
R million
Gross
financial
assets
Gross offsetting
financial
liabilities
Net amount
presented
30 June 2023
Cash and cash equivalents 	20 827 	(457) 	20 370
30 June 2022
Cash and cash equivalents 	19 807 	(32) 	19 775
Offsetting of cash and cash equivalents takes place as a result of sweeping arrangements that Discovery has in force with various
financial institutions. No other amounts presented on the financial statements are subject to netting arrangements.
Cash collateral
To reduce the credit risk exposure from derivative instruments purchased (refer to note 3.4.1), Discovery has entered into
collateral agreements with the relevant financial institutions to post cash collateral periodically, equal to the fair value of the
derivatives. A total of R27 million (2022: R72 million) cash collateral was being held by the various financial institutions and
R39 million (2022: R245 million) was held by Discovery at 30 June 2023.
The posting of the collateral does not result in legal settlement of the outstanding derivative balance. The collateral will only
be used to settle the derivative upon default or bankruptcy of either party. The offsetting requirements of IAS 32 Financial
Instruments: Presentation are therefore not met.

-- 77 of 217 --

77	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
4. 	SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS IN APPLYING
ACCOUNTING POLICIES
In preparing the Annual Financial Statements, estimates, assumptions and judgements are made that could materially affect the
reported amounts of assets and liabilities within the next financial year. Accounting estimates and judgements are regularly
reviewed and are based on historical experience, current best estimates and expectations of future outcomes as well as anticipated
changes in the environment. The following represents the most material key management assumptions applied by management in
preparing these Annual Financial Statements.
4.1 	Policyholder liabilities assumptions and estimates, including assets arising from
insurance contracts
Discovery Life and VitalityLife
Discovery values its insurance policies issued by Discovery Life and VitalityLife using various methodologies and assumptions.
Accounting policy 13.1 sets out the methodology used in its valuation of the policyholder liabilities, including the use of available
discretionary margins in accounting policy 13.1.1.
The assumptions used are best estimate assumptions, with the addition of explicit compulsory margins required by:
 SAP 104 of the Actuarial Society of South Africa for Discovery Life; and
 INSPRU of the PRA, SAP 104 and Benchmarking information in the UK
Per the accounting policy, the best estimate assumptions and margins are reset at every valuation date to reflect the underlying
profitability of the portfolio. The most recent valuation date is 30 June 2023.
MORTALITY AND MORBIDITY
Assumptions of future mortality and morbidity experience are derived from reinsurers and industry data and compared to actual
past experience. Where appropriate, the assumptions are adjusted to reflect actual past experience or for expected changes in
future experience.
The assumptions are modified for each policy based on actual data from underwriting performed on the policy and compared
against standard industry tables for reasonability. The key mortality and morbidity assumptions are reviewed and benchmarked
against the industry by independent actuarial consultants to ensure that the assumptions are reasonable upon implementing
significant new products for Discovery Life. An adjustment to the standard mortality and morbidity assumptions is made to reflect
the expected impact of engagement in the Vitality programme. It has been observed that higher rates of engagement result in lower
mortality and morbidity claims.
An allowance is made for the impact of AIDS on South African mortality rates. For individual life South African business, a fixed
loading is applied to the expected best estimate mortality rates to allow for the expected effect of AIDS. The loading varies based
on socio-economic class. Discovery Life further operates in the high end of the market, where the AIDS risk is lower than the full
market. The additional loading for AIDS is set in consultation with external independent actuaries and reinsurers.
For Group Life policies, a loading is applied at the underwriting stage to allow for the expected effect of AIDS. The loading varies
based on the industry and geographic area and composition of the group and is derived from advice received from the reinsurers.
The loading then forms the AIDS assumption for Group policies.
The sensitivity of the policyholder liabilities due to changes in mortality and morbidity assumptions are set out in note 2.5.1 for
Discovery Life and note 2.5.2 for VitalityLife.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 78 of 217 --

78	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
4. 	SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS IN APPLYING
ACCOUNTING POLICIES continued
4.1 	Policyholder liabilities assumptions and estimates, including assets arising from
insurance contracts continued
Discovery Life and VitalityLife continued
SURRENDER AND LAPSE RATES
Lapse rates are based on actual past experience where available. The lapse analysis is done by considering the in–force duration of
policies. For durations longer than actual data, lapse rates are set based on expectations of future experience based on internal and
external expert advice as well as available industry benchmarking. The lapse experience investigation covers at least the last two
years of lapse experience to identify trends.
Lapse assumptions are varied between different types of policies where the lapse experience is expected to differ significantly.
Allowance is made for the estimated impact of the economic environment. For Discovery Life and VitalityLife, an adjustment is made
to the lapse assumptions to reflect the expected impact of engagement in the Vitality programme because it has been observed that
higher rates of engagement result in lower lapses.
For Discovery Life, the surrender rates are also based on actual past experience where available.
The sensitivity of the policyholder liabilities due to changes in lapse rate assumptions are set out in note 2.5.1 for Discovery Life and
note 2.5.2 for VitalityLife.
ECONOMIC ASSUMPTIONS/INVESTMENT RETURNS
Discovery Life
The discount rate for Discovery Life and Discovery Invest is based on the risk-free rates at 30 June 2023. The real rate assumption
is based on the average of the real rate curves for the preceding twelve months. This real rate assumption will remain unchanged
over time unless the equivalent single rate, derived based on the weighted duration of the cash flows, moves by more than 25
basis points since the preceding valuation. The inflation assumption is set as the differential between the assumed nominal and
real interest rates.
For comparison purposes, it is noted that the single risk-free rate at 30 June 2023 would have increased to 13.2% (2022: increased
to 12.3%). The implied single real interest rate has also increased to 4.7% in June 2023 (2022: decreased to 4.2%).
Other investment returns and economic assumptions are set relative to this yield curve. The assumptions for Discovery Life are
as follows:
Cash: 	Risk-free – 1.5%
Fixed interest: 	Risk-free
Equity: 	Risk-free + 3.5%
Property: 	Risk-free +1%
The sensitivity of the policyholder liabilities due to changes in real curve assumptions are set out in note 2.5.1.
VitalityLife
For the PAC book the nominal investment return is set as the active market rate on UK long-term swap rates plus a fixed adjustment
(based on long-term averages) for liquidity premium, the gilt/swap spread and cash flow weighting. For the VitalityLife book, the
nominal investment return is set with reference to the UK gilt yield curve plus a fixed adjustment (based on long-term averages) for
liquidity premium. The best estimate inflation assumption is set in line with long-term UK inflation expectations and observed real
yields consistent with the term of the liabilities. The risk-free rate at 30 June 2023 was set at 4.4% (2022: 2.3%).
The investment fees and tax rates are taken into account in setting the economic assumptions.
The sensitivity of the policyholder liabilities due to changes in real curve assumptions are set out in note 2.5.2.
EXPENSE ASSUMPTIONS
Renewal expense assumptions are based on the results of the latest expense and budget information. Expenses are considered
non-recurring when they relate to the start-up of a new business area or when they are material and are specific to an event that
is not expected to occur in the future.
The allocation of expenses between initial and renewal is based on the latest expense analysis, where expenses are directly
allocated based on the function performed. Where an expense could relate to both initial and renewal functions, the expenses are
allocated proportionately based on estimates of the functions performed.
Per Discovery’s policy, expenses are projected to increase in line with consumer price inflation.
Non-recurring expenses are excluded from the expense analysis used to derive the assumption.
The sensitivity of the policyholder liabilities due to changes in expense assumptions are set out in note 2.5.1 for Discovery Life and
note 2.5.2 for VitalityLife.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 79 of 217 --

79	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
4. 	SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS IN APPLYING
ACCOUNTING POLICIES continued
4.1 	Policyholder liabilities assumptions and estimates, including assets arising from
insurance contracts continued
Discovery Life and VitalityLife continued
POLICY ALTERATIONS AND AUTOMATIC PREMIUM INCREASES
In calculating policyholder liabilities, allowance is made for overall negative policy alterations over time.
Automatic premium increases could include both contractual and voluntary increases. No allowance is made for voluntary premium
increases when calculating liabilities under insurance contracts.
Contractual premium increases are defined as increases that the policyholder cannot cancel without altering the terms of the
benefits provided under the policy. Contractual increases are included in the calculation of policyholder liabilities.
CHANGES IN ASSUMPTIONS
Expected profits regarding future options on products are not recognised, but expected losses in respect of such options are
allowed for, in line with actuarial guidance.
Modelling and assumptions changes were made to the valuation at 30 June 2023 to ensure that assumptions are in line with the
best estimate of future experience. For Discovery Life, the total effect of these changes on the Assets arising from insurance
contracts was a decrease in the assets on the Financial Soundness Valuation basis of R3 464 million (2022: R1 760 million decrease).
For VitalityLife, the total effect of these changes was an increase in the assets of R745 million (2022: R596 million increase).
In addition to this, for Discovery Life, discretionary margins were reset to reflect the underlying profitability of the overall portfolio.
The reset of margins increased the assets on the Financial Soundness Valuation basis by R194 million (2022: R377 million increase).
Refer to note 5 for an analysis of these changes.
TAXATION
Future tax is allowed according to the current tax legislation and current tax rates. It is assumed that future tax on statutory profits
will be payable at the prevailing company tax rate of 27% (2022: 28%) in South Africa. South Africa’s National Treasury announced
that the corporate tax rate should reduce to 27% for tax years commencing ending on or after 31 March 2023. The rate is deemed
substantively enacted, and deferred tax has been appropriately adjusted. The prevailing tax rate in the UK is 25% (2022: 19%). The
UK has enacted an increase in the tax rate to 25% effective from 1 April 2023.
Tax amendments for Life Insurance companies introduced a Risk Policy Fund for all new risk business written after 1 July 2016. In
terms of this legislation, Discovery Life elected to move existing risk business to this Fund. As a result of these changes, the assessed
loss in the Individual Policyholder Fund is expected to stop increasing and be utilised over time. Therefore, in terms of IAS 12 Income
Taxes, a value of R979 million (2022: R834 million), which was previously implicit in the valuation of insurance contract liabilities, was
recognised explicitly as a deferred tax asset. The value is net of deferred capital gains tax liabilities.
To calculate this value, Discovery Life performed a probability-weighted cash flow forecast of the annual cash flows expected to arise
from the utilisation of the assessed loss. The primary factors that management has considered when arriving at the probability are
the expected market growth and withdrawal rate of the Linked Asset and Guaranteed Endowment book. For Linked Assets, given
the uncertainty inherent in market growth assumptions and the fact that discounting of cash flows is not permitted by IAS 12, future
market growth was assumed to be 0% to calculate the deferred tax asset. The expected income on the debt portfolio held to match
policyholder liabilities has been fully allowed for at current rates. For both the linked and debt portfolio, cash flows arising from the
tax asset were further reduced to account for the uncertainty of future lapse rates and product mix as well as the broader economic
and legislative environment.
REINSURANCE
All prospective liabilities are valued gross of reinsurance and then adjusted for the expected effect of reinsurance. For outstanding
reported claims and IBNR, a specific allowance is made for reinsurance recoveries.
The Global Linkage Benefit is fully reinsured. The cost of the future reinsurance is dependent on the cost at which the reinsurer can
buy assets to match the liability under this benefit. Assumptions are made around the cost at which the reinsurer can purchase
these benefits based on the current and historical costs of these assets.
FINANCIAL SOUNDNESS VALUATION
The sensitivity of the policyholder liabilities on the Financial Soundness Valuation basis is set out in note 2.5.1. The sensitivity of the
policyholder liabilities on the INSPRU basis is set out in note 2.5.2.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 80 of 217 --

80	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
4. 	SIGNIFICANT ACCOUNTING ESTIMATES AND JUDGEMENTS IN APPLYING
ACCOUNTING POLICIES continued
4.2 	Annual assessment of goodwill impairment
Refer to note 10 Goodwill for a breakdown of business acquisitions resulting in goodwill.
Discovery annually assesses goodwill allocated to the respective businesses as set out in note 10.
Based on the work performed for the financial years ended 30 June 2023 and 30 June 2022, management considered that there is
a very low risk of material adjustment to the carrying amount of goodwill allocated to VitalityHealth and VitalityLife within the next
financial year. Accordingly, no further information is included within this note, as this no longer meets the requirement of significant
estimation uncertainty under IAS 1 Presentation of Financial Statements.
Discovery Bank
The Discovery Bank Cash Generating Unit (CGU) comprise the various assets that collectively produce independent cash flows for
Discovery Bank. Discovery Bank’s income streams comprise interest earned on loans to customers, interest on excess cash invested,
fees (e.g. banking fees, interchange fees and transaction fees) from banking. For the financial years ended 30 June 2023 and 30 June
2022, the recoverable amount of the Discovery Bank CGU was determined based on fair value less costs to sell. Inherent in the
determination of fair value less costs to sell is estimation uncertainty. The recoverable amount is the fair value less costs to sell using
the income approach.
In determining the assets to attribute to the Discovery Bank CGU, Discovery considered the assets required to perform banking
operations, including the banking license costs, the internally developed software in use, and the goodwill associated with the
DiscoveryCard business acquisition and related assets and liabilities. Therefore, the valuation also supports the recoverability of
goodwill, intangible assets and deferred tax.
Management has reviewed its business forecast, which comprises:
– 	A detailed 10-year business plan. The 10-year plan considers regulatory capital requirements, macro-economic forecasts and
customer behaviour assumptions when forecasting a Statement of financial position, income statement and resultant equity
cash flows to/from shareholders. The 10-year period used to assess the impairment is longer than the standard 5-year forecast
model generally applied in Discovery’s impairment testing. The business is still in the start-up phase, resulting in a 5-year
forecast not adequately reflecting the business plan. Management can project beyond the 5 years due to the insights from the
DiscoveryCard business it acquired.
– 	The terminal value was calculated using an extended cash flow forecasting method until the growth in earnings has stabilised
in year 20 and a final value considering perpetual terminal growth. This terminal value was discounted to year 10.
– 	As a reasonability check, Discovery Bank translates the value of the business at year 10 into a Price-Earnings (PE) multiple, which
it benchmarks against Discovery’s PE ratio and other emerging banks within the South African environment. The ratio was
determined to be within range.
The key assumptions used by Discovery in the estimation are as follows:
– 	Conservative customer growth, targeting an achievable level of customers in year 10. After that, the customer base is treated
as stable. From the point of stability in year 20, the projected growth in profits is estimated at a conservative 5.65% (2022: 5.55%)
considering long-term inflation and long-term nominal GDP estimations. The increase in growth projections is based on the
growth over the past financial year. System-build costs and intangible assets acquired in the business combination have been
amortised over 10 years (2022: 10 years). The useful lives of these assets are determined as 10 years.
– 	The discount rate applied to the cashflows comprises the following:
Group
2023
Group
2022
Risk-free rate based on 10-year SA bond curve 	11.59% 	10.60%
Beta factor: The beta factor is a weighted average of large SA banks and Discovery 	0.86 	1.07
Discount rate applied 	17.80% 	17.97%
For the year ended 30 June 2023, management has engaged independent external valuation experts to benchmark the key
assumptions and ratios within the South African market. This exercise determined that the assumptions are within acceptable ranges.
Management has further performed stress tests by increasing the discount rate to 21% while simultaneously decreasing the
terminal growth rate to 4.5%. Again, no impairment was triggered with these stressed scenarios.
Based on management’s assessment, Discovery did not identify any impairments in respect of the Discovery Bank CGU.

-- 81 of 217 --

81	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
5. 	ASSETS ARISING FROM INSURANCE CONTRACTS
Group
R million
2023
2022
Restated 2
Gross Reinsurance 	Net 	Gross 	Reinsurance 	Net
Movement in assets arising
from insurance contracts
Balance at beginning of the year 	56 645 	(10 610) 	46 035 	50 483 	(10 143) 	40 340
Expected movement in policyholder
liabilities 	(5 196) 	2 311 	(2 885) 	(2 659) 	1 297 	(1 362)
Unwinding of discount rate 	5 032 	(859) 	4 173 	3 748 	(640) 	3 108
New business written 	6 064 	(2 567) 	3 497 	5 389 	(2 019) 	3 370
Experience variances 	990 	275 	1 265 	1 200 	150 	1 350
– Economic 	1 086 	(64) 	1 022 	332 	(147) 	185
– Operational 	(96) 	339 	243 	868 	297 	1 165
Modelling and method changes 	2 	(20) 	(18) 	(202) 	23 	(179)
Changes in assumptions 	(3 495) 	794 	(2 701) 	(1 914) 	828 	(1 086)
– Economic 	(2 265) 	277 	(1 988) 	88 	81 	169
– Operational 	(1 230) 	517 	(713) 	(2 002) 	747 	(1 255)
Changes in margins1 	198 	(4) 	194 	394 	(17) 	377
Translation differences 	3 625 	(1 425) 	2 200 	206 	(89) 	117
Balance at end of the year 	63 865 	(12 105) 	51 760 	56 645 	(10 610) 	46 035
Current 	7 891 	(2 572) 	5 319 	7 178 	(2 051) 	5 127
Non-current 	55 974 	(9 533) 	46 441 	49 467 	(8 559) 	40 908
Total assets arising from
insurance contracts 	63 865 	(12 105) 	51 760 	56 645 	(10 610) 	46 035
1 In line with accounting policy 13.1.1, the best estimate assumptions and margins are reset at every valuation date to reflect the underlying
profitability of the overall portfolio. Assumptions and margins are not set on new business in isolation but on a portfolio level.
2 The comparative period has been restated to present the assets arising from insurance contracts on a gross basis.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 82 of 217 --

82	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
6. 	PROPERTY AND EQUIPMENT
Group
R million
Land and
buildings
Furniture,
fittings and
equipment
Computer
equipment
and
operating
systems
Leasehold
improve-
ments
Motor
Vehicles
Telematics
devices1 	Total
Year ended 30 June 2023
Opening carrying amount 	2 741 	35 	368 	556 	11 	100 	3 811
Additions 	219 	42 	325 	155 	12 	61 	814
Disposals
– Cost 	(76) 	– 	– 	– 	(7) 	(21) 	(104)
– Accumulated depreciation 	76 	– 	– 	– 	4 	14 	94
Derecognition
– Cost 	(59) 	(78) 	(67) 	(93) 	– 	(48) 	(345)
– Accumulated depreciation 	59 	77 	67 	91 	– 	17 	311
Impairment
– Accumulated depreciation 	(45) 	– 	– 	– 	– 	– 	(45)
Acquisition of subsidiary
– Cost 	– 	1 	– 	– 	– 	– 	1
Depreciation charge 	(293) 	(19) 	(194) 	(103) 	(8) 	(41) 	(658)
Lease termination 	(81) 	– 	– 	– 	– 	– 	(81)
Translation differences 	74 	4 	16 	17 	– 	1 	112
Closing carrying amount 	2 615 	62 	515 	623 	12 	83 	3 910
Year ended 30 June 2023
Cost 	4 076 	154 	1 191 	1 112 	69 	260 	6 862
Accumulated depreciation 	(1 461) 	(92) 	(676) 	(489) 	(57) 	(177) 	(2 952)
Carrying amount 	2 615 	62 	515 	623 	12 	83 	3 910
Year ended 30 June 2022
Opening carrying amount 	3 071 	45 	324 	638 	18 	92 	4 188
Additions 	95 	5 	211 	39 	4 	59 	413
Disposals
– Cost 	(24) 	– 	– 	(10) 	(12) 	(3) 	(49)
– Accumulated depreciation 	9 	– 	– 	1 	9 	2 	21
Derecognition
– Cost 	(12) 	(10) 	(302) 	(38) 	(11) 	(60) 	(433)
– Accumulated depreciation 	10 	10 	302 	37 	11 	51 	421
Depreciation charge 	(299) 	(15) 	(171) 	(116) 	(8) 	(41) 	(650)
Lease modification 	(125) 	– 	– 	– 	– 	– 	(125)
Translation differences 	16 	– 	4 	5 	– 	– 	25
Closing carrying amount 	2 741 	35 	368 	556 	11 	100 	3 811
Year ended 30 June 2022
Cost 	3 969 	168 	875 	1 018 	63 	269 	6 362
Accumulated depreciation 	(1 228) 	(133) 	(507) 	(462) 	(52) 	(169) 	(2 551)
Carrying amount 	2 741 	35 	368 	556 	11 	100 	3 811
1 In Discovery Insure, when policies relating to motor vehicle insurance lapse, the telematics devices installed in those vehicles are not always
recovered. The value of these unrecovered units are derecognised.
Impairment
The R45 million impairment pertains to a property in the UK Composite. UK commercial property values have come under pressure
during the last year as interest rates have increased. Rent levels in certain areas have also been under pressure, with several
buildings having significant vacant space. Consequently, rent levels have not experienced the growth needed to offset the impact of
interest rates on yields. An external valuation ascertained that the recoverable amount, being fair value less cost to sell, was
R45 million lower than the carrying value of the building.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 83 of 217 --

83	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
6. 	PROPERTY AND EQUIPMENT continued
LEASED ASSETS
Property and equipment includes the following assets which are leased under a finance lease:
R million
Group
2023
Group
2022
Land and buildings 	2 372 	2 480
Computer equipment and operating systems 	45 	11
Leasehold improvements 	71 	23
Motor vehicles 	1 	2
Total leased assets 	2 489 	2 516
7. 	INTANGIBLE ASSETS
Group
R million
Software
development
Business
acquisitions:
Identifiable
intangibles
Banking
license 	Total
Year ended 30 June 2023
Opening carrying amount 	6 133 	377 	29 	6 539
Additions 	1 760 	– 	– 	1 760
Amortisation charge 	(1 319) 	(56) 	– 	(1 375)
Derecognition
– Cost 	(1 873) 	(37) 	– 	(1 910)
– Accumulated amortisation 	1 583 	37 	– 	1 620
Translation differences 	298 	50 	– 	348
Closing carrying amount 	6 582 	371 	29 	6 982
Year ended 30 June 2023
Cost 	11 207 	2 548 	29 	13 784
Accumulated amortisation 	(4 625) 	(2 177) 	– 	(6 802)
Carrying amount 	6 582 	371 	29 	6 982
Business acquisitions
Intangibles identified in the acquisition of business combinations are amortised over their remaining useful lives and only tested for
impairment if an indication of impairment arises. There was no indication of impairment for the current reporting period.
Included in the value of business acquisitions are:
 Customer contracts represented by value of in-force business acquired in the Standard Life Healthcare and PrimeMed business
combinations. The carrying amount as at 30 June 2023 is R286 million (2022: R277 million); and
 Client relationships and Core Deposit Funding Benefit acquired in the DiscoveryCard business combination. The carrying
amounts as at 30 June 2023 are R74 million and R11 million respectively (2022: R87 million and R13 million).
Banking license
 During the 2018 financial year, Discovery incurred costs of R29 million in respect of the application for a banking license.
Discovery has capitalised these costs in terms of IAS 38 Intangible Assets. This asset has an indefinite useful life.

-- 84 of 217 --

84	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
7. 	INTANGIBLE ASSETS continued
Group
R million
Software
development
Business
acquisitions:
Identifiable
intangibles
Banking
license 	Total
Year ended 30 June 2022
Opening carrying amount 	5 911 	431 	29 	6 371
Additions 	1 567 	– 	– 	1 567
Amortisation charge 	(1 252) 	(59) 	– 	(1 311)
Impairment
– Cost 	(49) 	– 	– 	(49)
– Accumulated amortisation 	49 	– 	– 	49
Derecognition 1
– Cost 	(546) 	– 	– 	(546)
– Accumulated amortisation 	344 	– 	– 	344
Translation differences 	109 	5 	– 	114
Closing carrying amount 	6 133 	377 	29 	6 539
Year ended 30 June 2022
Cost 	10 663 	1 872 	29 	12 564
Accumulated amortisation 	(4 530) 	(1 495) 	– 	(6 025)
Carrying amount 	6 133 	377 	29 	6 539
1 Included in derecognition for the year is an amount of R164 million resulting from the IFRIC interpretation on capitalisation of costs associated
with configuration or customisation costs in a cloud arrangement. R75 million has been recognised in profit and loss and presented in salaries,
wages and allowances (refer to note 31) and R89 million was recognised in prepayments (refer to note 14) of which R45 million has been expensed
at 30 June 2022. Accordingly, the headline earnings per share has not been adjusted to reflect the derecognition as a result of this interpretation.

-- 85 of 217 --

85	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
8. 	DEFERRED ACQUISITION COSTS
R million
Group
2023
Group
2022
Balance at beginning of the year 	640 	585
Additions 	2 297 	1 524
Deferred acquisition costs amortised 	(2 255) 	(1 475)
Translation differences 	117 	6
Balance at the end of the year 	799 	640
9A. 	ASSETS ARISING FROM CONTRACTS WITH CUSTOMERS AND CONTRACT
LIABILITIES TO CUSTOMERS
Where either party to a contract has performed, Discovery presents either a contract asset or contract liability, depending on the
relationship between Discovery’s performance and the customer’s payment. Unconditional rights to consideration is presented
separately as a receivable.
Group
R million
Assets
arising from
contracts
with
customers 1
Costs of
obtaining
contracts 1
Contract
liabilities
Contract
receivables2
Year ended 30 June 2023
Balance at beginning of the year 	256 	1 436 	(944) 	1 209
Accrued income recognised during the year 	313 	– 	– 	–
Payments received 	(57) 	– 	– 	(13 614)
Costs of obtaining new contracts 	– 	550 	– 	–
Amortised during the year 	– 	(341) 	– 	–
Contract liabilities recognised in the current year 	– 	– 	(426) 	–
Revenue recognised in the year 	– 	– 	747 	13 629
Provision of impairment of contract receivables 	– 	– 	– 	(4)
Foreign exchange revaluations 	(21) 	13 	– 	–
Translation differences 	51 	1 	(33) 	48
Balance at end of the year 	542 	1 659 	(656) 	1 268
Year ended 30 June 2022 Restated 3
Balance at beginning of the year 	162 	1 213 	(776) 	1 217
Accrued income recognised during the year 	111 	– 	– 	–
Payments received 	(45) 	– 	– 	(12 100)
Costs of obtaining new contracts 	– 	465 	– 	–
Amortised during the year 	– 	(253) 	– 	–
Contract liabilities recognised in the current year 	– 	– 	(534) 	–
Revenue recognised in the year 	– 	– 	404 	12 016
Provision of impairment of contract receivables 	– 	– 	– 	24
Foreign exchange revaluations 	– 	8 	– 	7
Translation differences 	28 	3 	(38) 	45
Balance at end of the year 	256 	1 436 	(944) 	1 209
1 Presented as Assets arising from contracts with customers.
2 Presented as part of insurance receivables, contract receivables and other receivables.
3 The comparative information has been restated. Refer to note 45 for detail.

-- 86 of 217 --

86	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
9A. 	ASSETS ARISING FROM CONTRACTS WITH CUSTOMERS AND CONTRACT
LIABILITIES TO CUSTOMERS continued
The contract liability primarily relates to the advance consideration received from customers for the initial advisor fees, for which
revenue will be recognised over the expected terms of the arrangement. It further includes the Discovery Miles liability on the
Vitality programme.
Discovery has unsatisfied performance obligations relating to providing intellectual property services for the VitalityOne System.
The transaction price relating to unsatisfied performance obligations is expected to be recognised as revenue as follows:
R million
Group
2023
Group
2022
Provision of stand-ready Intellectual Property services
– <1 year 	519 	439
– 2 – 3 years 	1 042 	910
– 4 – 5 years 	584 	675
– >5 years 	1 004 	1 124
Total contract amount for future services 	3 149 	3 148
Where performance obligations are discharged within 12 months or where contracts are cancellable giving 12 months or less notice,
without the payment of a significant penalty, a practical expedient has been applied. Discovery has excluded these contracts from
the disclosures above. Contracts that include variable considerations have also not been included in the table above.
9B. 	REVENUE
Discovery Group’s Revenue includes ’Fee income from administration business’, ’Vitality income’ and ’Banking fee and commission
income’. Also refer to accounting policy 20 Revenue recognition.
The split of revenue per geographical region and reportable segment can be viewed in note 1 Segment information.
The split of revenue according to the timing of satisfaction of performance obligation, i.e. ’over time’ or a ’point-in-time’ is as follows:
R million
Group
2023
Group
2022
Fee income from administration business: Health income 	11 959 	10 971
– Over time 	11 932 	10 548
– Point-in-time 	27 	423
Fee income from administration business: Intellectual Property fees 	2 798 	1 781
– Over time 	2 798 	1 781
Vitality income 	3 891 	3 495
– Over time 	2 660 	2 348
– Point-in-time 	1 231 	1 147
Banking fee and commission income 	1 292 	853
– Over time 	687 	389
– Point-in-time 	605 	464

-- 87 of 217 --

87	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
10. 	GOODWILL
Goodwill is not amortised, but is tested on an annual basis for impairment. Any impairment is recognised immediately in profit or
loss and is not subsequently reversed.
The table below sets out the goodwill allocated to the respective CGUs which is expected to benefit from the synergies of the
combination. Impairment of goodwill is assessed at this CGU level.
R million
Goodwill per CGU
Value in functional currency on
date of acquisition
Group
2023
Group
2022
Goodwill
– VitalityHealth1, 2, 5, 6 	GBP100.3 million 	2 407 	2 007
– VitalityLife 1, 5, 7 	GBP23.4 million 	562 	468
– Discovery Bank3 	R2 417 million 	2 417 	2 417
– Discovery Administration Services4 	R20 million 	20 	20
– Nanolabs8 	R9 million 	- 	–
Total 	5 406 	4 912
1 GBP96.7 million and GBP23.4 million of the goodwill was allocated to VitalityHealth and VitalityLife respectively as at 31 July 2010. The goodwill
arose from the acquisition of Standard Life Healthcare and related capital restructure of the PAC joint venture.
2 GBP2.5 million goodwill from the acquisition of Insure Your Health (25 March 2013) and GBP1.1 million of goodwill from the acquisition of
KYS Paid Limited (30 April 2014) were allocated to the VitalityHealth CGU.
3 R2 417 million goodwill from the acquisition of the DiscoveryCard business on 1 March 2019 was allocated to the Discovery Bank CGU.
4 In October 2020, Discovery acquired Liberty Health Administration, a wholly owned subsidiary, which performs medical aid administration for
specified medical aids. Liberty Health Administration has been renamed to Discovery Administration Services Proprietary Limited as of 11 August 2021.
5 As part of the annual assessment of impairment, Discovery has done significant stresses on the goodwill of VitalityHealth and VitalityLIfe. The
value-in-use considers the value of in-force business as well as new business. The value-in-use is calculated as the present value of the best-estimate
pre-tax cash flows of the CGU for the in-force policies at the valuation date and 10 years of new business. The outcome of the working indicated
that the recoverable amount significantly exceeds the carrying amount of the CGUs, with little risk of impairment.
6 Net exchange rate differences of R400 million (2022: R27 million) were recognised in the financial year ended 30 June 2023.
7 Net exchange rate differences of R94 million (2022: R6 million) were recognised in the financial year ended 30 June 2023.
8 At the beginning of July 2022 Discovery acquired a controlling stake in Nanolabs Health Solutions Proprietary Limited (Nanolabs) with Point
of Care Testing technology. Subsequent to the acquisition this goodwill was fully impaired.

-- 88 of 217 --

88	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
11. 	INVESTMENT IN EQUITY-ACCOUNTED INVESTEES
R million
Group
2023
Group
2022
Carrying value of material interest in associates and joint ventures – Ping An Health Insurance 	5 380 	4 499
Carrying value of material interest in associates and joint ventures – CMT 	1 400 	1 263
Carrying value of individually immaterial interest in associates 	148 	112
Carrying value of individually immaterial interest in joint ventures 	96 	134
Investment in equity-accounted investees 	7 024 	6 008
11.1 Material interests in associates and joint ventures
The table below provides summarised financial information for the Group’s material joint ventures and associates. The information
disclosed reflects the amounts presented in the financial statements of the relevant associates and joint ventures and not
Discovery’s share of those amounts.
Ping An Health Insurance Company of China, Limited (PAHI)
Ping An Health Insurance offers policyholders in China cover for a range of private healthcare-related claims. PAHI is a strategic
partnership for the Group, providing access to new clients and markets in China.
Cambridge Mobile Telematics Inc. (CMT)
A United States of America based leading telematics technology provider. This partnership provides the Group with expertise in the
telematics environment that Discovery Insure harnesses to manage its insurance risk.
Ping an Health Insurance 	CMT
Ownership structure 	Equity-accounted associate 	Equity-accounted associate
Nature 	Insurance 	Telematics technology
Place of business 	China 	USA
R million 	2023 	2022 	2023 	2022
% of ownership interest at end of the year 	24.99% 	24.99% 	8.76% 	8.85%
Summarised statement of comprehensive income
Revenue 	36 300 	29 540 	3 292 	2 285
Net profit/(loss) for the year 	2 604 	1 637 	(461) 	(521)
Other comprehensive (loss)/income 	(62) 	69 	– 	–
Total comprehensive income/(loss) 	2 542 	1 706 	(461) 	(521)
Summarised statement of financial position
Current assets 	19 971 	19 048 	4 264 	3 852
Non-current assets 	53 046 	39 144 	12 929 	11 686
Current liabilities 	(9 169) 	(6 526) 	(1 204) 	(1 054)
Non-current liabilities 	(43 543) 	(34 833) 	(460) 	(604)
Net assets 	20 305 	16 833 	15 529 	13 880
Reconciliation to carrying amounts:
Opening net assets 	16 833 	7 725 	13 880 	12 270
Net profit/(loss) for the year 	2 604 	1 637 	(461) 	(521)
Other comprehensive (loss)/income 	(62) 	69 	– 	–
Increase in share capital and share premium 	– 	5 950 	110 	267
Foreign exchange gains 	930 	1 452 	2 000 	1 864
Closing net assets 	20 305 	16 833 	15 529 	13 880
Group’s share of net assets 	5 074 	4 207 	1 360 	1 228
Goodwill 	306 	292 	40 	35
Carrying value at 30 June 	5 380 	4 499 	1 400 	1 263

-- 89 of 217 --

89	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
11. 	INVESTMENT IN EQUITY-ACCOUNTED INVESTEES continued
11.2 Individually immaterial associates and joint ventures
11.2.1 Individually material transactions
DISPOSAL OF INVESTMENT IN AIAV
During the financial year ended 30 June 2022, the investment in AIA Vitality Proprietary Limited (AIAV) was reclassified from equity-
accounted investments to non-current assets held for sale in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued
Operations. At date of reclassification, there were no additional impairment losses or reversals due to reclassification. At 30 June 2022,
the disposal group was stated at fair value less costs to sell.
The disposal group comprised of:
– Investment in AIAV equity-accounted investment 	AUD15 million (R171 million)
The non-recurring fair value measurement for the investment in AIAV of AUD15 million (R171 million) was categorised as a level 3
fair value due to the binding offer being subject to significant unobservable inputs. Discovery used the binding offer without
adjustment as the fair value and therefore there are no quantitative unobservable inputs developed when measuring the fair value.
The investment was sold effective 1 February 2023 at AUD15 million (R184 million).
11.2.2 Summary of financial information
The table below provides summarised information of the aggregate amounts of the Group’s share of total income:
Group
R million
Associates 	Joint ventures
2023 	2022 	2023 	2022
Aggregate amount of the Group’s share of (loss)/profit 	(165) 	(21) 	69 	137
Reversal of Impairment of equity-accounted investment 	– 	134 	– 	–
Aggregate amount of the Group’s share of other comprehensive
income/(loss) 	8 	8 	6 	(5)
Aggregate amount of the Group’s share of
total comprehensive (loss)/income 	(157) 	121 	75 	132

-- 90 of 217 --

90	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
12. 	FINANCIAL ASSETS
The Group’s investment in financial assets are summarised by measurement category in the table below:
R million 	Notes
Group
2023
Group
2022
Financial assets at fair value through profit or loss – mandatorily: 	155 426 	141 494
– Equity portfolios 	56 525 	57 948
– Debt portfolios 	42 573 	47 592
– Money market portfolios 	22 656 	14 680
– Multi-asset portfolios 	33 672 	21 274
Financial assets at amortised cost 1 	14 612 	11 105
Investments at amortised cost 	9 910 	7 161
– South African Treasury Bills 	6 856 	5 205
– Deposits 	3 054 	1 956
Loans and advances to customers at amortised cost 	12.1 	4 702 	3 944
Total investments 	170 038 	152 599
Listed 	137 632 	130 192
Unlisted 	32 406 	22 407
170 038 	152 599
Shareholder investments: 	21 570 	19 828
– Investments at amortised cost 	3 	14 612 	11 105
– Investments at fair value through profit and loss – mandatorily 	6 958 	8 723
Policyholder investments: 	148 468 	132 771
– Investments at fair value through profit and loss – mandatorily 	148 468 	132 771
Total investments 	170 038 	152 599
1 The fair value of instruments at amortised cost approximates the carrying amount due to the relatively short-term nature of the instrument.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 91 of 217 --

91	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
12. 	FINANCIAL ASSETS continued
12.1 Loans and advances to customers at amortised cost
R million 	Notes
Group
2023
Group
2022
Gross loans and advances (unsecured) 	5 113 	4 308
Accrued interest 	58 	39
Total gross loans and advances 	5 171 	4 347
Less: IFRS9 Expected credit losses (ECL) 	12.1.2 	(469) 	(403)
Total net loans and advances 	4 702 	3 944
12.1.1 Loans and advances per credit risk rating
Group
R million 	DRG 1 – 4 	DRG 5 – 7 	DRG 8 – 10 	Not rated 	Total
As at 30 June 2023
Stage 1 	2 617 	1 468 	352 	– 	4 437
Stage 2: SICR1 	3 	12 	323 	– 	338
Stage 2: Arrears 	2 	11 	69 	– 	82
Stage 3 	1 	8 	247 	– 	256
Gross loans and advances 	2 623 	1 499 	991 	– 	5 113
As at 30 June 2022
Stage 1 	2 166 	1 272 	309 	– 	3 747
Stage 2: SICR1 	4 	24 	271 	5 	304
Stage 2: Arrears 	– 	1 	2 	62 	65
Stage 3 	2 	4 	10 	176 	192
Gross loans and advances 	2 172 	1 301 	592 	243 	4 308
1 Significant increase in credit risk.
Discovery risk grade (DRG), is an internal client rate allocated on the basis of their risk profile. An adjusted DRG is allocated for the
purposes of calculating the expected credit losses.
In the prior year, Loans and advances classified as ‘not rated’ pertained to loans and advances migrated from DiscoveryCard which
had not been through Discovery Bank credit assessment, and assigned a DRG. To determine the ECL on these customers in the prior
year, information from the DiscoveryCard back book was used. In the current financial year, these loans and advances have now
been through Discovery Bank credit assessment and assigned a DRG.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 92 of 217 --

92	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
12. 	FINANCIAL ASSETS continued
12.1.2 Reconciliation of the expected credit losses (ECL)
Group
R million
Stage 1
(12-month
ECL)
Stage 2
(Lifetime ECL,
but not
missed
payments)
Stage 2
(Lifetime
ECL,
and missed
payments)
Stage 3
(Lifetime
ECL,
and credit
impaired,
default) 	Total
30 June 2023
Balance at beginning of the year 	167 	37 	35 	164 	403
Total changes in ECL due to changes
in balances of advances 	(8) 	7 	5 	(90) 	(86)
– New loans originated and acquired 1 	4 	– 	– 	– 	4
– Repayments and other movements 	(10) 	7 	5 	21 	23
– Change in ECL due to derecognition
other than write-off 	(2) 	– 	– 	(3) 	(5)
– Change in ECL due to write-off3 	– 	– 	– 	(108) 	(108)
159 	44 	40 	74 	317
Transfers between stages 1 	(3) 	10 	6 	139 	152
– Transfer (to)/from stage 1 	– 	12 	18 	85 	115
– Transfer (to)/from stage 2: SICR 	1 	– 	1 	22 	24
– Transfer (to)/from stage 2: Arrears 	(1) 	– 	– 	32 	31
– Transfer (to)/from stage 3 	(3) 	(2) 	(13) 	– 	(18)
Balance at end of the year 	156 	54 	46 	213 	469
30 June 2022
Balance at beginning of the year 	192 	41 	24 	208 	465
Total changes in ECL due to changes
in balances of advances 	(16) 	2 	10 	(134) 	(138)
– New loans originated and acquired 	3 	1 	– 	– 	4
– Repayments and other movements 2 	(16) 	2 	10 	30 	26
– Change in ECL due to derecognition
other than write-off 	(3) 	(1) 	– 	(6) 	(10)
– Change in ECL due to write-off3 	– 	– 	– 	(158) 	(158)
176 	43 	34 	74 	327
Transfers between stages 1 	(9) 	(6) 	1 	90 	76
– Transfer (to)/from stage 1 	– 	(4) 	11 	51 	58
– Transfer (to)/from stage 2: SICR 	(3) 	– 	1 	10 	8
– Transfer (to)/from stage 2: Arrears 	(2) 	– 	– 	29 	27
– Transfer (to)/from stage 3 	(4) 	(2) 	(11) 	– 	(17)
Balance at end of the year 	167 	37 	35 	164 	403
1 Discovery Bank’s policy is to transfer accounts between stages based on the ECL stage at the end of the reporting period. Therefore, exposures can
be transferred directly from stage 3 to stage 1 as the curing requirements would have been satisfied during the reporting period. The expected
credit loss recognised on new exposures originated during the reporting period (which are not included in opening balances) are recognised in
new loans originated and acquired based on the exposures’ ECL stage as at the end of the month the account comes on book. Any change in
status will be reflected in the transfers between stages as described above.
2 For the year ended 30 June 2022, management had increased the ECL by R28.6 million for the effects of COVID-19 in considering forward looking
macroeconomic factors. These factors are no longer applicable and therefore no adjustment is required for June 2023.
3 The contractual amount outstanding on financial assets that were written off during the year ended 30 June 2023 and that are still subject to
enforcement activity is R113 million (2022: R158 million).
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 93 of 217 --

93	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
13. 	DERIVATIVE FINANCIAL INSTRUMENTS
R million
Group
2023
Assets
Group
2023
Liabilities
Group
2022
Assets
Group
2022
Liabilities
Derivatives used as cash flow hedges:
Interest rate derivatives1 	59 	(1) 	17 	(56)
Derivatives not designated as hedging instruments:
Equity price risk derivatives 	26 	(16) 	19 	(66)
Interest rate swaps 	31 	– 	– 	(79)
Swaptions 	– 	– 	216 	–
Currency derivative contracts 	3 	(3) 	24 	(1)
Total derivative financial instruments 	119 	(20) 	276 	(202)
Current 	31 	(19) 	36 	(62)
Non-current 	88 	(1) 	240 	(140)
Total derivative financial instruments 	119 	(20) 	276 	(202)
1 The interest rate derivative portfolio consists of both interest rate swaps and interest rate caps.
The effects of the derivatives used in cash flow hedges on the Group’s financial position and performance are as follows:
Year ended 30 June 2023
Group
R million
Notional
amount of
the hedging
instrument
Carrying amount
of the hedging
instrument
Line item
in the
Statement
of financial
position
where the
hedging
instrument
is presented
Changes
in value
of hedging
instrument
used for
calculating
hedge
ineffective-
ness
Ineffective-
ness
recognised
in profit
or loss
Line item in
which hedge
ineffectiveness
is presented
in profit or loss	Assets Liabilities
Interest rate risk 	4 518 	59 	(1) 	(76) 	–
Interest rate
derivatives 	4 518 	59 	(1)
Financial
Asset-
Derivative/
Financial
Liability-
Derivative 	(76) 	–
Net fair value
gains on
financial
assets at fair
value through
profit and loss
Refer to note 3.4.1 for a detailed description of the derivative financial instruments listed above.
Group
R million
Changes in
the value of
the hedging
instrument
recognised
in other
comprehen-
sive income
Amount
reclassified
from the
cash flow
hedge
reserve
to profit
or loss
Line item
in which
the
recycled
amount is
presented
in profit
or loss
Carrying amount
of the hedged item
Changes in
value of
hedged item
used for
calculating
hedge
ineffective-
ness
Cash flow
hedge
reserve	Assets Liabilities
Interest rate risk 1 	76 	4 	– 	(4 569) 	63 	41
Interest rate
derivatives 	76 	4
Cash flow
hedges-gains
recycled to
profit or loss 	– 	(4 569) 	63 	41
1 The interest rate risk derivatives have been recycled to the ’Cash flow hedges – gains recycled to profit or loss’ line item in the Statement of other
comprehensive income (SOCI).
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 94 of 217 --

94	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
13. 	DERIVATIVE FINANCIAL INSTRUMENTS continued
Year ended 30 June 2022
Group
R million
Notional
amount of
the hedging
instrument
Carrying amount
of the hedging
instrument
Line item
in the
Statement
of financial
position
where the
hedging
instrument
is presented
Changes
in value
of hedging
instrument
used for
calculating
hedge
ineffective-
ness
Ineffective-
ness
recognised
in profit
or loss
Line item in
which hedge
ineffectiveness
is presented
in profit or loss	Assets 	Liabilities
Interest rate risk 	5 000 	17 	(56) 	(295) 	–
Interest rate
derivatives 	5 000 	17 	(56)
Financial
Asset-
Derivative/
Financial
Liability-
Derivative 	(295) 	–
Net fair value
gains on financial
assets at fair
value through
profit or loss
Refer to note 3.4.1 for a detailed description of the derivative financial instruments listed above.
Group
R million
Changes in
the value of
the hedging
instrument
recognised
in other
comprehen-
sive income
Amount
reclassified
from the
cash flow
hedge
reserve to
profit or
loss
Line item
in which
the
recycled
amount is
presented
in profit
or loss
Carrying amount
of the hedged item
Changes in
value of
hedged item
used for
calculating
hedge
ineffective-
ness
Cash flow
hedge
reserve	Assets 	Liabilities
Interest rate risk 1 	295 	– 	– 	– 	(5 038) 	(185) 	(40)
Interest rate
derivatives
295 	– 	– 	– 	(5 038) 	(185) 	(40)
1 The interest rate risk derivatives have been recycled to the Cash flow hedges – gains recycled to profit or loss’ line item in the SOCI.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 95 of 217 --

95	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
14. 	INSURANCE RECEIVABLES, CONTRACT RECEIVABLES AND OTHER
RECEIVABLES
R million
Group
2023
Group
2022
Receivables arising from insurance and reinsurance contracts: 	10 316 	7 887
– Premium debtors 	1 070 	801
– Less provision for impairment of premium debtors 	14.1 	(97) 	(81)
– Reinsurance debtors 	9 343 	7 167
Contract receivables: 	9A 	1 268 	1 209
– Closed scheme debtors 	120 	107
– Discovery Health Medical Scheme 	775 	724
– Other contract receivables 	377 	382
– Less allowance for expected credit losses 	14.2 	(4) 	(4)
Other financial receivables: 	3 064 	2 642
– Agents and brokers 	534 	439
– Cash-in-transit debtors 	544 	443
– Consolidated unit trust debtors 	628 	770
– Loans to BEE initiatives 	309 	256
– Security deposit on derivatives 2 	27 	72
– Vitality partner debtors 	171 	148
– Other debtors 	1 261 	906
– Less allowance for expected credit losses 	14.2 	(410) 	(392)
Other non-financial receivables1 	1 411 	1 375
– Prepayments 	1 204 	1 022
– Value-added tax asset 	48 	158
– Other debtors 	159 	195
Total insurance receivables, contract receivables and other receivables 	16 059 	13 113
Current 	11 404 	8 822
Non-current 	4 655 	4 291
Total insurance receivables, contract receivables and other receivables 	16 059 	13 113
1 These non-financial assets have been excluded from the risk disclosures presented in note 3.
2 To reduce the credit risk exposure from the hedge derivative instruments purchased, Discovery has entered into collateral agreements with the
relevant financial institutions to post cash collateral periodically, equal to the fair value of the derivatives. The posting of the collateral does not
result in legal settlement of the outstanding derivative balance. The collateral will only be used to settle the derivative upon default or bankruptcy
of either party.
The fair value of short-term receivables approximates the carrying value. Long-term receivables are interest bearing at market rates
and fully secured.

-- 96 of 217 --

96	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
14. 	INSURANCE RECEIVABLES, CONTRACT RECEIVABLES AND OTHER
RECEIVABLES continued
14.1 Provision for impairment of premium debtors
Group
R million 	<30 days
30 – 60
days
60 – 120
days
more than
120 days 	Total
Year ended 30 June 2023
Balance at beginning of the year 	25 	22 	26 	7 	80
Increase in provision 	14 	10 	17 	2 	43
Amount utilised during the period 	(3) 	(10) 	(19) 	– 	(32)
Translation differences 	1 	2 	3 	– 	6
Balance at end of the year 	37 	24 	27 	9 	97
Year ended 30 June 2022
Balance at beginning of the year 	26 	16 	16 	6 	64
Increase in provision 	2 	25 	22 	7 	56
Amount utilised during the period 	(3) 	(19) 	(11) 	(6) 	(39)
Translation differences 	* 	* 	(1) 	* 	(1)
Balance at end of the year 	25 	22 	26 	7 	80
* Amount is less than R500 000.
14.2 Reconciliation of expected credit losses (ECL)
Group
R million
General model 	Simplified model
Stage 1
(12-month
ECL)
Stage 2
(Lifetime
ECL)
Stage 3
(Lifetime
ECL/credit
impaired)
Not
Credit
impaired
90 days
past due/
credit
impaired 	Total
Year ended 30 June 2023
Balance at beginning of the year 	8 	10 	228 	107 	43 	396
Increase in provision 	(1) 	(7) 	29 	8 	5 	34
Amount utilised during the period 	– 	– 	– 	(12) 	(10) 	(22)
Translation differences 	– 	– 	– 	5 	1 	6
Balance at end of the year 	7 	3 	257 	108 	39 	414
Year ended 30 June 2022
Balance at beginning of the year 	11 	8 	230 	98 	143 	490
Increase in provision 	1 	2 	2 	33 	39 	77
Amount utilised during the period 	(4) 	– 	(4) 	(26) 	(140) 	(174)
Translation differences 	* 	* 	* 	2 	1 	3
Balance at end of the year 	8 	10 	228 	107 	43 	396
* Amount is less than R500 000.
15. 	REINSURANCE CONTRACTS
R million
Group
2023
Group
2022
Reinsurers’ share of insurance contract liabilities 	709 	511
Current 	709 	511
Amounts due from reinsurers in respect of claims paid and reported by the Group on the contracts that are reinsured are included
in Insurance receivables, contract receivables and other receivables (refer to note 14).

-- 97 of 217 --

97	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
16. 	CASH AND CASH EQUIVALENTS
R million
Group
2023
Group
2022
Cash at bank and in hand 	19 113 	17 625
Short-term deposits 	1 257 	2 150
Total cash and cash equivalents 	20 370 	19 775
The fair value of cash and cash equivalents approximates the carrying amount due to the relatively short-term nature of the instrument.
17. 	SHARE CAPITAL AND SHARE PREMIUM
17.1 	Ordinary share capital and share premium
Issued 	Treasury shares
Group
R million
Share
capital
Share
premium
Discovery
Health
BEE
share trust 	LTIP
Total
outstanding
At 1 July 2021 	1 	11 121 	(14) 	(50) 	(907) 	10 151
Share movements:
– new issue 	– 	443 	– 	– 	– 	443
– treasury shares delivered 	– 	24 	– 	3 	– 	27
– treasury shares purchased 	– 	– 	– 	– 	(443) 	(443)
At 30 June 2022 	1 	11 588 	(14) 	(47) 	(1 350) 	10 178
Share movements:
– new issue 	– 	514 	– 	– 	– 	514
– treasury shares delivered 	– 	– 	– 	3 	170 	173
– treasury shares purchased 	– 	– 	– 	– 	(514) 	(514)
At 30 June 2023 	1 	12 102 	(14) 	(44) 	(1 694) 	10 351
Treasury shares
Number of shares 	Company
Discovery
Health
BEE
share trust 	LTIP
Total
outstanding
At 1 July 2021 	665 768 601 	(680 268) 	(805 961) 	(7 477 865) 	656 804 507
Share movements:
– new issue 	3 194 870 	– 	– 	– 	3 194 870
– treasury shares delivered 	– 	– 	152 104 	– 	152 104
– treasury shares purchased 	– 	– 	– 	(3 194 870) 	(3 194 870)
At 30 June 2022 	668 963 471 	(680 268) 	(653 857) 	(10 672 735) 	656 956 611
Share movements:
– new issue 	4 182 946 	– 	– 	– 	4 182 946
– treasury shares delivered 	– 	– 	64 714 	1 402 275 	1 466 989
– treasury shares purchased 	– 	– 	– 	(4 182 946) 	(4 182 946)
At 30 June 2023 	673 146 417 	(680 268) 	(589 143) 	(13 453 406) 	658 423 600
The total authorised number of ordinary shares is 1 billion (2022: 1 billion), with a par value of 0.1 cent per share.
Share issue in 2023 financial reporting period
Discovery issued 4 182 946 shares for a cash consideration of R514 189 249. This was a specific issuance, to the Discovery Long-term
Incentive Plan Trust. As approved at the AGM of 28 November 2019, Discovery is authorised pursuant to section 41 of the
Companies Act, as amended, and the requirements of the memorandum of incorporation to allot and issue, and representing
cumulatively the maximum allotment over the multiple year duration of the Discovery Long Term Incentive Plan (LTIP) (also see note
32 Share-based payments and long-term incentives), a maximum of 32 914 537 ordinary shares in the authorised share capital of
the Discovery.

-- 98 of 217 --

98	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
17. 	SHARE CAPITAL AND SHARE PREMIUM continued
17.2 Preference share capital
R million
Group
2023
Group
2022
Authorised
40 000 000 A no par value preference shares 	– 	–
20 000 000 B preference shares of R100 each 	2 000 	2 000
20 000 000 C no par value preference shares 	– 	–
2 000 	2 000
Issued
8 000 000 B preference shares of R100 each 	800 	800
Share issue costs 	(21) 	(21)
At 30 June 	779 	779
The B preference shares are non-compulsory, non-cumulative, non-participating, non-convertible, voluntarily redeemable (at option
of Discovery) preference shares and were issued at a coupon rate of 85% of prime rate. With the introduction of dividend
withholding tax on 1 April 2012, the coupon rate on the preference shares was increased to 100% of the prime rate.
18. 	LIABILITIES ARISING FROM INSURANCE CONTRACTS
R million
Group
2023
Restated2
Group
2022
Gross
– claims reported and loss adjustment expenses 	13 559 	12 662
– claims incurred but not reported 	2 938 	2 118
– IFA liability 	129 	100
– unearned premiums 	833 	1 007
– unit-linked insurance contracts 	75 261 	70 907
– with fixed and guaranteed terms 	22 087 	21 273
Total liabilities arising from insurance contracts, gross 	114 807 	108 067
Recoverable from reinsurers
– claims incurred but not reported 	(699) 	(501)
– unearned premiums 	(10) 	(10)
Total reinsurers’ share of liabilities arising from insurance contracts (refer to note 15) 	(709) 	(511)
Net
– claims reported and loss adjustment expenses 	13 559 	12 662
– claims incurred but not reported 	2 239 	1 617
– IFA liability 	129 	100
– unearned premiums 	823 	997
– unit-linked insurance contracts 	75 261 	70 907
– with fixed and guaranteed terms 	22 087 	21 273
Total liabilities arising from insurance contracts, net 	114 098 	107 556
Current1 	98 513 	91 784
Non-current 	15 585 	15 772
114 098 	107 556
1 Includes R81 031 million (2022: R76 448 million) which is repayable to policyholders on demand. For contractual maturity refer to note 3.2.3.
2 The comparative information has been restated. Refer to note 45 for detail.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 99 of 217 --

99	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
18. 	LIABILITIES ARISING FROM INSURANCE CONTRACTS continued
Movements in the liabilities are as follows:
Group
R million
2023 	2022
Gross Reinsurance 	Net 	Gross 	Reinsurance 	Net
Claims reported and loss
adjustment expenses and IBNR
Notified claims 	12 662 	– 	12 662 	11 234 	– 	11 234
Incurred but not reported 	2 118 	(501) 	1 617 	2 074 	(439) 	1 635
Balance at beginning of the year 	14 780 	(501) 	14 279 	13 308 	(439) 	12 869
Cash paid for claims settled in the year 	(15 438) 	76 	(15 362) 	(13 601) 	73 	(13 528)
Increase/(decrease) in liabilities:
– arising from current year claims 	18 919 	(316) 	18 603 	16 545 	(183) 	16 362
– arising from prior year claims 	(2 050) 	104 	(1 946) 	(1 500) 	50 	(1 450)
Economic assumptions movement1 	(306) 	– 	(306) 	– 	– 	–
Translation differences 	592 	(62) 	530 	28 	(2) 	26
Balance at end of the year 	16 497 	(699) 	15 798 	14 780 	(501) 	14 279
Notified claims 	13 559 	– 	13 559 	12 662 	– 	12 662
Incurred but not reported 	2 938 	(699) 	2 239 	2 118 	(501) 	1 617
Balance at end of the year 	16 497 	(699) 	15 798 	14 780 	(501) 	14 279
IFA liability
Balance at beginning of the year 	100 	– 	100 	82 	– 	82
Increase in the year 	64 	– 	64 	42 	– 	42
Cash paid 	(35) 	– 	(35) 	(24) 	– 	(24)
Balance at end of the year 	129 	– 	129 	100 	– 	100
Provisions for unearned premiums
Balance at beginning of the year 	1 007 	(10) 	997 	1 091 	(6) 	1 085
Increase in the year 	2 008 	(10) 	1 998 	1 625 	(10) 	1 615
Release in the year 	(2 313) 	10 	(2 303) 	(1 725) 	6 	(1 719)
Translation differences 	131 	– 	131 	16 	– 	16
Balance at end of the year 	833 	(10) 	823 	1 007 	(10) 	997
Additional unexpired risk reserve
Balance at beginning of the year 	– 	– 	– 	300 	– 	300
Decrease in the year 	– 	– 	– 	(300) 	– 	(300)
Balance at end of the year 	– 	– 	– 	– 	– 	–
1 Presented as Claims and policyholders’ benefits in the Income statement.
R million
Group
2023
Restated 1
Group
2022
Unit-linked insurance contracts
Balance at beginning of the year 	70 907 	63 496
Premiums received 	12 059 	17 256
Fair value adjustment 	8 833 	(536)
Withdrawals 	(16 797) 	(7 440)
Fees 	(1 534) 	(1 400)
Movement in negative insurance liability 	(229) 	(551)
Translation differences 	2 022 	82
Balance at end of the year 	75 261 	70 907
Balance is made up as follows:
Unit-linked liabilities 	81 031 	76 448
Negative insurance liability 	(5 770) 	(5 541)
75 261 	70 907
With fixed and guaranteed terms
Balance at beginning of the year 	21 273 	21 764
Expected movement in policyholder liabilities 	(4 226) 	(4 324)
Unwinding of discount rate 	1 297 	968
New business written 	3 993 	3 187
Experience variances 	(263) 	(322)
Economic assumptions movement 	9 	–
Translation differences 	4 	–
Balance at end of the year 	22 087 	21 273
1 The comparative information has been restated. Refer to note 45 for detail.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 100 of 217 --

100	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
19. 	LIABILITIES ARISING FROM REINSURANCE CONTRACTS
R million
Group
2023
Group
2022
Financial reinsurance 	2 564 	2 582
Reinsurance recoveries relating to assets arising from insurance contracts (refer to note 5) 	12 105 	10 610
14 669 	13 192
Balance at beginning of the year 	13 192 	12 525
Increase in liability1 	53 	577
– gross increase/(decrease) in liability 	700 	(458)
– receipt arising from reinsurance contracts 	3 272 	2 597
– reinsurance premiums paid 	(3 919) 	(1 562)
Translation differences 	1 424 	90
Balance at end of the year 	14 669 	13 192
Current 	2 927 	2 131
Non-current 	11 742 	11 061
14 669 	13 192
1 The increase in liability of R53 million for the current year includes economic assumptions gains of R277 million, which has been presented in
Economic assumptions adjustments net of discretionary margins in the Income statement.
The liabilities arising from reinsurance contracts releases with the associated underlying insurance contracts.
20. 	BORROWINGS AT AMORTISED COST
R million
Group
2023
Group
2022
Borrowings from banks 	20.1 	16 328 	16 308
Lease liabilities 	20.2 	4 225 	4 120
Bank overdraft 	33 	156
Balance at end of the year 	20 586 	20 584
Current 	2 490 	3 940
Non-current 	18 096 	16 644
Balance at end of the year 	20 586 	20 584
For variable rate loans, the fair value approximates the carrying amount because the variable rate is set on market related terms. For
fixed rate loans, the fair value is R4 806 million (2022: R6 122 million) relative to the carrying value of R4 827 million (2022: R 5 737 million).
20.1 Borrowings from banks
Movement analysis of borrowings
R million
Group
2023
Group
2022
Balance at beginning of the year 	16 308 	15 230
Loans raised 	7 450 	3 261
Loans repaid 	(8 038) 	(2 087)
Interest accrued 	1 335 	1 037
Interest paid 	(1 335) 	(1 188)
Raising fees capitalised 	(8) 	(3)
Translation differences 	616 	58
Balance at end of the year 	16 328 	16 308
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 101 of 217 --

101	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
20. 	BORROWINGS AT AMORTISED COST continued
20.1 Borrowings from banks continued
SA borrowing facilities
DISCOVERY LIMITED
Carrying value
R million
Facility amount
R million 	Variable rate
Interest
per annum
Capital repayment
and maturity date
Group
2023
Group
2022
Listed DMTN 4
500 	3-month Jibar + 161bps 	8.10%1,3 	At maturity – 21 November 2022 	– 	503
500 	3-month Jibar + 205bps 	4.25%1,3 	At maturity – 21 August 2023 	505 	503
200 	– 	10.46%2 	At maturity – 21 November 2024 	202 	202
800 	3-month Jibar + 191bps 	8.40%1,3 	At maturity – 21 November 2024 	808 	805
1 200 	3-month Jibar + 191bps 	7.30%1,3 	At maturity – 21 November 2024 	1 218 	1 217
700 	3-month Jibar + 180bps 	8.49%1,3 	At maturity – 21 August 2026 	707 	704
300 	3-month Jibar + 180bps 	7.60%1,3 	At maturity – 21 August 2026 	304 	303
792 	3-month Jibar + 173bps 	7.98%1,3 	At maturity – 21 May 2027 	799 	792
226 	3-month Jibar + 180bps 	7.98%1,3 	At maturity – 21 May 2029 	228 	226
Unlisted DMTN5
1 100 	– 	8.92%3 	At maturity – 10 March 2023 	– 	1 104
2 500 	– 	9.62%3 	At maturity – 22 February 2025 	2 522 	2 520
1 650 	– 	9.55%3 	At maturity – 10 March 2026 	1 658 	–
Other
1 400 	3-month Jibar + 125bps 	– 	At maturity – 12 October 2022 	– 	702
1 000 	3-month Jibar + 245bps 	7.83%1,3 	At maturity – 02 March 2023 	– 	1 003
1 000 	3-month Jibar + 190bps3 	– 	At maturity – 02 March 2028 	997 	–
9 948 	10 584
1 The interest rate has been fixed through interest rate swaps.
2 Interest is payable semi-annually in arrears.
3 Interest payable quarterly in arrears.
4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017.
5 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank syndicated loans through the issue of unlisted DMTN
notes. The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market
on an ongoing basis.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 102 of 217 --

102	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
20. 	BORROWINGS AT AMORTISED COST continued
20.1 Borrowings from banks continued
SA borrowing facilities
DISCOVERY CENTRAL SERVICES
Carrying value
R million
Facility amount
R million
Interest rate
per annum
Capital repayment and
maturity date
Group
2023
Group
2022
1 400 	3-month Jibar + 2.05%1,2 Instalments – 29 October 2027 	1 408 	1 417
650 	11.56%3 	At maturity – 29 October 2027 	445 	494
691 	3-month Jibar + 1.9% 	At maturity – 30 June 2027 	694 	691
1 500 	3-month Jibar + 1.45% 	At maturity – 8 June 2024 	151 	–
2 698 	2 602
1 Interest payable quarterly in arrears.
2 During the financial year, the rate was renegotiated from a fixed rate of 10.60%, to a floating interest rate.
3 Instalments of interest and capital is monthly.
UK borrowing facilities
UK BORROWINGS
Carrying value
GBP (Rand) million
Facility amount
GBP million 	Variable rate
Capital repayment
and maturity date
Group 2023 	Group 2022
GBP 	R 	GBP 	R
25 	SONIA + 2.75%1 	At maturity – 23 December 20252 	25 	597 	– 	–
75 	SONIA + 3.00%1 	At maturity – 21 December 20242,3 	75 	1 793 	– 	–
55 	SONIA + 2.85%1 	At maturity – 12 December 20254 	54 	1 292 	– 	–
100 	SONIA + 2.38%1 	At maturity – 31 July 20232 	– 	– 	100 	1 999
80 	SONIA + 2.73%1 	Instalments – 31 July 20234 	– 	– 	42 	847
34 	SONIA + 1.31%1 	At maturity – 19 October 20224 	– 	– 	14 	276
154 	3 682 	156 	3 122
1 Interest payable quarterly in arrears.
2 The GBP100 million facility drawn down at 30 June 2022, was refinanced in December 2022.
3 One year extension option available at discretion of lender.
4 The GBP80 million and GBP30 million facilities, of which GBP56 million was drawn down at 30 June 2022 in total, was refinanced
in December 2022.
20.2 Leases
R million
Group
2023
Group
2022
Balance at beginning of the year 	4 120 	4 263
New leases entered into 	260 	138
Lease incentive payment received 	58 	–
Interest accrued 	432 	426
Repayments 	(627) 	(600)
Modifications 	(81) 	(126)
Translation differences 	63 	19
Balance at end of the year 	4 225 	4 120
Total payments for leases for the year is R924 million (2022: R825 million).
During the 2018 financial year Discovery took occupation of a new head office building under a finance lease. A lease liability and
related asset (refer to note 6) of R3 155 million was raised. At year end, R3 326 million (2022: R3 373 million) remained outstanding.
Finance charges of R361 million (2022: R366 million) have been recognised in profit or loss and repayments of R408 million
(2022: R381 million) have been made.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 103 of 217 --

103	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
21. 	INVESTMENT CONTRACTS AT FAIR VALUE THROUGH PROFIT OR LOSS
R million
Group
2023
Restated2
Group
2022
The movements during the year were as follows:
Balance at beginning of the year 	38 637 	33 354
Deposits received 	10 719 	12 239
Account balances paid on withdrawal and other terminations in the year 	(6 884) 	(6 924)
Fair value adjustment 	5 572 	(32)
Balance at end of the year 	48 044 	38 637
Current1 	48 044 	38 637
1 There is no maturity profile for these liabilities as this will depend on policyholder behaviour. Contractually, policyholders may disinvest on demand.
2 The comparative information has been restated. Refer to note 45 for detail.
The benefits offered under the Group’s unit-linked investment contracts are based on the return of selected equities, debt securities
and money market securities. The Group communicates the actual performance of these contracts to its contract holders.
Investment contracts at fair value through profit or loss are exactly matched with related assets and managed collectively as a pool.
Discovery’s credit risk is not reflected in the measurement of the assets or consequently the liability, which is measured with
reference to the underlying assets. Own credit risk has been assessed and determined to be immaterial.
22. 	OTHER PAYABLES
R million
Group
2023
Group
2022
Commissions payable 	322 	251
Consolidated unit trust payables 	482 	512
Due to reinsurers 	1 100 	651
Expired hedge payables 	3 	6
Intermediary payables 	192 	130
Payables and accrued liabilities 	4 335 	3 672
Payroll creditors 	1 097 	987
Policyholder unallocated funds 	1 531 	1 180
Security deposits on derivatives 	39 	245
Unsettled trades 	190 	580
VitalityLife working capital funding1 	4 097 	5 477
Other financial payables 	1 031 	1 020
Other non-financial payables2 	361 	412
– Value-added tax liability 	189 	258
– Premiums and fees received in advance 	172 	154
Balance at end of the year 	14 780 	15 123
Current 	14 396 	14 827
Non-current 	384 	296
Total other payables 	14 780 	15 123
1 Includes the ’deposit back’ of GBP108.9 million (R2 612 million) (2022: GBP236 million (R4 780 million)) related to the level premium reinsurance
treaty in respect of business written on PAC’s life license, payable to the reinsurer.
2 Value-added tax liabilities and premiums received in advance are non-financial liabilities and have been excluded from the risk disclosures
presented in note 3.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 104 of 217 --

104	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
23. 	DEPOSITS FROM CUSTOMERS
R million
Group
2023
Group
2022
Term deposits from customers – fixed rate 	3 434 	3 372
Term deposits from customers – variable rates 	3 232 	1 807
On demand deposits from customers – non-rate sensitive 	394 	149
On demand deposits from customers – variable rate 	7 273 	5 249
Wholesale NCDs – variable rate 	– 	304
Total customer deposits 	14 333 	10 881
24. 	DEFERRED TAX
R million
Group
2023
Group
2022
Deferred tax asset – non-current 	4 404 	4 455
Deferred tax liability – non-current 	(9 559) 	(9 335)
Total deferred tax 	(5 155) 	(4 880)
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 105 of 217 --

105	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
24. 	DEFERRED TAX continued
Deferred tax comprises:
Charge for the year
Group
R million
Balance at
beginning of
the year
Recognised
in profit or
loss
Recognised
in other
comprehensive
income
Recognised
in equity
Translation
differences
Balance
at end of
the year
Year ended 30 June 2023
Assessed loss in Company Policyholders’ Fund 	160 	(5) 	– 	– 	– 	155
Assessed loss in Individual Policyholders’ Fund 	834 	145 	– 	– 	– 	979
Assessed loss in subsidiaries 	2 700 	98 	– 	– 	218 	3 016
Financial Instruments and share-based payments 	(15) 	(28) 	1 	8 	6 	(28)
Deferred acquisition costs 	(206) 	(3) 	– 	– 	2 	(207)
Contract liability 	89 	166 	– 	– 	20 	275
Difference between wear and tear and depreciation/amortisation and leases 	(299) 	86 	– 	– 	(22) 	(235)
Intangible asset recognised on acquisition of business 	(2) 	(11) 	– 	– 	3 	(10)
Prepayments 	(3) 	(6) 	– 	– 	– 	(9)
Provisions 	386 	96 	– 	– 	2 	484
Difference between accounting and tax balances arising from insurance contracts 	(8 480) 	(615) 	– 	– 	– 	(9 095)
Unrealised gains on revaluation of investments1 	(282) 	(36) 	– 	– 	17 	(301)
Other1 	238 	(389) 	– 	– 	(28) 	(179)
Total 	(4 880) 	(502) 	1 	8 	218 	(5 155)
Charge for the year
Group
R million
Balance at
beginning of
the year
Recognised
in profit or
loss
Recognised
in other
comprehensive
income
Recognised
in equity
Translation
differences
Balance
at end of
the year
Year ended 30 June 2022
Assessed loss in Company Policyholders’ Fund 	185 	(25) 	– 	– 	– 	160
Assessed loss in Individual Policyholders’ Fund 	1 134 	(300) 	– 	– 	– 	834
Assessed loss in subsidiaries 	2 439 	158 	– 	– 	103 	2 700
Financial Instruments and share-based payments 	169 	(181) 	(3) 	– 	– 	(15)
Deferred acquisition costs 	(227) 	19 	– 	– 	2 	(206)
Contract liability 	70 	10 	– 	– 	9 	89
Difference between wear and tear and depreciation and leases 	(276) 	(11) 	– 	– 	(12) 	(299)
Intangible asset recognised on acquisition of business 	(57) 	53 	– 	– 	2 	(2)
Prepayments 	(14) 	11 	– 	– 	– 	(3)
Provisions 	340 	26 	– 	17 	3 	386
Difference between accounting and tax balances arising from insurance contracts 	(8 929) 	449 	– 	– 	– 	(8 480)
Other 	300 	(141) 	– 	– 	(203) 	(44)
Total 	(4 866) 	68 	(3) 	17 	(96) 	(4 880)
1 The value of ‘unrealised gains on revaluations of investments’ has been separated out from ‘other’ during the year ended 30 June 2023 in order to provide better disclosure and disaggregate the ‘other’
category which, without this change, would have had a material closing value as at 30 June 2023.

-- 106 of 217 --

106	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
24. 	DEFERRED TAX continued
Assessed losses
Discovery did not recognise deferred tax assets in respect of the following assessed losses:
R million
Group
2023
Group
2022
Better Health Insurance Advice Limited 	40 	37
Cogence Proprietary Limited 	33 	2
Discovery Central Services Proprietary Limited 	4 806 	4 062
Discovery Group Europe Limited 	1 	52
Discovery Life Limited – Individual Policyholders’ Fund 	5 194 	7 907
Discovery Partner Market Services Private Limited 	– 	33
Discovery Vitality Australia Proprietary Limited 	306 	47
Grove Nursing Services Proprietary Limited 	43 	43
Medical Services Organisation International Proprietary Limited 	10 	3
Southern Rx Proprietary Limited 	96 	109
Vitality Healthy Workplace Limited 	– 	17
10 529 	12 312
A deferred tax asset has been partly recognised on assessed losses in the Discovery Life Limited – Individual Policyholders’ Fund.
Refer to note 4.1.
The Group recognises deferred tax assets on carried forward losses to the extent that there are sufficient estimated future taxable
profits and/or taxable temporary differences against which the tax losses can be utilised.
25. 	EMPLOYEE BENEFITS
R million
Group
2023
Group
2022
Leave pay
Balance at beginning of the year 	320 	315
Additional provisions raised 	325 	299
Used during the year 	(282) 	(262)
Paid to terminated employees 	(33) 	(32)
Translation differences 	4 	–
Balance at end of the year 	334 	320
Current 	280 	269
Non-current 	54 	51
Total employee benefits 	334 	320
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 107 of 217 --

107	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
26. 	NET INSURANCE PREMIUM REVENUE
R million
Group
2023
Restated2
Group
2022
Health 	11 527 	9 744
Recurring premiums 	13 667 	11 299
Reinsurance premiums 	(2 140) 	(1 555)
Individual life and invest 	29 767 	32 955
Recurring premiums 	26 719 	29 832
Single premiums 	10 109 	9 335
Reinsurance premiums1 	(7 061) 	(6 212)
Group life 	2 885 	2 411
Recurring premiums 	3 164 	2 634
Reinsurance premiums 	(279) 	(223)
Short-term insurance 	5 356 	4 940
Recurring premiums 	6 012 	5 212
Reinsurance premiums1 	(656) 	(272)
49 535 	50 050
Insurance premium revenue 	59 671 	58 312
Outward reinsurance premiums 	(10 136) 	(8 262)
Net insurance premium revenue 	49 535 	50 050
1 For June 2022, R230 million has been reclassified from Individual life and Invest reinsurance premiums to Short-term insurance reinsurance
premiums, to better reflect the nature of these reinsurance premiums.
2 The comparative information has been restated. Refer to note 45 for detail.
27. 	INVESTMENT INCOME
R million
Group
2023
Group
2022
At amortised cost interest income using the effective interest rate method 	151 	17
Cash and cash equivalents interest income using the effective interest rate method 	621 	279
772 	296
Attributable to:
– Shareholders 	310 	164
– Policyholders 	462 	132
Total investment income 	772 	296
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 108 of 217 --

108	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
28. 	NET FAIR VALUE GAINS/(LOSSES) ON FINANCIAL ASSETS AT FAIR VALUE
THROUGH PROFIT OR LOSS
R million
Group
2023
Group
2022
Investment income 	3 815 	3 128
– Interest 	3 087 	2 528
– Dividends 	728 	600
Mutual fund distributions 	2 124 	1 371
Net fair value gains/(losses) 	8 434 	(6 324)
14 373 	(1 825)
29. 	NET CLAIMS AND POLICYHOLDERS’ BENEFITS
R million
Group
2023
Restated 3
Group
2022
Health insurance claims 	5 364 	4 322
Gross claims 	7 134 	5 644
Less: Reinsurance recoveries 	(1 770) 	(1 322)
Individual life insurance claims 	6 897 	7 502
Death 	4 274 	6 499
Disability 	4 544 	4 484
Payback benefits 	2 145 	1 930
Less: Recapture of reinsurance 	– 	(89)
Less: Reinsurance recoveries 	(4 066) 	(5 322)
Group life insurance claims 	2 256 	2 594
Death 	996 	1 747
Disability 	1 425 	1 076
Payback benefits 	20 	10
Less: Reinsurance recoveries 	(185) 	(239)
Individual investment benefits 	22 532 	13 099
Surrenders1 	21 784 	12 405
Guaranteed payments 	117 	65
Annuity payments 	631 	629
Short-term insurance claims 	3 086 	3 198
Gross claims 	3 676 	3 533
Less: Reinsurance recoveries 	(590) 	(335)
40 135 	30 715
Claims and policyholders’ benefits2 	46 746 	38 022
Insurance claims recovered from reinsurers 	(6 611) 	(7 218)
Recapture of reinsurance 	– 	(89)
Net claims and policyholders’ benefits 	40 135 	30 715
1 Includes surrenders in respect of the wind down of VitalityInvest following the decision to exit the UK investment market.
2 Includes R306 million of economic assumption movements in respect of Discovery Life.
3 The comparative information has been restated. Refer to note 45 for detail.
30. 	ACQUISITION COSTS
R million
Group
2023
Restated 1
Group
2022
Commission and other costs of obtaining contracts 	6 255 	4 807
Movement in deferred acquisition costs (refer to note 8) 	(42) 	(49)
Total acquisition costs 	6 213 	4 758
1 The comparative information has been restated. Refer to note 45 for detail.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 109 of 217 --

109	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
31. 	MARKETING AND ADMINISTRATION EXPENSES
R million
Group
2023
Group
2022
Auditors remuneration
Audit fees 	130 	113
Fees for other services 	4 	1
Prior year 	13 	(8)
147 	106
Lease charges
Short-term leases 	80 	69
Low-value item leases 	217 	156
297 	225
Staff costs including executive directors1
Salaries, wages and allowances 	9 319 	8 456
Medical aid fund contributions 	529 	482
Defined contribution provident fund contributions 	444 	401
Social security levies 	397 	304
Share-based payment expenses
– equity-settled 	545 	326
– cash-settled 	95 	93
– (gains)/losses on cash flow hedge 	(1) 	22
Staff training 	89 	69
Recruitment fees 	64 	51
Temporary staff 	694 	537
Provision for leave pay 	43 	37
Other 	233 	168
12 451 	10 946
Other operating costs
Amortisation of software2 (note 7) 	1 319 	1 252
Building related and office costs 	530 	518
Depreciation of property and equipment (note 6) 	307 	229
Depreciation of right of use assets (note 6) 	351 	421
Loss on derecognition of property and equipment and intangible assets 	324 	50
Loss on disposal of property and equipment 	8 	3
Gain on disposal of intangible assets 	– 	(131)
Impairment of property and equipment (note 6) 	45 	–
Allowance for expected credit losses on receivables 	77 	(79)
Insurance 	75 	51
IT systems and consumables 	2 663 	2 183
Marketing and distribution costs 	2 101 	1 743
Non-executive directors fees 	47 	37
Professional fees 	964 	895
Vitality benefit expenses 	4 340 	3 694
Other operating expenses 	2 859 	3 066
16 010 	13 932
Total marketing and administration expenses 	28 905 	25 209
1 Executive directors’ and prescribed officers’ remuneration is included in employee costs. Refer to Annexure C - Directorate for detailed disclosure.
2 The transactions relating to business combinations are not included in marketing and administration expenses as it is disclosed separately in the
Income statement.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 110 of 217 --

110	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
32. 	SHARE-BASED PAYMENTS AND LONG-TERM INCENTIVES
Incentive schemes
Discovery operates various share-based payment and long-term incentive arrangements. The details of these arrangements are
described below:
1. BEE STAFF SHARE TRUST
In 2005, 5 290 000 shares in Discovery Limited’s shares were issued to the BEE staff share trust for current and future
employees. These shares had all been allocated during prior years. Additional shares have been purchased in prior years, for
future allocation to employees. The trusts consist of two components; the allocation scheme and the option scheme as
described below.
ALLOCATION SCHEME
Shares have been allocated to senior black employees based on level of seniority and length of past service. The shares vest to
employees two, three, four and five years after allocation at a rate of 25% per annum. On each vesting date, the trustees shall
distribute to the employees the allocated shares to which the employees may be entitled.
OPTION SCHEME
Options granted to black employees may be exercised two, three, four and five years after the option is granted at a rate of 25%
per annum. Any options not exercised by the end of the fifth year from the grant date shall lapse. On exercise of the option, the
employee pays cash to the trust for the full purchase price of the option.
2. DISCOVERY’S PHANTOM SCHEME
Participants earn a cash bonus based on allocation of bonus scheme units which in turn are linked to the performance of the
Discovery Limited share price. The bonus is earned if the participant is employed on each vesting date, with the vesting dates
ranging between one and five years after allocation of the bonus units. The bonus may not be carried forward.
3. DISCOVERY’S LONG-TERM INCENTIVE PLANS (EQUITY SETTLED)
DISCOVERY LONG-TERM INCENTIVE PLAN (LTIP)
The LTIP was introduced in the financial year ended 30 June 2020 and replaced the cash-settled Discovery Phantom scheme (see
point 2 above) with an equity-settled LTIP.
Participants will receive Discovery Limited shares subject to performance criteria and if the participant is employed on each vesting
date. For LTIP awards granted prior to the introduction of the Single Incentive Plan (SIP), the performance conditions are aligned
to the organic growth methodology of the Group and will vest from between the third and fifth anniversary of these awards.
SINGLE INCENTIVE PLAN
During the financial year ended 30 June 2022, Discovery replaced its management short-term incentive scheme and long-term
incentive schemes with a single incentive scheme called SIP, consisting of a cash incentive (short-term incentive) and deferred
share awards (long-term incentive). The SIP is based on the annual award of a single total incentive relating to the performance
of the Group, business unit and the individual, and is assessed against financial and non-financial measures as outlined by the
Group scorecard as well as business unit and individual scorecards.
The first deferred share awards were granted in November 2022. These shares will vest between one and three years after
allocation of the shares for senior management and between three and five years for executive directors and prescribed officers.
4. ACQUISITION SCHEMES
There are various schemes offered to franchise directors, agents and employees where participants are allocated share units
which replicate the economics of a Discovery Limited share. The share units are settled as a cash bonus on vesting. The bonus
is earned if the participant is employed by Discovery or Discovery’s contracted affiliates on the vesting date. The vesting periods
on the schemes vary from two to five years. The bonus may not be carried forward.
5. DISCOVERY BANK SCHEME
Participants will receive Discovery Limited shares subject to the ’Value Created’, which references the growth in the value of
Discovery Bank business after capital invested and interest. These awards vests from between the 3rd and 7th anniversary of the
market launch date of Discovery Bank, and each vesting is settled in three equal instalments over three years, if the participant
is employed on each vesting date.
Other long-term incentive schemes
The following schemes are long-term staff incentives where the value is determined with reference to something other than the
Discovery Limited share price. These schemes are accounted for in terms of IAS 19: Employee benefits.
6. THE VITALITYHEALTH AND VITALITYLIFE PHANTOM SHARE SCHEME
Participants earn a cash bonus based on allocation of bonus scheme units which in turn are linked to the performance of
VitalityLife and VitalityHealth, and more specifically the value of in-force (ViF) of VitalityLife and the Embedded Value (EV) of
VitalityHealth. The bonus is earned if the participant is employed on each vesting date. For units issued, the vesting of the units
is two, three and four years after allocation of the bonus units. The bonus may not be carried forward.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 111 of 217 --

111	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
32. 	SHARE-BASED PAYMENTS AND LONG-TERM INCENTIVES continued
7. OTHER DEVELOPMENT SEGMENT SCHEMES
Various other long-term incentive schemes exist in the Discovery Group in the development segments. These schemes are
individually and in aggregate immaterial and as a result no further information is disclosed.
The share/option schemes mentioned in bullet 1, 3 and 5 have been classified as equity-settled schemes and therefore a share-
based payment reserve has been recognised. The schemes mentioned in bullets 2 and 4 have been classified as cash-settled
schemes and a liability is raised in terms of IFRS 2 Share-based Payment. The other long-term incentive schemes, have been
accounted for in terms of IAS 19 Employee Benefits.
The following is a summary of the terms and conditions of the units granted:
Date granted
Share/
Option
price
Final
vesting
date
Shares
under
option at
beginning
of year
Share/
Options
granted
during
year
Share/
Options
vested
during
year
Share/
Options
cancelled
or adjusted
during year
Shares
under
option
at end
of year
1. BEE staff share trust
01/07/2016 – 30/06/2017 	R122.5 	30/09/2021 	1 722 	– 	– 	– 	1 722
01/07/2016 – 30/06/2017 	R0.00 	30/09/2021 	287 	– 	– 	– 	287
01/07/2016 – 30/06/2017 	R0.00 	22/05/2023 	4 655 	– 	(4 655) 	– 	–
01/07/2018 – 30/06/2019 	R0.00 	31/03/2024 	5 954 	– 	(2 976) 	(967) 	2 011
01/07/2019 – 30/06/2020 	R0.00 	30/09/2025 	47 194 	– 	(22 423) 	(1 961) 	22 810
01/07/2020 – 30/06/2021 	R0.00 	31/03/2026 	21 596 	– 	(5 339) 	(1 174) 	15 083
01/07/2021 – 30/06/2022 	R0.00 	30/09/2027 	115 628 	– 	(18 112) 	(27 308) 	70 208
01/07/2022 – 30/06/2023 	R0.00 	30/04/2028 	– 	14 604 	– 	– 	14 604
2. The Discovery Limited
phantom scheme
01/07/2016 – 30/06/2017 	R0.00 	30/09/2022 	58 897 	– 	(52 782) 	(6 115) 	–
01/07/2017 – 30/06/2018 	R141.65 	30/09/2022 	163 558 	– 	(163 346) 	(212) 	–
01/07/2017 – 30/06/2018 	R0.00 	31/03/2023 	640 818 	– 	(610 489) 	(28 990) 	1 339
01/07/2018 – 30/06/2019 	R0.00 	31/03/2024 	887 316 	– 	(429 076) 	(44 064) 	414 176
01/07/2022 – 30/06/2023 	R0.00 	30/09/2027 	– 	333 737 	– 	(6 447) 	327 290
3. Discovery LTIP and SIP
01/07/2019 – 30/06/2020 	R0.00 	30/09/2024 	3 049 840 	– 	(1 402 275) 	(138 010) 	1 509 555
01/07/2020 – 30/06/2021 	R0.00 	30/09/2025 	3 656 145 	– 	– 	(107 536) 	3 548 609
01/07/2021 – 30/06/2022 	R0.00 	30/09/2026 	3 352 235 	– 	– 	(118 790) 	3 233 445
01/07/2022 – 30/06/2023 	R0.00 	30/09/2027 	– 	5 050 816 	– 	(94 065) 	4 956 751
4. Acquisition schemes
01/07/2017 – 30/06/2018 	R0.00 	30/06/2023 	24 903 	– 	(23 791) 	(1 112) 	–
01/07/2018 – 30/06/2019 	R0.00 	30/06/2024 	63 728 	– 	(35 133) 	(1 587) 	27 008
01/07/2019 – 30/06/2020 	R0.00 	30/06/2025 	658 068 	– 	(557 635) 	(12 033) 	88 400
01/07/2020 – 30/06/2021 	R0.00 	30/06/2026 	767 414 	– 	(40 870) 	(19 695) 	706 849
01/07/2021 – 30/06/2022 	R0.00 	30/06/2027 	717 351 	– 	(6 979) 	(7 007) 	703 365
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 112 of 217 --

112	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
32. 	SHARE-BASED PAYMENTS AND LONG-TERM INCENTIVES continued
The VitalityHealth and VitalityLife phantom share scheme is cash-settled and thus repriced at each reporting date. The value of the
shares and options allocated are dependent on the performance of VitalityLife and VitalityHealth, more specifically the ViF of VitalityLife
and the EV of VitalityHealth.
The Discovery Limited phantom scheme and Acquisition schemes are cash-settled and are thus repriced at each reporting date. The
closing share price at 30 June 2023 was R145.85.
Discovery determines the grant date fair value of its equity-settled schemes at the date of allocating the grant to the employee. The
grant date fair value is then recognised over the vesting period. The significant assumptions in determining the grant date fair value
were as follows:
Spot price
Risk free
interest rate 	Vesting period 	Dividend yield
Discovery LTIP and SIP
01/07/2019 – 30/06/2020 	R113.81 	6.68% – 7.01% 	3 – 5 years 	2.21% – 2.52%
01/07/2020 – 30/06/2021 	R125.52 – R153.54 	3.90% – 5.02% 	3 – 5 years 	2.26% – 2.57%
01/07/2021 – 30/06/2022 	R135.94 	5.76% – 6.57% 	3 – 5 years 	2.29% – 2.46%
01/07/2022 – 30/06/2023 	R127.58 – R149.05 	5.96% – 8.01% 	1 – 5 years 	0.00% – 1.08%
BEE Staff share trust
01/07/2018 – 30/06/2019 	R139.49 – R170.16 	7.32% – 7.98% 	2 – 5 years 	1.46% – 2.01%
01/07/2019 – 30/06/2020 	R86.00 – R133.76 	4.85% – 7.54% 	2 – 5 years 	2.01% – 3.54%
01/07/2020 – 30/06/2021 	R127.60 – R148.89 	3.85% – 5.96% 	3 – 5 years 	2.34% – 2.78%
01/07/2021 – 30/06/2022 	R136.00 – R181.49 	4.91% – 7.49% 	2 – 5 years 	0.81% – 2.70%
01/07/2022 – 30/06/2023 	R120.00 – R143.77 	7.63% – 8.53% 	2 – 5 years 	0.85% – 1.47%
33. 	FINANCE COSTS
R million
Group
2023
Group
2022
Interest expense on:
– Borrowings measured at amortised cost using the effective interest method 	1 437 	1 037
– Release from other comprehensive income 	4 	–
– Lease liabilities (IFRS 16) 	432 	426
– Interest on other payables using the effective interest method 	49 	195
– Other 	19 	–
Total 	1 941 	1 658
34. 	FOREIGN EXCHANGE GAINS
R million
Group
2023
Group
2022
Net foreign exchange gains 	150 	155
The net foreign exchange gains and losses arised primarily from foreign denominated loans, some which are internal.
The total amount of foreign exchange gains recognised in profit or loss is R292 million (2022: R221 million) presented within various
lines associated with the underlying transaction.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 113 of 217 --

113	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
35. 	TAXATION
R million
Group
2023
Group
2022
Charge for the year:
Current taxation 	1 550 	1 533
Normal taxation
– prior year over provision 	– 	(22)
– current year charge 	1 524 	1 550
Capital gains taxation 	26 	5
Deferred taxation 	502 	(68)
Total income tax expense recognised in profit or loss 	2 052 	1 465
% 	%
Taxation rate reconciliation
Statutory rate 	27.0 	28.0
Non-taxable income: Equity-accounted profit or loss and dividend income 	(2.5) 	(2.7)
Non-taxable income: Other individually immaterial 	(0.1) 	(0.3)
Non-deductible expenditure: Including items of a capital nature and non-deductible provisions 	0.6 	4.0
Non-deductible expenditure: Other individually immaterial 	* 	*
Subsidiary current period losses for which no deferred tax asset was recognised, net of
deferred tax assets on losses recognised for prior period losses 	3.5 	3.1
PAC arrangement 	0.1 	(7.4)
Insurance policyholder funds I-E taxes and related DTA recognitions 	(0.1) 	2.0
Accounting gains and losses taxable at CGT rates 	(0.2) 	0.1
CFC imputations and WHT not recovered 	0.9 	0.7
Additional tax allowances 	(0.1) 	(0.3)
Prior year under provision 	* 	0.1
Tax rate changes 	(0.5) 	(4.6)
Tax rate differences 	(0.8) 	(1.6)
Effective taxation rate 	27.8 	21.1
* Amount is less than 0.1%.
The current tax rate for South African entities in a tax paying position is 27%. Discovery, a holding company listed on the JSE, uses
the South African tax rate for its tax rate reconciliation since it is based in South Africa and the most significant operations are in
South Africa. The South African life insurance operations tax rate is determined based on the rates and basis applicable to section
29A of the Income Tax Act 58 of 1962 at the reporting date.
Vitality Group International Inc, a subsidiary of Discovery Limited in the US, is subject to taxation under section 11(b) of the
Internal Revenue Code 1986. The applicable current tax rate for all of Vitality Group International Inc’s taxable profit is 21%.
Discovery Group Europe Limited, incorporated and operating in the UK, is governed by the Corporation Tax Act 2010 Chapter 2,
which sets the main corporation tax rate on taxable profit at 25%.
As of 23 May 2023, the UK has enacted the Finance (No.2) Act 2023. This new legislation establishes a minimum global effective tax
rate of 15%. It also enforces a top-up tax for domestic and multinational entities, which will apply for accounting periods beginning
on or after 1 January 2023. Discovery has utilised the IAS 12 amendment exception to recognise and disclose deferred tax assets
and liabilities for top-up income taxes.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 114 of 217 --

114	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
36. 	EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS
Basic earnings per share is the profit or loss attributable to the ordinary shareholders of the Company for the period, divided by
the weighted-average number of ordinary shares outstanding during the period.
To calculate diluted earnings per share, the Group adjusts the profit or loss attributable to the ordinary shareholders of the
Company for the period and the weighted-average number of shares outstanding during the period for the effects of all dilutive
potential ordinary shares.
Note
Group
2023
Group
2022
Number of shares used in calculation 	36.1
Weighted average number of shares in issue (’000) 	658 045 	656 901
Diluted weighted average number of shares (’000) 	661 328 	663 082
Earnings per share (cents): 	36.2
– basic 	785.4 	825.5
– diluted 	781.5 	817.8
Headline earnings per share (cents): 	36.3
– basic 	834.3 	792.4
– diluted 	830.1 	785.0
Normalised headline earnings per share (cents): 	36.4
– basic 	1 166.7 	885.5
– diluted 	1 160.9 	877.3
36.1 Weighted average number of ordinary shares
‘000
Group
2023
Group
2022
Issued ordinary shares at 1 July 	656 957 	656 805
Effect of treasury shares vested 	1 052 	–
Effect of share options exercised and vesting of share awards 	36 	96
Weighted average number of ordinary shares at 30 June (basic) 	658 045 	656 901
Effect of share options exercised and vesting of share awards 	3 283 	6 181
Weighted average number of ordinary shares at 30 June (diluted) 	661 328 	663 082
36.2 Earnings reconciliation
R million
Group
2023
Group
2022
Profit attributable to the ordinary shareholders 	5 258 	5 422
Adjusted for:
– Profit attributable to non-forfeitable dividend share plan 	(90) 	–
Profit attributable to ordinary shareholders of the Company (basic and diluted) 	5 168 	5 422
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 115 of 217 --

115	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
36. 	EARNINGS, HEADLINE EARNINGS AND NORMALISED HEADLINE EARNINGS
continued
36.3 Headline earnings reconciliation
Headline earnings per share is disclosed per the JSE Limited’s Listings Requirements and is calculated in accordance with the circular
titled Headline Earnings issued by SAICA, as amended from time to time. Headline earnings per share is based on the net profit after
tax attributable to ordinary shareholders adjusted for items of a capital nature and the weighted average number of ordinary shares
in issue.
Group 2023 	Group 2022
R million 	Gross 	Tax 	Net 	Gross 	Tax 	Net
Profit attributable to the ordinary shareholders 	5 168 	5 422
Adjusted for:
– IAS 38 Intangible assets: Gain on disposal
of intangible assets 	– 	– 	– 	(131) 	29 	(102)
– IAS 38 Intangible assets: Loss on derecognition
of intangible assets 	290 	(60) 	230 	37 	(5) 	32
– IAS 16 Property, plant and equipment: Loss on
derecognition of property and equipment 	34 	(7) 	27 	13 	(1) 	12
– IAS 16 Property, plant and equipment: Loss on
disposal of property and equipment 	8 	(1) 	7 	3 	– 	3
– IFRS 3 Business Combinations: Impairment
of goodwill 	9 	– 	9 	– 	– 	–
– IAS 36 Impairment of Assets: Impairment
of property and equipment 	45 	– 	45 	– 	– 	–
Adjustments attributable to equity-accounted
investments:
– IAS 28 Investments in Associates and Joint
Ventures: Loss/(gain) on dilution and disposal
of equity-accounted investments 	5 	(1) 	4 	(33) 	4 	(29)
– IAS 28 Investments in Associates and Joint
Ventures: Reversal of impairment of equity-
accounted investments1 	– 	– 	– 	(134) 	– 	(134)
Headline earnings (basic and diluted) 	5 490 	5 204
1 Impairment reversal was supported by a firm offer to purchase the equity accounted investment.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 116 of 217 --

116	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
36. 	EARNINGS PER SHARE continued
Earnings, Headline earnings and Normalised Headline Earnings
36.4 Normalised headline earnings reconciliation
Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policy 29.
Group 2023 	Group 2022
R million 	Gross 	Tax 	Net 	Gross 	Tax 	Net
Headline earnings 	5 490 	5 204
Adjusted for:
– Economic assumption adjustments net
of discretionary margins and interest
rate derivatives 	2 664 	(728) 	1 936 	84 	(74) 	10
– Loss/(gain) on economic assumption
adjustments net of discretionary margins 	1 691 	(529) 	1 162 	(169) 	(26) 	(195)
– Loss on fair value changes on VitalityLife
interest rate derivative 	973 	(199) 	774 	253 	(48) 	205
– Loss on fair value changes in the time value
of swaption contract in VitalityLife 	204 	(42) 	162 	454 	(87) 	367
– 	Other 	102 	(12) 	90 	233 	2 	235
– Amortisation of intangible assets arising
from business combinations 	56 	(12) 	44 	59 	(13) 	46
– Gain on disposal of intangible assets 	– 	– 	– 	131 	(29) 	102
– Recognition of deferred tax assets on
assessed losses not recognised in previous
periods 	– 	– 	– 	– 	(14) 	(14)
– Loss on fair value changes on foreign
exchange contracts not designated as hedges 	– 	– 	– 	2 	(1) 	1
– Increase or decrease in deferred tax balances
resulting from use of different tax rates on
items that were excluded from normalised
headline earnings 	– 	– 	– 	– 	59 	59
Adjustments attributable to equity-accounted
investments:
– Amortisation of intangible assets arising
from business combinations 	46 	– 	46 	41 	– 	41
Normalised headline earnings (basic and diluted) 	7 678 	5 816
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 117 of 217 --

117	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
37. 	CASH FLOW INFORMATION
37.1 Cash generated by operations
R million
Group
2023
Restated 1
Group
2022
Cash generated by operations
Profit before taxation 	7 372 	6 944
Adjusted for:
Investment income 	(4 587) 	(4 795)
Realised (gains)/losses on financial assets 	(604) 	3 574
Finance costs 	1 941 	1 658
Premiums, claims and investment charges for liabilities under investment contracts 	3 836 	5 315
Non-cash items:
Allowance for expected credit losses 	146 	96
Allowance for expected credit losses on receivables 	77 	(79)
Amortisation of intangibles from business combinations 	56 	59
Amortisation of software 	1 319 	1 252
Assets arising from contracts with customers 	28 	125
Cash flow hedge gains recycled to profit or loss 	(1) 	–
Contract liabilities movement 	(321) 	130
Deferred acquisition costs 	(42) 	(49)
Depreciation 	658 	650
Derecognition and impairment of intangible assets 	290 	170
Derecognition and impairment of property and equipment 	79 	12
Finance (income)/charge on negative reserve funding 	(1 098) 	(1 368)
Gain on disposal of intangible assets 	– 	(131)
Impairment of goodwill 	9 	–
Losses/(gains) from derivatives 	– 	(89)
Losses/(gains) on dilution and disposal of equity-accounted investments 	5 	(33)
Losses on disposal of property and equipment 	8 	3
Provision for employee benefits 	43 	37
Reversal of impairment of equity-accounted investment 	– 	(134)
Share-based payment expenses – cash settled 	95 	93
Share-based payment expenses – equity settled 	545 	326
Share of profits from equity-accounted investments 	(515) 	(422)
Transfer to assets under insurance contracts 	(5 860) 	(5 786)
Transfer to assets under reinsurance contracts 	(135) 	(63)
Transfer to liabilities under insurance contracts 	3 992 	6 738
Transfer to liabilities under reinsurance contracts 	328 	577
Economic assumptions adjustments net of discretionary margins 	1 997 	(169)
Fair value adjustment to liabilities under investment contracts 	5 572 	(32)
Translation differences 	(142) 	(166)
Unearned premiums 	(305) 	(100)
Unrealised (gains)/losses on investments at fair value through profit or loss 	(4 073) 	2 860
Working capital changes2:
Deposits from customers 	3 451 	1 897
Loans and advances to customers 	(897) 	(679)
Loans and receivables including insurance receivables 	(2 297) 	(2 457)
Trade and other payables 	(2 662) 	4 979
Cash generated by operations 	8 308 	20 943
1 The comparative information has been restated. Refer to note 45 for detail.
2 The comparatives for Working capital changes have been restated to separately present R96 million of Allowance for expected credit losses
and R1 368 million of Finance (income)/charge on negative reserve funding, in line with the current year presentation.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 118 of 217 --

118	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
37. 	CASH FLOW INFORMATION continued
37.2 Taxation paid
R million
Group
2023
Group
2022
Balance at beginning of the year 	(307) 	22
Taxation charged for the year in the income statement 	(2 052) 	(1 465)
Adjustment for movement in deferred taxation 	502 	(68)
Reallocation to separately disclosable items 	(115) 	20
Translation differences 	9 	3
Balance at end of the year 	124 	307
Taxation paid 	(1 839) 	(1 181)
37.3 Movement in borrowings
R million
Group
2023
Group
2022
Balance at beginning of the year excluding bank overdraft 	20 428 	19 493
Leased assets acquired 	260 	138
Increase in borrowings 	7 450 	3 261
Raising fees capitalised 	(8) 	(3)
Interest accrued on borrowings 	1 767 	1 463
Interest paid on borrowings 	(1 335) 	(1 188)
Repayment of borrowings 	(8 607) 	(2 687)
Modification to lease assets 	(81) 	(126)
Translation differences 	679 	77
Balance at end of the year excluding bank overdraft 	20 553 	20 428
37.4 Interest paid
R million
Group
2023
Group
2022
Finance cost per the income statement 	1 941 	1 658
Adjusted for:
– Lease liabilities interest accrual not paid 	(432) 	(426)
– Other payables or interest accrual 	(8) 	180
Interest paid 	1 501 	1 412
38. 	COMMITMENTS
Capital commitments
R million
Group
2023
Group
2022
Capital expenditure approved but not contracted for at the reporting date as follows:
– Property and equipment 	106 	41
– Intangible assets 	397 	120
– Developments costs for Discovery Bank 	328 	394
831 	555
Also refer to Capital section of Directors’ report.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 119 of 217 --

119	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
39. 	DIVIDENDS PER SHARE
39.1 Dividends per ordinary share
Due to the uncertain and potentially volatile environment caused by the COVID-19 pandemic, Discovery did not pay out any ordinary
dividends for the year ended 30 June 2023.
39.2 Dividends per preference share
The dividends paid in 2023 totalled R69 million and comprised a final dividend of 382.26027 cents (305.80822 cents net of
dividend withholding tax) per share paid on 26 September 2022 and an interim dividend of 476.91781 cents (381.53425 cents
net of dividend withholding tax) per share paid on 13 March 2023.
The dividends paid in 2022 totalled R56 million and comprised a final dividend of 347.12329 (277.69863 net of withholding tax)
cents per share paid on 27 September 2021 and an interim dividend of 355.75342 (284.60274 net of withholding tax) cents per
share paid on 14 March 2022.
40. 	CONTINGENCIES
The Group is not exposed to material contingencies at 30 June 2023.
41. 	RELATED PARTIES
41.1 List of related parties as defined
Subsidiaries, associates and joint ventures
Details of subsidiaries directly and indirectly owned by Discovery Limited are contained in Company note 2. Details of the Discovery
Group’s material associates and joint ventures are contained in note 11. Annexure A sets out details of all subsidiaries, associates
and joint ventures held within the Discovery Group.
Key management personnel
Key management personnel have been defined as directors of Discovery Limited, Discovery Health Proprietary Limited and
Discovery Life Limited, as these businesses constitute the majority of the Discovery Group.
A list of the directors and prescribed officers of Discovery Limited can be found in the Directors’ report. Also refer to Annexure C for
Directorate remuneration.
To the extent specific transactions have occurred between Discovery and key management personnel, including close family members
of key management, (as defined in IAS 24 Related Party Disclosures) the details are included in the aggregate disclosure contained
below under key management and where significant, full details of all relationships and terms of the transactions are provided.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 120 of 217 --

120	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
41. 	RELATED PARTIES continued
41.2 Transactions with related parties
Cambridge Mobile Telematics Inc. (CMT)
Discovery Insure paid fees monthly to CMT for the collation and interpretation of data and the translating of driving behaviour into
scorable events. Fees paid for the year totalled R17 million (2022: R16 million).
Key management personnel of Discovery Limited, families of key management (as
defined in IAS 24) and entities significantly influenced or controlled by key management
INSURANCE CONTRACTS
Aggregated insured cover 	Premiums received 	Claims paid
R’000 	2023 	2022 	2023 	2022 	2023 	2022
Life insurance 	1 259 392 	1 098 794 	9 673 	8 419 	– 	–
Short-term insurance 	692 874 	882 273 	2 639 	3 327 	1 034 	1 300
Short-term health insurance 	– 	– 	16 	12 	– 	7
INVESTMENT CONTRACTS
Investment values 	Premiums received 	Withdrawal benefits 	Investment returns
R’000 	2023 	2022 	2023 	2022 	2023 	2022 	2023 	2022
Investment contracts 	81 237 	86 526 	7 359 	13 461 	2 959 	11 902 	9 344 	6 778
VITALITY PROGRAMME
Premiums received 	Amounts paid
R’000 	2023 	2022 	2023 	2022
Vitality benefits 	190 	272 	2 789 	4 460
Key management personnel, their families (as defined in IAS 24) and entities significantly influenced or controlled by key management
accrued 360 431 Discovery miles as part of the Vitality Programme for the year ended 30 June 2023 (2022: 444 903).
DISCOVERY BANK
Loans 	Savings 	Fees
R’000 	2023 	2022 	2023 	2022 	2023 	2022
Discovery Bank 	2 347 	2 259 	38 915 	26 399 	219 	287
AGGREGATE SHAREHOLDING
Aggregate shareholdings of key management personnel, their families (as defined in IAS 24) and entities significantly influenced
or controlled by key management, in Discovery Limited as at 30 June 2023 was 77 576 400 ordinary shares (2022: 78 169 727
ordinary shares).
ENTITIES SIGNIFICANTLY INFLUENCED OR CONTROLLED BY KEY MANAGEMENT
In the prior year, sponsorship and enterprise development grants to the value of R0.7 million were made to organisations where
members of key management personnel have significant influence. No transactions occurred in the current year.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 121 of 217 --

121	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
41. 	RELATED PARTIES continued
41.3 Major customers and other Discovery entities not part of Discovery Group
Discovery Health Medical Scheme
Discovery Health administers Discovery Health Medical Scheme (DHMS) and provides managed care services for which it charges an
administration fee and a managed healthcare fee respectively. These fees are determined on an annual basis and approved by the
trustees of DHMS. The fees totalled R7 414 million (2022: R6 804 million). Discovery Health and its subsidiaries also provides wellness
services to DHMS. The fees received for these services totalled R69 million (2022: R28 million).
Discovery Third Party Recovery Services (DTPRS) paid DHMS R20 million (2022: R15 million) to purchase all the risks and rewards of
ownership to the claims due from the Road Accident Fund up to 7 February 2023 (2022: 14 January 2022). DTPRS also provides a service
to DHMS to recover all claims that are due from the Compensation for Occupational Injuries and Diseases. DTPRS received R16 million
(2022: R20 million) for this service. DTPRS owes DHMS R2 million (2022: R6 million) at year-end.
The Discovery Group offers the members of DHMS access to the Vitality programme. Discovery Vitality receives monthly contributions
from DHMS members that have activated this benefit through various product integrations. The membership fees totalled R1 840
million for the year ended 30 June 2023 (2022: R1 686 million).
DHMS owes the Discovery Group R775 million (2022: R724 million) at year-end.
Discovery Central Services received rental income of R7 million (2022: R9 million) from DHMS for office space at 1 Discovery Place.
Closed schemes
Discovery Health administers the following restricted membership medical schemes:
– Anglo Medical Scheme 	– Malcor Medical Scheme
– Anglovaal Group Medical Scheme 	– Multichoice Medical Aid Scheme
– Bankmed Medical Scheme 	– Netcare Medical Scheme
– BMW Employees Medical Aid Society 	– Remedi Medical Scheme
– Engen Medical Benefit Fund 	– Retail Medical Scheme
– Glencore Medical Scheme 	– SAB Medical Aid Scheme (terminated effective 31 December 2023)
– LA Health Medical Scheme 	– TFG Medical Scheme
– Libcare Medical Scheme 	– Tsogo Sun Group Medical Scheme
– Lonmin Medical Scheme 	– UKZN Medical Scheme
Discovery Health charges these schemes administration fees which are determined on an annual basis and approved by the trustees
of the respective closed schemes. The fees totalled R1 285 million (2022: R1 212 million). Discovery Health and its subsidiaries also
provide wellness services to these schemes. The fees received for these services totalled R5 million (2022: R1 million).
DTPRS did not purchase any risks and rewards of ownership for the claims due from the Road Accident Fund during the current
financial year from any of the closed schemes. During the prior financial year DTPRS paid Bankmed R2 million. DTPRS also provides
a service to some of the closed schemes to recover all claims that are due from the Compensation for Occupational Injuries and
Diseases. DTPRS received R0.3 million (2022: R0.5 million) for this service.
Discovery Vitality receives monthly contributions from the closed scheme members that have activated the Vitality Wellness
programme through various product integrations. The membership fees totalled R95 million (2022: R86 million). Amounts due to
the Discovery Group at year-end totalled R120 million (2022: R107 million).
Discovery Franchises
Discovery has established a network of 29 franchises in order to establish a national footprint for its products. Discovery has paid
R254 million (2022: R229 million) in fees to the franchises.
The franchises participate in the Acquisition Scheme (refer to note 32 for further details). During the year, R21 million (2022:
R15 million) was accrued for in terms of this scheme.
The Discovery Foundation
The Discovery Foundation, which is an independent shareholder of Discovery, received contributions of R12 million (2022: R3 million)
from Discovery in the current year.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 122 of 217 --

122	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
41. 	RELATED PARTIES continued
41.3 Major customers and other Discovery entities not part of Discovery Group continued
The Discovery Fund
The Discovery Fund is a fund for sustainable non-governmental healthcare projects, especially in primary healthcare. These projects
complement the delivery of primary and preventative care in the public sector and help to relieve the burden on state facilities.
The Discovery Fund received contributions from Discovery of R23 million during the year (2022: R24 million). Discovery also paid a
management fee of R2 million (2022: R2 million).
Discovery Retirement Funds
The Discovery Life Pension Umbrella Fund and the Discovery Life Provident Umbrella Fund (the Funds) are underwritten and
administered by Discovery Life and are the retirement funds used by all the Discovery staff employed by the Group in South Africa.
Contributions to the Funds by Discovery staff during the year amounted to R569 million (2022: R520 million). The Funds have
R5 167 million (2022: R4 334 million) of assets under administration on behalf of Discovery staff – R4 974 million is invested in
unit-linked insurance policies issued by Discovery Life (2022: R4 159 million) of which, R4 417 million (R3 732 million) of the unit-
linked insurance policies are in turn linked to unit trusts managed by Discovery Life Collective Investments.
42. 	ACCELERATED REINSURANCE PREMIUMS – VITALITYHEALTH
VitalityHealth uses quota share reinsurance treaties as one of the mechanisms to manage initial acquisition cost strain and
underwriting experience risk. During the 2021 financial year, VitalityHealth modified certain of its existing quota share reinsurance
treaties to adjust the repayment profile thereof. The modification resulted in VitalityHealth making additional repayments of
GBP39.7 million (R823 million) in 2021, with GBP19.8 million of reduced repayments in the financial year ended 30 June 2022 and
2023 respectively. The net impact in profit or loss over the three-year period to 30 June 2023, is nil.
43. 	DIVIDENDS PAID DURING THE CURRENT AND PRIOR FINANCIAL YEAR
B preference shares
Payment date 	Nature and financial period 	Dividend declared per share
13 March 2023 	Interim dividend Financial year 2023 	476.91781 cents
(381.53425 cents net of dividend withholding tax)
26 September 2022 	Final dividend Financial year 2022 	382.26027 cents
(305.80822 cents net of dividend withholding tax)
14 March 2022 	Interim dividend Financial year 2022 	355.75342
(284.60274 cents net of dividend withholding tax)
27 September 2021 	Final dividend Financial year 2021 	347.12329 cents
(277.69863 cents net of dividend withholding tax)
Ordinary shares
In the current and prior financial years, no ordinary dividends were paid as a result of the considerable uncertainty arising from the
COVID-19 pandemic and macro-economic risks. The Group followed a conservative approach to capital management – the dividend
was suspended, a strategy of reducing financial leverage was pursued, and further structures were implemented to ensure that the
Group remained protected from movements in interest rates. Importantly, the pursuit of growth was not curtailed most notably on
the build of Discovery Bank.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 123 of 217 --

123	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
44. 	EVENTS AFTER REPORTING DATE
B preference share cash dividend declaration
The directors declared a final gross cash dividend of 548.49315 cents (438.79452 cents net of dividend withholding tax) per B
preference share for the period 1 January 2023 to 30 June 2023, payable from the income reserves of the Company. A dividend
withholding tax of 20% will be applicable to all shareholders who are not exempt.
The issued preference share capital at the declaration date is 8 million B preference shares.
The salient dates for the dividend will be as follows
Last day of trade to receive a dividend 	Tuesday, 19 September 2023
Shares commence trading “ex” dividend 	Wednesday, 20 September 2023
Record date 	Friday, 22 September 2023
Payment date 	Tuesday, 26 September 2023
B Preference share certificates may not be dematerialised or rematerialised between Wednesday, 20 September 2023 and Friday,
22 September 2023, both days inclusive.
Ordinary share cash dividend declaration:
The Board of Directors declared a final gross cash dividend of 110 cents (88 cents net of dividend withholding tax) per ordinary
share, out of the income reserves of Discovery Limited. A dividend withholding tax of 20% will be applicable to all shareholders who
are not exempt.
The number of ordinary shares in issue at the date of declaration is 673 146 417.
The salient dates for the dividend will be as follows
Last day of trade to receive a dividend 	Tuesday, 10 October 2023
Shares commence trading “ex” dividend 	Wednesday, 11 October 2023
Record date 	Friday, 13 October 2023
Payment date 	Monday, 16 October 2023
Share certificates may not be dematerialised or rematerialised between Wednesday, 11 October 2023 and Friday 13 October 2023,
both days inclusive.
VitalityHealth termination of reinsurance based financing quota share treaty
VitalityHealth terminated all reinsurance based financing quota share treaties on 1 July 2023, after the end of the reporting period.
The termination was in response to the impact of IFRS 17 on the Company’s strategy to utilise reinsurance based financing to offset
the total strain of writing new business. VitalityHealth holds the following reinsurance related balances under IFRS 4 which would
have a net impact of £245.96m on the assets position as at 30 June 2023:
 Debtors arising out of reinsurance operations amounting to a GBP246 million asset (ZAR5 901.5 million).
 Reinsurers share of insurance contract liabilities, including UPR, amounting to a GBP94 million asset (ZAR2 255 million); and
 Creditors arising out of reinsurance operations amounting to a GBP 94 million liability (ZAR2 255 million).
The transition to IFRS 17 sees these assets and liabilities retrospectively revalued to nil upon implementation of IFRS 17 for the
financial year commencing 1 July 2023. The termination on 1 July 2023, following the retrospective revaluation under IFRS 17, is
expected to have a nil impact in the financial year commencing 1 July 2023.
Notes to the Group annual financial statements continued
for the year ended 30 June 2023

-- 124 of 217 --

124	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Group annual financial statements continued
for the year ended 30 June 2023
45. 	RESTATEMENT AS A RESULT OF PRIOR PERIOD ERROR – RECLASSIFICATION
OF UNIT-LINKED INSURANCE CONTRACTS TO UNIT-LINKED INVESTMENT
CONTRACTS
During its IFRS 17 project, Discovery performed a full reassessment of all its insurance contracts to ensure the products were
correctly included in the scope of the IFRS 17 project. This full assessment and evaluation was necessary to determine whether the
contracts transfer significant insurance risk, a prerequisite for the contract to be recognised under IFRS 17.
During the year, Discovery identified that certain offshore unit-linked policies do not transfer significant insurance risk as required
under IFRS 17. Instead of being classified as unit-linked insurance contracts, these policies should have been accounted for as unit-
linked investment contracts under IFRS 9 Financial Instruments.
Discovery noted that the definition of significant insurance risk under IFRS 17 and IFRS 4 is the same. Accordingly, the change in
treatment did not constitute a change because of the transition to IFRS 17. Instead, a correction would be required under IFRS 4 of
the previously published information. The error was rectified as a reclassification from IFRS 4 to IFRS 9.
Accordingly, these policies were reclassified from unit-linked insurance contracts as disclosed in note 18 Liabilities arising from
insurance contracts to note 21 Investment contracts at fair value through profit or loss which includes unit-linked investment
products. The unit priced component of the fair value measurement of the policyholder liability remained unchanged. The negative
rand reserve that was previously recognised under IFRS 4 was derecognised. The incremental costs to obtain the contracts have also
been recognised accordingly in note 9A Assets arising from contracts with customers and contract liabilities.
The change in presentation of the unit-linked policies also affected the Income statement but did not affect the previously
reported earnings.
The tables below summarise the restatement’s impact on the Statement of financial position and the Income statement.
STATEMENT OF FINANCIAL POSITION
R million
Group
30 June 2021
(previously
reported) 	Correction
Group
1 July 2021
(as restated)
Assets arising from contracts with customers 	1 248 	127 	1 375
Liabilities arising from insurance contracts 	(100 977) 	936 	(100 041)
Investment contracts at fair value through profit or loss 	(32 291) 	(1 063) 	(33 354)
STATEMENT OF FINANCIAL POSITION
R million
Group
30 June 2022
(previously
reported) 	Correction
Group
30 June 2022
(as restated)
Assets arising from contracts with customers 	1 549 	143 	1 692
Liabilities arising from insurance contracts 	(109 200) 	1 133 	(108 067)
Investment contracts at fair value through profit or loss 	(37 361) 	(1 276) 	(38 637)
INCOME STATEMENT
R million
Group
30 June 2022
(previously
reported) 	Correction
Group
30 June 2022
(as restated)
Insurance premium revenue 	58 782 	(470) 	58 312
Claims and policyholders’ benefits 	(38 207) 	185 	(38 022)
Acquisition cost 	(4 774) 	16 	(4 758)
Net transfer to/from assets and liabilities under insurance contracts 	(6 935) 	197 	(6 738)
Fair value adjustment to liabilities under investment contracts 	(40) 	72 	32
Profit from operations 	7 858 	– 	7 858
The restatement has had no change to operating, investing, and financing cash flows and no changes to the Statement of changes in
equity. There is no impact on Discovery’s Profit from operations; consequently, basic or diluted earnings per share remain unchanged.

-- 125 of 217 --

DISCOVERY
COMPANY ANNUAL
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE
2023

-- 126 of 217 --

126	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
R million 	Notes
Company
2023
Company
2022
Assets
Deferred tax asset 	12 	5 	82
Investments in subsidiaries 	2 	30 579 	29 027
Investment in associate 	3 	2 584 	2 584
Financial assets
– Loans to subsidiaries 	5 	9 614 	8 397
– Loans to BEE partners 	6 	219 	186
– Other receivables 	7 	229 	185
– Derivatives at fair value through profit or loss 	4 	59 	18
Cash and cash equivalents 	19.5 	282 	607
Total assets 	43 571 	41 086
Equity
Capital and reserves
Ordinary share capital and share premium 	8.1 	10 467 	10 293
Perpetual preference share capital 	8.2 	779 	779
Other reserves 	1 601 	1 129
Retained earnings 	11 315 	8 003
Total equity 	24 162 	20 204
Liabilities
Financial liabilities
– Borrowings at amortised cost 	9 	9 948 	10 584
– Financial guarantee contracts 	20 	12 	25
– Trade and other payables 	11 	9 403 	10 216
– Derivatives at fair value through profit or loss 	10 	1 	56
Current tax liability 	19.2 	45 	1
Total liabilities 	19 409 	20 882
Total liabilities and equity 	43 571 	41 086
Company statement of financial position
at 30 June 2023

-- 127 of 217 --

127	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
R million 	Notes
Company
2023
Company
2022
Investment income 	13 	4 056 	1 049
At amortised cost interest income, using the effective interest rate 	863 	688
Dividends received from subsidiaries 	3 193 	361
Other income 	14 	36 	57
Net fair value losses on financial instruments at fair value through
profit or loss 	15 	(2) 	(2)
Marketing and administration expenses 	16 	(16) 	(19)
Movement in allowance for expected credit losses 	17 	8 	*
Profit from operations 	4 082 	1 085
Finance costs 	(943) 	(937)
Foreign exchange gains 	386 	16
Profit before tax 	3 525 	164
Taxation 	18 	(124) 	(31)
Profit for the year 	3 401 	133
Attributable to:
– Ordinary shareholders 	3 332 	77
– Preference shareholders 	69 	56
3 401 	133
* Amount is less than R500 000.
Company Income statement
for the year ended 30 June 2023
R million
Company
2023
Company
2022
Profit for the year 	3 401 	133
Items that are or may be reclassified subsequently to profit or loss:
Cash flow hedges 	80 	295
– Unrealised gains 	76 	295
– Tax on unrealised gains 	– 	–
– Losses recycled to profit or loss 	4 	–
– Tax on recycled losses 	– 	–
Other comprehensive income for the year, net of tax 	80 	295
Total comprehensive income for the year 	3 481 	428
Attributable to:
– Ordinary shareholders 	3 412 	372
– Preference shareholders 	69 	56
3 481 	428
Company statement of other comprehensive income
for the year ended 30 June 2023

-- 128 of 217 --

128	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
R million 	Notes
Company
2023
Company
2022
Cash flow from operating activities 	1 600 	492
Cash generated by operations 	19.1 	1 864 	1 067
Dividends received 	425 	237
Interest received 	19.6 	231 	102
Interest paid 	(917) 	(914)
Taxation paid 	19.2 	(3) 	*
Cash flow from investing activities 	(1 713) 	(2 078)
Increase investment in subsidiaries 	19.3 	(1 493) 	(1 559)
Increase investment in associate 	– 	(1 487)
Increase in loans granted to subsidiaries 	5 	(4 686) 	(1 789)
Proceeds from settlement of subsidiary loans 	5 	4 466 	2 757
Cash flow from financing activities 	(230) 	2 106
Proceeds from treasury shares 	* 	9
Proceeds from issuance of ordinary shares 	514 	443
Proceeds from long-term borrowings 	19.4 	2 650 	2 410
Repayment of long-term borrowings 	19.4 	(3 304) 	(700)
Premium paid on interest rate swap 	(21) 	–
Dividends paid to preference shareholders 	(69) 	(56)
Net (decrease)/increase in cash and cash equivalents 	(343) 	520
Cash and cash equivalents at beginning of the year 	607 	93
Exchange gains/(losses) on cash and cash equivalents 	18 	(6)
Cash and cash equivalents at end of the year 	19.5 	282 	607
* Amount is less than R500 000.
Company statement of cash flows
for the year ended 30 June 2023

-- 129 of 217 --

129	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Company
R million
Share
capital
and share
premium
Preference
share
capital
Hedging
reserve
Share-
based
payment
reserve
Retained
earnings 	Total
Year ended 30 June 2022
At beginning of the year 	10 281 	779 	(334) 	844 	7 926 	19 496
Total comprehensive income for the year 	– 	56 	295 	– 	77 	428
Profit for the year 	– 	56 	– 	– 	77 	133
Other comprehensive income 	– 	– 	295 	– 	– 	295
Transactions with owners 	12 	(56) 	– 	324 	– 	280
Issue of shares 	443 	– 	– 	– 	– 	443
Increase in treasury shares 	(443) 	– 	– 	– 	– 	(443)
Delivery of treasury shares 	3 	– 	– 	(3) 	– 	–
Proceeds from treasury shares 	9 	– 	– 	– 	– 	9
Employee share option schemes:
– Value of employee services 	– 	– 	– 	327 	– 	327
Dividends paid to preference shareholders 	– 	(56) 	– 	– 	– 	(56)
Balance at 30 June 2022 	10 293 	779 	(39) 	1 168 	8 003 	20 204
Year ended 30 June 2023
At beginning of the year 	10 293 	779 	(39) 	1 168 	8 003 	20 204
Total comprehensive income for the year 	– 	69 	80 	– 	3 332 	3 481
Profit for the year 	– 	69 	– 	– 	3 332 	3 401
Other comprehensive income 	– 	– 	80 	– 	– 	80
Transactions with owners 	174 	(69) 	– 	392 	(20) 	477
Issue of shares 	514 	– 	– 	– 	– 	514
Increase in treasury shares 	(514) 	– 	– 	– 	– 	(514)
Delivery of treasury shares 	171 	– 	– 	(171) 	– 	–
Proceeds from treasury shares 	3 	– 	– 	(3) 	– 	–
Employee share option schemes:
– Value of employee services 	– 	– 	– 	546 	– 	546
Transfer of vested shares 	– 	– 	– 	20 	(20) 	–
Dividends paid to preference shareholders 	– 	(69) 	– 	– 	– 	(69)
Balance at 30 June 2023 	10 467 	779 	41 	1 560 	11 315 	24 162
Company statement of changes in equity
for the year ended 30 June 2023

-- 130 of 217 --

130	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The principal accounting policies applied in the preparation of these separate financial statements are consistent with those set out in
Annexure B. In addition to those policies, the following policies apply specifically to these separate financial statements.
1. 	Investment in subsidiaries and associates
The company is directly and indirectly the holding company of subsidiaries and investments as set out in Annexure A. Investments
in subsidiaries and associates are accounted for at cost less impairment. Cost includes the fair value of any asset or liability resulting
from a contingent consideration arrangement on initial recognition.
Discovery assesses at each reporting date whether there is objective evidence that the investment in subsidiaries and associates are
impaired. If such evidence of impairment exists, Discovery calculates the amount of impairment as the difference between the
recoverable amount of the investment and its carrying value.
1.1 	Common control transactions
Common control transactions refer to business combinations in which all the combining entities or businesses are ultimately
controlled by the same party (or parties) before and after the combination. This includes businesses which are associates and joint
ventures. Discovery Limited applies book value accounting to account for common control transactions. Discovery Limited will
dispose of its investment at the carrying amount. Any difference between the consideration received and the carrying amount of
the investment disposed of is recognised as an equity transaction with shareholders in equity. No gain or loss is recognised in profit
or loss on disposal.
2. 	Financial guarantee contracts
The Company accounts for financial guarantee contracts (FGCs) in accordance with IFRS 9 Financial Instruments (IFRS 9). The
Company issues FGCs to assist in securing funding for its subsidiaries.
FGCs are contracts which require the Company, as the issuer of the contract, to make specified payments to reimburse the holder
for a loss that the holder incurs because the specified debtor fails to make payment when it is due under the original or modified
terms of the debt instrument.
The Company measures the FGC:
 Initially at fair value; and
 Subsequently at the higher of:
– The amount of expected credit losses determined under IFRS 9 (calculation 1); and
– The amount initially recognised less, when appropriate, the cumulative amount of income recognised under the principles
of IFRS 15 Revenue from Contracts with Customers (calculation 2).
2.1 	Initial recognition
In instances where the Company issues FGCs for the debt of a related entity in the Discovery Group, the Company determines the
fair value. These FGCs are seen as transactions in a capacity as shareholder and are treated as capital contributions.
In some instances, the other Discovery Group entity can also pay a premium to the issuer of the FGCs. The Company then determines
if the price represents the fair value, or whether there is still an additional cost of the FGC that the Company should recognise.
In the instance where the Company does not receive all the premiums upfront, it recognises the FGC using a net approach. The
net approach requires that the Company presents the financial guarantee as its fair value less all future premiums.
COMPANY ACCOUNTING POLICIES
for the year ended 30 June 2023

-- 131 of 217 --

131	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
COMPANY ACCOUNTING POLICIES continued
for the year ended 30 June 2023
2. 	Financial guarantee contracts continued
2.2 	Subsequent measurement
The Company recognises financial guarantee fee income as follows:
 Amortises the fair value recognised on initial recognition over the period that the FGC is outstanding, being generally the period
of the underlying debt;
 Recognises any premiums received for issuing the FGC as financial guarantee fee income; and
 Where the Company has applied the net approach, the Company adjusts for the premiums subsequently received to ensure it
takes into account all premiums in using calculation 2.
The Company calculates the lifetime expected credit losses for purposes of calculation 1.
Where the outcome is such that calculation 1 is more than calculation 2, differences are recognised and presented as part of
expected credit losses.
Where the outcome is such that calculation 2 is more than calculation 1, no adjustments are required. Any previously recognised
expected credit losses can be reversed, but limited to the total value previously recognised.
2.3 	Derecognition
The Company derecognises FGCs when the FGC is extinguished, expires or the underlying debt is extinguished.
At the date of derecognition:
 Where the FGC is extinguished in exchange for a new FGC to the same holder and in respect of the same guaranteed entity, the
FGC derecognised is seen as compensation for the new FGC; or
 In all other instances, the FGC is derecognised with an associated gain or loss in profit or loss.
3. 	Share based payments
Also refer to Accounting Policies 17 Employee benefits set out in Annexure B and Group note 32 Share-based payments and long-
term incentives.
Two of the schemes that Discovery operates, namely the BEE staff share trust and Discovery long-term incentive plan (LTIP) (equity
settled), are both equity-settled share-based payment arrangements in accordance with the requirements of IFRS 2 Share-based
Payment. In these schemes, Discovery Limited grants the awards to the employees within the Discovery Group of entities. Discovery
classifies the share-based payment transaction according to whether the entity has the obligation to settle. As it is Discovery
Limited’s shares being awarded to employees, Discovery classifies the transaction as equity-settled.
Under IFRS, Discovery does not consider any repayment or recharge arrangements in determining the classification of these group
share-based payments. Any recharge payments Discovery receives from its subsidiaries is treated as a return on capital from
the subsidiary. Any excess of recharge above the carrying amount of investment in subsidiary is recognised immediately as
dividend income.
Discovery manages two share trusts. Discovery treats the share trusts set up to facilitate the share-based payment arrangements as
an agent, i.e., an extension of Discovery Limited. In other words, shares held by the trust is treated as treasury shares of Discovery Limited.
 BEE Staff Share Trust: Shares and option to acquire shares have been allocated to senior black employees based on level of
seniority and length of past service. The trust will hold shares until the date of vesting of the shares to the employee or exercise
date of the option.
 Discovery LTIP Trust: Participants will receive Discovery Limited shares subject to performance criteria and if the participant is
employed on each vesting date. The trust will hold shares until the date of vesting of the shares to the employee. Per the LTIP
Trust deed, the LTIP Trust recharges the costs of the shares acquired for the employees to the relevant subsidiary whose
employees are awarded the shares. The recharge is upfront.

-- 132 of 217 --

132	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements
for the year ended 30 June 2023
1. 	MANAGEMENT OF FINANCIAL RISK
The Company’s activities expose it to a variety of financial risks. Financial risks include market risk, credit risk and liquidity risk. Refer
to Group note 3 Management of financial risk for a detailed explanation of financial risks and how they are managed.
1.1 	Interest rate risk
Sensitivity to changes in interest rates is relevant to financial assets or liabilities bearing floating interest rates due to the risk that
future cash flows fluctuate. However, sensitivity will also be relevant to fixed-rated financial assets and financial liabilities that are
re-measured to fair value.
The table below details the specific interest rate risk that the Company is exposed to:
Company
R million
Carrying
amount 	Fixed 	Floating
Non-interest
bearing
At 30 June 2023
Derivative financial instruments at fair value:
– Used as cash flow hedges1 	59 	59 	– 	–
Loans to subsidiaries 	9 614 	2 453 	7 161 	–
Loans to BEE partners 	219 	– 	193 	26
Other receivables 	226 	– 	– 	226
Cash and cash equivalents 	282 	– 	282 	–
Total financial assets 	10 400 	2 512 	7 636 	252
Borrowings at amortised cost 	9 948 	4 382 	5 566 	–
Derivative financial instruments at fair value:
– Used as cash flow hedges 1 	1 	1 	– 	–
Financial guarantee contracts 	12 	– 	– 	12
Trade and other payables 	9 403 	– 	– 	9 403
Total financial liabilities 	19 364 	4 383 	5 566 	9 415
At 30 June 2022
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	1 	– 	– 	1
– Used as cash flow hedges 1 	17 	17 	– 	–
Loans to subsidiaries 	8 397 	2 216 	6 181 	–
Loans to BEE partners 	186 	– 	184 	2
Other receivables 	176 	– 	– 	176
Cash and cash equivalents 	607 	– 	607 	–
Total financial assets 	9 384 	2 233 	6 972 	179
Borrowings at amortised cost 	10 584 	3 826 	6 758 	–
Derivative financial instruments at fair value:
– Used as cash flow hedges 1 	56 	56 	– 	–
Financial guarantee contracts 	25 	– 	– 	25
Trade and other payables 	10 216 	– 	– 	10 216
Total financial liabilities 	20 881 	3 882 	6 758 	10 241
1 For further information on the use of interest rate swaps to manage the interest rate risk of Discovery Limited, refer to the following notes in the
Group financials, which equally apply to Discovery Limited:
– Note 3.4 Shareholder financial assets and liabilities, "Borrowings at amortised cost and related hedges", page 61.
For those financial assets at amortised cost, a change of 1% in the interest rate would result in an increase/decrease of R80 million
(2022: R69 million) in interest income. The sensitivity is based on the assumption that the interest rate has increased/decreased by
1% with all other variables held constant.
Borrowings at amortised cost include facilities at floating interest rates, which expose Discovery Limited to cash flow interest rate
risk. This risk has been managed by using floating-to-fixed interest rate swaps. These interest rate swaps have the economic effect
of converting the borrowings from floating to fixed rates. Interest is payable quarterly in arrears, with capital repayable on maturity.
The hedge ratio is 1:1. For borrowings at floating interest rates that have not been hedged, a change of 1% in the interest rate would
result in an increase of R4 million (2022: R6 million) in finance costs. The sensitivity is based on the assumption that the interest rate
has increased/decreased by 1% with all other variables held constant.

-- 133 of 217 --

133	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
1. 	MANAGEMENT OF FINANCIAL RISK continued
1.2 	Currency risk
The Company operates internationally and is exposed to foreign exchange risk arising from various currency exposures, primarily
with respect to the US dollar and the UK pound. Foreign exchange risk arises from future commercial transactions and recognised
assets and liabilities.
The following table segregates the currency exposure by major currency:
Company
R million 	Total 	Rand 	GBP 	USD
At 30 June 2023
Derivative financial instruments at fair value:
– Used as cash flow hedges 	59 	59 	– 	–
Loans to subsidiaries 	9 614 	7 456 	2 158 	–
Loans to BEE partners 	219 	219 	– 	–
Other receivables 	226 	191 	35 	–
Cash and cash equivalents 	282 	39 	243 	*
Total financial assets 	10 400 	7 964 	2 436 	*
Borrowings at amortised cost 	9 948 	9 948 	– 	–
Derivative financial instruments at fair value:
– Used as cash flow hedges 	1 	1 	– 	–
Financial guarantee contracts 	12 	12 	– 	–
Other payables 	9 403 	9 400 	3 	–
Total financial liabilities 	19 364 	19 361 	3 	–
At 30 June 2022
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	1 	1 	– 	–
– Used as cash flow hedges 	17 	17 	– 	–
Loans to subsidiaries 	8 397 	6 621 	1 776 	–
Loans to BEE partners 	186 	186 	– 	–
Other receivables 	176 	143 	33 	–
Cash and cash equivalents 	607 	526 	59 	22
Total financial assets 	9 384 	7 494 	1 868 	22
Borrowings at amortised cost 	10 584 	10 584 	– 	–
Derivative financial instruments at fair value:
– Used as cash flow hedges 	56 	56 	– 	–
Financial guarantee contracts 	25 	17 	8 	–
Other payables 	10 216 	10 216 	* 	–
Total financial liabilities 	20 881 	20 873 	8 	–
* Amount is less than R500 000.
A 10% increase on respective foreign exchange rates of GBP: ZAR would result in additional gains of R226 million (2022: R186 million),
or in the case of decrease, a loss of R226 million (R186 million), recognised in profit or loss.
1.3 	Credit risk
Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an
obligation. The credit risk associated with Cash and cash equivalents is managed by monitoring exposure to external financial
institutions against limits set by the CCIC.

-- 134 of 217 --

134	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
1. 	MANAGEMENT OF FINANCIAL RISK continued
1.3 	Credit risk continued
Credit exposure for debt instruments, money market instruments and cash and cash
equivalents
The following table provides information regarding the credit risk exposure categorised as set out in the Group note 3 Management
of financial risk. These assets are all in stage 1 for purposes of determining expected credit losses.
Company
R million 	Total 	Aa1-3 	Baa1-3 	Ba1-3 	B1-3
Internally
rated/
assessed
At 30 June 2023
Derivative financial instruments at fair value:
– Used as cash flow hedges 	59 	– 	– 	59 	– 	–
Loans to subsidiaries 	9 614 	– 	3 756 	5 858 	– 	–
Loans to BEE partners 	219 	– 	– 	– 	– 	219
Other receivables 	226 	– 	178 	48 	– 	–
Cash and cash equivalents 	282 	1 	– 	281 	– 	–
Total financial assets 	10 400 	1 	3 934 	6 246 	– 	219
Financial guarantee contracts 1 	12 	– 	– 	12 	– 	–
At 30 June 2022
Derivative financial instruments at fair value:
– Not designated as hedging instruments 	1 	– 	– 	1 	– 	–
– Used as cash flow hedges 	17 	– 	– 	17 	– 	–
Loans to subsidiaries 	8 397 	– 	– 	8 397 	– 	–
Loans to BEE partners 	186 	– 	– 	– 	– 	186
Other receivables 	176 	– 	– 	158 	18 	–
Cash and cash equivalents 	607 	– 	– 	607 	– 	–
Total financial assets 	9 384 	– 	– 	9 180 	18 	186
Financial guarantee contracts 1 	25 	– 	– 	25 	– 	–
1 Financial guarantee contracts have been included and comparative information has been restated.
Long-term credit ratings were used in the credit risk analysis above. Refer to Group note 3 Management of financial risk, ’Discovery’s
approach in monitoring credit risk’ for a summary of how credit ratings are aligned to external credit ratings.
Loans to BEE partners are not assigned formal credit ratings externally or internally. These loans are structured considering
creditworthiness of the individual partners, and the purpose of the BEE relationship. These loans are managed and monitored on
an individual basis, and ECL is accordingly recognised on an individual basis using management’s best estimate.
Discovery Limited has issued financial guarantees as security for loans incurred by subsidiaries in the group. The maximum credit
risk that Discovery Limited is exposed to on these contracts is the carrying amount, which amounted to R3 940 million (2022:
R6 917 million). For majority of the issued financial guarantees, Discovery Limited is co-guarantor with Discovery Health (Pty) Ltd
and Discovery Vitality (Pty) Ltd.
Loans to subsidiaries and financial guarantee contracts do not have external credit ratings. Credit ratings are internally assigned
using the RW rating scale. Prior period Loans to subsidiaries have been restated to align to the new RW ratings.

-- 135 of 217 --

135	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
1. 	MANAGEMENT OF FINANCIAL RISK continued
1.4 	Liquidity risk
Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities due to
insufficient cash available to meet commitments as and when due.
Liquidity is managed through the Group Treasury Management function, which considers the liquidity position at the respective Company
level as well as the overall Group position. As part of this assessment, the liquidity position in each entity is optimised and takes account
of available credit facilities to the Group within the Board approved maximum financial leverage ratio. The Company is in the process
of refinancing short-term borrowings as part of its ongoing debt capital management activities. The group structure is conducive for
the Company to receive dividends and other forms of funding from underlying subsidiaries to enable it to meet its obligations.
Cash flow forecasting is performed by the Company and liquidity requirements are monitored to ensure it has sufficient cash to
meet operational needs. Such forecasting takes into consideration the Company’s debt financing plans and covenant compliance.
Cash held by the Company is invested in interest-bearing accounts, term deposits and money market deposits with appropriate
maturities or sufficient liquidity to provide headroom as determined by the above-mentioned forecasts. At the reporting date, the
Company had money market funds and cash and cash equivalents of R282 million (2022: R607 million).
The table below analyses Discovery Limited’s financial liabilities into relevant maturity groupings based on the remaining period at
the reporting date to the contractual maturity date. These amounts do not agree to the Statement of financial position as these are
the undiscounted contractual payments.
Company
R million 	Total 	<1 year
1 – 2
years
3 – 5
years
6 – 10
years
At 30 June 2023
Borrowings 	12 187 	1 425 	5 429 	5 085 	248
Derivative financial instruments:
– Used as cash flow hedges 	59 	5 	22 	32 	–
Trade and other payables 	9 403 	9 403 	– 	– 	–
21 649 	10 833 	5 451 	5 117 	248
Financial guarantees 	3 940 	3 940 	– 	– 	–
25 589 	14 773 	5 451 	5 117 	248
At 30 June 2022
Borrowings 	12 416 	4 013 	1 036 	7 110 	257
Derivative financial instruments:
– Used as cash flow hedges 	311 	117 	90 	104 	–
Trade and other payables 	10 216 	10 216 	– 	– 	–
22 943 	14 346 	1 126 	7 214 	257
Financial guarantees 	6 917 	6 917 	– 	– 	–
29 860 	21 263 	1 126 	7 214 	257
1.5 	Fair value estimation
Discovery Limited’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has
three levels that reflect the significance of the inputs used in measuring fair value. Refer to Group note 3.6 Fair value estimation for
more details on the valuation techniques.
These are as follows:
Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial
instruments. An active market is a market in which transactions for the asset or liability take place with sufficient frequency and
volume to provide information on an ongoing basis. Quoted prices are readily and regularly available from an exchange, dealer,
broker, industry group, pricing service or regulatory agency and those prices represent actual and regularly occurring market
transactions on an arm’s length basis.
Level 2: includes financial instruments that are valued using techniques based significantly on observable market data.
Instruments in this category are valued using:
(a) Quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or
(b) Valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on
observable market data.
Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than
observable market data and where at least one input (which could have a significant effect on instrument’s valuation) cannot be
based on observable market data.

-- 136 of 217 --

136	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
1. 	MANAGEMENT OF FINANCIAL RISK continued
1.5 	Fair value estimation continued
Company
R million 	Total 	Level 1 	Level 2 	Level 3
At 30 June 2023
Derivative financial instruments at fair value:
– Used as cash flow hedges 	59 	– 	59 	–
Total financial assets 	59 	– 	59 	–
Derivative financial instruments at fair value:
– Used as cash flow hedges 	1 	– 	1 	–
Total financial liabilities 	1 	– 	1 	–
At 30 June 2022
Derivative financial instruments at fair value:
– not designated as hedging instruments 	1 	– 	1 	–
– Used as cash flow hedges 	17 	– 	17 	–
Total financial assets 	18 	– 	18 	–
Derivative financial instruments at fair value:
– Used as cash flow hedges 	56 	– 	56 	–
Total financial liabilities 	56 	– 	56 	–
2. 	INVESTMENTS IN SUBSIDIARIES
Issued ordinary
capital
R million
Effective
percentage holding
%
Investment
in subsidiaries3
R million
2023 	2022 	2023 	2022 	2023 	2022
Cogence Proprietary Limited 	* 	* 	100 	100 	* 	*
Discovery Bank Holdings Limited 	9 699 	8 771 	100 	100 	9 963 	8 996
Discovery Connect Distribution Services
Proprietary Limited 	555 	555 	100 	100 	546 	551
Discovery Central Services Proprietary
Limited 	* 	* 	100 	100 	34 	34
Discovery Finance Company Europe Limited1 	393 	393 	100 	100 	394 	394
Discovery Group Europe Limited 1 	14 172 	14 080 	100 	100 	14 159 	14 063
Discovery Health Proprietary Limited 	271 	271 	100 	100 	253 	216
Discovery Insure Limited 	2 552 	2 402 	100 	100 	1 588 	1 442
Discovery Life Limited 	1 416 	1 416 	100 	100 	1 502 	1 486
Discovery Life Collective Investments
Proprietary Limited 	15 	15 	100 	100 	15 	15
Discovery Life Investment Services
Proprietary Limited 	203 	203 	100 	100 	204 	203
Discovery Mauritius Asset Management 	1 	1 	100 	100 	1 	1
Discovery Vitality Proprietary Limited 	* 	* 	100 	100 	– 	–
Discovery Partner Markets Asia Private
Limited 2 	211 	211 	100 	100 	113 	113
Vitality Group International Incorporated 4 	3 643 	3 319 	100 	100 	1 807 	1 513
Balance at the end of the year 	30 579 	29 027
* Amount is less than R500 000.
1 Incorporated in England and Wales.
2 Incorporated in Singapore.
3 Investments in subsidiaries include cost less impairments plus the value of share options issued to subsidiary staff.
4 Incorporated in the United States of America.
Refer to Company note 19.3 for a detailed movement analysis.

-- 137 of 217 --

137	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
3. 	INVESTMENT IN ASSOCIATE
R million
% ownership interest Company
2023
Company
2022	2023 	2022
Investment at cost:
– Ping An Health Insurance Company in China, Limited 	24.99% 	24.99% 	2 584 	2 584
Refer to Group note 11 for disclosure of the investment in associate.
4. 	DERIVATIVES AT FAIR VALUE THROUGH PROFIT OR LOSS
R million
Company
2023
Company
2022
Interest rate derivatives – used as cash flow hedges1 	59 	17
Derivatives not designated as hedging instrument 	– 	1
Total 	59 	18
Current 	5 	1
Non-current 	54 	17
Total 	59 	18
1 The interest rate derivative portfolio consists of both interest rate swaps and interest rate caps.
Refer to the Group note 3.4.1 for a detailed description of the derivative financial instruments listed above.
5. 	LOANS TO SUBSIDIARIES 1
R million
Company
2023
Company
2022
Discovery Group Europe Limited 	2 639 	2 270
Discovery Health Proprietary Limited 	3 758 	3 410
Discovery Central Services Proprietary Limited 	3 225 	2 725
Total gross loans 	9 622 	8 405
Less: IFRS9 Expected credit losses (ECL)2 	(8) 	(8)
Total net loans 	9 614 	8 397
Current 	3 225 	3 214
Non-current 	6 389 	5 183
9 614 	8 397
Balance at beginning of the year 	8 397 	8 758
Additional loan granted 	4 686 	1 789
Repayment of loans
– capital portion 	(4 466) 	(2 757)
– interest portion 	(198) 	(93)
Interest receivable 	836 	676
Movement in allowance for expected credit losses 	– 	1
Exchange differences 	359 	23
Balance at end of the year 	9 614 	8 397
1 All loans to subsidiaries are measured at amortised cost, which approximates to fair value, as the loans bear interest at market related terms
2 The information is separately disclosed in the current period, and the comparative information has been restated accordingly.

-- 138 of 217 --

138	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
5. 	LOANS TO SUBSIDIARIES continued
GBP denominated
Discovery Limited has granted GBP denominated loans to Discovery Group Europe Limited, the terms are as follows:
Carrying value
Original
loan value
GBP million 	Variable rate
Capital repayment
and maturity date
Company 2023 	Company 2022
R million GBP million 	R million GBP million
11.9
Bank of England base rate
+ 400bps 	At maturity – 31 July 2025 	411 	17.2 	319 	16.0
24.7
Bank of England base rate
+ 600bps 	At maturity – 1 April 2027 	591 	24.6 	493 	24.6
6.0
Bank of England base rate
+ 600bps 	At maturity – 1 November 2027 	144 	6.0 	120 	6.0
10.5
Bank of England base rate
+ 600bps 	At maturity – 1 June 2028 	252 	10.5 	210 	10.5
9.0
Bank of England base rate
+ 600bps 	At maturity – 21 August 2028 	216 	9.0 	180 	9.0
6.5
Bank of England base rate
+ 600bps 	At maturity – 24 November 2028 	156 	6.5 	130 	6.5
2.8
Bank of England base rate
+ 615bps 	At maturity – 1 March 2029 	67 	2.8 	56 	2.8
7.1
Bank of England base rate
+ 615bps 	At maturity – 1 June 2029 	170 	7.1 	142 	7.1
6.5
Bank of England base rate
+ 615bps 	At maturity – 31 July 2029 	156 	6.5 	130 	6.5
2 163 	90.2 	1 780 	89.0
ZAR denominated
Discovery Limited has granted ZAR denominated loans to subsidiaries, the terms are as follows:
Carrying value
Rand million
Subsidiary the loan was granted to
Original
loan value
R million 	Variable rate
Capital repayment and
maturity date
Company
2023
Company
2022
Discovery Group Europe Limited 	268 	3-month Jibar + 200bps At maturity – 31 July 2030 	476 	489
Discovery Health Proprietary Limited1 	727 	3-month Jibar + 240bps At maturity – 30 June 2026 	1 304 	1 194
Discovery Health Proprietary Limited1,2 	93 	At maturity – 30 September 2026 	185 	167
Discovery Health Proprietary Limited1,2 	282 	At maturity – 30 September 2026 	561 	507
Discovery Health Proprietary Limited1,2 	235 	At maturity – 15 December 2026 	458 	414
Discovery Health Proprietary Limited1,2 	173 	At maturity – 28 March 2027 	328 	296
Discovery Health Proprietary Limited1,2 	288 	At maturity – 30 June 2027 	531 	480
Discovery Health Proprietary Limited1,2 	212 	At maturity – 3 July 2027 	391 	353
Discovery Central Services
Proprietary Limited
2 932 	South African prime
lending rate
On demand 	3 225 	2 725
7 459 	6 625
1 Interest payable quarterly in arrears, with the option available for Discovery Health to capitalise the interest to the value of the loan.
2 Interest accrues at a fixed rate of 10.2% per annum.
For the loans to Discovery Group Europe Limited, interest of R208 million was earned in respect of these loans in the current financial
year (2022: R136 million) and R359 million foreign exchange gain was recognised in profit and loss (2022: R23 million gain).

-- 139 of 217 --

139	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
6. 	LOANS TO BEE PARTNERS 1
R million
Company
2023
Company
2022
Balance at the beginning of the year 	186 	149
Interest receivable 	15 	9
Additional loan granted 	39 	35
Repayment of loans 	(21) 	(7)
Balance at the end of the year 	219 	186
Current 	219 	186
Balance at the end of the year 	219 	186
1 All loans to BEE partners are measured at amortised cost, which approximates to fair value.
These loans are due from Mohau Equity Partners. R193 million (2022: R184 million) is a bridge loan that accrues interest at prime
rate less 2%. R26 million (2022: R2 million) is an interest-free loan to provide empowerment financing towards a newly formed
brokerage. There are no repayment terms for these loans.
7. 	OTHER RECEIVABLES
R million
Company
2023
Company
2022
Intercompany receivables 	226 	176
Prepayments 	3 	9
Less allowance for credit losses 	* 	*
Balance at the end of the year 	229 	185
Intercompany receivables include:
Cogence Proprietary Limited 	7 	4
Discovery Bank Limited 	– 	29
Discovery Connect Distribution Services Proprietary Limited 	– 	6
Discovery Finance Company Europe Limited 	32 	14
Discovery Group Europe Limited 	– 	3
Discovery Holdings Europe Limited 	3 	19
Discovery Insure Limited 	– 	43
Discovery Life Investment Services Proprietary Limited 	93 	–
Discovery Vitality Proprietary Limited 	85 	58
Vitality Corporate Services Limited 	6 	–
Balance at the end of the year 	226 	176
* Amount is less than R500 000.
8. 	SHARE CAPITAL AND SHARE PREMIUM
8.1 	Ordinary share capital and share premium
Issued 	Treasury Shares
R million
Share
capital
Share
premium
BEE
Share
Trust
Long-term
incentive plan
Total
Outstanding
Issued
At 1 July 2021 	1 	11 237 	(51) 	(906) 	10 281
Share movements:
– shares issued 	* 	443 	– 	– 	443
– treasury shares delivered 	– 	8 	4 	– 	12
– treasury shares purchased 	– 	– 	– 	(443) 	(443)
At 30 June 2022 	1 	11 688 	(47) 	(1 349) 	10 293
Share movements:
– shares issued 	* 	514 	– 	– 	514
– treasury shares delivered 	– 	171 	3 	– 	174
– treasury shares purchased 	– 	– 	– 	(514) 	(514)
At 30 June 2023 	1 	12 373 	(44) 	(1 863) 	10 467
* Amount is less than R500 000.

-- 140 of 217 --

140	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
8. 	SHARE CAPITAL AND SHARE PREMIUM continued
8.1 	Ordinary share capital and share premium continued
Treasury Shares
Number of shares 	Company
BEE
Share
Trust
Long-term
incentive plan
Total
Outstanding
Issued
At 1 July 2021 	665 768 601 	(805 961) 	(7 477 865) 	657 484 775
Share movements:
– shares issued 	3 194 870 	– 	– 	3 194 870
– treasury shares delivered 	– 	152 104 	– 	152 104
– treasury shares purchased 	– 	– 	(3 194 870) 	(3 194 870)
At 30 June 2022 	668 963 471 	(653 857) 	(10 672 735) 	657 636 879
Share movements:
– shares issued 	4 182 946 	– 	– 	4 182 946
– treasury shares delivered 	– 	64 714 	1 402 275 	1 466 989
– treasury shares purchased 	– 	– 	(4 182 946) 	(4 182 946)
At 30 June 2023 	673 146 417 	(589 143) 	(13 453 406) 	659 103 868
The total authorised number of ordinary shares is 1 billion (2022: 1 billion), with a par value of 0.1 cent per share.
8.2 	Preference share capital
R million
Company
2023
Company
2022
Authorised
40 000 000 A no par value preference shares 	– 	–
20 000 000 B preference shares of R100 each 	2 000 	2 000
20 000 000 C no par value preference shares 	– 	–
2 000 	2 000
Issued
8 000 000 B preference shares of R100 each 	800 	800
Share issue costs 	(21) 	(21)
779 	779
The preference shares are non-compulsory, non-cumulative, non-participating, non-convertible, voluntarily redeemable (at option
of Discovery Limited) preference shares and were issued at a coupon rate of 85% of prime rate. With the introduction of dividend
withholding tax on 1 April 2012, the coupon rate on the preference shares was increased to 100% of the prime rate.
9. 	BORROWINGS AT AMORTISED COST
R million
Company
2023
Company
2022
Borrowings from banks1 	9 948 	10 584
Current 	587 	3 312
Non-current 	9 361 	7 272
Balance at the end of the year 	9 948 	10 584
1 Financial guarantees were provide by Discovery Health Proprietary Limited, Discovery Vitality Proprietary Limited and Discovery Central Services
Proprietary Limited has been given to secure these borrowings.
The borrowings were acquired for general corporate purposes in order to fund the various growth initiatives within the Group.
Credit rating
In January 2023 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s Global scale long-term issuer rating of Ba3 and
the national scale long-term issuer rating at A1.za. The outlook was unchanged as stable, aligned to the outlook of the country.

-- 141 of 217 --

141	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
9. 	BORROWINGS AT AMORTISED COST continued Carrying value
R million
Facility amount
R million 	Variable rate
Interest
per annum
Capital repayment and
maturity date
Company
2023
Company
2022
Listed DMTN4
500 	3-month Jibar + 161bps 	8.095%1, 3 	At maturity – 21 November 2022 	– 	503
500 	3-month Jibar + 205bps 	4.253%1, 3 	At maturity – 21 August 2023 	505 	503
200 	– 	10.46%2 	At maturity – 21 November 2024 	202 	202
800 	3-month Jibar + 191bps 	8.4% 1, 3 	At maturity – 21 November 2024 	808 	805
1 200 	3-month Jibar + 191bps 	7.295%1, 3 	At maturity – 21 November 2024 	1 218 	1 217
700 	3-month Jibar + 180bps 	8.49% 1, 3 	At maturity – 21 August 2026 	707 	704
300 	3-month Jibar + 180bps 	7.60% 1, 3 	At maturity – 21 August 2026 	304 	303
792 	3-month Jibar + 173bps 	7.98% 1, 3 	At maturity – 21 May 2027 	799 	792
226 	3-month Jibar + 180bps 	7.98% 1, 3 	At maturity – 21 May 2029 	228 	226
Unlisted DMTN5
1 100 	– 	8.915%3 	At maturity – 10 March 2023 	– 	1 104
2 500 	– 	9.615%3 	At maturity – 22 February 2025 	2 522 	2 520
1 650 	– 	9.55%3 	At maturity – 10 March 2026 	1 658 	–
Other
1 400 	3-month JIBAR + 125bps 	At maturity – 12 October 2022 	– 	702
1 000 	3-month JIBAR + 245bps 	7.83%1,3 	At maturity – 02 March 2023 	– 	1 003
1 000 	3-month JIBAR + 190bps 	At maturity – 02 March 2028 	997 	–
9 948 	10 584
1 The interest rate has been fixed through interest rate swaps.
2 Interest is payable semi-annually in arrears.
3 Interest payable quarterly in arrears.
4 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017.
5 During the financial year ended 30 June 2020, Discovery Limited refinanced R3.6 billion bank syndicated loans through the issue of unlisted DMTN
notes. The notes, although underwritten by a bank until maturity, are structured to enable short-term issuances into the commercial paper market
on an ongoing basis.
The borrowings are unsecured senior debt and are not callable or convertible. Interest is payable quarterly in arrears other than
footnote 2 in the table above. Refer to company note 19.4 for movement analysis and Group note 20.
10. 	DERIVATIVES AT FAIR VALUE THROUGH PROFIT OR LOSS
R million
Company
2023
Company
2022
Interest rate swaps – used as cash flow hedges1 	1 	56
Total 	1 	56
Current 	– 	21
Non-current 	1 	35
Total 	1 	56
1 For further information, refer to Group note 13, which sets out information on the ’Interest Rate Swaps’ which equally apply to the Company.

-- 142 of 217 --

142	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
11. 	TRADE AND OTHER PAYABLES
R million
Company
2023
Company
2022
Accrued expenditure 	10 	11
Dividends due to shareholders 	9 	10
Intercompany payables 	9 384 	10 195
9 403 	10 216
Intercompany payables include:
Discovery Bank Limited 	* 	–
Discovery Health Proprietary Limited 	4 615 	5 430
Discovery Insure Limited 	1 	–
Discovery Life Limited 	4 768 	4 765
9 384 	10 195
* Amount is less than R500 000.
Discovery Limited receives funds from its subsidiaries through intercompany loan accounts, to assist with operational requirements.
The loans are interest free and are settled as and when sufficient cash becomes available.
The amortised cost of the trade and other payables approximate the fair value due to the short-term nature of these payables.
12. 	DEFERRED TAX ASSET
R million
Company
2023
Company
2022
Deferred tax asset – non-current 	5 	82
Movement summary:
Balance at beginning of the year 	82 	113
Income statement charge 	(77) 	(31)
Balance at end of the year 	5 	82
Deferred taxation comprises:
Assessed losses 	– 	67
Section 6 quat credits 	3 	15
Unrealised gains on financial instruments 	– 	(1)
Realised capital losses 	2 	1
5 	82

-- 143 of 217 --

143	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
13. 	INVESTMENT INCOME1
R million
Company
2023
Company
2022
At amortised cost interest income, using the effective interest rate 	863 	688
Dividends received from subsidiaries 	3 193 	361
4 056 	1 049
Dividends received from subsidiaries include:
– Discovery Central Services Proprietary Limited 	23 	117
– Discovery Health Proprietary Limited2 	2 740 	–
– Discovery Insure Limited 	– 	30
– Discovery Life Collective Investments Proprietary Limited 	408 	–
– Discovery Mauritius Asset Management 	17 	7
– Discovery Vitality Proprietary Limited 	1 	207
– Vitality Corporate Services Limited 	4 	–
3 193 	361
1 Investment income for Discovery Limited is seen as Revenue.
2 The dividend received settled the loan due to Discovery Health Proprietary Limited and was not received in cash. .
14. 	OTHER INCOME
R million
Company
2023
Company
2022
Guarantee fees 	i 	31 	53
Amortisation of financial guarantee contracts 	ii 	5 	3
Other income 	– 	1
36 	57
i 	Discovery Limited issued guarantees in respect of Discovery Finance Company Europe Limited and Discovery Holdings Europe
Limited obligations. A guarantee fee is charged by Discovery Limited to Discovery Finance Company Europe Limited of
R13 million (2022: R25 million) and Discovery Holdings Europe Limited of R18 million (2022: R28 million).
ii Amortisation of initial financial guarantee contracts over the term of the loan. Refer to Company note 20 for a list of all the
guarantees that Discovery Limited has issued.
15. 	NET FAIR VALUE LOSSES ON FINANCIAL INSTRUMENTS AT FAIR VALUE
THROUGH PROFIT OR LOSS
R million
Company
2023
Company
2022
Net fair value losses/(gains) on non-hedge derivatives 	2 	2
2 	2
16. 	MARKETING AND ADMINISTRATION EXPENSES
R million
Company
2023
Company
2022
Marketing and administration expenses comprises:
– Audit fees 	6 	6
– Professional fees 	7 	11
– Other 	3 	2
16 	19

-- 144 of 217 --

144	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Notes to the Company annual financial statements continued
for the year ended 30 June 2023
17. 	MOVEMENT IN ALLOWANCE FOR EXPECTED CREDIT LOSSES1
R million
Company
2023
Company
2022
Financial guarantee contracts:
– Discovery Bank Limited 	1 	(*)
– Discovery Central Services Proprietary Limited 	* 	(*)
– Discovery Finance Company Europe Limited 	7 	–
8 	(*)
* Amount is less than R500 000.
1 In determining the expected credit loss, credit ratings are internally assigned using the RW rating scale. Refer to note 1.3 Credit risk, for more information.
12 month
credit losses
Lifetime
credit losses 	Total
30 June 2023
Balance at beginning of the year 	(16) 	– 	(16)
Decrease in allowance 	8 	– 	8
Balance at end of the year 	(8) 	– 	(8)
30 June 2022
Balance at beginning of the year 	(16) 	– 	(16)
Increase in allowance 	(*) 	– 	(*)
Balance at end of the year 	(16) 	– 	(16)
* Amount is less than R500 000.
18. 	TAXATION
R million
Company
2023
Company
2022
Charge for the year:
Current taxation 	47 	*
Normal taxation
– prior year under/(over) provision 	* 	(*)
– current year charge 	47 	*
Deferred taxation 	77 	31
– prior year under/(over) provision 	* 	(*)
– current year charge 	77 	31
Total income tax expense recognised in profit or loss 	124 	31
* Amount is less than R500 000.
% 	%
Taxation rate reconciliation
Effective taxation rate 	3.5 	18.8
Capital profits and dividend income 	24.2 	61.0
Exempt income 	0.2 	–
Disallowed expenditure: Capital in nature 	(0.6) 	(44.1)
Prior year over provision 	– 	0.5
Taxable Income: International tax adjustments 	(0.3) 	(6.5)
Change in tax rate 	– 	(1.5)
Difference in tax rate 	* 	(0.2)
Standard rate of taxation 	27.0 	28.0
The current tax rate for South African entities in a tax paying position is 27% (2022: 28%). Discovery, a holding company listed on the
JSE, uses the South African tax rate for its tax rate reconciliation since it is based in South Africa and the most significant operations
are in South Africa.

-- 145 of 217 --

145	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
19. 	CASH FLOW INFORMATION
19.1 Cash generated by operations
R million
Company
2023
Company
2022
Profit before taxation 	3 525 	164
Adjusted for:
Interest received 	(863) 	(688)
Dividends received 	(3 193) 	(361)
Finance costs 	943 	937
Non-cash items:
Movement in expected credit losses 	(8) 	*
Amortisation of financial guarantee contracts 	(5) 	(3)
Fair value losses/(gains) on derivatives not designated as hedging instruments 	2 	(73)
Unrealised foreign exchange gain 	(386) 	(16)
Working capital changes:
Loans and receivables 	(78) 	1 105
Trade and other payables and loans from subsidiaries 	1 927 	2
1 864 	1 067
19.2 	Taxation paid
R million
Company
2023
Company
2022
Balance at beginning of the year 	(1) 	*
Current taxation charged for the year in the income statement 	(47) 	*
Balance at end of the year 	45 	1
(3) 	*
19.3 	Increase in investments in subsidiaries
R million
Company
2023
Company
2022
Balance at beginning of the year 	29 027 	27 458
Value of share options issued to subsidiary staff 	546 	327
Financial guarantee contracts raised 	– 	1
Deemed dividends 	27 	125
Long-term incentive plan share recharges 	(514) 	(443)
Balance at end of the year 	(30 579) 	(29 027)
Increase in investment in subsidiary 	(1 493) 	(1 559)
19.4 	Long-term borrowings
R million
Company
2023
Company
2022
Balance at beginning of the year 	10 584 	8 858
Interest accrued 	860 	686
Interest paid 	(840) 	(683)
Increase in borrowings 	2 650 	2 418
Raising fees capitalised 	(9) 	(8)
Raising fees amortised 	7 	13
Repayment of borrowings 	(3 304) 	(700)
Balance at end of the year 	9 948 	10 584
19.5 	Cash and cash equivalents
R million
Company
2023
Company
2022
Cash at bank and in hand 	256 	93
Short-term deposits 	26 	514
282 	607
* Amount is less than R500 000.
Notes to the Company annual financial statements continued
for the year ended 30 June 2023

-- 146 of 217 --

146	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
19. 	CASH FLOW INFORMATION continued
19.6 	Interest received
R million
Company
2023
Company
2022
At amortised cost interest income, using the effective interest rate 	863 	688
Interest received from Loans to subsidiaries (note 5) 	(638) 	(583)
– accrued 	(836) 	(676)
– received 	198 	93
Interest received from Loans to BEE partners (note 6) 	6 	(3)
– accrued 	(15) 	(9)
– received 	21 	6
231 	102
20. 	FINANCIAL GUARANTEE CONTRACTS
R million
Company
2023
Company
2022
Discovery Limited has provided guarantees for the following subsidiaries:
Discovery Finance Company Europe Limited 	i 	– 	3
Discovery Central Services Proprietary Limited 	ii 	12 	16
Discovery Holdings Europe Limited 	iii 	– 	5
Discovery Bank Limited 	iv 	– 	1
Total 	12 	25
i 	Discovery Limited has issued guarantees for 2 facilities in respect of the obligations of Discovery Finance Company Europe
Limited for the amounts of GBP80 million and GBP34 million. Both these facilities were repaid during the current financial year.
In December 2022, a new facility of GBP56 million was entered into and Discovery Limited has guaranteed this loan.
As at 30 June 2023, Discovery Finance Company Europe Limited owed GBP54 million (2022: GBP56 million) in respect of these
borrowing facilities.
ii Discovery Limited has guaranteed the following borrowing facilities of Discovery Central Services Proprietary Limited:
– R650 million facility to fund the systems build of Discovery Bank. The full amount has been drawn down and the balance
outstanding at 30 June 2023 is R445 million (2022: R494 million).
– a 5-year borrowing facility for an amount of R1.4 billion. These funds were acquired for general corporate purposes and
the full amount has been drawn down and the balance outstanding at 30 June 2023 is R1 408 million (2022: R1 417 million).
– a R1.5 billion Financial Credit Facility. The balance outstanding at 30 June 2023 is R151 million (2022: Rnil).
– a R691 million facility and the full amount has been drawn down. The balance outstanding at 30 June 2023 is R694 million
(2022: R691 million).
– a R750 million facility, undrawn at 30 June 2023. This facility expired subsequent to year end on 31 July 2023 and was
renewed for a further 12 months to 31 July 2024.
iii During 2020, Discovery Holdings Europe Limited entered into borrowing facilities for an amount of GBP100 million to fund its
operations. In December 2022, GBP25 million was refinanced. This facility has been guaranteed by Discovery Limited.
iv In the prior year, Discovery Limited issued a guarantee for a facility in respect of the obligations of Discovery Bank Limited for the
amount of R300 million. This facility was settled during the current financial year.
21. 	EVENTS AFTER REPORTING DATE
Refer to Group note 44 for a list of the events after reporting date.
Notes to the Company annual financial statements continued
for the year ended 30 June 2023

-- 147 of 217 --

DISCOVERY
ANNEXURES

-- 148 of 217 --

148	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure A – Group structure
for the year ended 30 June 2023
Discovery is directly and indirectly the holding company of:
Audited information 	Classification
Percentage
Holding
at 30 June
2023 	Country
Discovery Limited which holds the interest in:
Cogence Proprietary Limited 	Subsidiary 	100% 	South Africa
Discovery Bank Holdings Limited which holds the interest in: 	Subsidiary 	100% 	South Africa
– Discovery Bank Limited 	Subsidiary 	100% 	South Africa
Discovery Central Services Proprietary Limited which holds the interest in: 	Subsidiary 	100% 	South Africa
– Glucode Proprietary Limited 	Associate 	25% 	South Africa
Discovery Connect Distribution Services Proprietary Limited 	Subsidiary 	100% 	South Africa
Discovery Finance Company Europe Limited 	Subsidiary 	100% 	United Kingdom
Discovery Group Europe Limited which holds the interest in: 	Subsidiary 	100% 	United Kingdom
– Discovery Holdings Europe Limited which holds the interest in: 	Subsidiary 	100% 	United Kingdom
○ Better Health Insurance Advice Limited 	Subsidiary 	100% 	United Kingdom
○ Healthcode Limited 	Associate 	20% 	United Kingdom
○ Vitality Corporate Services Limited which holds an interest in: 	Subsidiary 	100% 	United Kingdom
– Healthcare Purchasing Alliance Limited 	Joint venture 	50% 	United Kingdom
– Vitality Healthy Workplace Limited 	Subsidiary 	100% 	United Kingdom
○ Vitality Invest Trustee Company Limited 	Subsidiary 	100% 	United Kingdom
○ Vitality Life Limited which holds the interest in: 	Subsidiary 	100% 	United Kingdom
– Vitality Health Insurance Limited which holds the interest in: 	Subsidiary 	100% 	United Kingdom
○ Vitality Health Limited 	Subsidiary 	100% 	United Kingdom
– Discovery Offshore Holdings No.2 Limited 	Subsidiary 	100% 	United Kingdom
Discovery Health Proprietary Limited , which holds the interest in: 	Subsidiary 	100% 	South Africa
– Discovery Administration Services Proprietary Limited 	Subsidiary 	100% 	South Africa
– Discovery Third Party Recovery Services Proprietary Limited 	Subsidiary 	100% 	South Africa
– Discovery Healthcare Service Proprietary Limited which holds the
interest in: 	Subsidiary 	100% 	South Africa
○ Discovery Medical Suppliers Proprietary Limited 	Subsidiary 	100% 	South Africa
○ Grove Nursing Services Proprietary Limited 	Subsidiary 	100% 	South Africa
○ Southern Rx Distributors Proprietary Limited 	Subsidiary 	100% 	South Africa
– Medical Services Organisation International Proprietary Limited which
holds an interest in: 	Subsidiary 	70% 	South Africa
○ Mediguide Africa Proprietary Limited 	Associate 	25% 	South Africa
○ Medical Services Organisation Proprietary Limited 	Subsidiary 	51% 	Swaziland
– Medical Services Organisation International Limited which holds an
interest in: 	Subsidiary 	70% 	Isle of Man
○ Medical Services Organisation S.A (previously Global Access Health
Network SARL)
Subsidiary 	80%
Democratic Republic of Congo
○ MSOI Health Risk Managers Limited 	Subsidiary 	85% 	Nigeria
– Quantium Health SA Proprietary Limited 	Joint venture 	50% 	South Africa
– Nanolabs Health Solutions Proprietary Limited 	Subsidiary 	52% 	South Africa
Discovery Insure Limited which holds an interest in: 	Subsidiary 	100% 	South Africa
– Discovery Telematics Services Proprietary Limited which holds an
interest in: 	Subsidiary 	100% 	South Africa
○ Bi-Me Proprietary Limited 	Associate 	33% 	South Africa
○ ZeroG Network Proprietary Limited 	Associate 	19% 	South Africa
Discovery Life Limited 	Subsidiary 	100% 	South Africa
Discovery Life Collective Investments Proprietary Limited 	Subsidiary 	100% 	South Africa
Discovery Life Investment Services Proprietary Limited which holds an interest in: 	Subsidiary 	100% 	South Africa
– Discovery Life Nominees Proprietary Limited 	Subsidiary 	100% 	South Africa
Discovery Mauritius Asset Management which holds an interest in: 	Subsidiary 	100% 	Mauritius
– Discovery International Collective Investments PLC 	Subsidiary 	100% 	Mauritius
Discovery Partner Markets Asia Private Limited which holds an interest in: 	Subsidiary 	100% 	Singapore
– Discovery Partner Market Services Private Limited which holds an
interest in: 	Subsidiary 	100% 	Singapore
○ Vitality (Shangai) Business Consulting Services Company Limited 	Subsidiary 	100% 	China
Discovery Vitality Proprietary Limited 	Subsidiary 	100% 	South Africa
Ping An Health Insurance Company of China Limited 	Associate 	25% 	China
Vitality Group International Incorporated which holds an interest in: 	Subsidiary 	100% 	United States
– AIA Vitality (Hong Kong) Limited 	Joint venture 	44% 	Hong Kong
– Amplify Health Asia Private Limited 	Associate 	25% 	Singapore
– Cambridge Mobile Telematics Incorporated 	Associate 	9% 	United States
– Discovery Vitality Australia Proprietary Limited which holds an interest in: 	Subsidiary 	100% 	Australia
○ Quantium Health Proprietary Limited which holds an interest in: 	Joint venture 	50% 	Australia
– Health Outcomes Australia Proprietary Limited 	Joint venture 	100% 	Australia
– Quantium Health Hong Kong Proprietary Limited 	Joint venture 	100% 	Hong Kong
○ Quantium Health Limited UK 	Joint venture 	50% 	United Kingdom
– The Vitality Group Incorporated which holds an interest in: 	Subsidiary 	100% 	United States
○ The Vitality Group Limited Liability Company 	Subsidiary 	100% 	United States
– Vitality International Health Insurance Company Limited 	Subsidiary 	100% 	Isle of Man
– Vitality Management Company Limited Liability Company 	Subsidiary 	100% 	United States
Vitality Green Proprietary Limited was registered in South Africa in 2023. No shares have been issued yet.

-- 149 of 217 --

149	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure A – Group structure continued
for the year ended 30 June 2023
In addition to the above subsidiaries, Discovery consolidates unit trusts which are deemed to be under the Group’s control in terms
of IFRS 10 Consolidated Financial Statements. The consolidated unit trusts include:
Discovery Aggressive Dynamic Asset Optimiser Fund of Funds
Discovery Balanced Fund
Discovery Cautious Balanced Fund
Discovery Conservative Dynamic Asset Optimiser Fund of Funds
Discovery Diversified Income Fund
Discovery Equity Fund
Discovery Flexible Property Fund
Discovery Global Equity Feeder Fund
Discovery Global Real Estate Securities Feeder Fund
Discovery Global Value Equity Feeder Fund
Discovery Moderate Balanced Fund
Discovery Moderate Dynamic Asset Optimiser Fund of Funds
Discovery Money Market Fund
Discovery Target Retirement 2015 Fund
Discovery Target Retirement 2020 Fund
Discovery Target Retirement 2025 Fund
Discovery Target Retirement 2030 Fund
Discovery Target Retirement 2035 Fund
Discovery Target Retirement 2040 Fund
Discovery Target Retirement 2045 Fund
Discovery Target Retirement 2050 Fund
Discovery Target Retirement 2055 Fund
Discovery Target Retirement 2060 Fund
Discovery Global Multi Asset Fund (previously named
Discovery Worldwide Best Ideas Fund)
Discovery Strategic Bond Fund
Discovery Global Conservative Fund (Mauritius)
Discovery Global Moderate Fund (Mauritius)
Discovery Global Growth Portfolio Fund (Mauritius)

-- 150 of 217 --

150	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies
for the year ended 30 June 2023
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The principal accounting policies applied in the preparation of these consolidated and separate financial statements are set out below. These
policies have been consistently applied to all the years presented. Other interpretations, amendments and annual improvements effective for
the first time in the current year have been considered and have no impact on the current reporting period.
1. 	Basis of presentation
The consolidated and separate Annual Financial Statements have been prepared in accordance with IFRS Accounting
Standards, IFRIC Interpretations, the South African Institute of Chartered Accountants (SAICA), Financial Reporting Guides as issued
by the Accounting Practices Committee, the JSE Limited Listings and Debt Listings Requirements as well as the South African
Companies Act. They have been prepared in accordance with the going concern principle using the historical cost basis except
where otherwise stated in the accounting policies below.
The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also
requires management to exercise its judgement in the process of applying Discovery’s accounting policies. The areas involving a
higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial
statements, are outlined in Group note 4 to the Annual Financial Statements.
All monetary information and figures presented in these financial statements are stated in millions of Rand (R million), unless
otherwise indicated.
New standards and amendments which became effective during the financial year
Discovery has elected to early adopt the requirements of IFRS 9 general hedge accounting. Refer to accounting policy 10 Derivative
financial instruments. There were no other new standards, amendments, and interpretations which became effective during the
year that had a material impact on recognised amounts.
New standards and amendments to published standards not yet effective
 Discovery has not early adopted any accounting standards, amendments or annual improvements issued but not yet effective.
 The accounting standards, amendments and annual improvements described below are those that are expected to have an
impact on Discovery’s results and/or disclosures. Accounting standards, amendments and annual improvements not mentioned
below are not expected to have a significant impact on recognised amounts.
 For IFRS 17, please refer to accounting policy note 30.
2. 	Consolidation
The consolidated financial statements include the assets, liabilities and results of the operations of the holding company and its
subsidiaries, joint ventures and associates.
2.1 	Business combinations
The acquisition method of accounting is used to account for business combinations by the Group. The consideration transferred for
the acquisition of a business is the fair values of the assets transferred, the liabilities incurred and the equity interests issued by the
Group. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration
arrangement. Acquisition-related costs are expensed as incurred.
Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their
fair values at the acquisition date. On an acquisition-by-acquisition basis, Discovery recognises any non-controlling interest in the
acquiree either at fair value or at the non-controlling interest’s proportionate share of the acquiree’s net assets. The excess of the
consideration transferred, being the amount of any non-controlling interest in the acquiree and the acquisition-date fair value of
any previous equity interest in the acquiree over the fair value of the identifiable net assets acquired, is recorded as goodwill. If this
is less than the fair value of the net assets of the subsidiary acquired in the case of a bargain purchase, the difference is recognised
directly in profit or loss.

-- 151 of 217 --

151	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
2. 	Consolidation continued
2.2 	Consolidation of entities in which the Group holds less than 50%
Discovery analysed its relationships with the Discovery Unit Trusts and has determined that it has significant power to direct the
relevant activities of the funds, has sufficient exposure to the variable returns of the funds and has the ability to use its power over
the investee to affect its returns. This analysis concluded that Discovery has control of the Discovery Unit Trusts even if the economic
interest is less than 50% and is therefore required to consolidate these funds.
Discovery controls these unit trusts as it has the right to the variable returns in the form of fund management fees that it receives
from its involvement with the funds. Furthermore, Discovery exercises control over these unit trusts through the setting of the
mandates as well as the appointment of the independent trustees. Discovery can, within the regulatory framework, also amend the
mandates and change the independent trustees.
Of the 27 (2022: 27) Discovery Unit Trusts consolidated at 30 June 2023, Discovery holds less than a 50% economic interest in 1
(2022: 1) of these funds. Refer to Annexure A for a list of consolidated unit trustees.
2.3 	Subsidiaries
Subsidiaries are all entities (including structured entities) over which Discovery has control. Discovery controls an entity when it has
power over the investee, is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to
affect those returns through its power over the entity. Subsidiaries are fully consolidated from the date on which control is
transferred to Discovery. Consolidation is discontinued from the date on which control ceases.
Intra-group transactions, balances and unrealised gains or losses on intra-group transactions are eliminated. Subsidiaries’ accounting
policies have been changed where necessary to ensure consistency with the policies adopted by Discovery. Intra-group foreign
exchange gains or losses arising on intra-group balances do not eliminate.
2.4 	Associates and joint arrangements
ASSOCIATES AND JOINT VENTURES
Associates are entities over which Discovery has the ability to exercise significant influence but not control over the financial and
operational policies. Significant influence is determined based primarily on the percentage of voting rights, generally between 20%
and 50%, together with other factors such as board participation and participation in the policy-making process. In certain instances,
Discovery holds less than 20% equity interests, but holds rights that still give it significant influence. These rights include activities
such as board representation and material transactions. These are equity accounted.
A joint venture is a joint arrangement whereby the parties have joint control of an arrangement and have rights to the net assets of
the arrangement.
Discovery recognises its interest in an associate or a joint venture as an investment and accounts for that investment using the equity
method. Under the equity method, on initial recognition, the investment in an associate or a joint venture is recognised at cost. The
carrying amount is adjusted to recognise Discovery’s share of the post-acquisition profit or loss of the investee and is recognised in
profit or loss. Distributions received from an investee reduce the carrying amount of the investment. Dividends received from the
investee are presented as part of investing activities in the Statement of cash flows. Adjustments to the carrying amount may also be
necessary for changes in Discovery’s proportionate interest in the investee arising from changes in the investee’s other comprehensive
income. Such changes include those arising from foreign exchange translation differences. Discovery’s share of those changes is
recognised in other comprehensive income. Discovery will discontinue the use of the equity method from the date when its investment
ceases to be an associate or a joint venture.
Discovery discontinues equity accounting when the carrying amount of the investment in an associate or a joint venture reaches
zero, unless it has incurred obligations, guaranteed obligations or made payments on behalf of the associate or the joint venture.
Discovery resumes equity accounting only after its share of the profits equals the share of losses not recognised. Discovery
increases the carrying amount of investments with its share of the associate’s or joint venture’s income when equity accounting
is resumed.
Discovery’s investment in an associate or a joint venture includes goodwill identified on acquisition. Discovery assesses at each
reporting date whether there is objective evidence that an associate or a joint venture is impaired. If such evidence of impairment
exists, Discovery calculates the amount of impairment as the difference between the recoverable amount of the investment and its
carrying value.
Unrealised gains or losses on transactions between Discovery and its associates or joint ventures are eliminated to the extent of the
Group’s interest in these entities unless the transaction provides evidence of an impairment of the asset transferred. Accounting
policies of associates and joint ventures have been changed where necessary to ensure consistency with the policies adopted by
the Group. The carrying amounts of the equity-accounted investments are tested for impairment.
Annexure B – Group accounting policies continued
for the year ended 30 June 2023

-- 152 of 217 --

152	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
2. 	CONSOLIDATION continued
FINANCIAL GUARANTEE CONTRACTS (FGCs) ISSUED OVER THE DEBT OF AN EQUITY ACCOUNTED INVESTMENT
Discovery accounts for financial guarantee contracts (FGCs) under IFRS 9 Financial Instruments (IFRS 9) when Discovery becomes a
party to the contract.
FGCs are contracts which require Discovery, as the issuer of the contract, to make specified payments to reimburse the holder for
a loss that the holder incurs because the specified debtor fails to make payment when it is due under the original or modified terms
of the debt instrument. Discovery may issue FGCs over the debt of an equity accounted investment. Discovery measures the FGC:
 Initially at fair value, and
 Subsequently, at the higher of:
– The amount of expected credit losses determined under IFRS 9 (calculation 1), and
– The amount initially recognised less, when appropriate, the cumulative amount of income recognised under the principles
of IFRS 15 Revenue from Contracts with Customers (calculation 2).
In instances where Discovery issues FGCs over the debt of a related entity that is equity accounted in accordance with the provisions
of IAS 28 Investments in Associates and Joint Ventures, Discovery determines the fair value of the FGCs. These FGCs issued over the
debt of an associate entity are seen as transactions in the capacity as shareholder and are treated as capital contributions.
In some instances, the other associate entity can also pay a premium to the issuer of the FGCs. Discovery then determines if the
price represents the fair value or whether there is still an additional cost of the FGC that Discovery should recognise.
In the instance where Discovery does not receive all the premiums upfront, it recognises the FGC using a net approach. The net
approach requires that Discovery presents the financial guarantee as its fair value less all future premiums.
Discovery subsequently recognises financial guarantee fee income as follows:
 Amortises the fair value recognised on initial recognition over the period that the FGC is outstanding, being generally the period
of the underlying debt.
 Recognises any premiums received for issuing the FGC as financial guarantee fee income, and
 Where Discovery has applied the net approach, Discovery adjusts for the premiums subsequently received to ensure it takes
into account all premiums in using calculation 2.
Discovery calculates the lifetime expected credit losses for purposes of calculation 1.
Where the outcome is such that calculation 1 is more than calculation 2, differences are recognised and presented as part of
expected credit losses.
Where the outcome is such that calculation 2 is more than calculation 1, no adjustments are required. Any previously recognised
expected credit losses can be reversed but limited to the total value previously recognised.
Discovery derecognises FGCs when the FGC is extinguished, expires, or the underlying debt is extinguished.
At the date of derecognition:
 Where the FGC is extinguished in exchange for a new FGC to the same holder and in respect of the same guaranteed entity, the
FGC derecognised is seen as compensation for the new FGC, or
 In all other instances, the FGC is derecognised with an associated gain or loss in profit or loss.

-- 153 of 217 --

153	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
2. 	Consolidation continued
2.4 	Associates and joint arrangements continued
ASSOCIATES AND JOINT VENTURES continued
A decrease in interest while an investment continues to be classified as an associate can also result from a dilution. The gain or loss
on the dilution of an equity-accounted investee is calculated as the difference between:
 the entity’s ownership interest in the new assets received by the investee for the subscription of the new shares (e.g. the cash
paid by the other party); and
 the reduction in ownership interest in the previous carrying amount
JOINT OPERATIONS
A joint operation is a joint arrangement whereby the parties have joint control of an arrangement and rights to the assets and
obligations for the liabilities relating to the arrangement.
Discovery recognises its share of those assets, liabilities, revenues and expenses that the operators incur jointly.
3. 	Foreign currency translation
3.1 	Functional and presentation currency
Items included in the financial statements of each of Discovery’s entities are measured using the currency of the primary economic
environment in which the entity operates (the functional currency). The consolidated financial statements are presented in Rand,
which is the presentation currency of Discovery Limited.
3.2 	Transactions and balances
Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the
transactions. Foreign exchange gains and losses resulting from:
 The settlement of trading transactions is included in the results of operating activities in profit or loss,
 The settlement of financing transactions and the translation at year-end exchange rates of assets and liabilities denominated
in foreign currencies are recognised in profit or loss as foreign exchange gains and losses, and
 Qualifying cash flow hedges are deferred in the Statement of other comprehensive income and are recycled to profit or loss
in the periods in which the hedged item affects profit or loss.
3.3 	Group companies
The results and financial position of all Discovery entities (none of which has the currency of a hyperinflationary economy) that have
a functional currency different from the presentation currency are translated into the presentation currency as follows:
 Assets and liabilities for each Statement of financial position presented are translated at the closing rate at the date of that
statement of financial position.
 Income and expenses for each Income statement are translated at average exchange rates (unless this average is not a
reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and
expenses are translated at rates at the date of the transactions); and
 All resulting exchange differences are recognised as a separate component of equity, namely the foreign currency
translation reserve.
On consolidation, exchange differences arising from the translation of the net investment in foreign entities are recognised in the
foreign currency translation reserve in the Statement of other comprehensive income. When a foreign operation is partially
disposed of or sold, such exchange differences are recognised in profit or loss as part of the gain or loss on sale. Goodwill and fair
value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and
translated at the closing rate.

-- 154 of 217 --

154	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
4. 	Property and equipment
Items of property and equipment are measured at cost, which includes capitalised borrowing costs, less accumulated depreciation
and any accumulated impairment losses.
Subsequent costs are included in the asset’s carrying amount or recognised as a separate asset, as appropriate, only when it is
probable that future economic benefits associated with the item will flow to Discovery and the cost of the item can be measured
reliably. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.
If significant parts of an item of property and equipment have different useful lives, then they are accounted for as separate items
(major components) of property and equipment. Property and equipment are depreciated using the straight-line method to allocate
their cost to their residual values over their estimated useful lives, as follows:
Owner occupied property 	40 years
Leasehold improvements 	Shorter of estimated life or period of lease
Leased asset 	3 – 15 years
Computer equipment 	3 – 7 years
Furniture, fittings and building fit out 	5 – 15 years
Motor vehicles 	4 years
Telematics devices 	2 – 5 years
The assets’ residual values and useful lives are reviewed at each reporting period and adjusted if appropriate. An asset’s carrying
amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated
recoverable amount. The recoverable amount is the higher of the asset’s fair value less costs to sell and value-in-use.
Gains or losses on disposals are determined by comparing the proceeds with the carrying amount. These are recorded in profit
or loss.
5. 	Intangible assets
5.1 	Computer software development costs
Items of computer software development costs are measured at cost, less accumulated amortisation and any accumulated
impairment losses.
Costs associated with maintaining computer software programmes are recognised as an expense as incurred. Development costs
that are directly attributable to the design and testing of identifiable software products controlled by Discovery are recognised as
intangible assets when the following criteria are met:
 It is technically feasible to complete the software product so that it will be available for use.
 Management intends to complete the software product and use or sell it.
 There is an ability to use or sell the software product.
 It can be demonstrated how the software product will generate probable future economic benefits.
 Adequate technical, financial and other resources to complete the development and to use or sell the software product are
available, and
 The expenditure attributable to the software product during its development can be reliably measured.
Directly attributable costs that are capitalised as part of the software product include the software development employee costs
and an appropriate portion of directly attributable overheads. For cloud computing arrangements, implementation costs that do
not meet the requirements to be capitalised as an asset are expensed as incurred.
Other development expenditures that do not meet these criteria are recognised as an expense as incurred. Development costs
previously recognised as an expense are not recognised as an asset in a subsequent period.
Computer software development costs are recognised as assets from the point where the recognition criteria above are satisfied and
are amortised once the asset is ready for use over their useful lives. The amortisation is reflected under marketing and administration
expenses in profit or loss.
If significant parts of computer software development costs have different useful lives, then they are accounted for as separate
items (major components) of computer software development costs. Computer software development costs recognised as assets
are amortised over their useful lives.
Software applications 	3 – 7 years
Core Systems 	16 years (2022: 15 years)
An intangible asset is derecognised:
 On disposal, or
 When no future economic benefits are expected from its use or disposal.
The gain or loss arising from the derecognition of an intangible asset is determined as the difference between the net disposal
proceeds, if any, and the carrying amount of the asset. Discovery recognises such gains or losses in profit or loss when the
intangible asset is derecognised.

-- 155 of 217 --

155	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
5. 	Intangible assets continued
5.2 	Other intangible assets
Discovery does not recognise costs incurred to internally develop trademarks, patents and similar rights and assets, including
franchises and management contracts. These costs are recognised in profit or loss in the period in which they are incurred.
Purchased intangible assets, which represent rights to receive future profits, are capitalised at their fair values, represented by the
estimated net present value of future cash flows relating to existing business, or at a value as determined by an independent valuer.
These intangible assets are amortised into profit or loss as profits are expected to emerge and are only tested for impairment if an
indication of impairment arises.
Intangible assets acquired as part of business combinations are capitalised at their fair value, represented by the estimated net
present value of future cash flows relating to existing business, or at a value as determined by an independent valuer. These
intangible assets are amortised over their useful lives and only tested for impairment if an indication of impairment arises.
6. 	Deferred acquisition costs
The direct costs of acquiring new business, which are expected to be recovered out of future revenue margins, are deferred over the
period in which the related performance obligations are satisfied and recognised as an asset in the Statement of financial position. The
accounting policies relating specifically to deferred acquisition costs for insurance contracts are detailed in accounting policies 13.
7. 	Goodwill
Goodwill arises on the acquisition of businesses and represents the excess of the consideration transferred, the amount of any
non-controlling interest in the acquiree and the acquisition-date fair value of any previous equity interest in the acquiree over the
fair value of the identifiable net assets acquired.
Goodwill is reviewed for impairment annually or more frequently if events or changes in circumstances indicate a potential
impairment. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash
generating units (CGUs) or groups of CGUs that are expected to benefit from the synergies of the combination. Each unit or group
of units to which the goodwill is allocated represents the lowest level within the entity at which the goodwill is monitored for internal
management purposes. Goodwill is monitored at the operating segment level.
The carrying value of the CGU containing the goodwill is compared to the recoverable amount, which is the higher of value-in-use
and the fair value less costs to sell. Any impairment is recognised immediately as an expense and is not subsequently reversed.
8. 	Impairment of non-financial assets
Goodwill is tested annually for impairment or more frequently if events or changes in circumstances indicate that goodwill may be
impaired.
Other assets, including equity-accounted investments, intangible assets and costs of obtaining contracts other than those relating
to insurance contracts (see accounting policy 13), are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount may not be recoverable. Such indicators include continued losses, changes in technology, market,
economic, legal and operating environments.
An impairment loss is recognised for the amount by which the asset’s carrying amount exceeds its recoverable amount. The
recoverable amount is measured using the higher of the fair value less costs to sell and the value-in-use. Value-in-use is the present
value of projected cash flows covering the remaining useful life of the asset. An impairment loss is recognised in profit or loss
immediately.
Other assets, other than goodwill, that suffered an impairment are reviewed for possible reversal of the impairment at the end of
each reporting period.
9. 	Financial instruments
Discovery initially recognises financial instruments when it becomes a party to the contract.
Financial instruments are measured at initial recognition at fair value net of directly attributable transaction costs, unless the
financial instrument is classified as fair value through profit or loss. For instruments classified at fair value through profit or loss
attributable transaction costs are immediately expensed.

-- 156 of 217 --

156	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
9. 	Financial instruments continued
9.1 	Financial assets
9.1.1 	RECOGNITION, CLASSIFICATION, MEASUREMENT AND DERECOGNITION
At initial recognition, the Group considers the appropriate classification as at Amortised cost (AC), Fair value through profit or loss
(FVTPL) or Fair value through other comprehensive income (FVOCI) for debt instruments. Discovery considers:
 Whether the contractual cash flows of the financial asset are solely payments of principal and interest (SPPI). Such contractual
cash flows are consistent with a basic lending arrangement and compensate Discovery for the elements of time value of money,
credit risk and other basic lending risks and a profit margin. Examples of such instruments include Treasury Bills, Government
Bonds, cash and fixed-term deposits. It excludes instruments such as equity-linked financial assets or puttable investments in
unit trusts, and
 The business model for holding the financial assets.
Based on the criteria above, Discovery will classify a debt instrument as:
 Amortised cost, if the financial asset meets the SPPI criterion and is held for the purpose to collect the contractual cash flows.
Examples of this include loans and advances to customers (e.g. credit card advances) and fixed-term deposits;
 Fair value with changes in other comprehensive income (debt instruments), if the financial asset meets the SPPI criterion and is
held either to collect contractual cash flows or for sale. Discovery currently does not hold financial assets in this category.
However, specified associates do have certain of their debt instruments in the category.
 Fair value through profit or loss, for all other financial assets that do not meet the criteria above (mandatorily). In addition,
Discovery can irrevocably designate financial assets into this category if this will reduce measurement inconsistencies (i.e.
’accounting mismatch’) (designated). Discovery’s business includes, amongst others, providing unit-linked insurance, unit-linked
investment and non-linked insurance products to customers. Financial assets and liabilities in these portfolios are managed to
achieve the objectives of the portfolio and to ensure that liabilities are appropriately matched with assets. In considering
whether the objective of a portfolio is to collect contractual cash flows or to trade in financial instruments, Discovery considers
the purpose for which instruments are held, the methods of risk management in a portfolio, the manner of performance
reporting on a portfolio and the basis for determining compensation to managers for asset performance. For those financial
assets backing insurance contracts, Discovery measures these financial assets at fair value through profit or loss. Unit-linked
investment contracts are also mandatorily classified at fair value through profit or loss.
For equity instruments Discovery is permitted to make the irrevocable election to present changes in fair value in other
comprehensive income. However cumulative gains or losses recognised cannot be reclassified to profit or loss on disposal. This
election is available on an instrument-by-instrument basis. This election has only been made in the accounting records of specified
associates. All other equity instruments are measured at FVTPL.
Subsequent measurement
Amortised cost (AC) 	These instruments are measured at amortised cost using the effective interest
method. Movements in the balance of the instrument relate to expected credit
losses, interest income and foreign exchange gains and losses, which are
recognised on profit or loss.
Fair value through
profit or loss (FVTPL)
These instruments are measured at fair value with gains and losses recognised
in profit or loss. Movements in this balance are due to fair value gains or losses,
interest or dividends, and foreign exchange gains or losses. Dividends are
recognised in profit or loss.
Fair value through other
comprehensive income (FVOCI) – equity
These instruments are measured at fair value with gains and losses recognised
in other comprehensive income. On derecognition, gains and losses accumulated
in OCI are not reclassified to profit or loss. Dividends are recognised in profit
or loss.
Fair value through other
comprehensive income (FVOCI) – debt
These instruments are measured at fair value with changes in fair value
recognised in other comprehensive income. Discovery recognises interest using
effective interest method, movements in the balance related to expected credit
losses, interest income and foreign exchange gains and losses in profit or loss.
On derecognition, gains and losses accumulated in OCI are reclassified to
profit or loss.
There are no financial assets that have been designated at fair value through profit or loss.
The business model for managing a group of financial instruments is expected to remain stable. In rare instances where the
business model changes, there can be a reclassification of the business model. Any reclassifications are applied prospectively from
the first day of the first reporting period after the change in business model, with no restatement of any previously recognised gains,
losses or interest. Discovery has not had any changes in business models in the current reporting period and consequently there
have been no reclassifications.
Financial assets are derecognised when the rights to receive cash flows from them have expired or where they have been
transferred and Discovery has also transferred substantially all risks and rewards of ownership with no retention of control of the
financial asset.

-- 157 of 217 --

157	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
9. 	Financial instruments continued
9.1 	Financial assets continued
9.1.2 	EXPECTED CREDIT LOSSES
Expected credit losses are recognised on the following items:
 Debt instruments at amortised cost or fair value with changes in other comprehensive income (FVOCI), which includes treasury
bills, banking loans and advances and fixed deposits. This also includes loan commitment for undrawn credit facilities,
 Lease receivables
 Financial guarantee contracts
 Other receivables which are financial assets at amortised cost, and
 Contract receivables and contracts assets with non-insurance customers and cash and cash equivalents.
Discovery has a multitude of different debtors and loans included in other receivables as financial assets, which do not represent a
homogeneous group of assets. The approach to determining credit losses varies according to the asset type, past bad debt
experience and the potential to incorporate forward-looking information. In certain instances, financial assets have been grouped
based on shared characteristics (i.e. debt payment pattern similarities, financial instruments with collateral, debtor type) and
expected credit losses determined on a collective basis.
The general expected credit loss approach requires that Discovery assesses the credit risk of the instrument and determine whether
there has been a significant increase in credit risk since initial recognition.
 Where there has not been a significant increase in credit risk since initial recognition expected credit losses are measured as
the 12-month expected credit losses. These are referred to as Stage 1 financial assets.
 Where there has been a significant increase in credit risk, expected credit losses are recognised as the lifetime credit losses.
These are referred to as Stage 2 or Stage 3 financial assets.
Discovery measures expected credit losses on:
 Financial assets that are not credit-impaired after the reporting date: as the present value of all cash shortfalls (i.e. the difference
between the cash flows due to the entity in accordance with the contract and the cash flows that Discovery expects to receive)
 Financial assets that are credit-impaired at the reporting date: as the difference between the gross carrying amount and the
present value of estimated future cash flows, and
 Undrawn loan commitments: as the present value of the difference between the contractual cash flows that are due to Discovery if
the commitment is drawn down and the cash flows that Discovery expects to receive (adjusted using a credit conversion factor).
Discovery measures assets that are trade receivables, contract assets, and lease receivables using the simplified approach when
there is no significant financing component.
The simplified approach does not require Discovery to track the changes in credit risk, but instead requires it to recognise a loss
allowance based on lifetime expected credit loss at each reporting date.
Discovery does not recognise expected credit losses on Treasury Bills issued by the South African Reserve Bank as well as cash and
cash equivalents receivable on demand due to the assessment that it is immaterial.
SIGNIFICANT INCREASE IN CREDIT RISK
At each reporting date, Discovery assesses whether the credit risk on a financial asset has increased significantly since initial
recognition. When making the assessment, an entity uses the change in the risk of a default occurring over the expected life of the
financial instrument instead of the change in the amount of expected credit losses.
Qualitative 	Quantitative
 When contractual payments are more than 30 days past due,
the presumption is applied in conjunction with Discovery
Risk Grade (DRG).
 The eligibility rules used in the credit underwriting and
account management strategies are considered as triggers
of a significant increase in credit risk, since they provide a
view in terms of how the client performs on their other credit
facilities outside Discovery Bank. The rules comprise of a list
of statuses at the bureau such as: judgements, adverse,
deceased, and debt counselling statuses.
 Performing (up-to-date and current) accounts that have
shown deterioration with respect to Discovery Bank risk
grades will also be regarded as a significant increase in
credit risk.
Currently Discovery Bank is not considering the
quantitative triggers of a significant increase in credit risk
due to lack of origination data on the back book (i.e.
DiscoveryCard joint venture data). As the book in
Discovery Bank matures, it will be in a position to
perform the assessment.

-- 158 of 217 --

158	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
9. 	Financial instruments continued
9.1 	Financial assets continued
CREDIT IMPAIRED AND DEFAULT
Discovery considers a financial instrument to be credit-impaired where current circumstances and economic conditions indicate
that the expected future cash flows from a financial instrument may not be recoverable. These circumstances include but are not
limited to evidence of financial or operational challenges for the debtor and missed contractual payments.
Default is defined on a facility level and considers both quantitative and qualitative factors as provided in the Basel capital
framework. The qualitative criterion requires banks to identify credit deterioration before the exposure becomes delinquent
“unlikeliness to pay” events, while the quantitative criterion requires banks to look at the material delinquency status.
The following factors are what constitutes default from a qualitative and quantitative perspective, and it is in line with the
South African Reserve Bank definition.
Qualitative 	Quantitative
 The borrower is placed in debt counselling/debt review.
 The borrower is deceased.
 The facility has undergone a distressed restructure/special
arrangement.
 The facility has been transferred to charge-off/legal status.
 The client is under debt review.
 The client is insolvent, or
 The facility is written off.
A material amount on the facility is 90 days or more
in arrears, whereby material is set to avoid
technical defaults.
WRITE-OFF
Discovery Bank will reduce the gross carrying amount of a financial asset when it has no reasonable expectation of recovering a
financial asset in its entirety or a portion thereof. Currently the write-off point is based on time in default and is set as 12 months
in default. To ensure the appropriateness of the write-off point, the proposed write-off point will be assessed on an annual basis
and both time in default and recency of repayments will be considered.
Where Discovery has no reasonable expectation of recovery of a debt, the amount is written off. This is considered to occur when
all avenues of legal recourse to recover the debt have been unsuccessful.
9.2 	Financial liabilities
At initial recognition, the Group considers the appropriate classification as at Amortised costs (AC) or Fair value through profit or
loss (FVTPL).
Financial liabilities are measured at FVTPL if:
 It is held for trading, or
 The financial liabilities are part of a group of financial assets and financial liabilities, which are managed and performance
evaluated on a fair value basis. These include financial liabilities held within the portfolios of unit-linked insurance and unit-
linked investments.
All other financial liabilities in Discovery, which are in the scope of IFRS 9, are measured at amortised cost.
Qualitative 	Subsequent measurement
Amortised cost (AC) 	These instruments are measured at amortised cost using the effective interest method. Interest
and foreign exchange gains and losses are recognised in profit or loss.
Fair value through profit
or loss (FVTPL)
These instruments are measured at fair value with gains and losses and any interest recognised
in profit or loss.
Discovery has investment contracts which have financial risk and are consequently recognised and measured in terms of IFRS 9
rather than IFRS 4 Insurance Contracts. These contracts are classified at fair value through profit or loss. The policies are linked to
the return on underlying financial assets and are directly matched. The movement on Discovery’s own credit risk is considered
immaterial. The remaining financial liabilities are carried at amortised cost.
Financial liabilities are derecognised when the obligation is extinguished.

-- 159 of 217 --

159	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
9. 	Financial instruments continued
9.3 	Offset
Financial assets and liabilities are offset, and the net amount reported in the Statement of financial position when there is a legally
enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle
the liability simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the
normal course of business and in the event of default, insolvency or bankruptcy of Discovery or the counterparty.
9.4 	Modifications
Where an existing financial asset or liability is replaced by another with the same counterparty on substantially different terms, or
the terms of an existing financial asset or liability are substantially modified, such an exchange or modification is treated as a
derecognition of the original asset or liability and the recognition of a new asset or liability at fair value, including calculating a new
effective interest rate, with the difference in the respective carrying amounts being recognised in other gains and losses on financial
instruments within non-interest revenue. The date of recognition of a new asset is consequently considered to be the date of initial
recognition for impairment calculation purposes.
If the terms are not substantially different for financial assets or financial liabilities, the group recalculates the new gross carrying
amount by discounting the modified cash flows of the financial asset or financial liability using the original effective interest rate.
The difference between the new gross carrying amount and the original gross carrying amount is recognised as a modification gain
or loss within credit impairments (for distressed financial asset modifications) or in other gains and losses on financial instruments
within non-interest revenue (for all other modifications).
In assessing whether a financial asset was substantially modified, Discovery performs a qualitative assessment to determine if the
terms were substantially modified. In assessing whether a financial liability has been substantially modified, Discovery performs
both a qualitative and quantitative (10% threshold) assessment to determine if the terms were substantially modified. For discussion
on modifications as a result of the interbank offered rates (IBOR) reforms, refer to accounting policy 10.5.
10. 	Derivative financial instruments
Derivative financial instruments are classified as held for trading unless they are designated as effective hedging instruments.
Discovery initially recognises derivative financial instruments in the Statement of financial position at fair value on the date on which
a derivative contract is entered into (the best evidence of fair value on day one is the transaction price). Discovery subsequently
remeasures these instruments to fair value. The method of recognising the resulting fair value gain or loss depends on whether the
derivative is designated as a hedging instrument, and if so, the nature of the item being hedged. Fair values are obtained from
quoted prices in active markets, including recent market transactions, and valuation techniques, including discounted cash flow
models and options pricing models, as appropriate. All derivatives are carried as assets when the fair value is positive and as
liabilities when the fair value is negative.
10.1 	Hedge accounting
HEDGE ACCOUNTING PRIOR TO 1 JULY 2022
Discovery applied IAS 39 for its hedging relationships that met IAS 39 hedging accounting requirements for the financial year ended
30 June 2022 and prior periods.
Where Discovery held derivatives for risk management purposes, and the transactions met the IAS 39 required criteria for
documentation and hedge effectiveness, Discovery applied cash flow hedge accounting to the risks being hedged. Discovery
assessed on an ongoing basis whether the hedge(s) had been highly effective. A hedge under IAS 39 is regarded as highly effective
only when offsetting changes in fair value or cash flows attributable to the hedged risk during the period are within a range of
between 80% and 125%.
Discovery duly documented the following as required in IFRS under IAS 39 Financial Instruments: Recognition and Measurement for
hedge accounting purposes:
 Relationship between hedging instruments and hedged items
 Risk management objective and strategy for undertaking various hedge transactions, and
 Assessments, both at hedge inception and on an ongoing basis, of whether the derivatives that are used in hedging transactions
are expected to be and have been highly effective in offsetting changes in fair values or cash flows of hedged items.

-- 160 of 217 --

160	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
10. 	Derivative financial instruments continued
10.1 	Hedge accounting continued
HEDGE ACCOUNTING AFTER 1 JULY 2022
Discovery has elected to adopt and transition to IFRS 9 general hedge accounting prospectively from 1 July 2022. The revised general
hedge accounting requirements closer aligned with Discovery’s risk management activities. Discovery currently applies hedge
accounting to certain cash flow hedges of interest rate risk. The total hedge reserve remains unchanged on transition to IFRS 9
general hedge accounting. The impact on the Group financial results, disclosures or comparative information as a result of these
amendments is immaterial.
Under general hedge accounting, Discovery has ensured that derivatives that qualify for cash flow hedge accounting are those
derivatives designated as hedges of highly probable future cash flows attributable to a recognised asset or liability, or a forecasted
transaction. Discovery applies hedge accounting when the hedging relationship meets the following requirements:
 There is an economic relationship between the hedged item and the hedging instrument.
 The effect of credit risk does not dominate the value changes that result from that economic relationship, and
 The hedge ratio of the hedging relationship is the same as that resulting from the quantity of the hedged item that the entity
actually hedges and the quantity of the hedging instrument that the entity actually uses to hedge that quantity of hedged item.
Discovery documents at inception of the transaction, the relationship between hedged items and hedging instruments, as well as
its risk management objective and strategy for undertaking various hedging relationships. Discovery also documents its assessment,
both at the inception of the hedge and on an ongoing basis, of whether the derivatives that are used in hedging transactions are
expected to be and have been highly effective in offsetting changes in fair values or cash flows of hedged items. As of 1 July 2022,
the hedge documentation for all Discovery interest rate micro hedges has been updated to comply with the requirements of IFRS 9
general hedge accounting.
10.2 	Cash flow hedge
Discovery recognises the effective portion of fair value changes of derivatives that are designated as cash flow hedges in the cash
flow hedging reserve in the Statement of other comprehensive income. The gain or loss relating to the ineffective portion is
recognised immediately in profit or loss, within Net fair value gains on financial assets at fair value through profit or loss in the
Income statement.
Amounts accumulated in the Statement of other comprehensive income are recycled to profit or loss in the period in which the
hedged item will affect profit or loss. Where the forecast transaction or a foreign currency firm commitment results in the recognition
of a non-financial asset or liability, the gains and losses previously deferred are transferred from the Statement of other
comprehensive income and included in the initial measurement of the cost of the non-financial asset or liability. Where the forecast
transaction subsequently results in the recognition of a financial asset or liability, gains or losses deferred in equity are transferred
from the Statement of other comprehensive income to profit or loss when the financial asset or liability is sold or impaired.
When a hedging instrument expires or is sold, or when a hedge no longer meets the criteria for hedge accounting, any cumulative
gain or loss existing in equity at that time remains in equity and is recognised when the forecast transaction is ultimately recognised
in profit or loss. When a forecast transaction is no longer expected to occur, the cumulative gain or loss that was reported in equity
is immediately transferred to profit or loss.
10.3 	Derivatives that do not qualify for hedge accounting
Certain derivative instruments do not qualify for hedge accounting. Changes in the fair value of all such derivative instruments are
recognised immediately in profit or loss, within Net fair value gains on financial assets at fair value through profit or loss in the
Income statement.
10.4 	Hedging reserve
The hedging reserve includes the cash flow hedge reserve. The cash flow hedge reserve is used to recognise the effective portion
of gains or losses on derivatives that are designated and qualify as cash flow hedges. Amounts are subsequently recycled to profit
or loss as follows:
 For the effective portion recycled for hedges relating to share-based payments, as part of marketing and administration
expenses (staff costs), and
 For the effective portion recycled for hedges relating to interest rate risk, as part of finance costs.

-- 161 of 217 --

161	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
10. 	Derivative financial instruments continued
10.5 	Interbank offered rates (IBOR) reforms
A fundamental reform of major interest rate benchmarks is being undertaken globally, including the replacement of some IBORs
with alternative nearly risk-free rates (referred to as ’IBOR reform’). The Group has exposures to IBORs on its financial instruments,
which have been or will be replaced or reformed as part of these market-wide initiatives, such as Libor and Jibar.
The United Kingdom has seen a change from the GBP Libor to the Reformed Sterling Overnight Index Average (SONIA). The South
African Reserve Bank has indicated its intention to move away from Jibar and to create an alternative reference rate for South Africa.
However, there is currently no indication when the designated successor rate will be made available.
The IBOR reforms will generally result in changes in the basis for determining the contractual cash flows of financial assets and
financial liabilities, including derivatives.
For financial assets and liabilities measured at amortised cost, an entity will update the effective interest rate only if:
 The change is necessary as a direct consequence of reform, and
 The new basis for determining the contractual cash flows is economically equivalent to the previous basis.
For the purpose of cash flow hedges (see accounting policy 10.2), in determining whether a forecast transaction is highly probable,
an entity will assume that the interest rate benchmark on which the hedged cash flows are based is not altered as a result of IBOR
reforms. The Group anticipates that IBOR reform will impact some of its Jibar risk management and hedge accounting relationships
in the longer term. However, as noted, there is no indication of a designated successor rate for Jibar.
11. 	Cash and cash equivalents
Cash and cash equivalents comprise:
 Cash in hand
 Deposits held at call and short notice, and
 Balances with banks.
Cash and cash equivalents only include items held for the purpose of meeting short-term cash commitments rather than for
investing or other purposes. Cash and cash equivalents have a maturity of less than three months from the date of acquisition. Cash
and cash equivalents are carried at amortised cost (or in specified instances at fair value through profit or loss) which, due to their
short-term nature, approximates fair value.
Due to Discovery’s sweeping arrangements in force with various financial institutions, positive and negative cash balances are
presented on a net basis for the purpose of presenting cash and cash equivalents in the statement of cash flows.
12. 	Share capital
Shares are classified as equity when there is no contractual obligation to transfer cash or other financial assets to the holder.
Incremental costs directly related to the issue of new shares or options are shown in equity as a deduction from the proceeds, net
of tax.
Where any Group company purchases Discovery Limited equity share capital (treasury shares), the consideration paid, including any
directly attributable incremental costs (net of income taxes), is deducted from equity attributable to Discovery Limited equity
holders. Where such shares are subsequently sold, reissued or otherwise disposed of, any consideration received is included in
equity attributable to Discovery Limited equity holders, net of any directly attributable incremental transaction costs and the related
income tax effects.
13. 	Insurance contracts
Insurance contracts are those contracts that transfer significant insurance risk. Such contracts may also transfer financial risk.
Discovery defines significant insurance risk as the possibility of having to pay benefits, on the occurrence of an insured event, that
are significantly more than the benefits payable if the insured event did not occur.
Discovery developed its accounting policies for insurance contracts before the adoption of IFRS 4. As provided for in IFRS 4,
Discovery continues to apply these same accounting policies for the recognition and measurement of obligations arising from
insurance contracts that it issues and reinsurance contracts that it holds.

-- 162 of 217 --

162	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
13. 	Insurance contracts continued
13.1 	Recognition and measurement
Insurance contracts are classified into four main categories, depending on the duration of the risk and the type of risk insured.
13.1.1 INDIVIDUAL LIFE INSURANCE
These contracts insure against a comprehensive spectrum of risks, including life, disability, severe illness and income continuation
cover. These contracts are long term in nature.
VALUATION OF POLICYHOLDER LIABILITIES
The actuarial value of policyholder liabilities is determined based on a prospective discounted cash flow valuation basis calculated
as the difference between the present value of future benefit payments plus expenses and the present value of future premiums.
Best estimate assumptions regarding the future expected claims experience, premium income, expenses and commission are used.
Where the same policy includes both insurance and investment components and where the policy is classified as an insurance
policy, the liability for the insurance benefits and investment benefits are separately calculated. These components of the liability
are not unbundled for reporting purposes. (Refer to accounting policy 14 for the recognition and measurement of investment
benefit liabilities).
Where the value of policyholder liabilities is negative in aggregate, this is shown as Assets arising from insurance contracts.
Applying the valuation basis using the best estimate assumptions described above, would result in a gain at initial recognition.
Compulsory and discretionary margins are therefore added to the best estimate assumption to avoid the premature recognition of
future profits. At initial recognition, profits are recognised to the extent of the actual acquisition costs incurred but considering the
premium loadings available on the total portfolio to recoup acquisition costs.
Discretionary and compulsory margins are therefore added to the best estimate assumptions within the following framework.
 All margins are at least equal to the compulsory margins prescribed by regulations.
 For the discount rate and lapse rate margins, the direction of the margins may vary based on policy type and duration to ensure
that the margin is in the conservative direction, overall.
 Given the level of uncertainty in the best estimate assumptions for lapse, mortality and morbidity, margins are added to protect
against future possible adverse experience.
 Additional margins are added to allow for the release of profit over the term of the policy.
 Margins are released over the term of a policy in line with the risk borne.
 The best estimate assumptions and margins are reset at every valuation date to reflect the underlying profitability of the
portfolio. Changes to assumptions, models and benefits are therefore offset at the portfolio level through an increase in
discretionary margin (or release if sufficient discretionary margin exists). The impact of experience variances (with the exception
of lapse and mortality experience) on the end-of-period prospective liability recognised in respect of in-force policies is offset at
the portfolio level against an increase in discretionary margin (or release if sufficient discretionary margin exists). The impact of
experience variances on the in-period cash flows is accounted for in profit or loss for the period and not offset through changes
in discretionary margins.
 Where insurance contracts are backed by assets, other than negative reserves, changes in economic assumptions are recognised
directly in profit or loss.
 Discovery has established a procedure to utilise the available discretionary margin in a specified order. First, Discovery will
utilise available discretionary margins to absorb all experience items on in-force policies. This is after in-period experience
variances which are recognised immediately in profit or loss as noted above. Secondly, Discovery utilises available discretionary
margins to offset non-economic assumption variances, model, and benefit changes. Lastly, the discretionary margins are
utilised to offset economic assumption changes.
 Where there are insufficient discretionary margins to offset losses arising from negative changes in non-economic assumptions,
models and benefit and or negative changes in economic assumptions, those losses in excess of the discretionary margin are
recognised immediately in profit or loss; and
 In subsequent periods, positive changes in economic assumptions and positive variance in non-economic assumptions, models
and benefits are first recognised separately in profit or loss to extent that it reverses related losses previously recognised in
profit or loss. This is in the reversed sequence in which the negative variances were utilised against discretionary margin and
any excess previously recognised in profit or loss.

-- 163 of 217 --

163	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
13. 	Insurance contracts continued
13.1 	Recognition and measurement continued
13.1.1 INDIVIDUAL LIFE INSURANCE continued
Contractual premium and benefit increases are included in the valuation of the policyholder liability. It is further assumed that no
voluntary benefits are taken up where a future take-up of these benefits would reduce the liability. This is in line with South African
actuarial guidance which requires that expected profits in respect of future options that may be taken up by policyholders should
not be recognised in the policyholder liability.
The actuarial liabilities are calculated gross of reinsurance. The expected impact of reinsurance is valued separately.
The valuation basis meets the requirement of the liability adequacy test as required by IFRS 4 for individual life insurance and no
additional tests are performed.
The liability estimates are reviewed at every reporting period and any changes in estimates to the liability are reflected in profit or
loss as they occur.
PREMIUM REVENUE
For individual life insurance contracts, premiums are recognised as revenue when due. Premiums are shown net of premium
discounts received, premiums provided for as bad debts and before the deduction of commission. Premiums exclude taxes
and levies.
INSURANCE BENEFITS AND CLAIMS
Insurance benefits and claims relating to individual life insurance contracts are recognised in profit or loss based on the estimated
liability for benefits owed to the contract holders. Death, disability and severe illness and surrender claims are accounted for when
notified. These claims include claims reported but not yet validated. The estimate is determined taking into account the likelihood
of the claim being valid and the expected severity of the claim given that the claim is valid. The proportion to be included is
estimated separately for each benefit type. An estimate of the expected claim amount is charged to profit or loss and included in
liabilities under insurance contracts. Maturity and income disability are recorded as incurred. Liabilities are held to reflect incurred
but not yet reported (IBNR) claims. The IBNR liabilities are modified to reflect actual current operating conditions. The liabilities are
calculated gross of reinsurance. An asset is then raised to allow for the expected recoveries from reinsurers.
ACQUISITION COSTS
Acquisition costs for these contracts represent commission and other costs that relate to the securing of new contracts and the
renewing of existing contracts. The valuation basis for valuing insurance contracts makes implicit allowance for the deferral of
acquisition costs and, hence, no explicit deferred acquisition cost asset is recognised in the Statement of financial position. These
are expensed in profit or loss.
13.1.2 GROUP LIFE INSURANCE
These contracts insure against a comprehensive spectrum of protection benefits on a group basis. Life cover, severe illness,
disability and income continuation benefits are offered. These contracts are short term in nature.
PREMIUM REVENUE
For group life insurance contracts, premiums are recognised as revenue when due. Premiums are shown net of premiums provided
for as bad debts, before the deduction of commission and exclude taxes and levies.
INSURANCE BENEFITS AND CLAIMS
Insurance benefits and claims relating to group life insurance contracts are recognised in profit or loss based on the estimated
liability for benefits owed to the contract holder. Death, disability and severe illness claims are accounted for when notified. These
claims include claims reported but not yet validated. The estimate is determined taking into account the likelihood of the claim
being valid and the expected severity of the claim given that the claim is valid. The proportion to be included is estimated
separately for each benefit type. An estimate of the expected claim amount is charged to profit or loss and included in liabilities
under insurance contracts. Income disability is recorded as incurred. Liabilities are held to reflect IBNR claims. The IBNR is
modified to reflect actual current operating conditions. The liabilities are calculated gross of reinsurance. An asset is then raised
to allow for the expected recoveries from reinsurers.
ACQUISITION COSTS
Acquisition costs for group life insurance contracts comprise all direct costs arising from the sale of insurance contracts. Commission
expenses are expensed.

-- 164 of 217 --

164	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
13. 	Insurance contracts continued
13.1 	Recognition and measurement continued
13.1.3 HEALTH INSURANCE
These contracts insure policyholders against healthcare-related claims.
PREMIUM REVENUE
Health insurance premiums received in respect of annual contracts are recognised proportionally over the period of the coverage. The
portion of the premium received on in-force contracts that relates to unexpired risks at the reporting period is reported as unearned
premiums within Liabilities arising from insurance contracts. The unearned premium income is amortised on a straight- line basis.
INSURANCE BENEFITS AND CLAIMS
Benefits payable under health insurance contracts are accounted for as incurred. Liabilities are held to reflect IBNR claims. The IBNR
calculation is performed using the chain ladder approach. This allows for the historic patterns of claims payment in determining the
likely future emergence of claims. The IBNR is further modified to reflect current operational conditions or known events. The
liabilities are calculated gross of reinsurance. An asset is then raised to allow for the expected recovery from reinsurers.
DEFERRED ACQUISITION COSTS
The direct costs (commissions) of acquiring short-term health insurance business which are incurred during the year, but which are
expected to be recoverable out of future revenue margins, are deferred and disclosed as an asset in the Statement of financial
position (gross of tax). The costs are deferred over the period of the contract and amortised on a straight-line basis in line with
unearned premiums.
FINANCIAL REINSURANCE
Where a financial reinsurance contract is taken out to protect against lapses, all acquisition costs related to the policy are effectively
deferred over the period of the reinsurance contract.
13.1.4 SHORT-TERM INSURANCE
These contracts insure policyholders against a comprehensive spectrum of short-term risks including, but not limited to, motor
vehicle and household cover.
PREMIUM REVENUE
Short-term insurance premiums received in respect of contracts are recognised as revenue when due. Premiums are shown before
the deduction of commission, less the fuel cash back rewards described below, and exclude value-added tax.
UNEARNED PREMIUM PROVISION
An unearned premium provision (UPP) is created at the commencement of each insurance contract and is released as the risk
covered by the contract expires. The UPP represents a proportion of premiums underwritten in the current year, which relate to
risks which have not expired by the end of the financial year. This is calculated on a time-proportionate basis for even risks.
Therefore, the unearned premium is released over the period of insurance using a method which approximates the time period of
the risk covered. The unearned premium provision is calculated on a gross basis.
REINSURANCE COMMISSION INCOME
Reinsurance commission income is recognised in profit or loss over the period of the related direct insurance business assumed.
INSURANCE BENEFITS AND CLAIMS
Claims are accounted for as incurred and consist of claims paid, movement in the provision for outstanding claims and related
claims handling expenses.
The provision for outstanding claims is based on estimates of the cost of settling all claims incurred but unpaid at the reporting date,
whether reported or not. Related anticipated reinsurance recoveries are disclosed separately as assets in the Statement of financial
position and are included in recoveries from reinsurers in profit or loss.
SALVAGE AND SUBROGATION RECOVERIES
Certain short-term insurance contracts allow Discovery to sell property acquired as a result of a claim (salvage). Discovery may also
have the legal right to pursue third parties for payment of some or all of the costs (subrogation).
The estimated salvage and subrogation reimbursements are treated as a reduction in the measurement of claims liability.
ACQUISITION COSTS
Acquisition costs for these contracts comprise all direct costs arising from the sale of insurance contracts and are recognised in
profit or loss for monthly policies. For the remainder of the policies, the acquisitions costs are deferred and amortised over the term
of the contract.

-- 165 of 217 --

165	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
13. 	Insurance contracts continued
13.1 	Recognition and measurement continued
13.1.4 SHORT-TERM INSURANCE continued
INSURE FUNDER ACCOUNT (IFA)
This relates to a benefit on a short-term insurance product. A fuel cash back can be used to either reduce the premium that the
policyholder is required to pay for the month in question or can be doubled and paid into an IFA.
Where the policyholder has used the fuel cash back to reduce the monthly premium, the reduction has been shown in insurance
premium revenue in profit or loss as incurred.
If the policyholder has elected to double the fuel cash back and paid it into an IFA, an IFA liability is raised. The IFA liability is
calculated using a discounted cash flow approach and is disclosed in liabilities arising from insurance contracts in the Statement of
financial position, and the movement is disclosed in the transfer to liabilities under insurance contracts.
When the member uses funds in the IFA to pay for his excess or other costs, the excess is paid by Discovery, and an expense is
included in claims in the income statement.
Where the member withdraws the funds after three years, the member is paid out in cash, and an expense is disclosed against
insurance premium revenue in the income statement.
13.2 	Embedded derivatives arising from insurance contracts
A unit-linked insurance contract is an insurance contract with an embedded derivative linking payments on the contract to units of
an investment fund purchased with the consideration received from the contract holders. This embedded derivative meets the
definition of an insurance contract and is therefore not accounted for separately from the host insurance contract. The liability for
such contracts is adjusted for all changes in the fair value of the underlying assets.
Discovery does not separately measure embedded derivatives that meet the definition of an insurance contract or options to
surrender insurance contracts for a fixed amount (or amount based on a fixed amount and an interest rate). All other embedded
derivatives are separated and carried at fair value if they are not closely related to the host insurance contract and meet the
definition of a derivative. Embedded derivatives that are separated from the host contract are fair valued through profit or loss.
13.3 	Liability adequacy test
At the reporting date, liability adequacy tests are performed to ensure the adequacy of the contract liabilities net of related deferred
acquisition costs. In performing these tests, current best estimates of future contractual cash flows and claims handling and
administration expenses are used. Any deficiency is immediately charged to profit or loss initially by writing off deferred acquisition
costs and by subsequently establishing a provision for losses arising from the liability adequacy test.
13.4 	Reinsurance contracts
Contracts entered into by Discovery with reinsurers under which Discovery is compensated for insured events on one or more
contracts that meet the classification requirements for insurance contracts are classified as reinsurance contracts. Contracts that
do not meet these classification requirements are classified as financial assets.
Amounts recoverable from or due to reinsurers are measured consistently with the amounts associated with the reinsured
insurance contracts and in accordance with the terms of each reinsurance contract.
The amounts Discovery is required to pay under its reinsurance contracts held are recognised as reinsurance liabilities (liabilities
arising from reinsurance contracts).
Outward reinsurance premiums are recognised as an expense and are accounted for when due under the reinsurance contract. The
amounts due to Discovery under its reinsurance contracts are recognised as reinsurance assets (classified within insurance receivables).
Discovery assesses its reinsurance assets for impairment on an annual basis.
In certain cases there is a net gain or loss at inception of a reinsurance contract:
 Where these amounts relate directly to a reimbursement of expenses, the gain is disclosed as a recovery of expenses from
reinsurers, or
 Other gains or losses are amortised over the life of the reinsurance contract on a consistent basis as the profit is expected to
emerge on the underlying policies but considering the contractual terms and intent of the specific reinsurance contract.
A reinsurance asset is impaired if, and only if:
 there is objective evidence, as a result of an event that occurred after initial recognition of the reinsurance asset, that the cedant
may not receive all amounts due to it under the terms of the contract, and
 that event has a reliably measurable impact on the amounts that the cedant will receive from the reinsurer.
In certain cases there is a net gain or loss upon early termination of a reinsurance contract. Where these amounts result directly
from the termination, they are recognised as at the termination date and disclosed as recapture of reinsurance in profit or loss.

-- 166 of 217 --

166	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
13. 	Insurance contracts continued
13.5 	Receivables and payables related to insurance contracts
Receivables and payables are recognised when due. These include amounts due to and from agents, brokers and insurance contract
holders. Amounts due are measured consistently and where applicable, provisions for impairments are recognised.
13.6 	Derecognition of insurance contracts
An insurance liability, or a part of such a liability, can be removed from the statement of financial position (derecognised) when, and
only when, it lapses or is extinguished i.e., when the obligation specified in the contract is discharged, cancelled or expires.
14. 	Investment contracts
Investment contracts are those contracts that transfer financial risk without significant insurance risk. Financial risk refers to the risk
of a possible future change in the value of an asset or financial instrument due to a change in interest rate, commodity price, index
of prices, foreign exchange rate or other measurable variables.
Discovery issues investment contracts without fixed benefits (e.g. unit-linked and structured products) and investment contracts
with fixed and guaranteed benefits (e.g. term certain annuity).
Valuation of policyholder liabilities
Investment contracts without fixed benefits are financial liabilities whose fair value is dependent on the fair value of the underlying
financial assets and derivatives (unit-linked) which are classified at fair value through profit or loss. Discovery designates these
investment contracts to be measured at fair value through profit or loss because it eliminates or significantly reduces a measurement
or recognition inconsistency that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on
them on different bases. See accounting policy 9 for the accounting treatment of the financial assets backing these liabilities.
Discovery’s main valuation techniques incorporate all factors that market participants would consider and are based on observable
market data. The fair value of a unit-linked financial liability is determined using the current unit price that reflects the fair values of
the financial assets contained within Discovery’s unitised investment funds linked to the financial liability. The fair value of the
financial liabilities is obtained by multiplying the number of units attributed to each policyholder at the reporting date by the unit
price for the same date.
For investment contracts with fixed and guaranteed terms, valuation techniques are used to establish the fair value at inception and
at each reporting date. Valuation techniques include discounted cash flow analysis using current market rates of interest and
reference to other instruments that are substantially the same.
Premium revenue
All premiums received under investment contracts are recorded as deposits to investment contract liabilities and claims incurred
on investment contracts are recorded as deductions from investment contract liabilities.
Fees on investment contracts
Service fee income on investment management contracts is recognised over time as and when the related performance obligation is
satisfied. Refer to accounting policy note 20 Fees on investment contracts are included in fee income from administration business.
A deferred revenue liability (DRL) is recognised as a contract liability to contracts with customers in respect of upfront fees for
financial advice, investment management and other services which are directly attributable to a contract that is charged for securing
the investment management service contract. The DRL is then released to revenue when the performance obligations are satisfied,
which corresponds to the underlying expected profit signature of the contract.
Regular fees are charged to the customer monthly, either directly or by making a deduction from invested funds.
Costs of obtaining contracts
Deferred acquisition costs on investment contracts represent the contractual customer relationship and the right to receive future
investment management fees. Incremental costs directly attributable to securing rights to receive policy fees for services sold with
investment contracts are recognised as an asset where they can be identified separately and measured reliably and it is probable
that they will be recovered. An incremental cost is one that would not have been incurred if the Group had not secured the
investment contract.
The asset represents the Group’s contractual right to benefit from providing asset management services and is amortised over the
expected life of the contract as the entity recognises the related revenue.
15. 	Borrowings
Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently measured at
amortised cost. Any difference between the proceeds and the redemption value is recognised in profit or loss over the period of the
borrowings using the effective interest method.
Fees paid on the establishment of loan facilities are recognised as transaction costs against the loan to the extent that it is probable
that some or all of the facility will be drawn down. In this case, the fee is deferred until the draw-down occurs. To the extent there
is no evidence that it is probable that some or all of the facility will be drawn down, the fee is capitalised as a prepayment and
amortised over the period of the facility to which it relates.

-- 167 of 217 --

167	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
16. 	Income Tax
16.1 	Current tax
Discovery calculates and measures current tax at the amount expected to be paid to or recovered from the taxation authorities.
Discovery uses the tax rates and tax laws that have been enacted or substantively enacted at the end of the reporting period.
16.2 	Deferred tax
Discovery calculates deferred tax on all temporary differences using the Statement of financial position approach. Deferred tax
liabilities or assets are calculated by applying corporate tax rates that have been substantively enacted to the temporary differences
between the tax values of assets and liabilities and their carrying amount, where such temporary differences are expected to result
in taxable or deductible amounts in determining taxable income for future periods when the carrying amount of the assets or
liabilities are recovered or settled.
Discovery recognises deferred tax assets if the management of Discovery consider it probable that future taxable income will be
available against which the tax losses can be utilised.
Temporary differences arise primarily from the difference between accounting and tax balances arising from insurance contracts,
depreciation of property and equipment, effect of accounting for leases, revaluation of certain financial assets and liabilities,
provisions for leave pay, provisions for share-based payments and tax losses carried forward. For leases, Discovery assesses the
lease asset and lease liability together as a single transaction and assesses the temporary difference on a net basis.
Deferred tax is not accounted for if it arises from initial recognition of goodwill, or initial recognition of an asset or liability in a
transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable income at
the time of the transaction, does not give rise to equal taxable and deductible temporary differences.
Deferred tax related to cash flow hedges, which are charged or credited directly to the statement of other comprehensive income,
is also credited or charged directly to the statement of other comprehensive income and is subsequently recognised in profit or loss
when the gain or loss is realised.
Deferred tax assets and liabilities are offset when:
 There is a legally enforceable right to offset current tax assets against current tax liabilities, and
 When the deferred tax assets and liabilities relate to income taxes levied by the same taxation authority on either the taxable
entity or different taxable entities where there is an intention to settle the balances on a net basis.
If offsetting does not apply, Discovery separately discloses the deferred tax asset and deferred tax liability.
17. 	Employee benefits
17.1 	Short-term employee benefits
Short-term employee benefits are expensed as the related service is provided. A liability is recognised for the amount expected to
be paid if Discovery has a present legal or constructive obligation to pay this amount as a result of past service provided by the
employee and the obligation can be estimated reliably.
17.2 	Post-employment benefits
Discovery operates defined contribution schemes, the assets of which are held in separate private trustee-administered funds.
Discovery pays contributions to these funds on a mandatory basis. These funds are registered in terms of the Pension Funds Act,
1956, and membership is compulsory for all Discovery employees. Qualified actuaries perform annual valuations. Discovery has no
further payment obligations once the contributions have been paid. The contributions are recognised as an employee benefit
expense when they are due.
17.3 	Share-based compensation
Discovery operates equity-settled and cash-settled share-based compensation plans.
EQUITY-SETTLED SHARE-BASED COMPENSATION PLANS
Discovery expenses the fair value of the employee services received in exchange for the grant of the options, over the vesting period
of the awards, as employee costs in profit or loss, with a corresponding credit to a share-based payment reserve in the Statement of
changes in equity. The total value of the services received is calculated with reference to the fair value of the options on grant date.
The fair values of the options are determined excluding non-market vesting conditions. These vesting conditions are included in the
assumptions of the number of options expected to vest. At each reporting date, Discovery revises its estimate of the number of options
expected to vest. Any changes to the estimated number of options are recognised in profit or loss immediately.
CASH-SETTLED SHARE-BASED COMPENSATION PLANS
Discovery recognises employee services received in exchange for cash-settled share-based payments at the fair value of the liability
incurred and expenses these services over the vesting period of the benefits, as employee costs in profit or loss.
The liability is re-measured at each reporting period to its fair value, with all changes recognised immediately in profit or loss.

-- 168 of 217 --

168	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
17. 	Employee benefits continued
17.4 	Leave pay
Discovery accrues in full the employees’ rights to annual leave entitlement in respect of past service. This is expensed over the
period the services are rendered.
17.5 	Profit share and bonus plan
Discovery operates several other profit-sharing and bonus compensation arrangements and recognises these when a constructive
obligation has been created by past practice. These are calculated with reference to predetermined formulae. The Group has other
deferred compensation schemes in place where employees are incentivised based on a variable other than the share price of
Discovery Limited, such as embedded value, value of in-force and earnings multiples. Discovery recognises a liability and the related
expense is included in employee costs in profit or loss.
18. 	Trade and other payables
Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from
suppliers. Trade payables are classified as current liabilities if payment is due within one year or less from the reporting date. If not,
they are presented as non-current liabilities.
Trade payables are recognised initially at fair value net of directly attributable transaction costs and subsequently measured
at amortised cost using the effective interest method.
19. 	Contingent liabilities
Discovery discloses a contingent liability when:
 It has a possible obligation arising from past events, the existence of which will be confirmed, only by the occurrence or
non-occurrence of one or more uncertain future events not wholly within the control of the entity, or
 It has a present obligation that arises from past events but not recognised because:
– It is not probable that an outflow of resources will be required to settle an obligation, or
– The amount of the obligation cannot be measured with sufficient reliability.
20. 	Revenue recognition
The Group’s primary source of revenue arises on the sale of insurance contracts which are accounted for under IFRS 4 Insurance
Contracts and are excluded from the scope of IFRS 15 Revenue from Contracts with Customers. IFRS 15 is applicable to the Group’s
revenue from administration business, Vitality income and banking fee and commission income.
IFRS 15 requires that once contracts have been identified, the entity identifies the performance obligations in the contract. This is
determined on the basis of whether the customer can benefit from the promised good or service individually or together with other
readily available resources and whether the performance obligation is distinct in the context of the contract. For the Group, most
contracts contained a single performance obligation.
The timing of revenue recognition is dependent on whether the entity transfers control over the good or service over time or at a point
in time. In determining the appropriate timing for revenue recognition, the Group considers whether the customer benefits as the entity
performs. For most revenue types, Group entities provide stand-ready services to customers, where customers benefit as the entity’s
services are consumed. In limited instances where revenue is not recognised over time it is recognised at a point in time when control
transfers. For revenue recognised over time the stand-ready service is recognised straight line over the term of the contract.
In determining the amount of revenue to recognise, the Group considers any uncertainty created through variable consideration
contained in the contract, and constrains the recognition of revenue in order to recognise revenue only to the extent that it is highly
probable that a significant reversal in the amount of cumulative revenue recognised will not occur when the associated uncertainty is
resolved. The Group also considers the impact of the timing of receiving payments for revenue transactions and determines whether a
significant financing component should be taken into account in the measurement of the transaction price. As the Group’s contracts
routinely include single performance obligations, there is limited complexity in allocating transaction prices to performance obligations.
Payment terms vary across the different revenue types earned by the Group.
Where contracts with customers involve a third party, the Group considers whether it is acting as the principal or the agent in the
delivery of the promised goods or services to the customer. This assessment is based on whether the Group controls the goods or
services before it is transferred to the customer.
For certain contracts with customers, Discovery receives income in advance of discharging the related performance obligation. In
these instances, the amount is recognised as a contract liability incurred in the acquisition or fulfilment of a contract. Discovery
considers whether there are costs incurred for the acquisition or fulfilment of a contract. These costs are recognised as an asset
and amortised over the expected period over which performance obligations under the contract are satisfied. Contract costs
incurred that are considered to be of a general and administrative nature, that are not explicitly recovered from the customer, are
expensed as incurred.
Where the transaction price included in a contract is payable less than 12 months from the date of satisfying the related performance
obligation, the practical expedient is applied in that a significant financing component is not recognised. Similarly, where costs of
obtaining a contract would be amortised over 1 year or less, the costs are not recognised as a separate asset.

-- 169 of 217 --

169	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
20. 	Revenue recognition continued
Fee income from
administration business 	Vitality income
Banking fee and commission
income
Nature of
performance
obligations
Fee income is recognised on health
administration and managed care services
rendered. Fee income is also generated
on asset administration and fees earned
on use of intellectual property. In the
respective business, these are considered
revenue and are seen as single
performance obligations in the respective
legal entities. These are presented per
reporting entity in the segment report
shown in note 1.
Vitality income includes the
fee income that members pay
to access the Vitality benefit,
as well as various activation
fees for activating additional
benefits. The performance
obligation relates to access to
the Vitality programme and
partner benefits provided to
members.
Banking fee and commission
income includes banking
service fees for banking
services. The performance
obligation relates to the access
to banking and banking services
rendered. Commission income
relates to the interchange fees
which Discovery Bank earns on
transactions using debit or
credit cards. The performance
obligation relates to settlement
of transactions via the card
network.
When does
control pass –
Point in time
(PIT) vs over
time
Performance obligations to provide
administration services are considered
stand-ready services. The customer
obtains control over the service as the
entity makes its services available on an
“as and when” basis. As a result, revenue
is recognised over time, as the respective
entity makes the services available based
on the passage of time.
Performance obligations
to provide access to benefits
are considered stand-ready
services. The customers
obtain benefits when
required, over the duration of
the contract. As a result,
revenue is recognised
over time based on the
passage of time.
The performance obligation
associated with the banking fee
and commission income passes
over time because the client
obtains substantially all of the
remaining benefits from the
service over the period of the
month for which the banking
fee was charged.
When are
amounts
payable
Amounts are billed on health
administration and managed care
business at the end of the respective
month with amounts paid within 30 days.
For fees on asset administration business,
amounts are disinvested for the units
held at the end of the related month.
Certain fees, for example, advisor fees are
received upfront but are deferred as a
contract liability over the expected term
of the entity’s performance.
Amounts are billed either
monthly, payable within
30 days, or billed on activation
of the benefit, payable
immediately.
Banking fees are charged
monthly, and payment is
immediate. Interchange income
is charged at a point of
payment and settled daily in
batch format.

-- 170 of 217 --

170	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
20. 	Revenue recognition continued
Fee income from
administration business 	Vitality Income
Banking fee and commission
income
Variable
consideration
and estimates
There is no potential for amounts of
revenue to vary relating to discounts or
rebates on the health administration
business.
For the asset administration business, fees
are determined with reference to assets
under management at a point in time.
There are no benchmark performance-
based fees. The nature of the integrated
products that Discovery sells related to
the invest business allows for fee
discounts and rebates to be determined
based on client behaviour.
Revenue is estimated and recognised
in line with the constraint on variable
consideration, only to the extent that it is
highly probable that there will not be a
significant reversal of revenue already
recognised once the uncertainty is resolved.
The fee discounts and rebates are
determined according to a fixed
methodology incorporating policyholder
specific information including Vitality status.
Discovery has experience in estimating
these amounts, which are based on a
limited number of outcomes. There is no
financing component.
There are no adjustments to
the transaction price as a
result of any variable
consideration. There is no
significant financing
component.
There are no adjustments to
the transaction price as a result
of any variable consideration.
There is no significant financing
component.
Costs to
capitalise
Where costs are incurred directly to
secure a new health administration
customer, and the contract is expected to
exceed 12 months, the costs are
capitalised and amortised over the
expected term of the contract. Costs are
routinely incurred on the asset
administration business related to
commission and other incremental costs
of entering into the contract. These are
capitalised and recognised over the
expected duration of the customer
relationship. These assets are tested for
impairment to the extent that the
carrying amount of the asset exceeds the
expected remaining net cash inflows from
the customer contract.
In respect of the Apple watch
benefit, Discovery incurs costs
upfront to purchase the device
and provide it to the customer.
These costs are deferred and
recognised over the two-year
term of the benefit.
None.
Discovery presents any unconditional rights to consideration separately as a receivable. Discovery assesses a contract asset for
impairment in accordance with IFRS 9. An impairment of a contract asset is measured, presented and disclosed on the same basis
as a financial asset that is within the scope of IFRS 9. Any impairment losses recognised on any receivables or contract assets arising
from Discovery’s contracts with customers, is disclosed separately from impairment losses from other contracts.
Insurance premium revenue
Insurance premium revenue includes individual life insurance premiums, group life insurance premiums, health insurance
premiums and short-term insurance premiums. These are accounted for as described in accounting policy 13.

-- 171 of 217 --

171	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
21. 	Other non-revenue income
21.1 	Investment income
Investment income comprises dividends and interest received from assets held at amortised cost and cash and cash equivalents.
Discovery recognises dividends when Discovery’s right-to-receive payment is established. This is on the “last day to trade” for listed
shares and on the “date of declaration” for unlisted shares. Dividend income includes scrip dividends, irrespective of whether there
is an option to receive cash instead of shares.
Interest is accounted for on an accrual basis using the effective interest method.
21.2 	Net fair value gains on financial assets at fair value through profit or loss
Net fair value gains on financial assets at fair value through profit or loss include gains arising from interest, dividends and net
realised and unrealised gains on financial assets held at fair value through profit or loss.
22. 	Leases
IDENTIFICATION OF A LEASE
At inception of a contract, Discovery assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the
contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess
whether a contract conveys the right to control the use of an identified asset, Discovery uses the definition of a lease in IFRS 16.
Contracts where the service provider has a substantive right to substitute the asset for an alternative asset during the lease term is
not regarded as a lease, but instead a service contract. Accordingly, these contracts are not accounted for in accordance with IFRS
16. For Discovery, such contracts include items such as vending machines.
22.1 	As a lessee
At commencement or on modification of a contract that contains a lease component, Discovery allocates the consideration in the
contract to each lease component on the basis of its relative stand-alone prices. However, for the leases of property Discovery has
elected not to separate non-lease components and account for the lease and non-lease components as a single lease component.
Discovery recognises a right-of-use asset and a lease liability at the lease commencement date. Discovery presents right-of-use
assets in ’Property and equipment’ and lease liabilities in ’Borrowings at amortised cost’ in the Statement of financial position.
Discovery leases the following assets with a range of lease terms:
– Large offices 	5 – 15 years
– Small offices/Franchise offices (SA only) 	1 – 3 years
– Computer equipment (e.g. servers) (SA only) 	3 – 4 years
– Motor vehicles (UK only) 	3 years
MEASUREMENT
LEASE LIABILITY
The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date,
discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the lessee’s incremental
borrowing rate. Generally, Discovery uses its incremental borrowing rate as the discount rate.
Discovery determines its incremental borrowing rate by obtaining interest rates from various external financing sources and makes
certain adjustments to reflect the terms of the lease and type of the asset leased. The incremental borrowing rates were calculated
for each legal entity within Discovery that entered into lease arrangements. The incremental borrowing rate considers a base
interest rate reflective of the jurisdiction in which the legal entity operates (South Africa, United Kingdom and United States of
America), the term of the lease arrangement and the nature of the assets.

-- 172 of 217 --

172	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
22. 	Leases continued
22.1 	As a lessee continued
Lease payments included in the measurement of the lease liability comprise the following:
 Fixed payments, including in-substance fixed payments, less any lease incentives receivable.
 Variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date.
 Amounts expected to be payable under a residual value guarantee, and
 The exercise price under a purchase option that Discovery is reasonably certain to exercise, lease payments in an optional
renewal period if Discovery is reasonably certain to exercise an extension option, and penalties for early termination of a lease
unless Discovery is reasonably certain not to terminate early.
Extension or termination options are included in a number of the building leases across Discovery. These terms are used to
maximise operational flexibility in terms of managing contracts. In determining the lease term, management considers all facts and
circumstances that create an economic incentive to exercise an extension option, or not exercise a termination option. Extension
options (or periods after termination options) are considered in the lease term when there is reasonable certainty that those options
will be exercised.
The lease liability is measured at amortised cost using the effective interest method. It is remeasured when there is a change in
future lease payments arising from a change in an index or rate, if there is a change in Discovery’s estimate of the amount expected
to be payable under a residual value guarantee, if Discovery changes its assessment of whether it will exercise a purchase, extension
or termination option or if there is a revised in-substance fixed lease payment. When the lease liability is remeasured in this way, a
corresponding adjustment is made to the carrying amount of the right-of-use asset, or is recorded in profit or loss if the carrying
amount of the right-of-use asset has been reduced to zero.
RIGHT-OF-USE ASSET
The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease
payments made at or before the commencement date, including lease incentives received, plus any initial direct costs incurred and
an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset, less any lease incentives
received. Discovery receives incentives such as reimbursements for installations or rent-free periods.
The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the
lease term, unless the lease transfers ownership of the underlying asset to Discovery by the end of the lease term or the cost of the
right-of-use asset reflects that Discovery will exercise a purchase option.
In that case the right-of-use asset will be depreciated over the useful life of the underlying asset, which is determined on the same
basis as those of property and equipment. In addition, the right-of-use asset is periodically reduced by impairment losses, if any,
and adjusted for certain remeasurements of the lease liability.
SHORT-TERM LEASES AND LOW-VALUE ITEMS
Discovery has elected not to recognise right-of-use assets and lease liabilities for leases of low-value assets and short-term leases.
Discovery recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term.
Leases of low-value assets relate to those categories of assets which at inception of the lease typically have a value, if bought new,
of no more than approximately R70 000. For Discovery, these categories include computer equipment such as desktops, laptops,
monitors and related IT peripherals.
Short-term leases are those leases with a lease term of less than 12 months.
22.2 	As a lessor
At inception or on modification of a contract that contains a lease component, Discovery allocates the consideration in the contract
to each lease component on the basis of their relative standalone prices.
CLASSIFICATION
To classify the lease, Discovery makes an overall assessment of whether the lease transfers substantially all of the risks and rewards
incidental to ownership of the underlying asset. If this is the case, then the lease is a finance lease; if not, then it is an operating lease.
As part of this assessment, Discovery considers indicators such as whether the lease is for the major part of the economic life of the
asset, the specialised nature of the asset and the present value of lease payments.

-- 173 of 217 --

173	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
22. 	Leases continued
22.2 	As a lessor continued
Discovery leases out portions of its leased property in the form of subleases. Discovery has classified these leases as operating leases.
MEASUREMENT
As Discovery is an intermediate lessor, it accounts for its interests in the head lease and the sub-lease separately. It assesses the
lease classification of a sub-lease with reference to the right-of-use asset arising from the head lease, not with reference to the
underlying leased asset.
If an arrangement contains lease and non-lease components, Discovery applies IFRS 15 Revenue from Contracts with Customers to
allocate the consideration in the contract.
Discovery recognises lease payments received under operating leases as income on a straight-line basis over the lease term as part
of ’other income’.
23. 	Marketing and administration expenses
Marketing and administration expenses include marketing and development expenditure, all other non-acquisition related
expenditure and benefits paid under the Vitality programme. These costs are expensed in profit or loss as incurred.
24. 	Finance costs
Finance costs (net of investment income earned on the temporary investment of specific borrowings pending their expenditure on
qualifying assets) directly attributable to the acquisition, construction or production of assets that necessarily take a substantial
period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are
substantially ready for their intended use or sale. All other finance costs are recognised as an expense in profit or loss on an accrual
basis using the effective interest method.
In addition, finance costs include any recycled gains or losses from other comprehensive income arising from cash flow hedges of
interest rates, amortisation of financing related fees such as loan commitment fees and letter of credit fees as well as modification
gains and losses on borrowings.
25. 	Direct and indirect taxes
Direct taxes include South African and foreign jurisdiction corporate tax payable and are disclosed as taxation in profit or loss. Refer
to accounting policy 16.
Indirect taxes include various other taxes paid to central and local governments, including value-added tax and skills development
levies. Indirect taxes are included as part of marketing and administration expenses in profit or loss.
26. 	Dividend distribution
Dividend distribution to Discovery Limited’s shareholders is recognised as a liability in the Group’s financial statements in the period
in which the dividends are approved.

-- 174 of 217 --

174	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
27. 	Non-current assets held for sale
Non-current assets, or disposal groups comprising assets and liabilities, are classified as held for sale if it is highly probable that they
will be recovered primarily through sale rather than through continuing use. Such assets, or disposal groups, are generally
measured at the lower of their carrying amount and fair value less costs to sell.
Any impairment loss on a disposal group is allocated first to goodwill, and then to the remaining assets and liabilities on a pro-rata
basis, except that no loss is allocated to inventories, financial assets, deferred tax assets, employee benefit assets, investment
property or biological assets, which continue to be measured in accordance with the Group’s other accounting policies. Impairment
losses on initial classification as held for sale or held for distribution and subsequent gains and losses on remeasurement are
recognised in profit or loss.
Once classified as held for sale, intangible assets and property and equipment are no longer amortised or depreciated, and any
equity-accounted investee is no longer equity-accounted. Interest and other expenses attributable to the liabilities of a disposal
group classified as held for sale continue to be recognised.
Non-current assets and liabilities classified as held for sale are presented separately from the other assets and liabilities in the
Statement of financial position.
28. 	Government grants
Discovery obtains government grants, e.g. from the Sector Education and Training Authority (SETA) to access the Skills Development
Levies imposed on Discovery’s employees to encourage learning and development in South Africa. Discovery includes government
grants in profit or loss using the income approach, including costs for skills programs and deducting these from grants that cover
specific expenses in profit or loss.
Discovery recognises government grants as income only if they are reasonably assured of receiving them and fulfilling all associated
conditions. There are no other forms of government grants from which Discovery has directly benefited, and there are no conditions
that Discovery has not fulfilled in recognition of the government grants recognised.
29. 	Normalised headline earnings
Discovery assesses its performance using Normalised Headline Earnings, an alternative non-IFRS profit measure, alongside its IFRS
profit. Management considers that Normalised Headline Earnings Per Share (NHEPS) is an appropriate alternative performance
measure to enhance the comparability and understanding of the financial performance of Discovery.
Non-IFRS measures are not uniformly defined or used by all entities and may not be comparable with similarly labelled measures
and disclosures provided by other entities. Discovery has set out its policy to calculate NHEPS below.
Discovery calculates headline earnings in accordance with the latest SAICA Circular ’Headline Earnings’. NHEPS is calculated by
starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal
operations as follows:
 Once-off transactions, for example restructuring costs, transaction costs related to interest rate derivatives and initial deferred
tax assets raised on previously unrecognised assessed losses.
 Unusual items – Discovery considers items to be unusual when they have limited predictive value or it is reasonable that items
of a similar nature would not necessarily arise for several future annual reporting periods. These adjustments include those
gains or losses impacting profit or loss associated with changes in economic assumptions used by long-term insurers in the
Group to the extent those are recognised in profit or loss, net of any gains or losses on derivatives to offset such changes in
economic assumptions, or
 Income or expenses not considered to be part of Discovery’s normal operations, for example, amortisation of intangibles from
business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges.
In addition, specified items may be included in NHEPS that may otherwise be included if the income is considered part of Discovery’s
normal operations, for example ’gains on disposal of intellectual property’, if the sale arises from the monetisation of intellectual
property rights. Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in
accordance with the policy. The Discovery Limited Audit Committee (DLAC) reviews the normalised headline earnings for
transparency and consistency.

-- 175 of 217 --

175	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
29. 	Normalised headline earnings continued
During the financial period, Discovery has made the following adjustments in the determination of NHEPS:
Adjustment 	Explanation
Changes in economic
assumptions in excess of
available discretionary margin (in
future, this will also include the
reversals of economic
assumptions recognised in
profit or loss)
Economic assumptions include changes associated with interest rates as well as
currency exchange rates. The adjustment reflects changes in economic assumptions
for the time value of money and forex rates and the effect on insurance contracts
resulting from changes in the long-term interest rates as well as forex rates.
Under IFRS, where there are insufficient discretionary margins to offset losses arising
from negative changes in economic assumptions, those losses in excess of the
discretionary margin are recognised immediately in profit or loss. In subsequent
periods, positive changes in economic assumptions are first recognised separately in
profit or loss to the extent that it reverses related losses previously recognised in profit
or loss before it increases discretionary margins.
The effect of these economic assumptions is unusual and provides little predictive value
for future periods. This is because the value is dependent on available discretionary
margins at a given point in time and the long-term interest rates which could vary
period to period – thereby introducing volatility and inability to be predictive on results
during future periods. These adjustments are therefore excluded in assessing the
normal business operations of Discovery.
Intrinsic fair value changes on
specified derivatives to offset
changes in economic
assumptions
Long-term insurance business lines, for example VitalityLife enters into interest rate
derivative instruments to offset the impact of changes in economic assumptions on
insurance contracts.
The adjustment reflects the intrinsic value of fair value gains or losses on these
derivative instruments. The intrinsic value of fair value gains or losses on these
derivative instruments are excluded from NHEPS to be consistent with the treatment
of the changes in economic assumptions recognised in profit or loss.
Fair value (gains)/losses on
foreign exchange contracts not
designated as a hedge
The adjustment reflects fair value gains or losses on foreign exchange contracts entered
in anticipation of future capital injections in foreign operations, such as PAC book
transfer or Ping An Capital injections. These derivative instruments are not designated
as a hedge and as a result, the fair value adjustments are recognised in profit or loss.
The fair value adjustments of these derivative instruments can result in volatility in
profit or loss and is therefore excluded in assessing the normal business operations
of Discovery as it relates specifically to a future once-off transaction.
Amortisation of intangibles from
business combinations
The adjustment reflects the amortisation of intangible assets which arose from the
purchase of various subsidiaries within Discovery and are recognised in accordance with
IFRS 3 Business Combinations.
Intangible assets recognised from business combinations provide little predictive value
of the earnings from the business, as these assets will not be reacquired, renewed,
or replaced once depleted. Discovery also infrequently acquires businesses. The
amortisation of these assets is therefore excluded in assessing the normal business
operations of Discovery.
Annexure B – Group accounting policies continued
for the year ended 30 June 2023

-- 176 of 217 --

176	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
29. 	Normalised headline earnings continued
Adjustment 	Explanation
Deferred tax assets raised on
assessed losses
The adjustment reflects the initial recognition of deferred tax assets in respect of
assessed losses in prior financial periods, after evaluating that there is future taxable
income that will arise in the respective business.
The initial recognition of this deferred tax asset results in a once-off income recognised
in profit or loss. It provides no predictive value in assessing the normal business
operations of Discovery.
Initial expenses related to the
PAC book transfer
The adjustment reflects professional fees and legal fees of the book transfer incurred
in anticipation of the PAC book transfer.
As these expenses relate to a future once-off transaction it provides no predictive value
in assessing the normal business operations of Discovery and have therefore been
excluded from earnings.
Restructuring Costs 	The adjustment reflects restructuring costs which are once-off costs incurred to
restructure specified business areas.
These transaction costs are infrequent and therefore excluded in assessing the normal
business operations of Discovery.
Transaction costs related to
interest rate derivatives
Transaction costs paid to acquire specified derivative instruments to offset changes
in economic assumptions excluded from NHEPS.
These transaction costs are infrequent and therefore excluded in assessing the normal
business operations of Discovery.
Changes in tax balances
as a result of use of different
tax rates
The adjustments reflect the changes in current and deferred tax balances resulting from
the use of different tax rates related to items that were excluded from normalised
headlines earnings in the current or prior periods.
Gain on disposal of intangible
assets – Vitality Group
International
The adjustments include those gains on disposal of intangible assets, e.g. in the
AmplifyHealth deal, where Vitality Group International monetised a specified regional
right to an initial component of its intellectual property rights via sale as opposed
to a licensing arrangement.
These gains are considered part of normal operations for Discovery.
Annexure B – Group accounting policies continued
for the year ended 30 June 2023

-- 177 of 217 --

177	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts
Definitions and Abbreviations
The following abbreviations and terms are commonly used within the accounting policy:
Abbreviations 	Meaning
CSM 	Contractual Service Margin
DAC 	Deferred Acquisition Costs
DISCOVERY 	Discovery Group
DPF 	Direct Participation Features
DRO 	Discovery Retirement Optimiser
EFCF 	Expected Fulfilment Cash Flows
FINANCIAL RISK 	The risk of a possible future change in one or more of a specified interest rate, financial instrument
price, commodity price, currency exchange rate, index of prices or rates, credit rating or credit index
or other variable, provided in the case of a non-financial variable that the variable is not specific to a
party to the contract.
GMM 	General Measurement Model
IACF 	Initial Acquisition Cash Flows
IFIE 	Insurance finance income and expense comprises the change in the carrying amount of the group
of insurance contracts arising from:
 the effect of the time value of money and changes in the time value of money, and
 the effect of financial risk and changes in financial risk
IFRS 	IFRS® Accounting Standards
IFRS 4 	IFRS 4 Insurance Contracts (effective for Discovery pre-1 July 2023)
IFRS 17 	IFRS 17 Insurance Contracts (effective for Discovery post 1 July 2023)
IFRS 17 margins 	IFRS 17 margins refers to the contractual service margin plus the risk adjustment
ISE 	Insurance Service Expenses
LIC 	Liability for Incurred Claims
LRC 	Liability for Remaining Coverage
OCI 	Other Comprehensive Income
PAA 	Premium Allocation Approach
VFA 	Variable Fee Approach
30.1 	Introduction
The effective date of IFRS 17 Insurance Contracts is for reporting periods beginning on or after 1 January 2023, with comparative
restatement of the preceding year. IFRS 17 is therefore mandatory for the Discovery Group, effective from 1 July 2023, with
comparative restatement of the financial year ended 30 June 2023, including a restatement of the opening Statement of financial
position as at 1 July 2022.
IFRS 17 is a new accounting standard for insurance contracts that provides guidelines on recognising, measuring, presenting, and
disclosing insurance contracts. It was introduced by the International Accounting Standards Board (IASB) in May 2017. IFRS 17
replaces the previous standard, IFRS 4 Insurance Contracts, issued in 2005 as an interim standard with limited prescribed changes to
pre-existing insurance accounting practices applied by insurers.
IFRS 17 represents a positive step towards enhancing transparency, comparability, and understanding of how insurers earn profits
from insurance contracts, namely insurance service result and financial results. Consistent with the core objectives of IFRS 17,
Discovery has taken the opportunity to align its financial reporting approach and processes across its various jurisdictions where
insurance activities are undertaken.
The framework established by IFRS 17 outlines the specific requirements that companies must adhere to when reporting
information related to both the insurance contracts they issue and the reinsurance contracts they hold. One of the noteworthy
distinctions introduced by IFRS 17 pertains to the level of granularity at which insurance contracts are recognised and measured.
Discovery is well-prepared to embrace this enhanced granularity, as it aligns with the Group’s actuarial approach.

-- 178 of 217 --

178	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.1 	INTRODUCTION continued
IFRS 17 is not limited to insurance companies but also those companies that issue any contract that results in transfer of significant
insurance risk. For Discovery, the contracts within the scope of IFRS 17 are almost entirely aligned with those recognised in IFRS 4.
Whilst the underlying contractual terms and economic risks and rewards of each insurance contract remain unaltered, IFRS 17
impacts the accounting treatment of insurance contracts and most notably the timing of recognition of insurance related profits and
losses for accounting purposes. Importantly, it also separates the insurance related profit or losses between those arising from
insurance service results and those arising from financial results.
IFRS 17 does not result in a change in the underlying business value of contracts, including:
 No direct change to cash flows or underlying risk and reward of contracts. Future tax cash flow impacts are expected to be
immaterial.
 Immaterial impact on regulatory or economic solvency, capital position and capital management.
 The ability to pay dividends unaffected as cash flows and solvency remain unchanged.
 Immaterial impact on Embedded Value.
30.2 	Transition to IFRS 17 and estimated impact
Upon first-time adoption, IFRS 17 requires the standard to be applied fully retrospectively as if the standard always applied unless
impracticable. If impracticable to do so, the entity can elect to either apply a modified retrospective approach or use the fair value
approach.
As noted, Discovery is in a position to apply a fully retrospective restatement from inception for all material groups of insurance
contracts. Discovery did not measure any of its portfolios using the fair value approach. Note 30.10.1 below contains a summary of
those less material instances where a modified retrospective approach was applied.
The fully retrospective approach requires that Discovery identify, recognise, and measure groups of insurance contracts as if IFRS
17 had always applied. While this approach brought about significant complexity to the transition project, it has provided Discovery
with valuable historical insights as to how results will be impacted by model and assumption changes, changes in the discount rates
and significant stress events such as the financial crisis of 2008/09 and the COVID-19 pandemic.
Based on the work completed, the restatement is much more pronounced for the long-term insurance business of Discovery Life in
SA and VitalityLife in the UK. In contrast, the impact of the retrospective restatement is limited for the short-term businesses except
for VitalityHealth where the impact is more significant due to change in the treatment of insurance acquisition costs.
Discovery has assessed the estimated impact that the initial application of IFRS 17 will have on its financial statements. The changes
resulting from the transition to IFRS 17 can be summarised as follows:
 Those changes that result in differences to the IFRS 17 margins relative to the IFRS 4 margins. These changes result in
concomitant temporary changes in equity. For example, to the extent that changes resulted in the strengthening of contractual
service margins that will release to profit in future periods, such changes are mirrored by a reduction in shareholders’ equity
upon transition.
 Other changes, such as remeasurement basis of the expected future cash flows or recognised assets and liabilities from short-
term insurance, e.g., deferred acquisition costs. These remeasurements would result in a change in equity on transition without
a visible offset of insurance margins but similarly will indirectly result in higher or lower net profits in future periods (for a
reduction or increase in equity respectively).
In the case of Discovery, increases in insurance margins, most notably CSM, have a far more material impact. Such resulting
increases of additional IFRS 17 margins on transition will be available as future profit. The main cause for this significant increase in
CSM margins is that Discovery has a more recent and rapidly growing history compared to very long-standing insurers. As Discovery
businesses mature, there is a point of convergence where the annual profit recognition under IFRS 4 and IFRS 17 inevitably cross
over.

-- 179 of 217 --

179	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.2 	Transition to IFRS 17 and estimated impact continued
The most significant changes that result in an increase in IFRS 17 margins relative to margins under IFRS 4 can be summarised as
follows:
 The measurement under IFRS 17 includes only those cash inflows and outflows relating directly to the fulfilment of the group
of insurance contracts, termed directly attributable expenses. In addition to claims and benefits, these may include certain
directly attributable overhead expenses. However, non-directly attributable expenses such as general marketing and
sponsorships, allocated group executive and group function costs and research and development activities of new products,
are not included in the initial recognition value of the contract. Under IFRS 17, these non-directly attributable expenses are
immediately expensed and are therefore not considered when determining the EFCF of the insurance contracts being
measured. The immediate expensing of such non-directly attributable expenses increases the available margin on the portfolio
compared to the IFRS 4 treatment where such expenses were brought into account when determining the available margins. It
should be noted that such expenses are brought into consideration when determining the pricing of products and these
increased IFRS 17 margins are therefore similarly available for recognition as profits in future or to absorb adverse changes.
 Contracts are measured at a more granular level where portfolios are established and as a minimum with annual business
cohorts of no more than twelve months apart. Each of these cohorts is further categorised into separate groups based on
expected profitability being profitable, profitable at risk, and onerous groups. Losses are immediately expensed when they arise
on onerous contracts, effectively eliminating any cross-subsidisation or set-off applied within a portfolio. This immediate write-
off of shortfalls on contracts effectively increases the available margin on the remainder of the portfolio, which will be
recognised to profit in future.
 Other items, including, amongst others, the different treatment of certain basis changes and variances through the margin, the
different rates at which interest is accreted on the margins, and small differences in the run-off of the margins over time are
less material in the case of Discovery.
 Unlike IFRS 4, IFRS 17 separately recognises the finance related consequences of insurance contracts from the underlying
insurance activities. Finance income and expense related to insurance contracts and the changes in the measurement of finance
related items are recognised as IFIE either immediately in profit or loss or disaggregated and allocated using a systematic
allocation to profit or loss with variances being recognised through OCI.
 As will be noted below, Discovery has elected to apply the OCI option to certain long-term insurance contracts. The exclusion of
certain elements of IFIE from the profit or loss is largely aligned to the existing treatment where Discovery excludes the impact
of economic assumptions, net of associated derivatives, from its normalised profit and normalised headline earnings. The use
of OCI removes the need for this normalisation after adoption of IFRS 17.
Other changes, resulting in a change in equity on transition without a visible offset of insurance margins:
 The remeasurement of best estimates of the future fulfilment cash flows and measurement and accounting treatment of
insurance acquisition cash flows, i.e., deferred acquisition costs, on the short-term business lines and
 Associated deferred tax and future tax impacts of the changes noted above.

-- 180 of 217 --

180	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.2 	Transition to IFRS 17 and estimated impact continued
IFRS 17 acknowledges that different companies may manage their insurance contracts differently. As a result, IFRS 17 is principle-
based and permits several accounting policy elections. The following is a summary of these accounting elections and specific
elections made by Discovery:
Election 	Options 	Discovery elections
Transition
approach
Three transition approaches
 IFRS 17 requires full retrospective
unless impracticable.
 If full retrospective is impracticable,
then accounting election of modified
retrospective, or
 fair value approach.
 Given the availability of reliable and accurate data
and actuarial models, Discovery is required to apply IFRS
17 fully retrospective to all material groups of insurance
contracts.
 For the remainder of portfolios, when full retrospective
was impracticable, then modified retrospective was
applied. Discovery has not applied the fair value
approach to any groups of insurance contracts.
Changes in time
value of money
(Insurance
finance income
and expense
presentation)
Two alternatives:
 Present all IFIE and IFIE changes in
profit or loss.
 Include IFIE in profit or loss using
systematic allocation. Remainder
recognised in OCI.
 The use of the OCI removes the volatility from changes
in IFIE (previously economic assumptions) in the
measurement of the insurance contract. The amount
recognised in OCI is then reclassified to profit or loss
using a systematic allocation.
 Discovery has elected OCI on its long-term life-insurance
business lines in Discovery Individual Life and VitalityLife.
For the remainder of business lines, the change in
measurement of the insurance contracts is offset by a
change in the measurement of the assets backing those
insurance contracts.
Risk adjustment 	No prescriptive approach is provided
under IFRS 17.
 Discovery uses the confidence level approach.
 For its long-term businesses and group life insurance,
Discovery sets the confidence level at 90%.
 For its short-term businesses, Discovery sets the
confidence level at 75%.
Acquisition cost
(for portfolios
at PAA)
Two alternatives:
 The default under IFRS 17 for
contracts with PAA is to defer the
insurance acquisitions cash flows and
allocate the expense to initial and
renewal periods, i.e., Defer acquisition
costs and amortise.
 Entity can elect to immediately
expense insurance acquisition cash
flows.
 VitalityHealth applies the default requirement of IFRS 17.
This treatment results in a largely similar treatment to
the FinRe arrangements VitalityHealth held under IFRS 4.
 For other insurance portfolios measured using the PAA,
Discovery has elected to immediately expense in profit
or loss the insurance acquisition cash flows as these are
not significant.
Reflect time
value of money
(i.e., discount)
in measuring
coverage units
Two alternatives:
 Reflect time value of money in
measuring coverage units.
 Don’t reflect time value of money in
measuring coverage units.
 Discovery elected to reflect time value of money in the
measurement of coverage units. The discounting of
coverage units provides the most reasonable emergence
of profit, considering the projected level of future
margins on retained business for Discovery.

-- 181 of 217 --

181	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.2 	Transition to IFRS 17 and estimated impact continued
ESTIMATED TRANSITIONAL IMPACT
Based on the restatement work undertaken to date, the transition change is primarily a result of the increased IFRS 17 margins, as
represented by the CSM plus the risk adjustment. This adjustment, available for future profit release, falls within the range of R14.5
billion to R15.5 billion pre-tax. Other factors contributing to the change in equity include alterations in the methodology used to
determine fulfilment cash flows, difference in short-term business lines such as risk adjustment for non-financial risks, and the tax
effects of changes in the measurement of insurance contracts.
The concomitant net impact of transition adjustment (after tax) to the balance of the Group’s shareholders’ equity is estimated to be as
follows:
R million
Group total equity 30 June 2022
Audited and previously reported 	53 555
IFRS 17 adjustment, net of tax
Mainly resulting from the increases in the CSM and available for release to profit in future.
Accumulated IFIE recognised in OCI is less than 10% of total impact of shareholders equity 	(12 000 – 13 000)
Group total equity 1 July 2022
Restated 	41 555 – 40 555
As mentioned above, the impact of the above reduction in equity is effectively offset by a significant increase in insurance margins, most
notably CSM, that is available for release to profit in future years or to absorb any adverse changes.
On this basis, the total value created through the insurance activities of the Group remains largely unchanged, however, the timing of
recognition of insurance related profits has been deferred. The strengthened IFRS 17 margins result in higher future release of profits
and in less volatility due to its ability to absorb negative variances, while the election of OCI results in less volatility as a result of its ability
to manage variances in financial risks.
The material recognition, measurement and presentation policies of insurance contracts under IFRS 17 are set out below.
30.3 	Insurance contracts scope and grouping
30.3.1 DEFINITION AND CLASSIFICATION
Insurance contracts are contracts under which Discovery accepts significant insurance risk from a policyholder by agreeing to
compensate the policyholder should a specified uncertain future event adversely affect the policyholder.
A reinsurance contract transfers significant risk if it transfers substantially all the insurance risk resulting from the insured portion of the
underlying insurance contracts, even if it does not expose the reinsurer to the possibility of a significant loss.
Discovery determines whether it has assumed significant insurance risk by comparing benefits payable after an insured event with
benefits payable if the insured event had not occurred. Insurance and reinsurance contracts can also expose Discovery to financial risk,
which is not taken into account in the determination of significant insurance risk.
Significant judgements and estimates
IFRS 17 does not specify what significant insurance risk is. Discovery’s policy defines significant insurance risk as follows: The possibility
that the present value of losses arising on the insurance contract exceeds 10% of the present value of income and receipts collected
when applying a worst-case scenario upon inception of the insurance contract.
30.3.2 SEPARATING COMPONENTS WITHIN INSURANCE CONTRACTS
IFRS 17 requires an analysis of whether the contract contains components that should be separated from the insurance contract and
accounted for under different IFRS Accounting Standards. IFRS 17 requires that cash flows relating to embedded derivatives, cash flows
relating to distinct investment components and promises to transfer distinct goods or distinct services, other than insurance contract
services, be accounted for separately.
Discovery presently has no contracts requiring further separation or a combination of insurance contracts.

-- 182 of 217 --

182	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.3 	Insurance contracts scope and grouping
30.3.3 UNIT OF ACCOUNT, AGGREGATION AND RECOGNITION OF INSURANCE AND REINSURANCE CONTRACTS
Under IFRS 17, the unit of account is defined as a group of insurance contracts. The manner in which insurance contracts are
grouped, affects the timing of profit recognition for insurance services but does not affect the measurement of the estimated cash
flows to fulfil the insurance contracts. In terms of IFRS 17, the unit of account is determined by first establishing a portfolio of
insurance contracts and then creating separate cohorts within the portfolio based on the date of origination. Each such cohort is
further grouped into three groupings based on estimated profitability.
Insurance contracts that are subject to similar risks and managed together
E.g., whole-of-life insurance, guarantee endowments, household insurance
Only contracts issued within a given 12-month period (cohort) can be included in the same group.
Annual cohorts are further grouped into one of the following:
Portfolio
Cohort
Groups
Onerous at initial Recognition
(Onerous)
At initial recognition, no
significant possibility of
becoming onerous
(Profitable)
Other
(Profitable at risk)
IFRS 17 Illustration of principles 1: Unit of account
At initial recognition, groups of insurance contracts issued are recognised from the earliest of the following:
 The beginning of the coverage period.
 The date when the policyholder’s first payment is due or received if there is no due date.
 When Discovery determines that a group of insurance contracts become onerous.
Significant judgements and estimates
Discovery uses judgement to determine at what level of granularity Discovery has reasonable and supportable information that
is sufficient to conclude that all contracts within a set are sufficiently homogeneous and will be allocated to the same group
without performing an individual contract assessment.
Discovery performs stress testing on portfolios measured using GMM/VFA. The stresses may differ between portfolios but will
correspond to the most significant non-financial stresses currently run as part of the risk appetite work. If any policy that was
originally determined to be profitable becomes onerous under any of the three additional stresses calculated, that policy is
classified as profitable-at-risk.
30.3.4 MEASUREMENT MODELS
IFRS 17 provides three possible measurement models.
1. The default model is the General Measurement Model (GMM). The GMM is typically used for measuring long-term insurance risk
and annuity contracts. The basic principles of which are set out below.
2. The GMM is supplemented by the Variable Fee Approach (VFA) for contracts where policyholders have purchased investment-
linked insurance contracts integrated with insurance coverage (i.e., insurance contracts with direct participating features).
3. The Premium Allocation Approach (PAA) is a simplified approach of the GMM for short-duration contracts such as group risk,
personal lines and private medical insurance.
Direct participating contracts are contracts for which, at inception:
 the contractual terms specify that the policyholder participates in a share of a clearly identified pool of underlying items.
 Discovery expects to pay to the policyholder an amount equal to a substantial share of the fair value returns on the underlying
items; Discovery considers that a substantial share is a majority of returns, and
 Discovery expects a substantial proportion of any change in the amounts to be paid to the policyholder to vary with the change
in fair value of the underlying items. Discovery considers that a substantial proportion is a majority proportion of change on a
present value probability-weight average of all scenarios.
Within Discovery the unit-linked products and Discovery Optimiser products offered by Discovery Life are examples of insurance
contracts with DPFs.

-- 183 of 217 --

183	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.4 	Overview of discovery group portfolios, measurement models and accounting
policy elections
The table below summarises the material insurance contracts Discovery issues and reinsurance contracts it holds. It sets out the
measurement model applied and key assumptions and elections.
Measurement
Model
Risk adjustment
confidence
level 1 	Elections on IFIE
PAA only – election for
treatment of initial
acquisition cash flows (IACF)
Insurance contract issued and business lines
Individual life insurance
contracts:
Discovery Life and VitalityLife GMM
90%
Elected to present
changes in IFIE in OCI
n/a
Insurance-linked investment
contracts:
General endowments in
Discovery Invest
Elected to present
changes in IFIE in profit
or loss
Investment contracts:
Unit-linked and DRO in
Discovery Invest
VFA
Group life insurance
contracts:
Discovery Life
PAA
90%
Elected not to reflect
interest for cash flows
less than 12 months
Elected to immediately
expense initial acquisition
cash flows (IACF)
Car, household and business
insurance:
Discovery Insure 75%
Health insurance:
VitalityHealth
Consistent with default IFRS
17 requirement, defer IACF
and amortise over the initial
and renewal periods
Reinsurance contracts held
Individual life:
quota share reinsurance
for Discovery Individual Life
and VitalityLife 	GMM 	90% 	Elected to present
changes in IFIE in OCI
n/a
Individual life:
excess of loss reinsurance
Group life insurance
contracts:
catastrophe, group continuation
and mass lapse treaties
PAA
90%
Elected not to reflect
interest for cash flows
less than 12 months
Elected to immediately
expense initial acquisition
cash flows (IACF)	Car, household and
business insurance:
quota share reinsurance and
excess of loss insurance
75%
Health insurance:
quota share reinsurance
1 Risk adjustment was determined using the confidence level technique unless otherwise stated.

-- 184 of 217 --

184	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.5 	Contracts measured under the GMM and VFA
Under IFRS 17, any company that issues insurance contracts must report those contracts on the Statement of financial position as
the total of
 The expected fulfilment cash flows (EFCF): the current estimates of amounts that the company expects to collect from premiums
net of and payout for claims, benefits, and expenses, including an adjustment for the timing and risk of those amounts, and
 The CSM: the expected profit for providing insurance coverage recognised in profit or loss over the period of insurance coverage.
Under IFRS 17, Insurance Contracts are measured
as the sum of:
the expected fulfilment cash flows (EFCF), representing
the present value of current estimates of amounts that
the insurer expects to collect from premiums net of and
pay out for claims, benefits and expenses, including an
adjustment for the risk of those cash flows.
Those cash flows for future services is known as “liability
for remaining coverage” (LRC) and those cash flows
for services already incurred constitutes “liability for
insurance claims” (LIC)
the contractual service margin (CSM) —, i.e. represents
the remaining inherent value of the cohort and is similar
to unearned profit for providing future insurance
coverage. On initial recognition, for profitable contract,
the CSM is the equal and opposite amount of the net
cash inflow, resulting in no income or expense arising on
initial recognition.
+
EFCF –
Inflow
EFCF –
Outflow
EFCF –
Risk adj
CSM	EFCF –
discounting
= 	+Insurance
contracts
Present value of expected
fulfilment cash flows
Unearned
profit
IFRS 17 Illustration of principles 2: General Measurement Model (GMM)
30.5.1 EXPECTED FULFILMENT CASH FLOWS (EFCF)
The measurement of a group of insurance contracts includes all future cash flows expected to arise within the contract boundary
of each contract in the group. Cash flows are within the contract boundary if they arise from substantive rights and obligations that
exist during the reporting period in which Discovery can compel the policyholder to pay premiums or has a substantive obligation
to provide services (including insurance coverage and any investment services).
EFCF include payments to (or on behalf) of policyholders, insurance acquisition cash flows and other costs incurred in fulfilling
contracts. Other costs incurred to fulfil a group of contracts include direct costs and an allocation of fixed and variable overheads
directly attributable to fulfilling the group of insurance contracts.
The estimates of these future cash flows are based on probability-weighted expected future cash flows. Discovery estimates which
cash flows are expected and the probability that they will occur as at the measurement date. When estimating, Discovery uses
information about past events, current conditions and forecasts of future conditions.
Significant judgements and estimates
Discovery applies judgement to determine which cash flows within the boundary of insurance contracts relate directly to the
fulfilment of the contracts, including the extent to which fixed and variable overheads are directly attributable to fulfilling
insurance contracts..
Discovery primarily uses deterministic projections to estimate the present value of future cash flows, and for some groups, it
uses stochastic modelling techniques. The following assumptions were used when estimating future cash flows:
 Mortality and morbidity rates.
 Surrender and lapse rates.
 Economic assumptions/Investment returns.
 Vitality status assumptions.
 Expense assumptions.
 Policy alterations and automatic premium increases.
Insurance acquisition cash flows arise from activities of selling, underwriting and commencing a group of contracts that are directly
attributable to the portfolio of contracts to which the group belongs.

-- 185 of 217 --

185	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.5 	Contracts measured under the GMM and VFA continued
30.5.2 REFLECTING THE TIME VALUE OF MONEY AND DISCOUNT RATES
Discounting adjusts the estimates of expected cash flows to reflect the time value of money and the financial risks associated with
those cash flows to the extent that the financial risks are not already included in the cash flow estimates.
The following table shows which discount rate to apply throughout measuring a group of insurance contracts and the general
objective of determining that discount rate.
GMM AND VFA
Element of measurement model
Fulfilment cash flows 	Current discount rates
CSM interest accretion for contracts without direct
participation features (i.e., portfolios under GMM).
Discount rates are determined on initial recognition of the
group, i.e., locked-in at inception.
Adjustments to the CSM for changes in the fulfilment cash
flows for contracts without direct participation features (i.e.,
portfolios under GMM).
Discount rates are determined on initial recognition of the
group, i.e., locked-in at inception.
Adjustments to the CSM for changes in the fulfilment cash
flows for DPF contracts that do not vary based on the returns
on underlying items (i.e., portfolios under VFA), excluding
the change in the effect of the time value of money and
financial risks.
Current discount rates.
The “bottom-up” approach is used to derive the discount rate for the cash flows. Under this approach, the discount rate is determined
as the risk-free yield, adjusted for differences in liquidity characteristics of the insurance contracts sold. For portfolios of contracts
where the insurance contract liability is materially matched with assets, a “top-down” approach is used to derive the discount rate for
the cash flows.
For Discovery, the risk-free yield curve will be ‘current’ and reflect the risk-free yield curve derived on the last day of the reporting
period. The nominal risk-free yield curve is used to discount nominal cash flows, while real cash flows are discounted using the real
risk-free yield curve.
30.5.3 RISK ADJUSTMENT
The risk adjustment for non-financial risk for a group of insurance contracts, determined separately from the other estimates, is the
compensation required for bearing uncertainty about the amount and timing of the cash flows that arise from non-financial risk as
Discovery fulfils insurance contracts. It measures the compensation that the entity would require to make it indifferent between:
 Fulfilling a liability that has a range of possible outcomes arising from non-financial risk and
 Fulfilling a liability that will generate fixed cash flows with the same expected present value as the insurance contract.
A lower risk adjustment would be observed for those insurance contracts with shorter duration, high frequency and low severity
type products and narrow probability of distributions. Higher risk adjustment would be observed for insurance contracts that are
longer in duration, have a low frequency and high severity and have a wide probability of distributions.
IFRS 17 does not prescribe methods for determining the risk adjustment for non-financial risk. Therefore, management’s judgement
is necessary to determine an appropriate risk adjustment technique.
When applying a confidence level technique, the first step in the process is to calculate the best estimate reserve, where there is an
equal chance that the actual amount needed to pay future claims will be higher or lower than the calculated best estimate. The risk
adjustment is then calculated such that there is a specified percentage probability that the reserves will be sufficient to cover future
claims. For Discovery, the determination of specified percentage has been determined as follows:
Significant judgements and estimates
Portfolio 	Methodology 	Confidence level
Life insurance contracts include
Discovery LifePlan and VitalityLife
whole-of-life and term-life policies
Confidence level 	90%
Investment contracts with DPF include
the unit-linked products and the
Discovery Retirement Optimiser
offered by Discovery Invest
Confidence level 	90%

-- 186 of 217 --

186	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.5 	Contracts measured under the GMM and VFA continued
30.5.4 CONTRACTUAL SERVICE MARGIN (CSM)
The CSM represents the future unearned profit. On initial recognition of a group of insurance contracts, if the total of the fulfilment
cash flows, including insurance acquisition cash flows:
 is a net inflow, then the group is profitable. In this case, the CSM is measured as the equal and opposite amount of the net
inflow, which results in no income or expenses arising on initial recognition.
 is a net outflow, then the group is onerous. In this case, the net outflow is recognised immediately as a loss in profit or loss. A
loss component is created to depict the amount of the net cash outflow, which determines the amounts that are subsequently
presented in profit or loss as reversals of losses on onerous contracts and are excluded from insurance revenue.
30.5.5 SUBSEQUENT MEASUREMENT
The carrying amount of a group of insurance contracts at each reporting date is the sum of the liability for remaining coverage (LRC)
and the liability for incurred claims (LIC).
 The LRC comprises the fulfilment cash flows related to services that will be provided under the contracts in future periods and
any remaining CSM at that date.
 The LIC includes the fulfilment cash flows for incurred claims and expenses that have not yet been paid, including claims that
have been incurred but not yet reported.
IFRS 17 requires a company to update the EFCF at each reporting date, using current estimates of the amount, timing, and
uncertainty of cash flows and discount rates. Discovery:
 accounts for changes to estimates of future cash flows from one reporting date to another, either as an amount in profit or loss
or as an adjustment to the expected profit for providing insurance coverage, depending on the type of change and the reason
for it; and
 chooses where to present IFIE either:
– all in profit or loss, or
– include IFIE in profit or loss using systematic allocation. The remainder of IFIE is recognised in OCI.
The treatment can be summarised as follows:
Fulfillment
cash
inflows
OCI
P/L
CSM
CSM allocation
Financial risk assumptions (e.g., interest rates)
Past and current service
Future service
Reclassify
Either
Or

-- 187 of 217 --

187	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.5 	Contracts measured under the GMM and VFA continued
30.5.5 SUBSEQUENT MEASUREMENT
30.5.5.1 Changes in EFCF
Changes in expected fulfilment cash flows from the estimates at the previous reporting date or inceptions of the contracts are
recognised as follows:
Nature of change 	Treatment
Changes relating to current or past services 	Recognised in the insurance service results in profit or
loss.
Changes relating to future services 	Adjusted against the CSM (or recognised in the insurance
service results in profit or loss if the group is onerous).
Effects of the time value of money, financial risk and changes
therein on estimated future cash flows
Recognised as insurance finance income or expenses.
Changes in the obligation to pay policyholders an amount equal to
the fair value of the underlying items for a group of direct
participating contracts (VFA)
Recognised in the insurance service results in profit or
loss.
Accounting policy election: Presentation of IFIE
Discovery has elected to disaggregate IFIE for the period in OCI and present in profit or loss IFIE using a systematic allocation
on its long-term life insurance business lines in Discovery Life and VitalityLife. For the remainder of business lines, the IFIE and
changes therein relating to insurance contracts are presented in profit or loss, offset by the changes in the value of assets
backing the insurance contracts.
Changes in CSM
As noted in policy 30.5.4, the CSM represents the future unearned profit. The movement in the CSM during a financial reporting
period can be summarised as follows:
Opening CSM 	1. Accretion/Unwind
of interest
2. New business
written during
the period
3. Release to
p/l using
coverage units
4. Changes in
assumptions
(not IFIE)
5. VFA only – change
in the amount of the
entity’s share
of the fair value of the
underlying items
Closing CSM
Movement in CSM during reporting period
IFRS 17 Illustration of principles 4: Subsequent changes in CSM

-- 188 of 217 --

188	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.5 	Contracts measured under the GMM and VFA continued
30.5.5 SUBSEQUENT MEASUREMENT continued
30.5.5.1 Changes in EFCF continued
The carrying amount of the CSM at each reporting date is the carrying amount at the start of the financial year, adjusted for:
1. Interest accreted on the carrying amount of the CSM during the year. As noted in policy 30.7.4.2, discount rates are determined
on initial recognition of the group, i.e., locked-in at inception.
2. The CSM of any new contracts added to the group in the year.
3. The amount recognised as insurance revenue because of the services provided in the year, i.e., release of CSM using coverage
units. In determining the coverage units, Discovery has elected to reflect the time value of money in the coverage units using a
real rate of return for insurance contracts measured using the GMM. For insurance contracts measured using the VFA, Discovery
has elected to reflect the time value of money in the coverage units using a nominal rate of return.
4. The effect of any currency exchange differences on the CSM and changes in fulfilment cash flows that relate to future services,
except to the extent that:
a. any increases in the fulfilment cash outflows exceed the carrying amount of the CSM, in which case the excess is recognised
immediately in profit or loss.
b. any decreases in the fulfilment cash outflows are allocated to the loss component, reversing losses previously recognised in
profit or loss.
5. For contracts measured using the VFA, the change in the amount of the insurer’s share of the fair value of the underlying item.
30.6. Contracts measured under the PAA
As permitted in IFRS 17, Discovery has elected to apply the premium allocation approach (PAA) to measure a group of insurance
contracts issued or reinsurance contracts held if, at the inception of the group:
 The coverage period of each contract in the group of insurance contracts is one year or less or
 Discovery reasonably expects that the PAA would produce a measurement of the LRC for a group of insurance contracts that
would not differ materially from the measurement achieved by applying the GMM.
The PAA simplifies the general measurement model. At initial recognition, the insurance contract is measured as:
 The premiums, if any, received at initial recognition.
 Minus any insurance acquisition cash flows (applicable only if the group has elected to defer the insurance acquisition cash
flows), and
 Plus/minus non-acquisition assets or liabilities previously recognised for cash flows related to the group of insurance contracts.
Where insurance acquisition cash flows are directly attributable to a group of contracts, Discovery allocates costs to that group and
the groups that will include renewals of those contracts. Discovery expects to recover part of the related insurance acquisition cash
flows through renewals of these contracts. The allocation to renewals is based on how Discovery expects to recover those cash flows.
At each reporting date, Discovery revises the amounts allocated to groups to reflect any changes in assumptions that determine the
inputs to the allocation method used. Amounts allocated to a group are not revised once all contracts have been added to the group.
At each reporting date, if facts and circumstances indicate that an asset for insurance acquisition cash flows may be impaired,
Discovery:
 Recognises an impairment loss in profit or loss so that the carrying amount of the asset does not exceed the expected net cash
inflow for the related group and
 If the asset relates to future renewals, recognises an impairment loss in profit or loss to the extent that it expects those
insurance acquisition cash flows to exceed the net cash inflow for the expected renewals, and this excess has not already been
recognised as an impairment loss.
Discovery reverses any impairment losses in profit or loss and increases the asset’s carrying amount to the extent that the
impairment conditions have improved.
IFRS 17 permits an accounting policy election on a group-by-group basis:
 Not to adjust the components of the insurance contracts and onerous contracts for the time value of money (i.e., no discounting).
 An entity may elect to immediately expense insurance acquisition cash flows when incurred.
Annexure B – Group accounting policies continued
for the year ended 30 June 2023

-- 189 of 217 --

189	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.6. Contracts measured under the PAA continued
Accounting policy elections
For those contracts that apply the PAA, Discovery has elected not to reflect the time value of money in the measurement
of the LRC and the LIC when:
 LRC: On initial recognition of the contract, the time between the insurance service and the related premium is less than
a year.
 LIC: The cash flows are expected to be paid or received in less than one year from the date the claim is incurred. In
some instances, claims might be disputed. If the claim is expected to be disputed and settlement deferred beyond 12
months, the exception would not apply.
Discovery has elected to immediately expense insurance acquisition cash flows for the following material portfolios:
 Group Life
 Discovery Insure – Discovery Insure has the following portfolios: Personal lines for motor and household, Business
insurance, Medical gap, trauma cover and travel insurance.
 AfricaHealth portfolios.
Significant judgements and estimates
Discovery uses judgement in determining the initial and renewal periods for which the insurance acquisition cash flows are
attributed to groups. For VitalityHealth, the initial and subsequent renewal period is set at ten years.
30.6.1 RISK ADJUSTMENT
Also refer to policy 30.5.3.
For contracts measured under the PAA, the explicit risk adjustment for non-financial risk is estimated to measure the LIC. The risk
adjustment will be determined by applying a confidence level technique. For Discovery, the determination of specified percentage
has been determined as follows:
Significant judgements and estimates
Portfolio 	Methodology 	Confidence level
Discovery Insure personal and business
lines, VitalityHealth private medical
insurance, AfricaHealth health insurance
Confidence level 	75%
Group Life portfolio 	Confidence level 	90%

-- 190 of 217 --

190	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.7. Reinsurance contracts
Groups of reinsurance contracts are established such that each treaty is allocated to the applicable group of reinsurance contracts,
which differs to the group to which the underlying insurance contract is included. Discovery concludes that the reinsurance
contract’s legal form of a single contract reflects the substance of Discovery’s contractual rights and obligations.
A group of reinsurance contracts is recognised, as required under IFRS 17, on the following dates.
 Reinsurance contracts initiated by Discovery that provide proportionate coverage: The date on which any underlying insurance
contract is initially recognised. This applies to Discovery’s quota share reinsurance contracts.
 Other reinsurance contracts initiated by Discovery: The beginning of the coverage period of the group of reinsurance contracts.
Where Discovery recognises an onerous group of underlying insurance contracts on an earlier date and the related reinsurance
contract was entered into before that earlier date; in that case, the group of reinsurance contracts is recognised on that earlier
date. This applies to Discovery’s excess of loss and stop-loss reinsurance contracts.
 Reinsurance contracts acquired: The date of acquisition.
Discovery applies the same accounting policies to measure a group of reinsurance contracts, adapted where necessary to reflect
features that differ from those of the underlying insurance contracts. When a loss-recovery component is created for a group of
reinsurance contracts measured under the PAA, Discovery will adjust the asset’s carrying amount for remaining coverage instead of
adjusting the CSM.
30.8 	Derecognition and modifications
Discovery derecognises a contract when it is extinguished – i.e., when the specified obligations in the contract expire or are discharged
or the contract is cancelled.
Discovery also derecognises a contract if its terms are modified in a way that would have changed the accounting for the contract
significantly had the new terms always existed, in which case a new contract based on the modified terms is recognised. If a contract
modification does not result in derecognition, Discovery treats the changes in cash flows caused by the modification as changes in
estimates of fulfilment cash flows.
On derecognition of a contract from within a group of contracts not measured under the PAA:
 The fulfilment cash flows allocated to the group are adjusted to eliminate those that relate to the rights and obligations
derecognised.
 The CSM of the group is adjusted for the change in the fulfilment cash flows, except where such changes are allocated to a loss
component.
 The number of coverage units for the expected remaining services is adjusted to reflect the coverage units derecognised from
the group.
If a contract is derecognised because it is transferred to a third party, then the CSM is also adjusted for the premium charged by the
third party unless the group is onerous.

-- 191 of 217 --

191	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.9 	Presentation and disclosure
30.9.1 OVERVIEW OF PRESENTATION AND DISCLOSURE
Portfolios of insurance contracts that are assets and liabilities and portfolios of reinsurance contracts that are assets and liabilities
are presented separately in the Statement of financial position. Any assets or liabilities recognised for cash flows arising before the
recognition of the related group of contracts (including any assets for insurance acquisition cash flows under ‘Insurance acquisition
cash flows’) are included in the carrying amount of the related portfolios of contracts.
IFRS 17 requires a company to provide information that distinguishes two ways insurers earn profits from insurance contracts:
1. The insurance service result, which depicts the profit earned from providing insurance coverage and
2. The financial result, which captures the investment income from managing financial assets and insurance finance income and
expenses (IFIE) resulting from the insurance rights and obligations. The IFIE reflects the effects of financial variables such as
discount rates on the value of insurance rights and obligations.
Income and expenses from reinsurance contracts are presented separately from income and expenses from insurance contracts.
Income and expenses from reinsurance contracts, other than insurance finance income or expenses, are presented on a net basis
as ‘net expenses from reinsurance contracts’ in the insurance service result.
Discovery disaggregates changes in the risk adjustment for non-financial risk between the insurance service result and insurance
finance income or expenses. The insurance service result includes all changes in the risk adjustment for non-financial risk.
The result of insurance performance in the income statement can be summarised as follows:
Element
Insurance Revenue – GMM/ VFA 	Expected Insurance Service Expense plus CSM release plus release of risk
adjustment.
Insurance Revenue - PAA 	For contracts measured under the PAA, the insurance revenue for each period is
the expected premium receipts for providing services in the period. Discovery
allocates the expected premium receipts to each period based on the passage of
time.
Insurance Service expenses 	Actual claims and directly attributable costs, including past and in-period variances.
Net expenses from reinsurance
contracts
Net expenses from reinsurance contracts comprise an allocation of reinsurance
premiums paid less amounts recovered from reinsurers. Discovery has elected to
present the income and expenses from a group of reinsurance contracts held as a
single amount.
Insurance finance income and
expense
Discovery has elected to disaggregate changes in the risk adjustment for non-
financial risk between the insurance service result and insurance finance income or
expenses.
Discovery has elected to disaggregate IFIE for the period in OCI and present in
profit or loss IFIE using a systematic allocation on its long-term life insurance
business lines in Discovery Life and VitalityLife. For the remainder of business lines,
the change in IFIE of the insurance contracts is presented in profit or loss, offset by
the changes in the value of assets backing the insurance contracts.

-- 192 of 217 --

192	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure B – Group accounting policies continued
for the year ended 30 June 2023
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.9 	Presentation and disclosure
30.9.2 CHANGE IN PRESENTATION AND DISCLOSURE RELATIVE TO IFRS 4
Statement of financial position
Assets arising from insurance contracts 	Assets arising from insurance contracts issued
Contract receivables and other receivables
Assets arising from reinsurance contracts held
Liabilities arising from insurance contracts 	Liabilities arising from insurance contracts issued
Liabilities arising from reinsurance contracts held
Other equity (includes reserve for IFIE
presented in OCI)
Liabilities arising from reinsurance
contracts
Deferred acquisition costs
Insurance receivables, contract
receivables and other receivables
Reinsurance contracts
IFRS 4 	IFRS 17
Assets
Liabilities
Assets
Liabilities
Equity
1
1
3
4
2
3
Flowchart 1: Changes in Discovery’s presentation in Statement of financial position from IFRS 4 to IFRS 17
1 	All insurance cash flows (LRC + LIC), payables and receivables presented net either as a liability or an asset from insurance
contracts.
2 	Premium debtors are included in the measurement of insurance contracts.
3 	All reinsurance cash flows, payables and receivables presented net either as a liability or an asset from reinsurance
contracts.
4 	New reserve for the cumulative insurance finance income and expense (IFIE) recognised in OCI.

-- 193 of 217 --

193	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Income statement and other comprehensive income
30. 	New Standards in Interpretation – IFRS 17 Insurance Contracts continued
30.9 	Presentation and disclosure
30.9.2 CHANGE IN PRESENTATION AND DISCLOSURE RELATIVE TO IFRS 4
Net premium insurance
Insurance premium revenue
Reinsurance premiums Insurance Revenue
Net finance income/(expense) from insurance contracts issued
Net finance income/(expense) from reinsurance contracts held
Marketing and administration expenses (non-attributable)
Net finance income/(expense) from insurance contracts issued
Net finance income/(expense) from reinsurance contracts held
STATEMENT OF COMPREHENSIVE INCOME
INCOME STATEMENT
Accelerated reinsurance premiums
Receipts arising from reinsurance
Clients and policyholder benefits
– Insurance claims recovered from policyholders
– Recapture of reinsurance
Acquisition costs
Marketing and administration expenses
Recovery of expenses from reinsurers
Net transfer to/from Assets and Liabilities from insurance contracts
– change in assets arising from insurance contracts
– change in assets arising from reinsurance contracts
– change in assets arising from insurance contracts
– change in assets arising from reinsurance contracts
– economic assumption adjustments net of discretionary margins
Reinsurance receipts
Claims
Operating expenses
Changes in margins
IFRS 4 	IFRS 17
Reclassify over time
Insurance service result 	1
2
3	Net expenses from reinsurance contracts held
Insurance Service Expenses
Net insurance financial result 	4
Operating expenses 	5
4	Net insurance financial result
Flowchart 2: Changes in Discovery’s presentation in Income statement from IFRS 4 to IFRS 17.
1 	 For short-term insurance, the Insurance revenue includes earned revenues.
 For long-term insurance, the Insurance revenue includes the recognition of CSM, release of risk adjustment and release
of expected insurance service expenses (i.e., expected directly attributable costs
2 	 Insurance service expenses comprise of actual incurred claims and directly attributable expenses, the recognition of
onerous contracts. Insurance acquisition cash flows are immediately expensed or amortised.
3 	 The net expense of reinsurance expenses and reinsurance receipts
4 	 Changes in assumptions for future services of time value of money, inflation index and foreign exchanges are recognised
in period in OCI. The amount is reclassified to profit or loss on a systematic basis over the coverage period. In period,
variances are recognised in profit or loss.
5 	 Includes those expenses and costs not directly attributable to the insurance contract
30.10 Transition
IFRS 17 requires the standard to be applied fully retrospectively unless impracticable. If impracticable, the entity can elect to apply a
modified retrospective approach or use the fair value approach. As discussed earlier, Discovery has applied the fully retrospective
approach for all material groups of insurance contracts.
Given some constraints to the availability of reasonable and supportable data, Discovery has elected to apply IFRS 17 in certain
circumstances by using the modified retrospective approach. The less material portfolios which applied modifications are noted below.
Annexure B – Group accounting policies continued
for the year ended 30 June 2023

-- 194 of 217 --

194	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
30.10 Transition continued
30.10.1 EXCEPTIONS WHERE THE MODIFIED RETROSPECTIVE APPROACH WAS APPLIED
Discovery Individual life portfolio
Discovery has applied the modified retrospective approach within the Discovery Individual Life portfolio by aggregating contracts
issued more than one year apart prior to 2003 into a single group of insurance contracts in respect of insurance contracts issued
before June 2003. The application of the full retrospective approach on transition for these groups were determined to be
impracticable as Discovery Life does not have the model used nor data of sufficient quality to either retrospectively model business
sold before the June 2002 financial year or to identify new business policies sold in the June 2002 financial year. It should be noted
that these portfolios or cohorts of business are immaterial in the context as Discovery Life only commenced business in 2000.
Discovery Invest portfolios - the unit-linked and DRO portfolio and the general endowments portfolio
Discovery has applied the modified retrospective approach within the Discovery Invest portfolios by aggregating contracts issued
more than one year apart into a single group of insurance contracts issued before June 2016 for the DRO portfolio and groups of
insurance contracts issued before June 2012 for the general endowments and unit-linked portfolio.
The application of the fully retrospective approach on transition for these portfolios was determined to be impracticable for
Discovery Invest as it did not collect the data of policies sold with sufficient granularity in the periods prior to June 2012. Discovery
Invest only commenced trading in 2007.
VitalityHealth private medical insurance contracts
Discovery applied the modified approach to identify, recognise, and measure assets arising from insurance acquisition cash flows
for the VitalityHealth PMI portfolio as of 1 July 2022. It is impracticable to apply the full retrospective approach as eight years ago
(of the ten years that DAC is being applied for), the data was not collected with sufficient granularity for the purposes of setting up
a deferred acquisition cost reserve, and its omission has an immaterial impact on the equity.
30.11 Implementation progress
Work on the finalisation of key policy and methodology decisions is complete. Management has substantially finalised the financial
impact assessment to enable the restatement of the comparative opening balance adjustments as at 1 July 2022 and the
retrospective reporting periods leading up to the transitional Statement of financial position.
The IFRS 17 project has been managed as follows:
 The Group CFO heads up the IFRS 17 Executive Working Committee (EWC), which comprises the respective Insurance business
CFOs, Chief Actuaries, and IT specialists. The IFRS 17 Executive Working Committee is supported by a Technical Advisory Group
comprising IFRS Specialists, Actuaries, Financial Managers, and Tax specialists. The Committee also consults with external audit
firms where necessary.
 The EWC is responsible for providing overall strategic direction to the project across the Group and for monitoring progress and
interdependencies with other group initiatives. The EWC also provides policy guidance and technical support for the
implementation in each of its subsidiaries.
 The EWC reports to the Group Finance and Capital Committee (FCC) as a sub-committee of the Group Executive Committee and
recommends and suggests its final proposals to the IFRS 17 Governance Committee. The IFRS 17 Governance Committee
comprises amongst others non-executive directors from the various Actuarial and Audit Committees within the insurance
business lines and ultimately makes recommendations to the various Audit Committees and Actuarial Committees that, in turn,
make recommendations to their respective Boards.
KPMG Inc., as the current joint auditor, and Deloitte & Touche, as the proposed joint auditor following the mandatory audit firm
rotation of PwC Inc., have been engaged to provide the external audit assurance for IFRS 17 in their capacity as the external auditors
for the financial year ending 30 June 2024, the first financial year that Discovery will apply IFRS 17. A combined assurance approach
is being followed whereby group internal and external auditors incrementally test the new IFRS 17 landscape.
For the disclosures included within this audited set of Financial Statements, the external auditors, KPMG Inc. and PwC Inc., have
performed procedures, including evaluating the decisions made by management and the results to date. These procedures include,
but are not limited to, evaluating the transition methodology decisions, product classification, and other policy and methodology
decisions relevant to the IFRS 17 results, as well as performing audit procedures over the valuation of portfolios considered material
to the disclosures provided. The auditors have reported on the annual financial statements as a whole.
PROJECT FOCUS FOR THE NEXT FINANCIAL YEAR
Management will focus on the following key areas during the next financial year:
 Finalisation of the IFRS 17 transitional tax arrangements.
 Finalise and produce IFRS 17 compliant financial statements for the first interim reporting period for the six months ending 31
December 2023, including restated information for the financial year ended 30 June 2023 and interim reporting period for the
six months ended 31 December 2022.
 External audit of restated balances, models and controls.
 Management reporting and, where applicable, key performance measures.
 Finalise business-as-usual future financial and data governance processes and financial reporting controls.
 Reporting to and educating financial analysts and investors about the application and impact from a Discovery Group perspective.
Annexure B – Group accounting policies continued
for the year ended 30 June 2023

-- 195 of 217 --

195	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure C – Directorate
REMUNERATION AND FEES
Payment to directors and prescribed officers for the year ended 30 June 2023 for services rendered are set out in the table below. It should
be noted that these payments reflect cash payments made to directors and prescribed officers during the financial year and therefore all
variable pay components are reflective of performance measurements relating to previous periods. The variable pay components relating
to the current year under review are physically paid in the following financial year and are analysed in detail in the Group’s annual
remuneration report and are more reflective of the performance of the period under review.
Payments to directors and prescribed officers for the year ended 30 June 2023 for services rendered are as follows:
R’000
Services
as
directors
Basic
salary
Perfor-
mance
bonus 	LTIP2
Provident
fund
contri-
butions
Other
benefits 1 	Total
Executive
A Gore 	– 	7 987 	9 603 	8 692 	1 198 	422 	27 902
B Swartzberg 	– 	5 592 	13 032 	2 522 	586 	265 	21 997
DM Viljoen 	– 	5 995 	6 358 	4 417 	945 	303 	18 018
HD Kallner7 	– 	7 472 	7 062 	23 823 	374 	228 	38 959
NS Koopowitz8 	– 	21 255 	22 734 	10 816 	118 	563 	55 486
Dr A Ntsaluba9 	– 	4 999 	5 811 	4 961 	375 	316 	16 462
A Pollard10 	– 	8 968 	9 368 	6 677 	225 	388 	25 626
Sub-total 	– 	62 268 	73 968 	61 908 	3 821 	2 485 	204 450
Non-executive
ME Tucker3 	7 541 	– 	– 	– 	– 	– 	7 541
HL Bosman4 	1 033 	– 	– 	– 	– 	– 	1 033
R Farber5 	3 713 	– 	– 	– 	– 	4 010 	7 723
M Hlahla 	1 411 	– 	– 	– 	– 	– 	1 411
FN Khanyile 	1 964 	– 	– 	– 	– 	– 	1 964
D Macready 	2 087 	– 	– 	– 	– 	– 	2 087
Dr TV Maphai 	1 651 	– 	– 	– 	– 	– 	1 651
T Mboweni 	1 391 	– 	– 	– 	– 	– 	1 391
M Schreuder 	2 033 	– 	– 	– 	– 	– 	2 033
B Van Kralingen6 	1 901 	– 	– 	– 	– 	108 	2 009
SV Zilwa 	2 687 	– 	– 	– 	– 	– 	2 687
Sub-total 	27 412 	– 	– 	– 	– 	4 118 	31 530
Total 	27 412 	62 268 	73 968 	61 908 	3 821 	6 603 	235 980
Less: paid by subsidiaries 	(27 412) 	(62 268) 	(73 968) 	(61 908) 	(3 821) 	(6 603) 	(235 980)
Paid by holding company 	– 	– 	– 	– 	– 	– 	–
1 “Other benefits” comprise medical aid contributions, travel, other allowances and fees from group subsidiaries.
2 “LTIP” comprises cash-settled and equity-settled incentives.
3 Director’s fees for services rendered are paid in GBP.
4 Director’s fees for services rendered by HL Bosman (retired effective 1 December 2022) were paid to Rand Merchant Insurance Holdings Limited.
5 Director’s fees for services and fees for other consulting services rendered by R Farber were paid in AUD. Director’s fees for consulting services are included
as part of other benefits.
6 Director’s fees for services rendered are paid in USD.
7 Transitioned from Group Executive Director to Prescribed Officer with effect from 1 March 2023. The remuneration presented above is for the full financial
year.
8 Salary and incentive are paid in GBP. Transitioned from Group Executive Director to Prescribed Officer with effect from 1 March 2023.
9 Stepped down as Executive Director with effect from 1 March 2023. Group Executive 1 March to 30 June 2023. The remuneration presented above is for the
full financial year.
10 Salary and incentive are paid in USD. Stepped down as Executive Director with effect from 1 March 2023. Group Executive 1 March to 30 June 2023.

-- 196 of 217 --

196	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure C – Directorate continued
REMUNERATION AND FEES continued
Payment to directors and prescribed officers for the year ended 30 June 2022 for services rendered are set out in the table below. It should
be noted that these payments reflect cash payments made to directors and prescribed officers during the financial year and therefore all
variable pay components are reflective of performance measurements relating to previous periods. The variable pay components relating
to the current year under review are physically paid in the following financial year and are analysed in detail in the Group’s annual
remuneration report and are more reflective of the performance of the period under review.
Payments to directors and prescribed officers for the year ended 30 June 2022 for services rendered are as follows:
R’000
Services
as
directors 1
Basic
salary
Perfor-
mance
bonus
Phantom
scheme
payments
Provident
fund
contri-
butions
Other
benefits1 	Total
Executive
A Gore 	– 	7 611 	8 172 	– 	1 107 	387 	17 277
HD Kallner 	– 	5 650 	6 891 	– 	282 	174 	12 997
NS Koopowitz2 	– 	19 428 	21 286 	8 664 	81 	552 	50 011
Dr A Ntsaluba 	– 	4 749 	5 216 	– 	356 	290 	10 611
A Pollard3 	– 	7 343 	6 684 	2 057 	122 	336 	16 542
B Swartzberg 	– 	5 314 	5 933 	2 532 	555 	237 	14 571
DM Viljoen 	– 	5 019 	5 381 	2 995 	780 	183 	14 358
Sub-total 	– 	55 114 	59 563 	16 248 	3 283 	2 159 	136 367
Non-executive
ME Tucker4 	6 539 	– 	– 	– 	– 	– 	6 539
HL Bosman6 	1 743 	– 	– 	– 	– 	– 	1 743
Dr BA Brink 	614 	– 	– 	– 	– 	– 	614
SE De Bruyn 	591 	– 	– 	– 	– 	– 	591
R Farber5 	3 219 	– 	– 	– 	– 	3 633 	6 852
MH Hlala 	1 102 	– 	– 	– 	– 	– 	1 102
FN Khanyile 	1 500 	– 	– 	– 	– 	– 	1 500
D Macready 	1 851 	– 	– 	– 	– 	– 	1 851
Dr TV Maphai 	1 797 	– 	– 	– 	– 	– 	1 797
T Mboweni 	209 	– 	– 	– 	– 	– 	209
M Schreuder 	1 621 	– 	– 	– 	– 	– 	1 621
B Van Kralingen7 	348 	– 	– 	– 	– 	– 	348
SV Zilwa8 	2 176 	– 	– 	– 	– 	– 	2 176
Sub-total 	23 310 	– 	– 	– 	– 	3 633 	26 943
Total 	23 310 	55 114 	59 563 	16 248 	3 283 	5 793 	163 310
Less: paid by subsidiaries 	(23 310) 	(55 114) 	(59 563) 	(16 248) 	(3 283) 	(5 793) 	(163 310)
Paid by holding company 	– 	– 	– 	– 	– 	– 	–
1 “Other benefits” comprise medical aid contributions, travel, other allowances and fees from group subsidiaries.
2 Salary and incentives paid in GBP.
3 Salary and incentives paid in USD.
4 Director’s fees for services rendered are paid in GBP.
5 Director’s fees for services rendered by R Farber were paid in AUD components.
6 Director’s fees for services rendered by HL Bosman were paid to Rand Merchant Insurance Holdings Limited.
7 Director’s fees for services rendered are paid in USD.
8 Participated in Discovery Limited 2015 BEE transaction, which loan outstanding to the Company was fully settled during the 2022 financial year.

-- 197 of 217 --

197	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure C – Directorate continued
DIRECTORS’ PARTICIPATION IN LONG-TERM INCENTIVE SCHEMES
Discovery’s directors and prescribed officers participate in the various long-term incentive schemes offered by the Group and their
participation is disclosed below. Refer to Group note 32 for a detailed description of the various schemes offered.
Discovery Limited phantom share scheme
Directors and prescribed officers participation as at 30 June 2023:
Directors and prescribed officers
Outstanding
shares
Date
granted
Final
vesting
date
Value at
30 June 2023
R
A Gore 	12 007 	2018/09/30 	2023/09/30 	1 751 221
HD Kallner 	8 053 	2018/09/30 	2023/09/30 	1 174 530
Dr A Ntsaluba 	7 078 	2018/09/30 	2023/09/30 	1 032 326
A Pollard 	1 640 	2018/09/30 	2023/09/30 	239 194
B Swartzberg 	2 819 	2018/09/30 	2023/09/30 	411 151
DM Viljoen 	7 597 	2018/09/30 	2023/09/30 	1 108 022
Discovery Limited long-term incentive plan
Directors and prescribed officers participation as at 30 June 2023:
Directors and prescribed officers
Outstanding
shares
Date
granted
Final
vesting
date
Value at
30 June 2023
R
A Gore 	38 200 	2019/09/30 	2024/09/30 	5 571 470
30 434 	2020/09/30 	2023/09/30 	4 438 799
69 707 	2020/09/30 	2025/09/30 	10 166 766
68 786 	2021/09/30 	2026/09/30 	10 032 438
HD Kallner 	25 620 	2019/09/30 	2024/09/30 	3 736 677
98 985 	2020/09/30 	2023/09/30 	14 436 962
46 752 	2020/09/30 	2025/09/30 	6 818 779
46 135 	2021/09/30 	2026/09/30 	6 728 790
Dr A Ntsaluba 	22 627 	2019/09/30 	2024/09/30 	3 300 148
17 846 	2020/09/30 	2023/09/30 	2 602 839
41 289 	2020/09/30 	2025/09/30 	6 022 001
40 744 	2021/09/30 	2026/09/30 	5 942 512
51 786 	2022/11/30 	2025/09/30 	7 552 988
A Pollard 	7 331 	2019/09/30 	2024/09/30 	1 069 226
3 145 	2020/09/30 	2023/09/30 	458 698
22 362 	2020/09/30 	2025/09/30 	3 261 498
22 276 	2021/09/30 	2026/09/30 	3 248 955
83 453 	2022/11/30 	2025/09/30 	12 171 620
7 709 	2022/11/30 	2027/09/30 	1 124 358
B Swartzberg 	7 686 	2019/09/30 	2024/09/30 	1 121 003
11 501 	2020/09/30 	2023/09/30 	1 677 421
23 376 	2020/09/30 	2025/09/30 	3 409 390
23 068 	2021/09/30 	2026/09/30 	3 364 468
8 075 	2022/11/30 	2027/09/30 	1 177 739
DM Viljoen 	24 170 	2019/09/30 	2024/09/30 	3 525 195
24 797 	2020/09/30 	2023/09/30 	3 616 642
44 105 	2020/09/30 	2025/09/30 	6 432 714
45 197 	2021/09/30 	2026/09/30 	6 591 982

-- 198 of 217 --

198	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure C – Directorate continued
DIRECTORS’ PARTICIPATION IN LONG-TERM INCENTIVE SCHEMES continued
The Vitality Group Cash-settled plan
Directors and prescribed officers
Directors and prescribed officers
Outstanding
shares
Date
granted
Exercise
price
USD
Final
vesting
date
Value at
30 June 2023
USD
A Pollard 	36 467 	2018/09/30 	– 	2023/09/30 	37 312
139 268 	2019/09/30 	– 	2024/09/30 	194 975
153 330 	2020/09/30 	– 	2025/09/30 	214 662
167 813 	2021/09/30 	– 	2026/09/30 	234 938
B Swartzberg 	62 665 	2018/09/30 	– 	2023/09/30 	64 118
143 771 	2019/09/30 	– 	2024/09/30 	201 279
160 280 	2020/09/30 	– 	2025/09/30 	224 393
173 772 	2021/09/30 	– 	2026/09/30 	243 281
The VitalityHealth and VitalityLife phantom share schemes
Directors and prescribed officers participation as at 30 June 2023:
Directors and prescribed officers
Outstanding
shares
Date
granted
Exercise
price
GBP
Final
vesting
date
Value at
30 June 2023
GBP
NS Koopowitz 	4 336 	2020/03/01 	– 	2023 	192 995
27 430 	2022/01/05 	– 	2024 	1 123 533
DIRECTORS’ PARTICIPATION IN SINGLE INCENTIVE PLAN
Discovery Limited Single Incentive Plan
Directors and prescribed officers participation as at 30 June 2023:
Directors and prescribed officers
Outstanding
shares
Date
granted
Final
vesting
date
Value at
30 June 2023
R
A Gore 	92 223 	2022/11/30 	2027/09/30 	13 450 725
HD Kallner 	67 823 	2022/11/30 	2027/09/30 	9 891 985
Dr A Ntsaluba 	55 807 	2022/11/30 	2027/09/30 	8 139 451
A Pollard 	91 102 	2022/11/30 	2027/09/30 	13 287 227
B Swartzberg 	67 999 	2022/11/30 	2027/09/30 	9 917 654
DM Viljoen 	61 054 	2022/11/30 	2027/09/30 	8 904 726

-- 199 of 217 --

199	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure C – Directorate continued
Directors’ interests in shares
According to the Register of Directors’ Interests, maintained by Discovery in accordance with the provisions of section 30(4)(d) of the
Companies Act, directors and prescribed officers of Discovery have disclosed the following interest in the ordinary shares of the Company
at 30 June 2023:
Directors and prescribed officers
Direct
beneficial
Indirect
beneficial
Total
2023
Direct
beneficial
Indirect
beneficial
Total
2022
Executive
A Gore1 	31 372 	48 561 559 	48 592 931 	– 	49 046 559 	49 046 559
B Swartzberg 2 	3 146 461 	22 635 115 	25 781 576 	3 202 227 	22 635 115 	25 837 342
DM Viljoen 	29 850 	– 	29 850 	10 000 	– 	10 000
HD Kallner4 	100 398 	– 	100 398 	100 398 	– 	100 398
NS Koopowitz4 	– 	792 004 	792 004 	– 	852 004 	852 004
Dr A Ntsaluba5 	89 455 	– 	89 455 	80 164 	– 	80 164
A Pollard5 	1 073 099 	– 	1 073 099 	1 193 099 	– 	1 193 099
Non-executive
HL Bosman3 	– 	164 370 	164 370 	– 	164 370 	164 370
R Farber 	55 076 	– 	55 076 	55 076 	– 	55 076
FN Khanyile 	1 300 	– 	1 300 	1 300 	– 	1 300
Dr TV Maphai 	1 919 	196 505 	198 424 	1 919 	196 505 	198 424
SV Zilwa 	– 	680 	680 	– 	680 	680
4 528 930 	72 350 233 	76 879 163 	4 644 183 	72 895 233 	77 539 416
1 Includes 39 300 000 (2022: 39 300 000) ordinary shares which are subject to security.
2 Includes 11 5000 000 (2022: 11 500 000) ordinary shares which are subject to security.
3 Retired effective 1 December 2023
4 Transitioned from Group Executive Director to Prescribed Officer with effect from 1 March 2023
5 Stepped down as Executive Director with effect from 1 March 2023.
There has been no change in the directors’ interests in Discovery Limited’s shares between 30 June 2023 and the date of publication of these
annual financial statements.

-- 200 of 217 --

200	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure D – Unaudited analysis of shareholders
at 30 June 2023
ORDINARY SHAREHOLDERS
Number of
shareholders
% of total
shareholders
Number of
shares
% of
issued
capital
Shareholder spread
1 – 1 000 shares 	38 753 	86.89 	5 883 083 	0.87
1 001 – 10 000 shares 	4 650 	10.43 	12 676 392 	1.88
10 001 – 100 000 shares 	878 	1.97 	27 157 201 	4.03
100 001 – 1 000 000 shares 	238 	0.53 	79 460 026 	11.81
1 000 001 shares and over 	82 	0.18 	547 969 715 	81.41
44 601 	100.00 	673 146 417 	100.00
Public/non-public shareholders
Non-public shareholders 	19 	0.03 	178 244 562 	26.48
– Directors of the Company, including their associates 	9 	0.02 	75 552 239 	11.23
– Employee share trusts 	2 	0.00 	14 045 368 	2.09
– Own holdings 	1 	0.00 	680 268 	0.10
– Key management personnel and trustees of pension funds 	6 	0.01 	699 089 	0.10
– Strategic holdings (more than 10%) 	1 	0.00 	87 267 598 	12.96
Public shareholders 	44 582 	99.97 	494 901 855 	73.52
44 601 	100.00 	673 146 417 	100.00
Number of
shares 	%
Beneficial shareholders’ holding of 5% or more
Government Employees Pension Fund (including shares managed by Public Investment Corporation) 	87 267 598 	12.96
Remgro Limited 	51 254 365 	7.61
Baillie Gifford & Co Limited 	50 465 898 	7.50
Adrian Gore 	48 592 931 	7.22
B PREFERENCE SHAREHOLDERS
Number of
shareholders
% of total
shareholders
Number of
shares
% of
issued
capital
Shareholder spread
1 – 1 000 shares 	2 611 	74.58 	305 068 	3.81
1 001 – 10 000 shares 	756 	21.59 	2 408 357 	30.10
10 001 – 100 000 shares 	126 	3.60 	3 202 255 	40.04
100 001 – 1 000 000 shares 	8 	0.23 	2 084 320 	26.05
3 501 	100.00 	8 000 000 	100.00
Public/non-public shareholders
Public shareholders 3 501 	100.00 	8 000 000 	100.00
Number of
shares 	%
Beneficial shareholders’ holding of 5% or more
Outsurance Insurance Company Ltd 	500 000 	6.25
PSG Diversified Income Fund 	497 457 	6.22

-- 201 of 217 --

201	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement
Report on the review of the Embedded Value Statement
of Discovery Limited and its subsidiaries to the Directors of Discovery Limited
INTRODUCTION
We have reviewed the Embedded Value Statement of Discovery Limited and its subsidiaries (together the Discovery Limited Group) for the
year ended 30 June 2023, as set out on pages 202 to 212 of the Discovery Annual Financial Statements for the year ended 30 June 2023 (the
Report). The Report is prepared for the purpose of determining the embedded value and performance of Discovery Limited Group. The
directors of Discovery Limited are responsible for the preparation and presentation of the Report in accordance with the embedded value
basis set out in the Basis of Preparation section of the Report, and for determining that the basis of preparation is acceptable in the
circumstances. Our responsibility is to express a conclusion on this Report based on our review.
SCOPE OF REVIEW
We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, Review of Interim Financial
Information Performed by the Independent Auditor of the Entity. A review of financial information consists of making inquiries, primarily of
persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially
less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to
obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express
an audit opinion.
CONCLUSION
Based on our review, nothing has come to our attention that causes us to believe that the Report is not prepared, in all material respects,
in accordance with the basis set out in the Basis of Preparation section of the Report.
BASIS OF ACCOUNTING AND RESTRICTION ON USE
Without modifying our conclusion, we draw attention to the Basis of Preparation section of the Report, which describes the basis of
accounting. The Report is prepared for the purpose of determining the value and performance of Discovery Limited Group. As a result, the
Report may not be suitable for another purpose. Our report is intended solely for the directors of Discovery Limited and should not be used
by any other parties. We agree to the publication of our report in the Discovery Annual Financial Statements for the year ended
30 June 2023, provided it is clearly understood by the recipients of the Discovery Annual Financial Statements for the year ended
30 June 2023 that they enjoy such receipt for information only and that we accept no duty of care to them in respect of our report.
PricewaterhouseCoopers Inc. 	KPMG Inc.
Director: Andrew Graham Taylor 	Director: Mark Danckwerts
Registered Auditor 	Registered Auditor
Johannesburg 	Johannesburg
21 September 2023 	21 September 2023

-- 202 of 217 --

202	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
The embedded value of the Discovery Group consists of the following components:
 the adjusted net worth attributed to the business at the valuation date;
 plus: the present value of expected future shareholder cash flows from the in-force covered business;
 less: the cost of required capital.
The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future after-tax
shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities, whose
distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new
business written by the Discovery Group, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses and
cost of required capital. The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Group. Covered business
includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and Discovery
Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping an Health Insurance, Discovery
Insure, Discovery Bank and Umbrella Funds, no published value has been placed on the current in-force business.
In August 2011, the Discovery Group raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference
shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth.
From June 2022, the VitalityLife embedded value has been adjusted to allow for the agreement with the Prudential Assurance Company (“PAC”)
in May 2022 to defer the transfer of the VitalityLife business on the PAC licence to the Vitality Life Limited licence (“the Part VII transfer”).
The 30 June 2023 embedded value results and disclosures were subjected to an external review.

-- 203 of 217 --

203	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
TABLE 1: GROUP EMBEDDED VALUE
R million
30 June
2023
30 June
2022
%
change
Shareholders’ funds 	63 974 	53 555 	19
Adjustment to shareholders’ funds from published basis1 	(45 688) 	(39 764) 	15
Adjusted net worth2 	18 286 	13 791 	33
Value of in-force covered business before cost of required capital 	83 906 	76 077 	10
Cost of required capital 	(4 016) 	(3 610) 	11
Discovery Group embedded value 	98 176 	86 258 	14
Number of shares (millions) 	658.4 	657.0
Embedded value per share 	R149.11 	R131.29 	14
Diluted number of shares (millions) 	672.5 	668.3
Diluted embedded value per share3 	R145.99 	R129.07 	13
1 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using
the closing exchange rate of R23.99/GBP (June 2022: R20.00/GBP).
R million
30 June
2023
30 June
2022
Life net assets under insurance contracts 	(25 491) 	(24 793)
Vitality Life Limited net assets under insurance contracts 	(12 051) 	(8 608)
VitalityHealth financial reinsurance asset 	(4 465) 	(3 021)
VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax) 	(536) 	(450)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) 	(13) 	(11)
Goodwill relating to the acquisition of Standard Life Healthcare and the PAC joint venture 	(2 969) 	(2 475)
Intangible assets (net of deferred tax) in covered businesses 	(893) 	(864)
Net preference share capital 	(779) 	(779)
Reversal of 1 Discovery Place IFRS 16 financial lease accounting 	1 333 	1 170
Equity settled share based payment mark-to-market adjustment 	176 	67
(45 688) 	(39 764)
The “equity settled share based payment mark-to-market adjustment” reflects the difference between the provision in the IFRS equity and the
mark-to-market value of the equity settled share based payments.

-- 204 of 217 --

204	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
2 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the
embedded value:
R million
30 June
2023
30 June
2022
Shareholders’ funds 	63 974 	53 555
Adjustment to shareholders’ funds 	(45 688) 	(39 764)
Adjusted net worth 	18 286 	13 791
Excess of available capital over adjusted net worth 	40 336 	35 342
Available capital 	58 622 	49 133
Required capital 	41 987 	38 658
Excess available capital 	16 635 	10 475
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth and the available capital. This includes:
– The net preference share capital of R779 million which is included as available capital.
– The difference between Vitality Life Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth.
– The difference between Life’s Pillar 1 Own Funds and its adjusted net worth.
The following table sets out the required capital for each of the covered businesses:
R million
30 June
2023
30 June
2022
Health and Vitality 	1 108 	1 000
Life and Invest 	26 011 	25 403
VitalityHealth 	4 238 	3 164
VitalityLife 	10 630 	9 091
Total required capital 	41 987 	38 658
– For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost.
– For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
– For VitalityHealth, the required capital amount was set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement.
– For the VitalityLife business on the PAC licence, the required capital was set equal to 1.5 times the UK Solvency I long-term insurance capital
requirement as per the agreement with PAC following the long-term delay of the Part VII transfer. For the business sold on the Vitality Life Limited
licence, the required capital was set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement. Note that for the prior period ended
30 June 2022, the total required capital for VitalityLife was incorrectly reported as R9 751 million resulting in a total required capital of
R39 318 million and total excess available capital of R9 815 million. This misstatement has been corrected above, and did not affect the
embedded value as at 30 June 2022.
3 The diluted embedded value per share adjusts for treasury shares held in the Discovery Group BEE Share Trust and as part of the Discovery Group’s
Long-term Incentive Plan where the impact is dilutive.

-- 205 of 217 --

205	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS
R million
Value before cost of
required capital
Cost of required
capital
Value after cost of
required capital
at 30 June 2023
Health and Vitality 	25 985 	(512) 	25 473
Life and Invest1 	33 301 	(1 665) 	31 636
VitalityHealth2 	12 797 	(698) 	12 099
VitalityLife 2 	11 823 	(1 141) 	10 682
Total 	83 906 	(4 016) 	79 890
at 30 June 2022
Health and Vitality 	24 528 	(479) 	24 049
Life and Invest1 	32 073 	(1 509) 	30 564
VitalityHealth2 	10 658 	(583) 	10 075
VitalityLife2 	8 818 	(1 039) 	7 779
Total 	76 077 	(3 610) 	72 467
1 Included in the Life and Invest value of in-force covered business is R2 005 million (June 2022: R1 734 million) in respect of investment management
services provided on off balance sheet investment business. The net assets of the investment service provider are included in the adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R23.99/GBP (June 2022: R20.00/GBP).
TABLE 3: GROUP EMBEDDED VALUE EARNINGS
R million
30 June
2023
30 June
2022
Embedded value at end of period 	98 176 	86 258
Less: embedded value at beginning of period 	(86 258) 	(74 645)
Increase in embedded value 	11 918 	11 613
Net change in capital1 	– 	(10)
Dividends paid 	69 	56
Transfer to hedging reserve 	(76) 	(309)
Employee share option schemes 	(553) 	(326)
Increase in treasury shares 	– 	–
Acquisition of subsidiaries with non-controlling interest 	(6) 	–
Embedded value earnings 	11 352 	11 024
Annualised return on opening embedded value 	13.2% 	14.8%
1 The net change in capital reflects share issues (net of costs and proceeds) and an increase (decrease) in treasury shares in the period.

-- 206 of 217 --

206	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS
Year ended
30 June 2023
Year ended
30 June
2022
R million
Net
worth
Cost of
required
capital
Value of
in-force
covered
business
Embedded
value
Embedded
value
Total profit from new business (at point of sale) 	(5 213) 	(302) 	6 955 	1 440 	2 061
Profit from existing business
– 	Expected return 	7 196 	(33) 	1 426 	8 589 	6 799
– 	Change in methodology and assumptions1 	1 989 	172 	(7 015) 	(4 854) 	867
– 	Experience variances 	716 	68 	2 420 	3 204 	3 124
Impairment, amortisation and fair value adjustment2 	(67) 	– 	– 	(67) 	(52)
Increase in goodwill and intangibles 	(263) 	– 	– 	(263) 	(418)
Other initiatives 3 	– 	– 	24 	24 	(836)
Non-recurring expenses 	(193) 	– 	– 	(193) 	(130)
Acquisition costs 4 	(50) 	– 	2 	(48) 	(41)
Finance costs 	(2 848) 	– 	– 	(2 848) 	(2 318)
Foreign exchange rate movements 5 	1 365 	(312) 	4 017 	5 070 	1 171
Other6 	89 	1 	– 	90 	(16)
Return on shareholders’ funds7 	1 208 	– 	– 	1 208 	813
Embedded value earnings 	3 929 	(406) 	7 829 	11 352 	11 024
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the
operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous
embedded value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital
expenditure in Discovery Group Europe Limited.
3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health Insurance) and costs of start-up
businesses (including Discovery Bank, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest). Head office costs which
relate to non-covered business are also included in this item.
4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been
written over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the
value of new business and therefore the costs are not deducted from the value of new business.
5 This item includes foreign exchange gains/(losses) emerging through the income statement, in addition to translation impacts on the cost of required
capital and value of in-force.
6 This item includes, among other items, the tangible tax impact from movements in covered business intangible assets, which are excluded from
the net worth.
7 The return on shareholders’ funds is shown net of tax and management charges.

-- 207 of 217 --

207	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
TABLE 5: EXPERIENCE VARIANCES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Renewal expenses 	67 	– 	32 	2 	(93) 	– 	(16) 	– 	(8)
Lapses and surrenders 1,2 	(4) 	(78) 	1 	189 	– 	372 	(161) 	218 	537
Mortality and morbidity 	– 	– 	130 	(79) 	(93) 	– 	34 	– 	(8)
Policy alterations2 	– 	(5) 	(521) 	163 	– 	– 	30 	(54) 	(387)
Backdated cancellations 	– 	– 	– 	– 	– 	– 	– 	– 	–
Premium and fee income 3 	150 	– 	14 	232 	218 	– 	7 	61 	682
Inflation-linked indexation2,4 	– 	– 	4 	242 	– 	– 	(107) 	606 	745
Economic5 	– 	– 	260 	284 	64 	– 	(2) 	– 	606
Commission 	– 	– 	– 	– 	(36) 	– 	– 	– 	(36)
Tax6 	110 	– 	305 	(307) 	(33) 	– 	46 	– 	121
Reinsurance 	– 	– 	– 	– 	84 	– 	(106) 	46 	24
Maintain modelling term7 	– 	335 	– 	137 	– 	117 	– 	– 	589
Vitality benefits 	(32) 	– 	– 	– 	– 	– 	(5) 	– 	(37)
Other8 	161 	(1) 	(58) 	35 	19 	– 	247 	(27) 	376
Total 	452 	251 	167 	898 	130 	489 	(33) 	850 	3 204
1 For Health and Vitality, the lapse and surrender experience was driven by the termination of an in-house scheme for the period under review
– excluding this impact would have resulted in a positive experience variance for the business. For VitalityHealth, the experience reflects improved
retention rates from strong performance across all channels coupled with a continued focus on renewal pricing strategies. Better than expected lapse
experience has been observed for the other covered businesses.
2 For Life and Invest, the policy alterations experience relates mainly to acquisition costs on positive servicing, but should be considered in the context
of the overall positive lapse and surrender and economic experience variances given its correlation to current economic conditions and the high
inflationary environment.
3 Other than higher than expected premium and fee income, this experience variance item includes the impact of positive integration experience for
Individual Life, and an increased demand for private medical insurance in the United Kingdom improving premium retention for VitalityHealth.
4 This experience variance relates to premium and benefit increases for inflation-linked policies, net of increase holidays. During the period the actual
inflation was higher than expected for those policies passing through an anniversary increase in-period. In previous embedded value statements, this
experience variance was included under economic experience. Due to the significance of these experience variances in the current period as a result
of the high inflationary environment, this amount has been shown separately.
5 For Life and Invest, the experience includes higher than expected growth in asset values in the Invest business.
6 The tax variance arises due to the timing difference between the expected tax payments and actual payments.
7 For Health and Vitality, Life and Invest and VitalityHealth, the projection term is rebased at each year-end. Therefore, an experience variance arises
because the total term of the in-force covered business is effectively increased by twelve months.
8 The key Other experience relates to cash flow timing variances in Life and Invest, profits and losses from companies within the Health, VitalityHealth
and VitalityLife segments which are not part of covered business, including the net impact of the VitalityLife swaption program, excluding gains
or losses from the hedge which are included in the economic assumption changes item.

-- 208 of 217 --

208	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Modelling changes 1 	41 	– 	(121) 	202 	– 	– 	48 	(190) 	(20)
Expenses 2 	– 	(495) 	5 	(133) 	– 	– 	– 	– 	(623)
Lapses 3 	– 	– 	(170) 	(1 115) 	– 	– 	– 	– 	(1 285)
Mortality and morbidity4 	– 	– 	– 	– 	– 	– 	81 	(219) 	(138)
Benefit changes 	– 	(18) 	– 	– 	– 	– 	– 	– 	(18)
Vitality 	– 	– 	– 	– 	– 	– 	– 	– 	–
Tax 	– 	– 	– 	– 	– 	– 	– 	(13) 	(13)
Economic assumptions 5 	– 	(1 318) 	23 	(2 126) 	– 	(1 072) 	106 	(293) 	(4 680)
Premium and fee income6 	– 	1 084 	108 	454 	– 	– 	– 	– 	1 646
Reinsurance and financing 7 	– 	– 	1 867 	(1 735) 	– 	63 	– 	– 	195
Other 	– 	– 	1 	81 	– 	– 	– 	– 	82
Total 	41 	(747) 	1 713 	(4 372) 	– 	(1 009) 	235 	(715) 	(4 854)
1 For Health and Vitality and Life and Invest, the item reflects refinements to the data and models. For VitalityLife, the item reflects modelling
improvements related to commission and reinsurance.
2 For Health and Vitality and Life and Invest, the expense assumption update reflects an alignment to the expense budget for the next financial year.
3 For Life and Invest, the long-term decrement basis was reviewed and updated in line with lower exit rates observed on certain Invest product lines, and
a short-term allowance for elevated expected lapse and policy alterations experience on the Life business.
4 For VitalityLife, the mortality basis, with respect to future mortality improvements, and the serious illness cover basis was reviewed. The existing shared
value model was reviewed and replaced with a new model to more appropriately capture the impact that shared value has on the business’
underlying demographic basis.
5 For Health and Vitality and Life and Invest, the economic assumptions were updated in line with observed market nominal and real yield risk-free
curves at 30 June 2023. For VitalityLife, the item includes the impact of updating the assumptions relative to the Solvency II yield curves and the IFRS
interest rates, offset by the net change in the interest rate hedge. For VitalityHealth, the impact of updating the assumptions relative to the Solvency II
yield curves results in a reduction to the annuity factor.
6 For Health and Vitality, the premium and fee income item relates to an update of the administration fee income escalations for certain plans recently
renewed. For Life and Invest, Invest fee structures were reviewed in response to updated persistency expectations.
7 For Life and Invest, the reinsurance and financing item primarily relates to the impact of financing arrangements, where the future expected
cash flows arising from part of the negative reserves are monetised to match other positive policy liabilities.

-- 209 of 217 --

209	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
TABLE 7: EMBEDDED VALUE OF NEW BUSINESS
R million
30 June
2023
30 June
2022
%
Change
Health and Vitality
Present value of future profits from new business (at point of sale) 	954 	958
Cost of required capital 	(39) 	(30)
Present value of future profits from new business (at point of sale) after cost
of required capital 	915 	928 	(1)
New business annualised premium income1 	4 959 	4 185 	18
Life and Invest
Present value of future profits from new business (at point of sale)2 	516 	795
Cost of required capital 	(87) 	(90)
Present value of future profits from new business (at point of sale) after cost of
required capital 	429 	705 	(39)
New business annualised premium income3 	2 965 	2 995 	(1)
Annualised profit margin4 	1.8% 	3.0%
Annualised profit margin excluding Invest business 	2.5% 	5.3%
VitalityHealth5
Present value of future profits from new business (at point of sale) 	269 	398
Cost of required capital 	(87) 	(81)
Present value of future profits from new business (at point of sale) after cost of
required capital 	182 	317 	(43)
New business annualised premium income6 	2 001 	1 648 	21
Annualised profit margin4 	1.4% 	2.6%
VitalityLife7
Present value of future profits from new business (at point of sale) 	3 	219
Cost of required capital 	(89) 	(108)
Present value of future profits from new business (at point of sale) after cost of
required capital 	(86) 	111 	(177)
New business annualised premium income 	1 124 	882 	27
Annualised profit margin4 	(1.0%) 	1.4%
1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown
above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums
in respect of new business written during the period but only activated after 30 June 2023.
The total Health and Vitality new business annualised premium income written over the period was R9 051 million (June 2022: R7 548 million).
2 Included in the Life and Invest embedded value of new business is R21 million (June 2022: R54 million) in respect of investment management services
provided on off balance sheet investment business.
Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has been
recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium
is due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded
after receipt. Invest new business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the
reporting period, including policies whose first premium is due after the valuation date.
The new business annualised premium income of R2 965 million (June 2022: R2 995 million) (single premium APE: R1 430 million (June 2022:
R1 421 million)) shown above excludes automatic premium increases and servicing increases in respect of existing business. The total new business
annualised premium income written over the period, including automatic premium increases of R2 208 million (June 2022: R1 801 million) and servicing
increases of R716 million (June 2022: R668 million), was R5 889 million (June 2022: R5 464 million) (single premium APE: R1 499 million (June 2022:
R1 492 million)). Single premium business is included at 10% of the value of the single premium.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans are shown in Table 5 as
experience variances and not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date
multiplied by the Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for
the Margin and Annuity Factor are shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised
premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month,
as well as premiums in respect of new business written during the period but only activated after 30 June 2023.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first
premium is due after the valuation date.

-- 210 of 217 --

210	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
Basis of preparation
TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS
30 June
2023
30 June
2022
Beta coefficient 	0.75 	0.75
Equity risk premium (%) 	3.5 	3.5
Risk discount rate (%)
– 	Health and Vitality1 	15.125 	14.375
– 	Life and Invest1 	15.875 	14.875
– 	VitalityHealth 	7.000 	5.016
– 	VitalityLife 	7.042 	4.997
Rand/GBP exchange rate
Closing 	23.99 	20.00
Average 	21.43 	20.25
Margin over Expense inflation to derive Medical inflation (%)
South Africa 	3.00 	3.00
Expense inflation (%)2
South Africa 	– 	Health and Vitality 	7.96 	7.85
– 	Life and Invest 	8.13 	7.74
United Kingdom 	3.75 	3.75
Pre-tax investment return (%)
South Africa 	– 	Cash1 	11.75 	10.75
– 	Life and Invest bonds3 	13.25 	12.25
– 	Health and Vitality bonds3 	12.50 	11.75
– 	Equity1 	16.75 	15.75
United Kingdom 	– 	VitalityHealth risk-free rate 	4.38 	2.39
– 	VitalityLife risk-free rate 	4.42 	2.37
– 	VitalityLife IFRS interest rate 	3.98 	2.92
– 	VitalityLife investment return 	4.31 	2.00
Long-term corporation tax rate (%)
South Africa 	27 	27
United Kingdom 	25 	25
VitalityHealth Assumptions
– 	Margin (net of tax and cost of capital) (%) 	12.05 	12.00
– 	Annuity Factor 	6.28 	7.00
Projection term
– 	Health and Vitality 	20 years 	20 years
– 	Discovery Life – VIF 	40 years 	40 years
– 	Group Life 	20 years 	20 years
– 	VitalityLife 	No cap 	No cap
– 	VitalityHealth4 	20 years 	20 years
1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow
weighted average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view
of inflation.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.

-- 211 of 217 --

211	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
The Discovery Group embedded value is calculated based on a risk discount rate using the Capital Asset Pricing Model (CAPM) approach with
specific reference to the Discovery Group beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount
rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed
beta calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta
will only change if the capital structure of the Group and/or the observed beta calculated using daily returns over a long time period suggest
the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect the historic
performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors may
want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available,
augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery Group
group information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses of
an exceptional or non-recurring nature.
The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to the publicly available JSE risk-free
nominal yield curve.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the
net investment return assumption.
The risk-free rate assumption for VitalityHealth and VitalityLife was based on the single interest rate derived from the Prudential Regulatory
Authority yield curve. The inflation rate is consistent with the long-term market view of inflation.
From 30 June 2018, VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the
Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse
rates and premium increases. The Margin assumption reflects profit margins after tax and Cost of Capital. The assumptions underlying the
Annuity Factor and Margin are set taking into account the current experience in the business at different durations.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible
assets. The Vitality Life Limited and the VitalityLife business on the PAC licence required capital amount is assumed to earn the investment
return assumption, which is set based on the return on a portfolio of government and corporate bonds assumed to back the required
capital. The Life and Invest cost of required capital is calculated assuming shareholder cash flow is limited to the cash flow available after
having met both the required capital amount and an internally defined liquidity target capital requirement of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107:
Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into
account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 2.

-- 212 of 217 --

212	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure E – Embedded value statement continued
for the year ended 30 June 2023
Sensitivity to the embedded value assumptions
The risk discount rate uses the CAPM approach with specific reference to the Discovery Group beta coefficient. As beta values reflect the historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors may
want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the embedded value and the embedded value of new business at 30 June 2023 to changes in the risk discount rate is included in the tables below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action such as risk premium increases where future experience is worse than the base assumptions.
TABLE 9: EMBEDDED VALUE SENSITIVITY
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Embedded
value
%
change	R million
Adjusted
net worth2
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Base 	18 286 	25 985 	(512) 	33 301 	(1 665) 	12 797 	(698) 	11 823 	(1 141) 	98 176
Impact of:
Risk discount rate + 1% 	18 286 	24 563 	(551) 	30 350 	(1 759) 	12 160 	(664) 	11 106 	(1 002) 	92 489 	(6)
Risk discount rate – 1% 	18 286 	27 555 	(467) 	36 786 	(1 555) 	13 501 	(737) 	12 625 	(1 310) 	104 684 	7
Lapses – 10% 	18 054 	26 824 	(536) 	36 226 	(1 760) 	14 943 	(815) 	12 579 	(1 374) 	104 141 	6
Interest rates – 1% 1 	17 316 	25 887 	(494) 	33 841 	(1 636) 	13 501 	(737) 	11 987 	(1 454) 	98 211 	–
Equity and property market value – 10% 	18 247 	25 985 	(512) 	32 595 	(1 658) 	12 797 	(698) 	11 823 	(1 141) 	97 438 	(1)
Equity and property return + 1% 	18 286 	25 985 	(512) 	33 657 	(1 665) 	12 797 	(698) 	11 823 	(1 141) 	98 532 	–
Renewal expenses – 10% 	18 402 	28 602 	(473) 	33 978 	(1 636) 	13 925 	(698) 	12 077 	(1 126) 	103 051 	5
Mortality and morbidity – 5% 	18 560 	25 985 	(512) 	35 550 	(1 544) 	14 876 	(698) 	12 279 	(1 105) 	103 391 	5
Projection term + 1 year 	18 286 	26 295 	(517) 	33 391 	(1 667) 	12 889 	(703) 	11 823 	(1 141) 	98 656 	–
1 All economic assumptions were reduced by 1%.
2 The sensitivity impact on the VitalityLife net of tax change in negative reserves is included in the adjusted net worth column.
The following table shows the effect of using different assumptions on the embedded value of new business.
TABLE 10: 	VALUE OF NEW BUSINESS SENSITIVITY
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Value of
new
business
%
change	R million
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Base 	954 	(39) 	516 	(87) 	269 	(87) 	3 	(89) 	1 440
Impact of:
Risk discount rate + 1% 	875 	(43) 	341 	(92) 	170 	(82) 	(103) 	(75) 	991 	(31)
Risk discount rate – 1% 	1 040 	(36) 	718 	(81) 	379 	(93) 	122 	(107) 	1 942 	35
Lapses – 10% 	1 022 	(43) 	707 	(92) 	509 	(100) 	120 	(106) 	2 017 	40
Interest rates – 1%1 	960 	(38) 	508 	(85) 	379 	(93) 	90 	(123) 	1 598 	11
Equity and property return + 1% 	954 	(39) 	543 	(87) 	269 	(87) 	3 	(89) 	1 467 	2
Renewal expense – 10% 	1 094 	(37) 	567 	(85) 	399 	(87) 	41 	(85) 	1 807 	25
Mortality and morbidity – 5% 	954 	(39) 	609 	(80) 	508 	(87) 	39 	(82) 	1 822 	27
Projection term + 1 year 	970 	(40) 	521 	(87) 	284 	(87) 	3 	(89) 	1 475 	2
Acquisition costs – 10% 	985 	(39) 	686 	(87) 	317 	(87) 	172 	(89) 	1 858 	29
1 All economic assumptions were reduced by 1%.

-- 213 of 217 --

213	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Annexure F – Unaudited five-year review
for the year ended 30 June 2023
Group
2019
Group
2020
Group
2021
Group
2022
Group
2023
Compound
growth %
Income statement extracts (R million)
Profit from operations 	7 536 	1 532 	5 304 	7 858 	8 662 	4%
Headline earnings 	5 147 	296 	2 986 	5 204 	5 490 	2%
Abnormal expenses/(income) 	(112) 	3 451 	420 	612 	2 188
Normalised headline earnings 	5 035 	3 747 	3 406 	5 816 	7 678 	11%
Diluted normalised headline earnings
per share (cents) 	771.6 	566.7 	512.9 	877.3 	1 160.9 	11%
Statement of financial position extracts
(R million)
Total assets 	180 233 	210 328 	246 694 	271 224 	301 773 	14%
Shareholders' funds 	43 083 	44 549 	46 415 	53 550 	63 970 	10%
Embedded value
Embedded value (R million) 	71 217 	70 834 	74 645 	86 258 	98 315 	8%
Diluted embedded value per share (R) 	108.30 	107.71 	112.23 	129.07 	146.20 	8%
Key ratios
Return on average equity (%) 	16.4 	0.4 	7.1 	11.0 	9.1
Return on average assets (%) 	3.9 	0.1 	1.4 	2.1 	1.9
Exchange rates
Rand/USD
– Closing 	14.15 	17.41 	14.28 	16.47 	18.87
– Average 	14.17 	15.70 	15.42 	15.22 	17.79
Rand/GBP
– Closing 	17.98 	21.44 	19.74 	20.00 	23.99
– Average 	18.32 	19.75 	20.74 	20.25 	21.43
Share statistics
Number of ordinary shares in issue
– Weighted average (000's) 	652 295 	656 648 	656 710 	656 901 	658 045
– Diluted weighted average (000's) 	652 568 	661 242 	664 073 	663 082 	661 328
– End of period (000's) 	658 291 	658 291 	665 769 	668 963 	673 146
Price/diluted headline earnings (times) 	19.3 	18.3 	24.7 	14.6 	12.6
Share price (cents per share):
– High 	17 830 	15 163 	15 738 	18 280 	15 266
– Low 	13 287 	5 815 	10 047 	11 760 	10 241
– Closing 	14 911 	10 455 	12 667 	12 810 	14 585
Market capitalisation (R million) 	98 158 	68 824 	84 333 	85 694 	98 172

-- 214 of 217 --

214	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Glossary of terms
Abbreviation 	Meaning
AIAV 	AIA Vitality Proprietary Limited
API 	Annual Premium Income
CAE 	Chief Audit Executive
CCIC 	Capital, Currency and Investment Committee
CEO 	Chief Executive Officer
CFC 	Controlled Foreign Company
CFO 	Chief Financial Officer
CGU 	Cash generating unit
CIPC 	Companies and Intellectual Property Commission
CMT 	Cambridge Mobile Telematics
CODM 	Chief Operating Decision-Maker
Companies Act 	South African Companies Act, 71 of 2008
CRO 	Chief Risk Officer
CSM 	Contractual Service Margin (unearned profit)
DHEL 	Discovery Holdings Europe Limited
DHMS 	Discovery Health Medical Scheme
Discovery 	Discovery Limited Group
DLAC 	Discovery Limited Audit Committee
DMTN 	Domestic Medium Term Note
DRG 	Discovery Risk Grades
DVA 	Discovery Vitality Australia Proprietary Limited
ECL 	Expected credit losses
ESG 	Environmental, Social, and Corporate Governance
FCA 	Finance Conduct Authority
FCC 	Finance and Capital Committee
FEC 	Foreign Exchange Contracts
FGC 	Financial Guarantee Contracts
FinRe 	Financial Reinsurance – with risk transfer
FLR 	Financial Leverage Ratio
FRC 	United Kingdom Financial Reporting Council
FSV 	Financial Soundness Valuation
FVTPL 	Fair value through profit or loss
GIA 	Group Internal Audit
GMM 	General Measurement Model
HAF 	Head of Actuarial Function
IASB 	International Accounting Standards Board
IBNR 	incurred but not yet reported claims
ICA 	Individual Capital Assessment
IFA 	Insurance Fund Account
IFRS 	International Financial Reporting Standards
INSPRU 	The Prudential Sourcebook for Insurers
IRBA 	South African Independent Regulatory Board of Auditors

-- 215 of 217 --

215	DISCOVERY ANNUAL FINANCIAL STATEMENTS 2023
Abbreviation 	Meaning
JSE 	Johannesburg Stock Exchange
KAM 	Key Audit Matters
LIC 	Liability for Incurred Claims
LRC 	Liability for Remaining Coverage
LTICR 	Long-term Insurance Capital Requirement
LTIP 	Long-term Incentive Plan
MAFR 	Mandatory audit firm rotation
Morbidity 	Morbidity claims are claims which arise as a result of an impairment of life due to an
illness or disability event insured by the policyholder
Mortality 	Mortality claims are claims which arise from the death of an insured life
NCD 	Negotiable certificates of deposits
OCI 	Other Comprehensive Income
OCR 	Outstanding Claims Reserve
ORSA 	Own Risk and Solvency Assessment
PA 	Prudential Authority (South Africa)
PAA 	Premium Allocation Approach
PAC 	Prudential Assurance Company
PAHI 	Ping An Health Insurance Company of China Ltd
PRA 	Prudential Regulatory Authority (United Kingdom)
ROEV 	Return On Opening Embedded Value
SA 	South Africa
SAICA 	South African Institute of Chartered Accountants
SAM 	Solvency Assessment and Management
SAP 	Standard of Actuarial Practice
SCR 	Solvency Capital Requirement
SME 	Small and Medium-sized Enterprises
TCFD 	Task Force on Climate-related Financial Disclosure
TRS 	Total Return equity Swaps
UK 	United Kingdom
VFA 	Variable Fee Approach
VGI 	Vitality Group International Inc.
WHT 	Withholding Tax
Glossary of terms continued

-- 216 of 217 --

Discovery Limited | +27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za
Copyright 2021. Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group.
Registration number: 1999/007789/06. Companies in the Group are licensed insurers and authorised financial services providers.

-- 217 of 217 --